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 Cyclic di-GMP (cdiGMP) is a ubiquitous prokaryotic nucleotide signaling 
molecule that regulates important bacterial processes, including biofilm formation, 
motility, and virulence. The differential radial capillary action of ligand assay 
(DRaCALA) was developed to determine protein-ligand interactions and provide insight 
into the mechanism of cdiGMP signal transduction. DRaCALA is based on the ability of 
nitrocellulose membranes to separate free ligand from bound protein-ligand complexes 
resulting in precise measurements of the fraction of bound ligand. The principle of 
DRaCALA was demonstrated by detection of 3 radiolabeled nucleotides binding to their 
cognate receptors. DRaCALA also enabled the determination of affinity, specificity, and 
kinetics of cdiGMP-binding to Alg44. A unique feature of DRaCALA is the ability to 
determine specific binding interactions to heterologously expressed proteins in whole cell 
lysates, suggesting that individual open reading frames could be screened for the 
expression of a cdiGMP-binding protein. DRaCALA was applied on a genome-wide 
	   	  
scale to systematically screen protein products of over 98% of Vibrio cholerae open 
reading frames for cdiGMP-binding activity. The DRaCALA ORFeome screen identified 
5 of 10 previously described cdiGMP-binding proteins, 19 proteins with predicted 
cdiGMP-binding domains, and 6 novel putative cdiGMP-binding proteins lacking a 
defined cdiGMP-binding site. Direct cdiGMP-binding was demonstrated for the T2SE 
ATPase MshE, and cdiGMP-binding activity was observed for a Pseudomonas 
aeruginosa homolog PA14_29490. These results suggest that cdiGMP-binding may be a 
conserved feature of a subset of T2SE ATPases that regulate type IV pili and type II 
secretion. Finally, the applications of DRaCALA were extended for the determination of 
protein binding to nucleotide polymers of DNA and RNA and cdiGMP-binding to a RNA 
aptamer. In total these studies report the development of DRaCALA as a novel 
biochemical assay and its use in the systematic identification and characterization of 
protein-ligand interactions.  
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Chapter 1: Introduction 
1.1 Low Molecular Weight Molecules are Biological Signals 
 Living organisms rely on low molecular weight signaling molecules to regulate 
critical cellular processes. These signaling molecules are produced from metabolic 
precursors, but are primarily used for signal transduction. For example, steroid hormones 
such as testosterone and estradiol are produced from cholesterol, neurotransmitters 
dopamine and serotonin are modified amino acids, and cyclic nucleotides such as cAMP 
and cGMP are synthesized from ATP and GTP precursors (1-3). These molecules can 
mediate inter- or intra-cellular signaling depending on their ability to cross cell 
membranes. Steroid hormones can passively diffuse across cellular membranes to bind 
cytosolic receptors, while membrane-impermeable neurotransmitters are actively secreted 
to bind cell-surface receptors. In contrast, cyclic nucleotides are generally not transported 
across cell membranes and therefore typically signal through intracellular receptors. 
 Signaling by these molecules regulates important, yet diverse, biological 
processes such as gender determination by steroid hormones, cognitive reward seeking by 
dopamine, and preferential carbon metabolite utilization in E. coli (4-6). As a result of 
these powerful regulatory activities, low molecular weight signaling pathways are targets 
for pharmaceutical intervention. The amount of signaling molecule can be manipulated as 
in the case of birth control through ingestion of progestin and estradiol, or manipulating 
signaling metabolism as in the prevention of cGMP degradation by Viagra (7,8). 
Alternatively, molecular analogs can alter the activity of signal receptors such as 
inhibition of the NMDA receptor by ketamine (9). Elucidating the molecular targets of 
signaling by low molecular weight molecules is critical to our understanding of biological 
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regulation, signal transduction, and the rational design of pharmaceuticals that target 
these processes. 
1.1.1 Architecture of Signaling by Low Molecular Weight Molecules 
 Signaling by low molecular weight molecules involves four steps that are present 
in all signaling modules: 1) signal generation, 2) signal binding to effector, 3) allosteric 
regulation of effector activity, and 4) signal elimination (Figure 1). First, a signal is 
generated by the synthesis or release of a low molecular weight signaling molecule. The 
signaling molecule must then bind to an effector molecule to regulate cellular activity. 
Effectors are genomically-encoded proteins or RNAs with a biological activity that is 
allosterically regulated by ligand binding. Upon binding at the allosteric site, a 
conformational change is transduced through the structure of the effector molecule to 
regulate its biological output. In the final step, elimination of the signaling molecule is 
required to allow dynamic response to further signal generation. This can be 
accomplished by catalytic inactivation of the signaling molecule or sequestration of the 
signaling molecule from cells or subcellular compartments. Each of the four processes 
listed above are universal to signaling by low molecular weight molecules and define the 
minimal components of a signaling module. 
1.2 A Minimal Signaling Module: cAMP Regulation of Carbon Catabolite 
Utilization in E. coli 
 Cyclic adenosine monophosphate (cAMP) is one of the most well-characterized 
low molecular weight signaling molecules with regulatory activities in prokaryotes and 
eukaryotes. In Escherichia coli, cAMP regulates the preferential catabolism of glucose 
over other  
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Figure 1. Architecture of signaling by low molecular weight molecules. Signaling 
molecules are (1) generated, (2) bind effectors, (3) allosterically regulate effector activity, 
and (4) are eliminated by sequestration or chemical modification. 
 
 
carbon sources such as lactose (Figure 2) (10). When present in the environment, glucose 
is imported by EIIGlc and simultaneously phosphorylated by phosphotransfer from the 
EIIAGlc subunit (11). In the absence of glucose as a substrate for phosphotransfer, EIIAGlc 
remains phosphorylated and EIIAGlc-P interacts with the E. coli adenlyate cyclase (AC) to 
activate cAMP synthesis (12,13). Through this mechanism, cAMP synthesis acts as a 
signal for decreasing glucose availability. cAMP has one well-characterized effector in E. 
coli called the cAMP receptor protein (CRP) that specifically binds cAMP with high 
affinity (14). Binding to cAMP allosterically promotes CRP dimerization and increases 
its affinity for specific regulatory DNA sequences called CAP sites (15). CAP sites are 
found in the promoters of the lac, gal, and mal utilization operons, allowing CRP to 
regulate transcription of these operons (16). In the presence of high glucose, cAMP is not 
generated. As a consequence, CRP does not dimerize and bind CAP sites, thereby 
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Figure 2. cAMP-dependent carbon catabolite regulation in E. coli. (A) In the 
presence of glucose, EIIAGlc phosphorylates glucose during import into the cell. (B) In 
the absence of glucose, EIIAGlc phosphorylates adenylcate cyclase (AC), which then 
produces cAMP. cAMP binds cAMP receptor protein (CRP), inducing dimerization and 
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operons and prioritizing glucose catabolism (17). As glucose levels fall, cAMP will be 
synthesized, bind to CRP, and promote transcription of genes for non-glucose carbon 
catabolite utilization (18,19). To maintain a dynamic response to glucose availability, E. 
coli must be able to remove cAMP produced from previous periods of low glucose. Low 
intracellular levels of cAMP are maintained by a cAMP-specific phosphodiesterase 
(PDE) CpdA and active transport of cAMP from the cytoplasm by TolC (20,21). Thus 
cAMP signaling in E. coli demonstrates the four minimal components of a biological 
signaling module including: 1) signal generation by adenylate cyclase synthesis of 
cAMP, 2) signal recognition by cAMP binding to CRP, 3) signal output through 
increased affinity of CRP to CAP sites, and 4) signal elimination through enzymatic 




Figure 3. Architecture of cAMP signaling in E. coli. In E. coli, cAMP is (1) 
synthesized by adenylate cyclase (AC) from an ATP precursor, (2) binds CRP, (3) 
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1.3 Complexity in Eukaryotic cAMP Signaling  
 In eukaryotic systems, the architecture of cAMP signaling has increased 
complexity. Complexity is a result of multiple ACs, cAMP effector proteins, regulatory 
targets, and PDEs. Humans encode at least 9 membrane bound ACs as well as a soluble 
AC, which are regulated both transcriptionally and post-translationally (22). AC 
expression is differentially-regulated in tissues, although the molecular mechanisms of 
differential expression are not well characterized. The most common mechanism of post-
translational AC regulation is through the activity of G-protein-coupled receptors 
(GPCRs) (23). GPCRs respond to environmental signals by releasing a trimeric complex 
of regulatory G-protein subunits. G-protein α-subunits can either stimulate or inhibit AC 
activity, while the G-protein β/γ heterodimers are potent inhibitors of specific ACs (24-
26). In addition to GPCR regulation, AC activity can be inhibited through 
phosphorylation by several kinases, including a cAMP-dependent protein kinase A 
providing a mechanism of feedback inhibition (27). The presence of multiple ACs that 
are individually regulated by different mechanisms creates complex cAMP signal 
production in eukaryotes. 
 There is additional complexity in cAMP signaling due to the presence of multiple 
cAMP-dependent effector molecules (Figure 4). The most well-studied effector of 
eukaryotic cAMP signals is the cAMP-dependent protein kinase A (PKA). In its inactive 
form, PKA exists as a heterotetramer composed of a regulatory homodimers and two 
catalytic subunits containing kinase activity (28). cAMP binding to the regulatory 
subunits of PKA causes  
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Figure 4. Architecture of cAMP signaling in eukaryotes. In eukaryotes, cAMP is (1) 
synthesized by multiple isoforms of adenylate cyclase (AC), (2) binds multiple effector 
types, (3) regulates diverse cellular processes, and (4) is degraded by multiple 
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release of the active catalytic monomers, which can then phosphorylate target proteins to 
regulate cellular activity (29). Multiple isoforms of PKA exist based on the differential 
expression of 3 genes encoding catalytic subunits and 4 genes encoding regulatory 
subunits, each of which are subject to post-transcriptional splicing creating multiple 
subunit splice variants (30-38). Furthermore, catalytic and regulatory subunits are 
differentially assembled into PKA tetramers, providing a large variety of PKA isoforms 
(39). The multitude of PKA isoforms created by transcriptional, post-transcriptional, and 
post-translational regulation creates complexity in cAMP regulation of PKA activity.  
 In addition to PKA, two other classes of eukaryotic cAMP effectors have been 
described, including a guanine exchange factor protein directly activated by cAMP 
(EPAC or cAMP-GEF) and cAMP-gated ion channels. EPACs were discovered as a 
result of the PKA-independent cAMP-dependent regulation of the Rap1small GTPase 
(40). EPACs activate the small GTPases Rap1 and Rap2 by promoting the exchange of 
GDP for GTP and allowing regulation of further downstream protein effectors (41). For 
example, regulation of Rap signaling by cAMP-dependent EPACs is required for 
maintenance of cellular adhesion and tight junction localization (42). cAMP-gated ion 
channels are a third class of cAMP-dependent effectors, which are involved in sensory 
and neural processes such as olfactory perception (43). From these examples, it is 
apparent that different cAMP effectors have different effector mechanisms including 
enzymatic phosphorylation, protein-protein interactions, and ion flux that provide a 
complex set of outputs for cAMP signaling. 
 In eukaryotic systems, cAMP degradation is accomplished by multiple PDEs with 
specific regulatory features. Mammalian PDEs fall into 8 structure/function families of 
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which the Class-4 PDEs are specific for cAMP and account for the majority of cAMP 
PDE activity in mammalian cells (44). Class-4 PDEs are generated from 4 genetic loci 
with differential splicing leading to the production of at least 20 PDE isoforms with 
different N-terminal and C-terminal regulatory domains flanking a conserved catalytic 
domain (45). PDE activity of different isoforms is regulated by multiple mechanisms 
including phosphorylation by ERK MAP-kinase or PKA and binding to phosphatidic acid 
(46-48). The presence of multiple differentially-regulated PDE isoforms provides 
complexity in eukaryotic cAMP signal degradation. 
 cAMP signaling components are regulated to create specific interactions between 
ACs, effectors, and PDEs. Signaling specificity can be achieved by expression of subsets 
of ACs, effectors, and PDEs in different cells or tissues. For example, a soluble AC 
activated by bicarbonate is expressed only in the testes, providing a unique cAMP 
signaling response to bicarbonate concentrations (49). Signaling specificity of co-
expressed ACs, effectors, and PDEs can also be achieved by subcellular localization. In 
one example, a class of structurally diverse proteins called A-kinase anchoring proteins 
(AKAPs) localizes specific AC, PKA and PDE proteins to create localized signaling 
modules (50). In cardiac myocytes, muscle-specific AKAP (mAKAP) directly binds 
AC5, a specific PKA isoform, and a isoform of PDE4 to regulate opening of a calcium 
channel (51-53). Genetic ablation of the mAKAP binding site prevents proper PKA 
localization and regulation, resulting in decreased PKA activity and improper regulation 
of the calcium channel. A result of localization of signaling components is the production 
of localized differences in cAMP concentration. FRET sensors have revealed the 
presence of sub-cellular cAMP concentration gradients in cardiac myocytes that are 
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dependent upon the activity of PDEs (54). Activity of specific cAMP effectors could be 
regulated by their subcellular localization with respect to high and low cAMP 
concentrations (55). Thus, in addition to the large number of eukaryotic cAMP signaling 
components, differential expression and subcellular localization creates further 
complexity in eukaryotic cAMP signaling. 
1.3.1 Complexity in Prokaryotic cAMP Signaling  
 The identification of multiple ACs, effectors, and PDEs in bacterial genomes 
suggests that prokaryotes may also posesses complex cAMP signaling networks. 
Pseudomonas aeruginosa encodes 2 intracellular ACs, CyaA and CyaB, that produce 
cAMP to regulate expression of virulence factors (56). A third AC, ExoY, is injected into 
eukaryotic cells by a type III secretion system to target eukaryotic cAMP-dependent 
processes (57). cAMP production by CyaA and CyaB targets a single cAMP effector, a 
CRP homolog called Vfr (58,59). Unlike the CRP of E. coli, Vfr appears to regulate 
virulence factor production rather than carbon catabolite utilization in P. aeruginosa (60). 
Regulation of CyaA and CyaB activity are not fully understood, but the presence of two 
cyclases suggests that P. aeruginosa may generate cAMP in response to multiple inputs. 
 In Mycobacteria tuberculosis, a complex cAMP signaling system containing 
multiple ACs and cAMP effectors was discovered by in silico prediction of cyclic 
nucleotide monophosphate binding domains and cyclases (61). Of the 16 predicted ACs, 
10 have been demonstrated to synthesize cAMP in response to distinct environmental 
cues including fatty acids, pH, bicarbonate, and growth in macrophages (62). In addition 
to the cyclases, 10 cAMP binding proteins have been predicted, although only CRPMt and 
a lysine acetyl transferase (KATMt) have been shown empirically to directly bind cAMP 
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(63,64). A second CRP ortholog (CMR) with a predicted cAMP binding site regulates 
transcription in a cAMP-dependent manner, although direct binding has not been 
demonstrated (65). CMR and CRPMt bind distinct regulatory DNA sites allowing CMR to 
regulate a specific set of genes, which may explain the requirement for CMR but not 
CRPMt during M. tuberculosis growth in macrophages (66). In contrast to the multiplicity 
of ACs and effectors, only one PDE has been identified in M. tuberculosis (67). 
However, M. tuberculosis can export cAMP, providing an alternative mechanism for 
signal elimination (68). Indeed, cAMP levels increase 50-fold upon passage in 
macrophages, and cAMP is directly exported into macrophages to disrupt immune 
signaling (69,70). In total, these studies describe a complex cAMP signaling system 
containing multiple cyclases, multiple cAMP binding proteins with different regulatory 
activities, and multiple cAMP removal mechanisms.  
1.4 Discovery of a Cyclic di-Nucleotide Signaling Molecule in Prokaryotes   
  Bis-(3’,5’)-cyclic-dimeric-guanosine monophosphate or cyclic di-GMP 
(cdiGMP) is a cyclic di-nucleotide signaling molecule in prokaryotes. Unlike cAMP and 
cGMP which are monomers, cdiGMP is composed of two guanosine monophosphates 
joined through phosphodiester bonds between the C-3 and C-5 hydroxyl groups of their 
ribose (71). The unique cyclic di-nucleotide was initially identified as an activator of 
cellulose synthase in membrane preparations of Gluconacetobacter xylinus (Figure 5) 
(72). Addition of GTP to membrane preparations from G. xylinus induced cdiGMP 
synthesis by a diguanylate cyclase (DGC). Addition of purified cdiGMP to these 
membrane preparations was shown to allosterically enhance the rate of cellulose 
polymerization by direct interactions with cellulose synthase (73,74). In addition to DGC 
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activity, the original membrane preps contained cdiGMP specific PDE activity. PDE 
activity sequentially hydrolyzed both phosphodiester bonds, producing a linear pGpG 
intermediate, which was subsequently hydrolyzed to 2 GMP (72). These early studies 
described the minimal components of a cdiGMP signaling module composed of synthesis 
by DGC, effector binding, allosteric regulation of effector activity, and subsequent 




Figure 5. Architecture of cdiGMP signaling. cdiGMP is (1) synthesized from 2GTP by 
diguanylate cyclases (DGC), (2) binds cellulose synthase, (3) upregulates cellulose 
biosynthesis, and (4) is degraded to pGpG and subsequently 2GMP. 
 
 
1.4.1 GGDEF Domains Catalyze cdiGMP Synthesis 
  Studies of cdiGMP signaling have been greatly aided by the identification of a 
conserved GGDEF domain required for cdiGMP synthesis. Initial experiments to identify 
genes that regulate DGC activity in G. xylinus identified several genes encoding proteins 
with GGDEF domains (75). Alignment of GGDEF domains with adenlyate cyclases of 
Mycobacteria revealed conservation of secondary structure motifs, suggesting GGDEFs 
may also have nucleotide cyclase activity (76). Direct cdiGMP synthesis by a GGDEF-
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PleD was found to catalyze cdiGMP formation from GTP in vitro, and mutation of the 
conserved GGDEF residues abolished cdiGMP synthesis. Numerous proteins containing 
GGDEF domains have now been shown to have DGC activity and no other source of 
cdiGMP synthesis has been identified, suggesting that cdiGMP synthesis is accomplished 
only by GGDEF domains (78). 
 The ability to identify DGCs based on the presence of a GGDEF domain has 
enabled systematic genetic and biochemical analysis of DGC activity. Surprisingly, 
individual organisms can encode dozens of GGDEF-domain proteins, including 41 in 
Vibrio cholerae and 33 in P. aeruginosa (79). Systematic analyses of GGDEF-domain 
proteins in P. aeruginosa, Salmonella typhimurium, E. coli, and V. cholerae has revealed 
that a majority of proteins containing a GGDEF domain are active DGCs and can 
contribute to regulation of cdiGMP-dependent phenotypes in vivo (80-83). Interestingly, 
the production of cdiGMP by individual DGCs was not absolutely correlated with 
regulation of cdiGMP-dependent phenotypes. For example, PA2870 and PA3343 of P. 
aeruginosa produced high levels of cdiGMP, but failed to upregulate cdiGMP-dependent 
biofilm formation, suggesting that individual DGCs may target specific effectors (80). 
The presence of numerous DGCs with varying enzymatic activity and specific cellular 
targets creates complex cdiGMP signaling in prokaryotes. 
 Structural studies have revealed the mechanism of cdiGMP synthesis by GGDEF 
domains and identified a conserved regulatory motif required for feedback inhibition of 
DGC activity by cdiGMP.  Crystallization of the PleD protein revealed a dimer structure 
with conserved GGDEF residues binding and positioning two GTP molecules at the 
catalytic GGDEF domain interface for condensation to cdiGMP (84). This suggests that 
	   14	  
DGC activity requires dimerization, which is supported by the finding that only dimer 
fractions of PleD contain DGC activity (85). In addition to revealing a catalytic 
mechanism for cdiGMP, the crystal structure of PleD revealed bound cdiGMP at an 
allosteric inhibitory site (I-site) (84). Sequence alignment of residues in the I-site 
revealed a conserved RxxD motif that is present in the majority of GGDEF-domain 
proteins, especially those with conserved residues for cdiGMP catalysis (86). Systematic  
mutation of the RxxD motif of PleD demonstrated that the conserved arginine and 
aspartate residues of the RxxD motif are required for cdiGMP-binding and feedback 
inhibition (86). Thus, activation of cyclase activity by dimerization and product inhibition 
through cdiGMP-binding at the I-site appear to be conserved regulatory features of 
DGCs. 
 DGC activity can also be regulated by N-terminal domains that effect 
dimerization or the positioning of GGDEF domains. PleD contains an N-terminal REC 
domain that is phosphorylated to promote dimerization and activate cdiGMP synthesis 
(77,85). The structure of PleD was solved after modification with BeF3-, which mimics 
aspartate phosphorylation of REC domains (87). This structure confirmed that PleD 
dimers are stabilized by phosphorylation-dependent N-terminal REC domain interactions 
(88). A similar regulatory mechanism has been described for WspR in which DGC 
activity is upregulated by phosphorylation-dependent dimerization of its N-terminal REC 
(89-91). In addition to regulation of dimerization, N-terminal domains may affect the 
tertiary structure of GGDEF domains to regulate DGC activity. DgcZ (YdeH) of E. coli is 
a constitutive dimer with an N-terminal zinc binding domain (92). A crystal structure of 
DgcZ shows that zinc binding prevents proper positioning of the GTP molecules at the 
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dimer interface (93). Thus, N-terminal domains can regulate DGC activity through a 
variety of mechanisms including dimerization and ligand binding. The combination of 
multiple DGCs with unique N-terminal regulatory domains creates a high level of 
complexity in cdiGMP signal production.   
1.4.2 EAL and HD-GYP Domains Catalyze cdiGMP Hydrolysis 
 Early genetic and biochemical studies of cdiGMP metabolism demonstrated that 
EAL-domain proteins decreased cellular cdiGMP levels and repressed cdiGMP-
dependent phenotypes in multiple organisms (75,94). The purified EAL-domain protein 
VieA of V. cholerae was shown to directly hydrolyze cdiGMP in a manner that depended 
on the conserved glutamate residue of the EAL motif (95). VieA can hydrolyze both 
phosphodiester bonds of cdiGMP to produce linear pGpG and subsequently 2 GMP. 
However, pGpG formation is several orders of magnitude faster than GMP production, 
indicating that pGpG may be the physiologically relevant product of EAL-domain 
proteins (95). Rapid hydrolysis of cdiGMP to pGpG has now been demonstrated for 
numerous EAL-domain proteins, indicating that cdiGMP hydrolysis is a conserved 
feature of EAL domains (80,95-98). 
 Structural studies have revealed that EAL domains function as dimers with inter- 
and intra-molecular domain interactions regulating catalytic activity. Blrp1 of Klebsiella 
pneumonia encodes an N-terminal blue light-responsive BLUF domain and a C-terminal 
EAL domain (99). Blue light induces structural changes in the BLUF domain that are 
transmitted to the EAL domain, specifically affecting conserved alpha helices at the 
EAL-EAL dimer interface. Interactions between the EAL domains reciprocally 
repositions the catalytic divalent cation clusters of each other’s active sites, thereby 
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promoting PDE activity. Regulation of PDE activity through the EAL dimer interface has 
also been demonstrated for YahA of E. coli (98). Isolated EAL domains of YahA are 
normally monomers that can form dimers at high concentrations that activates PDE 
activity (100). cdiGMP-binding at the active site causes changes in the structure of the 
EAL domain dimer interface, thereby promoting dimerization and PDE activity in the 
presence of the cdiGMP substrate. Thus, EAL domain PDE activity is reciprocally 
regulated by a conserved EAL-EAL dimer interface. The inter-domain interactions can be 
regulated by N-terminal signaling domains or substrate-dependent dimerization, creating 
complex regulation of cdiGMP hydrolysis by EAL domains. 
 The HD-GYP domain, a subclass of the HD family of metal-dependent 
phosphohydrolases, defines a second class of cdiGMP specific PDE proteins. In contrast 
to EAL domains, HD-GYP domains efficiently hydrolyze both phosphodiester bonds of 
cdiGMP and therefore produce 2 GMP as the major product (101,102). Regulation of 
HD-GYP domain PDE activity is not well characterized, although several mechanisms 
have been proposed. HD-GYP domains are often paired with signal receiver domains 
such as REC, GAF and PAS, suggesting that PDE activity could be regulated by the 
activity of associated domains (79). Indeed, the prototypical HD-GYP domain protein 
RpfG contains an N-terminal REC domain that, in the absence of phosphorylation, 
inhibits cdiGMP-binding at the active site (101,103). Alternatively, a recent report has 
described an HD-GYP domain protein from V. cholerae that is active in the presence of 
reduced ferrous iron, but not oxidized ferric iron (104). This suggests that PDE activity 
could be regulated by redox activity. A crystal structure of a catalytically-active HD-GYP 
protein PmGH of Persephonella marina was recently solved, revealing a possible 
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mechanism for PDE activity (105). The authors proposed a two step model. First cdiGMP 
is linearized to pGpG, which is then rotated in the active site for hydrolysis of the second 
phosphodiester bond. Although not as numerous or well-characterized as the EAL 
domain PDEs, HD-GYP domains define a second class of cdiGMP PDEs with distinct 
mechanistic features creating further complexity in cdiGMP elimination.  
1.4.3 Enzymes Containing Both GGDEF and EAL Domains 
 One further aspect of complexity in cdiGMP metabolism is the common 
occurrence of both GGDEF and EAL domains in a single hybrid protein. Bioinformatic 
analysis has revealed that 68% of EAL domains are associated with a GGDEF domain, 
and 40% of GGDEF-domain proteins also contain an EAL domain (106). One possibility 
for these hybrid GGDEF/EAL-domain proteins is that one or both domains may be 
inactive, thereby preventing paradoxical biochemical activities. Analysis of catalytic 
residue conservation in hybrid GGDEF/EAL-domain proteins suggests that PDE activity 
is typically conserved while approximately 40% of GGDEF domains in hybrid proteins 
lack catalytic residues for DGC activity (106). In C. crescentus, CC3396 was shown to 
contain a degenerate GGDEF domain that retained GTP binding at the active site, but 
lacked DGC activity (96). Instead, GTP binding to the GGDEF domain promoted PDE 
activity of the C-terminal EAL domain, providing a potential mechanism of PDE 
regulation in response to cellular GTP levels. Another possibility is that both DGC and 
PDE activity are retained, but differentially-regulated. Several examples of bi-functional 
DGC/PDE enzymes have been described, including ScrC in Vibrio parahaemolyticus and 
BphG1 in Rhodobacter sphaeroides (107,108). The opposing DGC and PDE activities of 
ScrC and BphG1 are regulated by different mechanisms. ScrC is encoded in an operon 
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that also produces ScrA and ScrB. In the absence of ScrAB, ScrC demonstrates DGC 
activity, but in the presence of ScrAB, ScrC has PDE activity, providing dynamic 
switching between DGC and PDE activity (107). In contrast, BphG1 is a constitutive 
PDE with N-terminal red-light sensing and GGDEF domains. When expressed in E. coli, 
BphG1 was shown to be proteolytically cleaved resulting in the separation of the N-
terminal GGDEF and C-terminal EAL domains (108). The remaining N-terminal 
fragment possessed DGC activity that was strongly upregulated by exposure to red light. 
These results suggests a potential mechanism for irreversible transition from PDE to 
DGC activity, although endogenous proteolysis of ScrC has not been demonstrated in R. 
sphaeroides. In summary, proteins encoding GGDEF and EAL domains can exhibit both 
DGC or PDE activity, and these enzymatic activities are subject to a variety of regulatory 
mechanisms, creating further complexity in cdiGMP metabolism.   
1.4.4 cdiGMP Effectors with Conserved Binding Sites  
 The identification of cdiGMP effectors with conserved cdiGMP-binding domains 
has revealed the cellular targets and molecular mechanisms of cdiGMP regulated 
phenotypes (Figure 6). The I-site of GGDEF domains represents the first conserved 
cdiGMP-binding site identified for cdiGMP effectors. In catalytically-competent DGCs, 
the I-site binding provides feedback inhibition of cyclase activity (86). PopA of C. 
crescentus contains a GGDEF domain but lacks the conserved glycine and glutamate 
residues required for cdiGMP synthesis (109). However, purified PopA retains the ability 
to bind cdiGMP with high affinity at the I-site. The same study showed that PopA is 
sequestered to the cell poll to regulate C. crescentus cell cycle progression in a cdiGMP-




Figure 6. Complexity in cdiGMP signaling. cdiGMP is produced by DGCs and binds to I-sites to provide feedback inhibition. 
Multiple effector types bind cdiGMP, some with conserved binding sites, to regulate diverse cellular processes. Finally, cdiGMP is 
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cdiGMP-dependent cell cycle progression, demonstrating that PopA is a cdiGMP 
effector. Several other degenerate GGDEF-domain proteins have been identified that 
retain high-affinity cdiGMP-binding to regulate protein function, demonstrating that 
GGDEF domains that retain the RxxD motif in the I-site are a conserved class of cdiGMP 
effectors (110,111).  
 In addition to the I-site of GGDEF domains, catalytically inactive EAL domains 
that retain cdiGMP-binding represent a second class of cdiGMP effectors with a 
conserved cdiGMP-binding domain. The P. aeruginosa protein FimX contains a GGDEF 
and EAL domain, but lacks conserved residues for catalysis in both domains (112,113). 
Further studies revealed that FimX binds cdiGMP with high affinity and that binding is 
dependent on the EVL residues of the EAL domain (114,115). FimX was first studied for 
its role in assembly of type IV pili at cell poles (116). A ∆fimX mutant is unable to 
assemble type IV pili, which can be complemented by expression of wild type FimX, but 
not the non-binding EVL motif mutant (112). This suggests that cdiGMP-binding to 
FimX is essential for regulation of type IV pili biogenesis in P. aeruginosa. Several other 
proteins that bind cdiGMP with a non-catalytic EAL domain have been described, 
including LapD of P. fluorescens and YkuI of B. subtilis (117,118). Genetic and 
structural studies have demonstrated that cdiGMP-binding to the cytoplasmic EAL 
domain of LapD regulates proteolysis of a cell-surface adhesin (119,120). In total, these 
studies demonstrate that EAL domains lacking catalytic activity can be re-purposed as 
high affinity cdiGMP effectors with diverse regulatory functions.  
 The PilZ domain defines a third class of cdiGMP effectors that utilize a conserved 
cdiGMP-binding domain. In a seminal bioinformatic study, Amikam and Galperin 
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predicted that PilZ domains would bind cdiGMP based on PSI-BLAST identification of 
the PilZ domain in prokaryotic cellulose synthase (121). Notably, PilZ domains were 
absent in the closely related cellulose synthases of eukaryotes that lack cdiGMP 
regulation. After this report, the PilZ domain protein YcgR of E. coli was purified and 
shown to bind cdiGMP with high affinity in a manner that required conserved residues of 
the PilZ domain (122). YcgR had previously been characterized as a regulator of flagellar 
motility in E. coli, and genetic manipulation of DGCs and PDEs in S. typhimurium had 
revealed that flagellar motility was a cdiGMP-dependent phenotype (123,124). Deletion 
of the PDE YahA repressed flagellar motility in E. coli, and subsequent deletion of YcgR 
restored flagellar motility, suggesting that YcgR repressed flagellar motility in response 
to increasing cdiGMP concentrations. Complementation of a ∆yahA ∆ycgR E. coli strain 
with a cdiGMP-binding deficient ycgR allele failed to repress swimming motility, 
demonstrating that YcgR is a cdiGMP effector that binds cdiGMP using conserved 
residues of the PilZ domain (122). The ability to identify PilZ domains from primary 
sequence has since enabled the identification and characterization of numerous cdiGMP 
effectors in many organisms. For example, a PilZ domain was identified in the Alg44 
protein that regulates alginate biosynthesis in P. aeruginosa  (125). cdiGMP-binding to 
purified Alg44 required conserved residues in the PilZ domain and mutation of these 
residues abolished alginate biosynthesis in vivo (126). Similar results have been reported 
for numerous PilZ domain proteins, demonstrating that cdiGMP-binding and regulation 
of cdiGMP-dependent phenotypes are conserved features of PilZ domain proteins (127-
135). 
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 In addition to three classes of cdiGMP protein effectors with conserved binding 
domains, two classes of cdiGMP-binding RNA riboswitches have been described. 
Riboswitches are structured RNA, typically found in 5’ UTRs, that bind low molecular 
weight molecules to regulate gene expression (136,137). Class-I cdiGMP-binding 
riboswitches contain a GEMM motif and are widely distributed among proteobacteria 
(138). A Class-I cdiGMP-binding riboswitch from Clostridium difficile placed upstream 
of a β-galactosidase reporter was shown to regulate gene expression in response to 
changes in cellular cdiGMP concentrations (138). Class-2 cdiGMP riboswitches are 
mostly found in Clostridia, and are structurally distinct from Class-1 riboswitches, 
suggesting that they evolved independently (139). Intriguingly, the target sequence of a 
self-splicing ribozyme containing a Class-2 riboswitch was altered by cdiGMP-binding 
(139). A self-splicing ribozyme is a structured RNA molecule that can catalyze 
endonuclease cleavage and subsequent re-ligation of its own RNA strand (140). In the 
absence of cdiGMP, the ribozyme splicing removes 4 nucleotides of a putative ribosome 
binding site. cdiGMP-binding causes the ribozyme to splice upstream of the ribosome 
binding site, providing a potential mechanism for cdiGMP-dependent regulation of 
protein translation. Since their discovery the structure and biochemistry of these cdiGMP 
riboswitches has been intensely studied (141-147), but relatively little is known about 
their role in the regulation of cdiGMP-dependent phenotypes.  
 The I-sites of GGDEF domains, catalytically inactive EAL domains, PilZ 
domains, and RNA riboswitches all contain conserved motifs for binding cdiGMP. 
Bioinformatic identification of these motifs from primary nucleotide sequence has 
enabled identification and characterization of numerous cdiGMP effectors revealing the 
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cellular targets and molecular mechanisms of cdiGMP-regulated phenotypes. However, 
not all cdiGMP-dependent phenotypes are regulated by effectors containing these 
conserved binding domains.  
1.4.5 cdiGMP Effectors Lacking Conserved Binding Domains 
 Genetic and biochemical investigation of cdiGMP regulated phenotypes have 
identified cdiGMP effectors lacking conserved cdiGMP-binding domains. For example, a 
P. aeruginosa ∆fleQ mutant resulted in a rugose or rough colony morphology, which was 
indicative of increased PEL or PSL production (148-150). Alginate and cellulose 
production had previously been described as cdiGMP-dependent phenotypes, suggesting 
that FleQ may be required for cdiGMP-dependent exopolysaccharides (EPS) 
biosynthesis. FleQ was purified and shown to bind cdiGMP directly and transcriptional 
reporters of the pel and psl biosynthetic operons were shown to be upregulated in a fleQ 
mutant (148). Purified FleQ was shown to bind to the pel promoter in vitro, and the 
presence of cdiGMP in EMSA experiments prevented FleQ from binding the pel 
promoter (148). These studies suggested that cdiGMP-binding to FleQ prevents binding 
to the pel promoter, thus relieving transcriptional repression of the pel operon. However, 
DNAse footprinting studies have revealed a more complex mechanism of cdiGMP-
dependent FleQ regulation. In the absence of cdiGMP, FleQ binds at two sites in the pel 
promoter and FleQ interactions with FleN produce a bend in the DNA of the pel 
promoter that is proposed to inhibit transcription initiation (151). In the presence of 
cdiGMP, FleQ remains bound to the pel promoter, but the DNA is no longer bent and 
cdiGMP bound FleQ activity switches from a repressor to a transcriptional activator 
(151). Furthermore, cdiGMP and FleN have been shown to regulate ATPase activity of 
	   24	  
FleQ, which in homologous transcription factors regulates sigma factor-dependent 
transcription initiation (152). In total these studies suggest that transcriptional regulation 
by FleQ requires multiple regulatory factors, including FleN and cdiGMP. FleQ 
represents the first description of a cdiGMP-dependent transcription factor lacking a 
defined cdiGMP-binding domain, and its identification based on the regulation of 
cdiGMP-dependent phenotypes represents a general approach for the identification of 
cdiGMP effectors. 
 Biosynthesis of the PEL polysaccharide requires the 7-gene pel operon that is 
transcriptionally regulated by both cdiGMP-binding to FleQ and a RetS-dependent 
signaling pathway (148,153). Despite similar transcriptional induction of pel, 
biosynthesis of PEL via the RetS pathway was significantly reduced in comparison to 
regulation by cdiGMP (154). This suggested there may be cdiGMP-dependent post-
transcriptional regulation of PEL biosynthesis, but no cdiGMP-binding domains could be 
identified in Pel proteins. Purification of the 7 proteins of the pel operon and subsequent 
biochemical analysis revealed that PelD specifically bound cdiGMP with high affinity 
(154). Alignment of PelD homologs revealed a RxxD motif similar to the I-site of 
GGDEF domains and conserved secondary structural features between PelD and the 
DGC PleD. Mutation of the RxxD motif prevented cdiGMP-binding in vitro and 
cdiGMP-binding mutants failed to complement PEL biosynthesis in a pelD mutant strain, 
suggesting that PelD is a cdiGMP effector (154). While PelD lacks a recognizable 
GGDEF domain based on primary sequence information, crystallization has revealed that 
the C-terminus adopts a similar structure to GGDEF domains of active DGCs with 
alterations of several conserved secondary structures (155,156). Thus, PelD probably 
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evolved from a degenerate DGC that maintained structural features of the GGDEF 
domain and the RxxD I-site motif to bind cdiGMP and thereby regulate PEL 
biosynthesis. 
 In addition to PelD and FleQ, several other cdiGMP-dependent transcription 
factors have been identified that lack a canonical cdiGMP-binding domain. A CRP-like 
transcription factor (Clp) has been identified in X. campestris (157). Both Clp and 
cdiGMP were known to regulate pathogenesis of X. campestris, and X. campestris lacked 
an adenylate cyclase, suggesting that Clp did not respond to cAMP (158,159). 
Purification and biochemical analysis of Clp revealed high affinity cdiGMP-binding that 
regulated Clp binding to DNA binding, demonstrating that Clp is a cdiGMP effector. In 
addition to Clp, three cdiGMP-binding transcription factors have been identified in V. 
cholerae. A FleQ homolog FlrA, was recently shown to bind cdiGMP and regulate 
flagellar transcription in V. cholerae (160). Similar to PEL regulation in P. aeruginosa, 
cdiGMP regulates transcription of the Vibrio Polysaccharide (VPS) biosynthetic operon 
vps, but in contrast to FleQ, loss of flrA does not affect cdiGMP-dependent vps 
transcription (160-164). Instead, cdiGMP-dependent vps transcription is mediated by 
VpsR and VpsT, which were shown to bind cdiGMP after the discovery of their 
regulatory role in vps transcription (165,166). Interestingly, FleQ, VpsR, and FlrA are all 
members of the NtrC family of enhancer-binding proteins containing a N-terminal Rec 
domain, a central AAA+ ATPase domain, and a C-terminal DNA binding domain (167). 
For both FleQ and FlrA, cdiGMP-binding requires residues in the AAA+ ATPase 
domain, while the location of cdiGMP-binding to VpsR has not been investigated 
(152,160,165). These results suggest that there may be a conserved cdiGMP-binding site 
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among the NtrC family of enhancer-binding proteins, but conserved residues required for 
cdiGMP-binding have yet to be reported.  
 The identification of cdiGMP-dependent phenotypes that are not regulated by 
known cdiGMP effectors suggests that more cdiGMP effectors await discovery. For 
example, a single PilZ-domain protein PlzA has been described for the causitive agent of 
lyme disease, Borrelia burgdorferi. B. burgdorferi encodes a single DGC Rrp1 that is 
required for survival in the tick vector, but the only known cdiGMP effector PlzA is not 
required for surivival (168-171). Thus, it appears that in addition to PlzA, the cdiGMP 
signal from Rrp1 must have another unidentified effector in B. burgdorferi. Similarly in 
V. cholerae, cdiGMP regulates a number of phenotypes, including transcription of ctxAB 
encoding cholera toxin (172). PDE activity of VieA has been shown to reduce cellular 
cdiGMP levels that results in the expression of ctxAB (173). However, genetic studies 
have indicated that neither the three cdiGMP-binding transcription factors nor the five 
PilZ domain proteins of V. cholerae are required for cdiGMP-dependent repression of 
ctxAB transcription (95,127,165). In addition to ctxAB, several other cdiGMP-dependent 
promoters have been described that are not regulated by a known cdiGMP-dependent 
effector in Vibrio cholerae (160). These studies indicate that known cdiGMP effectors 
are not sufficient to explain observed cdiGMP-dependent phenotypes suggesting that 
more effectors remain to be discovered. 
 In subsequent chapters, I will describe the differential radial capillary action of 
ligand assay (DRaCALA) as a novel biochemical assay of protein-ligand interactions. In 
Chapter 2, I will show that DRaCALA can detect specific binding between proteins and 
nucleotides. DRaCALA can determine specificity, affinity, and kinetics of purified 
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protein ligand interactions and detect specific cdiGMP-binding to heterologously 
expressed proteins in E. coli whole cell lysates. In Chapter 3, DRaCALA will be used to 
screen a Vibrio cholerae open reading frame library to systematically identify cdiGMP-
binding proteins with positive hits encoding both characterized and novel cdiGMP-
binding proteins. Finally, Chapter 4 extends DRaCALA beyond protein interactions with 
small RNA oligonucleotides by demonstrating its ability to determine protein-DNA, 
protein-RNA, and RNA-ligand binding interactions. Overall, this dissertation describes 
the DRaCALA assay and its varied uses in exploring the genetic and molecular basis of 
biological regulation by nucleotide signaling molecules. 
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Chapter 2: Differential Radial Capillary Action of Ligand Assay for 
High-throughput Detection of Protein-Metabolite Interactions 
2.1 Introduction 
 Interactions of low molecular weight ligands with protein receptors are critical in 
biological signaling both between cells and within individual cells. Examples of 
intercellular signaling include quorum signaling in bacteria, hormone and 
neurotransmitter responses in endocrine systems of animals, and auxin and abscisic acid 
regulation in plants (174). Intracellular signaling also involves regulatory protein binding 
molecules such as secondary signaling molecules (e.g. cAMP, cGMP, calcium and 
cyclic-di-GMP (cdiGMP) (97,175). In fact, nucleotide receptors are often targets for 
therapeutic intervention (176). Thus, these protein-ligand interactions have important 
implications in modern drug design and use. As each protein-ligand interaction pair may 
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represent a possible therapeutic intervention, there is an urgent need to collect qualitative 
and quantitative functional metabolomic data for protein-ligand interaction in a high 
throughput manner. Current efforts in metabolomics are directed at cataloging the 
presence of various metabolites through mass spectrometric analysis of biological 
samples (177-180). However, this approach lacks the ability to confirm interactions with 
protein partners, and therefore fails to reveal functional significance. Thus, the study of 
the interactions of a specific metabolite with all available cellular proteins, which we 
term “metabolite interactomics,” has been limited by the available assay systems. Current 
assays for specific protein-ligand interactions, including equilibrium dialysis, filter-
binding assays, ultracentrifugation, isothermal calorimetry (ITC), surface plasmon 
resonance, and many other assays (181-186), are not high throughput because they are 
limited by sample processing time, equipment requirements, and assay-specific 
manipulations. Protein array technology requires purified proteins fixed on solid support 
(187). Although protein array technology is feasible and quite powerful (188-190), large-
scale protein purification is limited by individual protein characteristics that often hinder 
isolation of functionally active proteins. Currently, protein array technology is limited to 
only a few laboratories capable of performing mass parallel purification of functional 
proteins and arraying them. To bypass such constraints of existing assays, we have 
developed a high-throughput differential radial capillary action of ligand assay 
(DRaCALA) that can be used to detect binding and to quantitate the fraction of a small-
molecule ligand that is bound to a protein of interest. DRaCALA is rapid and 
quantitative, and it allows detection of protein-ligand interactions for both purified 
proteins and proteins expressed in whole cells, thus bypassing the requirement for protein 
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purification. Unlike most comparable protein-ligand detection systems, DRaCALA does 
not require a wash step; thus, the total ligand available to protein is quantifiable, resulting 
in an accurate, simple, and precise measure of the fraction of ligand bound. 
2.2 Principle of DRaCALA 
DRaCALA exploits the ability of nitrocellulose membranes to sequester proteins 
preferentially over small molecule ligands. When a mixture of protein and radiolabeled 
ligand is spotted onto a dry nitrocellulose membrane, protein and bound ligand are 
immobilized at the site of contact, whereas free ligand is mobilized by capillary action 
with the liquid phase (Figure 7A). DRaCALA is a rapid assay because the capillary 
action can be completed in less than 5 s. Also, since DRaCALA does not use a wash step, 
the pattern of ligand migration allows rapid detection of both the total ligand and the 
ligand sequestered by proteins. Capillary action distributes the unbound ligand 
throughout the mobile phase, the calculation for the fraction bound (FB) must correct for 
this background (see below for edge effects at the solvent front and annulation of the 
protein). Therefore, FB is defined by the equation in Figure 7B, where Iinner is the intensity 
of signal in the area with protein (inner circle) and Itotal is the intensity of total signal of 
the entire sample (outer circle). The Iinner signal consists of both ligand bound to protein 
and unbound ligand that has not mobilized beyond the area of the inner circle, which we 
define as Ibackground. Ibackground can be calculated by subtracting the Iinner from the total 
ligand Itotal and adjusting for the relative areas of the inner (Ainner) and outer (Atotal) circles 
(Figure 7B). For free ligand alone, the signal for the ligand is not sequestered, and 
therefore has a baseline FB of 0.01 ± 0.04 (Figure 8A), whereas protein alone does not 
mobilize on nitrocellulose (Figure 8B). Herein, we demonstrate the uses of DRaCALA 
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Figure 7. Principle of DRaCALA. (A) Schematic representation of DRaCALA assay on 
application of protein-ligand mixture onto nitrocellulose and capillary action. Protein (P), 
ligand (L), and protein–ligand complex (P•L) distribution during the assay is shown. (B) 
Equations are used to analyze DRaCALA data for FB for purified proteins. An 
explanation of the apparent edge effect at the capillary migration front is provided in 
Figure 12. 
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Figure 8. Proof of principle for DRaCALA. (A) Ligand distribution in the absence of 
protein when spotted on nitrocellulose. (B) Coomassie-stained MBP immobilized on 
nitrocellulose. Pencil marks were drawn before staining to indicate the darker protein 
spot and total capillary action. (C) DRaCALA image of E. coli BL21(DE3) whole-cell 
lysates overexpressing MBP or MBP-Alg44PilZ incubated with 8 nM 32P-cdiGMP and 
spotted onto nitrocellulose. (D) Graph of DRaCALA spots from Figure 8C. 
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for rapid detection of metabolite binding to proteins and describe potential uses for 
identification of unknown interactions and pharmaceutical screening of protein agonists 
and antagonists.  
2.3 DRaCALA Detection of Protein-Ligand Interactions 
 The principle of DRaCALA was illustrated by measuring ligand binding to 
known nucleotide binding proteins: Pseudomonas aeruginosa Alg44PilZ binds cdiGMP 
(191), Escherichia coli cyclic AMP receptor protein (CRP) binds cAMP (14,192), and E. 
coli nitrogen regulator B (NtrB) binds ATP (193). Radiolabeled ligands were incubated 
with each of the proteins, and the mixtures were spotted on a nitrocellulose membrane. 
After spreading by capillary action, membranes were dried and quantitated using a 
phosphorimager. Maltose binding protein (MBP), which does not bind to any of these 
small molecules, was used as a control. As expected, each of the radiolabel signals from 
MBP mixtures was distributed by capillary action (Figure 9A). CRP specifically bound 
cAMP, as demonstrated by the sequestration of the signal, but it did not bind cdiGMP or 
ATP (14,192) (Figure 9A). NtrB bound ATP, but not cdiGMP or cAMP (193) (Figure 
9A). Similarly, Alg44PilZ bound cdiGMP, but not cAMP or ATP (191) (Figure 9A). The 
specificity of Alg44PilZ binding to cdiGMP was further tested by competition with excess 
unlabeled nucleotides (400-fold molar excess relative to the Alg44PilZ protein). Alg44PilZ 
binding to 32P-cdiGMP was abolished by cdiGMP but not by cGMP, GMP, GDP, GTP, 
ATP, CTP, or UTP as was previously described (Figure 9B). Unlabeled cdiGMP was 
synthesized by Dr. Herman Sintim and Jingxin Wang. The FB for cdiGMP was 0.47 ± 
0.01, which was reversed by competition with unlabeled cdiGMP to the background level 
of 0.03 ± 0.01 (Figure 9C). 
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Figure 9. Detection of specific protein-ligand interactions by DRaCALA. (A) 
DRaCALA images of interactions between purified proteins (20 µM) incubated with 500 
nM 14C-cAMP, 4 nM 32P-ATP, or 4 nM 32P-cdiGMP. Protein- ligand mixtures were 
spotted on nitrocellulose and allowed to dry before imaging using a Fuji FLA7100 
PhosphorImager. Cognate protein-nucleotide combinations are indicated by arrowheads. 
MBP was used as a negative control. (B) DRaCALA images of competition assays 
assessing the ability of 1 mM indicated cold nucleotides to compete with binding 
interactions be- tween 4 nM 32P-cdiGMP and 2.5 µM HisMBP-Alg44PilZ. (C) Graph of FB 
for each sample in Figure 9B, with averages indicated by a horizontal bar. NC, no 
competitor. P values were determined by a Student t test for significant differences 
compared with the NC control for three independent experiments. The Itotal of each 
DRaCALA spot in Figure 9 A and B is provided in Table 9 and Table 10 (see Appendix 
A), respectively. Unlabeled cdiGMP was synthesized by Dr. Herman Sintim and Jingxin 
Wang. 
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2.4 Use of DRaCALA to Quantitate Protein-Ligand Interactions 
 In addition to qualitative assessments of specific protein-ligand interactions, 
DRaCALA is useful for quantitating biochemical parameters, including the dissociation 
constant (Kd) and the dissociation rate (koff). The Kd can be measured by altering either 
the protein or ligand concentration in titration experiments; because DRaCALA detects 
only the ligand mobility, ligand concentrations are always held constant. As an example, 
the Kd of Alg44PilZ binding to cdiGMP was determined by analyzing mixtures of 4 nM 
32P-cdiGMP with 0.006–100 µM Alg44PilZ (Figure 10A). At concentrations of protein 
above the Kd, the FB approaches saturation; this binding decreases as the Alg44PilZ 
concentration is decreased, reaching a level indistinguishable from background at the 
lowest protein concentrations. Analysis of this binding curve indicated that Kd = 1.6 ± 0.1 
µM, which is in reasonable agreement with our previously reported value of 5.6 µM 
determined by ITC (191) (Figure 10B). Application of identical samples to the dot blot 
apparatus for a vacuum-mediated filter-binding assay resulted in problems associated 
with high protein concentrations and, as a consequence, difficulty in assessing saturation 
of binding (Figure 11). Because the assay is completed in less than 5 s, DRaCALA can 
also be used to determine the koff for those protein–ligand complexes with slower off 
rates. The koff was determined for cdiGMP and Alg44PilZ by spotting at the indicated time 
points after the addition of 1 mM unlabeled cdiGMP to a preincubated mixture of 
Alg44PilZ and 32P-cdiGMP (Figure 10C). The fractions bound were plotted against time 
and analyzed by nonlinear regression, which yielded a koff of 0.017 ± 0.002 s−1, 
corresponding to a t1/2 of 35.6 ± 10.7 s (Figure 10D). The binding of 32P-cdiGMP to 
Alg44PilZ was completely competed away by 1 mM unlabeled cdiGMP within 90 s.  




Figure 10. Determination of Kd and koff by DRaCALA. (A) DRaCALA images were 
used for Kd determination for the interaction of Alg44PilZ and cdiGMP. His-MBP- 
Alg44PilZ was varied from 100 µM to 6 nM, and the 32P-cdiGMP was held constant at 4 
nM. Representative images of six sets of DRaCALA experiments are shown for 40 nM to 
25 µM Alg44 protein. (B) FB from data in A were plotted as a function of [MBP-
Alg44PilZ], and the best-fit line was determined by nonlinear regression using the 
indicated equation. A no-protein control was also plotted. The fitting program varied both 
Kd and Bmax to obtain the best fit, indicated by the solid line. (C) koff was determined by 
spotting protein-ligand mixtures onto nitrocellulose at various times after the addition of 
1 mM cold cdiGMP to a mixture of 4 nM 32P-cdiGMP and HisMBP-Alg44PilZ. (D) Time 
course of decrease of FB from analysis of the data in C was fitted to a single exponential 
decay, indicating koff. The Itotal of each DRaCALA spot in Figure 10 A and C is provided 
in Table 11 and Table 12 (see Appendix A), respectively. Unlabeled cdiGMP was 
synthesized by Dr. Herman Sintim and Jingxin Wang. 
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Figure 11. Dot-blot analysis of cdiGMP-binding to Alg44PilZ. MBP-Alg44PilZ at the 
indicated concentration was mixed with 4 nM 32P-cdiGMP and incubated for 10 min. 
Samples were applied to the dot apparatus and washed with 10 mM Tris (pH 8.0) and 100 
mM KCl. The filter was dried and exposed to the phosphorimager screen. (A) Image of 
the dot-blot experiment performed in triplicate. (B) 32P counts graphed against each 
concentration of Alg44PilZ. 
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Occasionally, we observed an increased signal at the leading edge of the capillary action 
and in the protein portion of the DRaCALA spot. Both edge and annulation effects are 
explained in Figure 12. The edge effect is attributable to evaporation of the solvent 
during the time of the experiment, and it is dependent on the humidity of the local 
environment around the nitrocellulose support. The evaporation results in a smaller total 
area (Atotal observed in Figure 12A) and leads to an increased value in the calculated 
Ibackground. As a secondary correction for the edge effect, the FB determined for spotted 
ligand in the absence of protein can be subtracted from all samples in parallel (Figure 
12B). The annulation effect does not alter the FB calculation (Figure 12C). Results from 
these experiments demonstrate the utility of DRaCALA for rapid and precise quantitation 
of biochemical parameters. 
2.5 DRaCALA Detection of Ligand-Binding Proteins in Whole Cells 
 A major limitation of most biochemical assays is the requirement for purified 
protein. We asked whether DRaCALA could be applied to crude extracts to overcome 
this limitation. Alg44PilZ binding to cdiGMP requires a number of conserved residues, 
including R17, R21, D44, and S46, in the PilZ domain of the protein (191). E. coli 
BL21(DE3) expressing Alg44PilZ and variants with R21A, D44A, S46A, and R17A/R21A 
substitutions were lysed and tested for binding to cdiGMP using DRaCALA. Protein 
extracts from E. coli expressing MBP alone did not bind cdiGMP (Figure 8 C and D). 
Only the whole-cell lysates from E. coli expressing WT Alg44PilZ sequestered 32P-
cdiGMP (Figure 13A). Specificity of 32P-cdiGMP sequestration in the background of all 
other cellular macromolecules was demonstrated by competition with 1 mM unlabeled 
specific competitor cdiGMP or the nonspecific competitor GTP. A significant difference  
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Figure 12. Edge and annulation effects of DRaCALA. (A) Schematic for the basis of 
the edge effect attributable to evaporation. obs, observed. (B) Correction factor for the 
edge effect. (C) Schematic indicating the basis of the annulation of the protein signal. P, 
protein; L, ligand; P•L, protein–ligand complex. 
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between the bound fractions for cdiGMP or GTP competition experiments was detected 
for the WT Alg44PilZ but not for the PilZ domain mutants (Figure 13 A and B). The 
results from whole-cell lysates are in agreement with the results obtained with purified 
proteins (191) (Figure 13B). The sensitivity of DRaCALA detection of MBP-Alg44PilZ 
binding to cdiGMP was tested by testing serial dilutions of purified protein alone or in 
the presence of BL21(DE3) whole-cell lysates. The results show that the binding of 
cdiGMP by MBP- Alg44PilZ is not affected by the presence of cellular proteins (Figure 
13C). Furthermore, serial dilution of extracts from BL21(DE3) cells expressing MBP- 
Alg44PilZ also resulted in a similar binding curve for comparable levels of MBP- 
Alg44PilZ proteins (Figure 13C and Figure 14). A common problem during expression of 
heterologous protein in a foreign host is that the protein is often insoluble and forms 
inclusion bodies. Expression of both Alg44PilZ and PelD without the MBP tag resulted in 
insoluble proteins (Figure 15A). We tested the whole-cell extracts with soluble and 
insoluble proteins and found that either form of the protein can specifically sequester 
cdiGMP by DRaCALA (Figure 15 B and C). Serial dilution of the whole-cell extracts 
reduced cdiGMP sequestration to background levels for BL21 whole-cell extracts (Figure 
15D). The ability to detect protein-ligand interactions in whole-cell lysates makes 
DRaCALA amenable to high-throughput analysis of whole-cell lysates for the presence 
of ligand-binding proteins. 
2.6 DRaCALA Detection of cdiGMP-Binding Proteins in Diverse Prokaryotic and 
Eukaryotic Organisms 
 The applicability of DRaCALA to high-throughput metabolite interactomics was 
demonstrated by screening for binding proteins of an important secondary signaling  
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Figure 13. Detection of specific protein-ligand interaction in whole-cell lysates by 
DRaCALA. (A) Images of Alg44PilZ interaction with 4 nM 32P-cdiGMP and either 1 mM 
cold cdiGMP or GTP with purified proteins or when expressed in E. coli BL21(DE3). C, 
cdiGMP; G, GTP. (B) Graph of 32P-cdiGMP-binding by whole-cell lysate samples (open 
circles) and purified proteins (triangles) in Figure 13A, with the average indicated by a 
horizontal bar. P values were determined by a Student t-test for significant differences 
compared with the no-competitor control for three independent experiments. The Itotal of 
each DRaCALA spot in Figure 13B is provided in Table 13 and Table 14 (see Appendix 
A). Unlabeled cdiGMP was synthesized by Dr. Herman Sintim and Jingxin Wang. (C) 
Graph of 32P-cdiGMP-binding by purified MBP-Alg44PilZ, purified MBP- Alg44PilZ 
added to BL21 whole-cell lysates, and whole-cell lysates of BL21(DE3) overexpressing 
MBP- Alg44PilZ. Protein concentrations were determined by separation on SDS/PAGE 
and staining with Coomassie blue (Figure 14).  
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Figure 14. Protein pattern of purified and expressed MBP-Alg44PilZ. Coomassie-
stained PAGE of two-fold serial dilutions of MBP-Alg44PilZ as a purified protein in 
cdiGMP-binding buffer (A), a purified protein added to BL21 whole cell lysate (B), or an 
overexpressed protein in BL21 cells (C). whole cell lysate, whole-cell lysate. The protein 
concentration for the purified protein in A and B was determined as described in 2.8 
Materials and Methods. The protein concentrations of the MBP-Alg44PilZ in whole-cell 
lysates in C were estimated based on comparison with A and B. 
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Figure 15. Binding of cdiGMP to whole-cell lysates expressing soluble or insoluble 
cdiGMP-binding proteins. (A) BL21(DE3) cells expressing the indicated proteins were 
analyzed by PAGE and Coomassie staining of whole-cell (WC) and soluble (S) fractions. 
Arrows indicate the overexpressed protein of the correct molecular weight in whole-cell 
lysates. Molecular weights of proteins are indicated on the left in kilodaltons. (B) Spots 
of BL21 cells overexpressing the indicated proteins were assayed for 32P-cdiGMP-
binding by DRaCALA when competed (comp.) with unlabeled cdiGMP or GTP as 
indicated. Unlabeled cdiGMP was synthesized by Dr. Herman Sintim and Jingxin Wang. 
(C) Quantification of the data shown in B. (D) Binding of 32P-cdiGMP to various 
dilutions of lysates of BL21(DE3) cells expressing the indicated proteins.  
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dinucleotide, cdiGMP. Recent findings have identified cdiGMP as the signaling molecule 
that controls biofilm formation, motility, and a number of other bacterial functions 
(97,175,194-196). Although the enzymes known to synthesize and degrade cdiGMP are 
restricted to bacteria, there are questions as to which bacterial species express cdiGMP-
binding proteins. cdiGMP has also proven to be useful as an adjuvant during 
immunization to enhance the mammalian immune response (197), which suggests that 
there may be cdiGMP-binding proteins in higher eukaryotes. We used DRaCALA to test 
191 strains of P. aeruginosa and a panel of 61 other species in a 96-well plate format. As 
a control for specificity, each extract was tested for binding to the labeled ligand by 
competition with the unlabeled specific or nonspecific ligand. As in the example of 
whole-cell lysates of E. coli, unlabeled GTP competitor was used to detect specific 32P-
cdiGMP-binding [bound during GTP competition (BG)] and unlabeled cdiGMP 
competitor was used to detect nonspecific 32P-cdiGMP-binding [bound during cdiGMP 
competition (BC)] (Figure 16A). The ratio of BG to BC is called specific binding (BSp). 
The limit of nonspecific binding was calculated by adding 2 SDs to the average BC, 
resulting in a conservative cutoff value for a positive BSp value of 1.17 (Figure 16A and 
Table 15 (see Appendix A)). Of the 191 P. aeruginosa isolated from various sources, 184 
(96%) displayed a positive BSp value greater than 1.17 (96 samples shown in Figure 16B 
and all data presented in Table 15 (see Appendix A)). These results suggest that most P. 
aeruginosa strains express detectable levels of cdiGMP-binding proteins. When strains 
isolated from different sources were analyzed for cdiGMP-binding, all groups had an 
average BSp value greater than 1.48, suggesting that cdiGMP signaling is retained (Figure 
17 and Table 15 (see Appendix A)). The range of cell lysate concentrations required for  
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Figure 16. Analysis of cdiGMP-binding proteins in various organisms. BSp values of 
whole-cell lysates are shown as a heat map using the range indicated in the legend. (A) 
Equations used to analyze DRaCALA data for BSp for whole-cell lysates or tissue 
extracts. (B) Plate 1 is the analysis of cdiGMP-binding by lysates from P. aeruginosa 
isolates. Specific strains discussed in the text are indicated by arrows. Sources of all 
strains in plates 1 and 2, as well as the raw data for each lysate, are shown in Table 15 
(see Appendix A). (C) Plate 3 is the analysis of cdiGMP-binding by lysates from various 
organisms. Plate numbers, column numbers, and row letters correspond to the strains and 
organisms listed in Table 15 and Table 16 (see Appendix A). Unlabeled cdiGMP was 
synthesized by Dr. Herman Sintim and Jingxin Wang. 
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Figure 17. BSp distribution of P. aeruginosa strains from different sources. BSp values 
of 32P-cdiGMP for P. aeruginosa isolates of different origins, with mean and SD, are 
shown. The mean ± SD is noted above each group; no significant differences were 
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consistent signal detection was tested by diluting cell extracts to 10–60 absorbance (280  
nm) units in intervals of 10. Each lysate dilution yielded similar BSp values, suggesting 
that this range of cell lysate concentration provides a reliable readout for the detection of 
cdiGMP-binding (Figure 18). 
 One potential complicating factor is the effect of cdiGMP metabolism and 
endogenous cdiGMP levels on the DRaCALA readout. Extracts of the laboratory P. 
aeruginosa strain PA14 overexpressing either the PDE RocR (198) or the DGC WspR 
(89) were tested for their ability to bind cdiGMP. WT PA14 showed a BSp value of 1.27 
indicating that cdiGMP-binding proteins are not fully occupied by endogenous cdiGMP 
consistent with what is expected for signaling systems (F12 of plate 1 of Figure 16B and 
Table 15 (see Appendix A)). Increasing the cellular cdiGMP concentration through 
WspR overexpression decreased the BSp value to 1.19 (D12 of Figure 16B and Table 15 
(see Appendix A)). Reducing cellular cdiGMP through RocR overexpression increased 
the BSp value to 3.51 (A12 in Figure 16B and Table 15 (see Appendix A)). The amount of 
cdiGMP sequestered by a whole-cell extract should reflect the amount and affinity of the 
binding proteins present. This was tested by overexpression of RocR in the PA14ΔpelD 
background, which lacks the cdiGMP-binding protein PelD (199). Without PelD, the BSp 
value was reduced to 2.70 (B12 in Figure 16B and Table 15 (see Appendix A)), 
indicating that PelD is an important binding protein for cdiGMP and that other proteins 
also bind cdiGMP (191,199). These results indicate that endogenous cdiGMP metabolism 
affects but does not abolish the ability of DRaCALA to detect cdiGMP-binding proteins.
 cdiGMP signaling occurs in a wide variety of bacterial species but is not known to 
be present in Eukarya (200). We tested 54 bacterial species from 37 genus and 7  
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Figure 18. Effect of Dilution on Organism Whole Cell Lysate Binding. The effect of 
whole cell lysate A280 on organism Bsp was examined for eight representative strains 
examined in Figure 16. Four strains displaying a positive Bsp Delftia acidovorans 
(3_A12), Vibrio cholerae (3_A2), Pseudomonas aeruginosa (1_A10),  Pseudomonas 
aeruginosa (1_D10) and four strains displaying a negative Bsp Pseudomonas putida 
(3_B3), Proteus mirabilis (3_C3), Providencia stuartii (3_C4), Moraxella osloensis 
(3_F4) were diluted to have A280 = 60, 50, 40, 30, 20, or 10 as assessed by NanoDrop. 
The dotted line indicates the cutoff for specific binding of the whole cell lysate for 
cdiGMP, while the solid line indicates the positive cutoff for specific binding indicative 
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eukaryotic species, including protozoa, fungi, nematodes, plants, and mammals. Of the  
82 tested bacteria strains, 31 (38%) displayed a BSp value greater than 1.17. Included in 
the 31 positive samples are 21 species for which functional cdiGMP signaling has yet to 
be demonstrated, of which 4 species, Serratia marcescens, Pseudomonas alcaligenes, 
Pseudomonas diminuta, and Brevundimonas vesicularis, have not yet been sequenced 
(Figure 16C and Table 15 (see Appendix A)). We tested 6 bacterial species with 
sequenced genomes that do not have annotated DGCs, and all of them failed to sequester 
cdiGMP above the threshold. We also tested 8 eukaryotic species, none of which have 
annotated DGCs. Whole-cell extracts of protozoa, fungi, and nematodes displayed a BSp 
value below 1.17, indicating that cdiGMP-binding proteins are absent or below the limit 
of detection. Mammalian tissue extracts from rodent and human cell lines displayed high 
nonspecific binding with BC values greater than 3 SDs above the average BC value (> 
0.233; F6, E12, G12, and H12 in Figure 16C and Table S2.8). Furthermore, the 
nonspecific binding was eliminated after three twofold dilutions of these tissue extracts, 
indicating that mammalian tissues may contain receptors with low affinity or low 
abundance. Only positive BSp results from DRaCALA can be interpreted for utilization of 
cdiGMP signaling. As a result, DRaCALA is most effective in whole-cell extracts with 
low nonspecific binding. Utilization of DRaCALA in a high-throughput format has 
expanded our knowledge of the bacterial organisms harboring cdiGMP-binding proteins 
and confirmed the absence of abundant high-affinity cdiGMP-binding proteins in 
eukaryotes. 
2.7 Discussion 
 In this work, we have developed and characterized DRaCALA as a rapid and 
	   50	  
precise method for quantitatively measuring protein-ligand interactions. We show the 
utility of DRaCALA by using the example of cdiGMP-binding to Alg44PilZ as a proof of 
principle. The dissociation constant of 1.6 µM obtained by DRaCALA is similar to those 
obtained in previous studies using filter binding, ITC, and surface plasmon resonance 
assays (191,199). Previous studies of the dissociation rate of cdiGMP from Alg44PilZ 
were based on saturating the protein with radiolabeled cdiGMP and separating the 
protein–ligand complex from unbound cdiGMP over a Sephadex column. The t1/2 of the 
complex was estimated by filter binding as 5 min, in contrast to 35.6 ± 10.7 s as detected 
by DRaCALA. This discrepancy is likely attributable to two key differences between the 
two assays. First, DRaCALA is able to quantify the total signal directly in each sample. 
Because of the various separation steps required for the filter-binding assay, the total 
ligand in each sample is just assumed to be equivalent. For DRaCALA, the total signal of 
labeled ligand is known for each individual sample, therefore eliminating the need to 
assume that the total signal is equivalent. The ability to detect the total signal and FB 
significantly increases the precision of the measurement and reduces the error incurred 
from pipetting and other physical manipulations. Second, the processing times of the 
assays are dramatically different. The filter assay involved binding, separation of bound 
ligand from free ligand, filter binding, and the associated wash time, requiring at least 5 
to 10 min of processing time. DRaCALA directly assays the binding without prior 
processing or the subsequent wash steps. As a result, DRaCALA can be completed within 
5 to 30 s, depending on the volume of the sample spotted. Because all binding 
interactions have off-rates, the speed of the assay is critical to capture accurate data. 
Other techniques for determining biochemical interaction are also available, such as ITC 
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or surface plasmon resonance; however, these techniques require dedicated specialized 
instrumentation and individual processing of samples, resulting in longer assay time and 
lower throughput. An important feature of DRaCALA is that it will make biochemical 
approaches accessible to molecular and cellular biologists interested in precise and 
simple measurements of interactions between protein-ligand pairs of interest. The ability 
to determine koff, in addition to Kd, allows calculation of the on-rate. Differences in the 
koff can be useful in understanding biological processes, because interactions with similar 
affinities can result in distinct biological outputs. 
 As protein concentrations increase, fraction bound of the labeled ligand 
eventually saturates, with some fraction of the label unable to be immobilized by 
increasing protein concentration. There are three potential factors that contribute to the 
amount of label that cannot be immobilized in DRaCALA assays. First, some label may 
not be associated with the desired ligand. For example, during synthesis of 32P-cdiGMP, 
approximately 1 – 4 % of radiolabel is not associated with cdiGMP when assayed by thin 
layer chromatography. Second, labeled ligands may degrade over time and lose their 
ability to interact with cognate binding proteins. Label that is not associated with the 
appropriate ligand cannot be immobilized in the DRaCALA assay and likely contributes 
to saturating fraction bound < 1.0. A third potential factor affecting maximum fraction 
bound is that labeled ligands can dissociate from proteins during the DRaCALA assay 
time. During the time that liquid drops are wicked into the membrane, bound ligand can 
dissociate from immobilized protein. Ligand that dissociates during wicking will be 
mobilized away from the protein, thereby systematically reducing apparent fraction 
bound. The magnitude of this effect is expected to decrease with slower off-rates. 
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Supporting this idea, protein-ligand interactions with slow off-rates, such as the biotin-
streptavidin interaction presented in Chapter 4 with a half-life of 112 h achieves an 
apparent fraction bound close to 1.0. In contrast, the Alg44-cdiGMP complex has a half-
life of approximately 35 s, which is on the same scale as the time of the DRaCALA assay 
(5 - 10 s), and achieves a maximum fraction bound of  approximately 0.6. Thus, protein-
ligand interactions with off-rates that are faster or of the same magnitude as the assay 
time will have systematically decreased apparent fraction bound. Variations in maximum 
fraction bound likely do not affect quantification of dissociation constants and 
dissociation rates. Linear regression models used to determine these parameters do not 
assume a maximum fraction bound of 1.0 and measurements of  protein-ligand 
interactions with Alg44 (Chapter 2) and CRP (Chapter 4) closely match previous 
observations. 
 The principle of DRaCALA should be universally applicable to any system in 
which the ligand can be mobilized by capillary action in conjunction with a solid support 
capable of sequestering the macromolecule. Thus, the choice of the support, the solvent 
composition of the mobile phase, and the specific properties of the ligand can be altered 
to enhance the effectiveness of DRaCALA for various protein-ligand systems. In this 
paper, we have described the application of DRaCALA only for radiolabeled ligands; 
however, the principle of the assay should also apply to fluorescently labeled ligands. 
The solid support could also be changed to sequester other macromolecules based on 
their unique chemical properties. For example, nucleic acids can be retained by DEAE-
cellulose (183). The solvent composition could also be changed to alter the chemical 
properties of the mobile phase. Detergents, salts, and other agents may be added to alter 
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the relative behavior of the protein and ligand on the solid support. 
 Studies of numerous systems involving low molecular weight biological ligands 
and receptor macromolecules can benefit from DRaCALA, including nucleotide 
derivatives, amino acid derivatives, metal ions, sugars, and other small signaling 
molecules. The function of biological ligands can be specific to subset of organisms that 
produce or use these molecules. To identify biological samples that may be enriched in a 
specific ligand-binding protein, a similar approach to the screen for cdiGMP-binding 
proteins (Figure 16C) can be taken to identify model organisms for study of the ligand of 
interest. Alternatively, expression of ligand-binding proteins may be regulated. 
DRaCALA provides a method for rapidly screening a single organism grown in different 
conditions, as in phenotypic arrays, and a test for ligand binding activity. 
 The systematic identification of protein receptors for each of these small 
molecular ligands will allow for a comprehensive understanding of the biological effect 
of these signaling molecules, and DRaCALA offers a high-throughput platform that 
should greatly facilitate this process. Furthermore, the ability of DRaCALA to detect 
ligand binding in whole-cell extracts should allow for systematic screening of whole-
genome ORF libraries (ORFeomes) for proteins that bind various small molecules. 
Although the binding proteins have been overexpressed, the key parameter for detection 
is that the cellular concentration of expressed protein is greater than the Kd for the ligand. 
For proteins with low affinities, these interactions will be difficult to detect in whole cells 
similar to purified systems. DRaCALA is scalable, and it has been performed using both 
a standard single-channel pipette and an eight-channel multichannel pipette with equal 
precision and accuracy. Thus, DRaCALA could be easily adapted for high-throughput 
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applications by using a 96-well pin tool in combination with standard robotics. The 
volume required for the DRaCALA assay can be further reduced to allow for screening 
using the 384-well format. A current limitation of the whole cell-based DRaCALA 
system is the requirement to identify a cell that has low background expression of 
proteins that bind the ligand of interest. This problem can be solved using protein array 
technology (187-189,201,202). However, high-volume parallel protein purification 
requires specialized equipment, and it is difficult to assess the stability and functionality 
of all proteins on the chip. Nonetheless, DRaCALA and protein arrays can be viewed as 
complementary technologies. This is analogous to the identification of protein-protein 
interactions using the genetic/molecular biology approach of the yeast two-hybrid assay 
(203), which is complementary to the biochemical approach of mass spectrometric 
identification of co-precipitated proteins. An important advantage of DRaCALA is that 
insoluble proteins appear to have a similar behavior as soluble protein in whole-cell 
lysates, thus avoiding purification problems associated with insoluble proteins. 
 Development of DRaCALA as a high-throughput assay for the detection of 
protein-ligand interactions will be useful for identifying new targets for pharmaceutical 
intervention. To this end, DRaCALA might be used initially as a screening tool to 
identify new interaction pairs and then in a second round of DRaCALA to identify 
inhibitors that prevent the interaction. Labeling of the identified specific inhibitor would 
then allow for rapid sequential screening for even more potent molecules that can 
displace the original inhibitor. Our results show that DRaCALA can be developed as a 
platform to enable critical advances in metabolite interactomics and therapeutic 
intervention. 
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2.8 Materials and Methods 
Protein purification  
 pBAD-CRP was a generous gift from Dr. Sankar Adhya, and purified NtrB was a 
generous gift from Dr. Richard Stewart. E. coli strain BL21(DE3) harboring a modified 
pET19 expression vector (pVL847) expressing an N-terminal histidine-MBP-Alg44 were 
induced for 6 hours at 30 ˚C with 1mM IPTG. Induced bacteria were collected by 
centrifugation and resuspended in His Buffer A (10 mM Tris, 100 mM NaCl and 25 mM 
imidazole, pH8.0) and frozen at -80 ˚C until purification. After addition of DNase, 
lysozyme and PMSF (1 mM final concentation), thawed bacteria were lysed by 
sonication. Insoluble material was removed by centrifugation and the His-fusion protein 
was purified from the clarified whole cell lysate by separation over an Ni-NTA column. 
Proteins were subsequently purified and concentrated using anion exchange to a 
concentration of at least 100 µM, supplemented with 25% glycerol, and frozen at -80 °C 
until thawed for use.  
Detailed Protein Purification  
 His affinity purification: Clarified whole cell lysates were loaded onto a 10mL 
column containing Ni-Nta resin. The Ni-NTA column was washed with 120mL of His 
Buffer A to remove non-specifically bound proteins. Elution of the His-tagged protein 
was accomplished by linearly increasing the imidazole concentration from 25 to 250 mM 
over 30mL. Eluted proteins were pooled and dialysed twice against 40 volumes of 100 
mM NaCl, 10 mM Tris pH = 8.0.  
 Anion exchange purification: The dialyzed eluent from Ni-NTA was loaded onto 
an 5 mL Q-Sepharose anion exchange column, followed by a wash of 120 mL of 10 mM 
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Tris pH = 8.0 and 100 mM NaCl. Proteins were eluted by linearly increasing the 
concentration of NaCl from 100 mM to 500 mM over an 80 mL volume. Eluent fractions 
containing the protein of interest were pooled, dialysed twice against 40 volumes of 100 
mM NaCl, 10 mM Tris pH = 8.0, supplemented with 25% glycerol, and frozen at -80°C 
until thawed for use. Protein concentration was determined by absorbance 280 nm and 
calculated using predicted extinction co-efficient as determined by ProtParam program at 
the ExPASy website (http://expasy.org/tools/protparam.html). 
Radiolabeled nucleotides  
 14C labeled cAMP, γ-32P labeled ATP, α-32P labeled GTP were purchased from 
Perkin Elmer. cdiGMP was synthesized from α-32P labeled GTP by incubating overnight 
in 1X cdiGMP-binding Buffer with a constitutively active diguanylate cyclase 
WspR(D70E). Purity of cdiGMP was assessed by TLC and was greater than 98%. 
Differential Radial Capillary Assays 
 20 µl of protein or whole-cell lysates in 1x cdiGMP-binding buffer was mixed 
with 4 nM of radiolabeled nucleotide and allowed to incubate for 10 minutes at room 
temperature. Radiolabeled nucleotide was competed away by cold nucleotides in 
concentrations and for times indicated. 2-5 µl drops of these solutions were placed on 
dry, untreated nitrocellulose (GE Healthcare) in triplicate and allowed to dry completely 
before quantification. An FLA7100 Fujifilm Life Science Phosphorimager was used to 
detect luminescence following a 5-minute exposure of blotted nitrocellulose to 
phosphorimager film. Data was quantified using Fujifilm Multi Gauge software v3.0. 
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Whole-cell lysate preparation  
 BL21(DE3) cells expressing pVL847 (MBP), pVL882 (MBP-Alg44) or Alg44 
point mutations were induced for overexpression with 100 µM IPTG. All bacterial 
samples and eukaryotic tissue were collected and resuspended in one-tenth volume of 1X 
cdiGMP-binding Buffer (100 mM KCl, 5 mM MgCl2, 100 mM Tris, pH = 8.0 and 100 
µM PMSF). Bacterial samples were also supplemented with lysozyme and DNase. Cells 
were lysed by two 10-second sonication pulses with 1 minute recovery on ice or by bead 
beating using the Q-Bio lysis system. Extracts were flash frozen in liquid nitrogen and 
stored at -80 ˚C. After thawing, 10 µL of whole cell lysates were incubated with 8 nM 
32P-cdiGMP for 45 seconds prior to spotting 2 µL drops on nitrocellulose using an 8-
channel pipette. 
Detailed Whole-cell lysate preparation  
 Samples from Figure 16B and Table 15 (see Appendix A) excepting those listed 
below, were grown in LB broth at 37 ˚C with 200 rpm shaking. Samples 75, 90, 91 were 
grown on YPD plates at 30 ˚C; 74 on TSB plate in anaerobic chamber at 37 ˚C; 16, 58, 
67, 70, 79 in TSB broth at 37 ˚C; 83, 84, 85, 86 in THB broth at 37 ˚C; 20, 42, 46, 50, 89 
are tissue samples; 51 in Marine Media at 30 ˚C with shaking; 37 in LB broth 
supplemented with 1 M NaCl; 5, 6, 7, 49, 63 in LB broth at 30 ˚C; 93, 94, 95, 96 in 
DMEM F12 from Gibco (Catalog # 10565) supplemented with 10% FBS, 1& Penn/Strep, 
and 1% glutamine; 92 in a 50/50 mixture of Sigma Media 199 (Catalog #M7528) and 
Sigma Schneider’s Complete Media (Catalog #S0146) supplemented with 10%FBS, 1% 
glutamine, and 1% Penn/Strep; Sample 3G_11 Mycobacterium smegmatis (strain mc2 
155) was grown in modified 7H9 medium (DIFCO) as previously described (204); 
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Samples 3H_10 and 3A_11 Neisseria gonorrhoeae and 3B_11 Neisseria sicca were 
grown in phosphate-buffered gonococcal medium (Difco) supplemented with 20 mM d-
glucose and growth supplements in broth with addition of 0.042% NaHCO3 in a CO2 
incubator at 37°C (205). 
 All bacterial samples were collected by centrifugation and all tissues were 
collected by dissection and resuspended in one-tenth volume of 1X cdiGMP-binding 
Buffer (100 mM KCl, 5 mM MgCl2, 100 mM Tris, pH = 8.0 and 100 µM PMSF). 
Bacterial samples were also supplemented with lysozyme and DNase. Cells were lysed 
by two 10-second sonication pulses with 1 minute recovery on ice or by bead beating 
using the Q-Bio lysis system. Extracts were flash frozen in liquid nitrogen and stored at -
80 ˚C. After thawing, 10 µL of whole cell lysates were incubated with 8 nM 32P-cdiGMP 
for 45 seconds prior to spotting 2 µL drops on nitrocellulose using an 8-channel pipette. 
	   59	  
Chapter 3: Systematic Identification of Cyclic di-GMP Binding Proteins 
in Vibrio cholerae  
3.1 Introduction 
 Cyclic di-GMP (cdiGMP) is a ubiquitous prokaryotic nucleotide second 
messenger produced by members of every major bacterial phylum to regulate diverse 
cellular processes (78,206). cdiGMP is synthesized by diguanylate cyclases (DGCs), 
which encode a conserved GGDEF domain, and degraded by phosphodiesterases (PDEs) 
that contain either an EAL or HD-GYP domain (84,95,101). Individual organisms can 
encode dozens of DGCs and PDEs creating complex regulation of cdiGMP metabolism 
(79). Genetic manipulation of DGCs and PDEs has revealed numerous cdiGMP-
dependent phenotypes including biofilm formation, motility, cell cycle progression, and 
pathogenesis (94,124,173,207). The cdiGMP signal is sensed by protein and RNA 
effectors that bind cdiGMP to allosterically regulate effector activity. To understand how 
cdiGMP regulates these phenotypes, considerable effort has been spent identifying the 
cellular effectors of cdiGMP signaling. 
 cdiGMP effector proteins have been identified by bioinformatic, biochemical, and 
genetic approaches. Bioinformatics can identify proteins with conserved cdiGMP-binding 
domains, including the PilZ domain, the I-sites of GGDEF domains, and non-catalytic 
EAL domains that retain cdiGMP-binding activity (106,121). However, several cdiGMP 
effectors that lack a recognizable cdiGMP-binding domain have been identified by 
biochemical and genetic approaches. Genetic experiments can identify target proteins 
required for cdiGMP-dependent phenotypes, which can be subsequently purified and 
assayed for cdiGMP-binding (148,154). While this approach has been successful, several 
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constraints prevent the systematic identification of cdiGMP effectors. First, not all 
cdiGMP effectors display a phenotype under laboratory conditions. Second, cdiGMP-
dependent phenotypes can be complex with multiple effectors and regulation by specific 
DGCs and PDES. Finally, biochemical approaches for cdiGMP-binding protein 
identification rely on affinity pull down of endogenously expressed proteins or systematic 
purification of individual genomically-encoded proteins (187,208). However, not all 
cdiGMP-binding proteins are expressed in laboratory conditions and not all are able to be 
purified.  
 We have developed a differential radial capillary action of ligand assay 
(DRaCALA) and demonstrated its ability to detect cdiGMP-binding proteins when 
expressed at levels that exceed the dissociation constant of their respective complexes 
with cdiGMP in E. coli whole cell lysates (209). DRaCALA provides a rapid biochemical 
assay suitable for determining if an individual open reading frame (ORF) encodes a 
cdiGMP-binding protein. Overexpressing all annotated ORFs from a sequenced organism 
and testing each one for cdiGMP-binding activity provides a systematic approach to 
identifying cdiGMP binding proteins. This approach does not require protein purification, 
overcomes potentially low endogenous protein expression by driving the expression of 
individual proteins in a heterologous system, and provides a direct measure of cdiGMP 
binding instead of observing a cdiGMP-dependent phenotype. Several libraries 
representing the majority of genomically-encoded ORFs (ORFeomes) have been 
constructed for prokaryotic organisms that contain a cdiGMP signaling system (210-213). 
A Vibiro cholerae O1 El Tor N16961 library contains >98% of sequenced ORFs and thus 
represents the majority of genomically-encoded proteins of V. cholerae(213). V. cholerae 
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represents a model system for the study of complex cdiGMP signaling with genes 
encoding 41 GGDEF, 22 EAL, 9 HD-GYP, and 6 PilZ domains as well as 3 cdiGMP-
dependent transcription factors (79,127,160,165,166). However, several cdiGMP-
dependent phenotypes including expression of cholera toxin are not regulated by known 
cdiGMP-binding proteins, suggesting that more remain to be discovered (172). 
 Here we report the use of the DRaCALA screening to systematically identify 
cdiGMP-binding proteins from two V. cholerae protein expression libraries. Of these, we 
show that purified MshE binds cdiGMP and expression of a homologous ATPase 
PA14_29490 from P. aeruginosa also increases cdiGMP-binding in whole cell lysate. 
These results demonstrate the utility of a DRaCALA ORFeome screen for the 
identification of cdiGMP-binding proteins and suggest an expanded repertoire of cdiGMP 
regulated processes in V. cholerae. 
3.2 Systematic Identification of cdiGMP-binding Proteins in Vibrio cholerae 
 We sought to systematically identify protein effectors of cdiGMP by individually 
testing Vibrio cholerae ORFs (VC ORFs) in E. coli whole cell lysates for 32P-cdiGMP-
binding activity by DRaCALA. To overexpress the protein products of V. cholerae 
ORFs, we mobilized 3812 unique ORFs from the V. cholerae O1 El Tor N16961 
ORFeome into Gateway-compatible protein expression vectors (Figure 19) (214). To 
increase the probability of expressing proteins above their dissociation constant, we 
created two protein expression libraries producing either N-terminal histidine (His-ORF) 
or his-maltose binding protein (His-MBP-ORF) fusions. MBP fusions have been shown 
to increase protein solubility enabling a higher level of protein accumulation during 
overexpression (215). E. coli expressing individual ORF fusions were pooled by 
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Figure 19. Construction of Vibrio cholerae open reading frame expression libraries. 
The V. cholerae pDONR-ORF plasmids were miniprepped and recombined with 
pVL791Cb and pVL847Gm expression plasmids containing a Gateway destination 
casette with the ccdB counter-selection cell death gene. These reactions were transformed 
to E. coli expression strain and recombinants were selected on LB Agar plates containing 
carbenicillin or getamycin. Multiple CFU from agar plates were inoculated into liquid 
media in 96-well plates to create His-ORF and His-MBP-ORF libraries for DRaCALA 
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 streaking pipette tips through multiple transformants to facillitate inoculation of 96-well 
microtiter plates to create the His-ORF and His-MBP-ORF libraries. Multiple clones of 
individual recombination reactions and transformations were pooled to expedite 
inoculation of liquid culture from agar-selected transformants.  To determine if proteins 
were overexpressed, ~600 whole cell lysates were examined by PAGE with coomassie 
staining for the presence of an overexpressed protein band of the appropriate size. 
Approximately 50% of His-ORF and 75% of His-MBP-ORF fusions were identified by 
PAGE for a combined estimated coverage of 81% (data not shown). This is likely a 
conservative estimate of ORF coverage as DRaCALA can detect high affinity 
interactions in the absence of observable protein expression by coomassie staining. 
 To identify ORFs encoding cdiGMP-binding proteins, we analyzed whole cell 
lysates from His-ORF and His-MBP-ORF libraries by DRaCALA. We assume that the 
majority VC ORFs do not encode a cdiGMP-binding protein and therefore most whole 
cell lysates will demonstrate a background level of binding due to the presence of an 
endogenous cdiGMP signaling system in E. coli. To identify ORFs that significantly 
elevated fraction bound 32P-cdiGMP, we created a positive cutoff three standard 
deviations above the mean fraction bound of a 96-well plate of whole cell lysates. 
Positive ORFs were iteratively removed from calculations of mean and standard 
deviation, thereby decreasing the positive cutoff for individual plates until no additional 
positives were identified. This method provided different positive cutoffs for plates with 
different levels of background cdiGMP-binding and was able to identify PelD as a 
positive control in each plate. Based on this analysis, our primary screen identified 55 
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His-ORF and 47 His-MBP-ORF fusions whose expression significantly increased 32P-
cdiGMP in E. coli whole cell lysates (Table 17 in Appendix A).  
 Our primary screen of the VC ORF expression libraries may have identified false 
positives due to cross-contamination or random variation in whole cell lysate 
composition. Each primary screen whole cell lysate was generated from a pool of CFU 
expressing a single VC ORF inoculated into liquid culture. We deconvoluted this pool by 
testing 8 single colonies for cdiGMP-binding and verified ORF size by colony PCR. 
Typically, all clones from a given ORF produced either positive or negative fraction 
bound 32P-cdiGMP, although several instances of cross-contamination were identified by 
PCR. In total 23 His-ORFs and 21 His-MBP-ORFs (28 unique ORFs total) were 
identified that produced at least 7 of 8 whole cell lysates with significantly increased 
cdiGMP-binding and a PCR product of the correct size (Figure 20, Table 1). 
 To determine if cdiGMP-binding is specific, DRaCALA was performed on whole 
cell lysates generated from a sequence-validated clone in the presence of specific and 
non-specific unlabeled guanosine inhibitors (Table 2). Unlabeled cdiGMP significantly 
reduced 32P-cdiGMP-binding for all positive ORFs with the exception of His-MBP-
VCA0071 and His-MBP-VC2370, which did not significantly increase cdiGMP-binding 
in this assay. In contrast to cdiGMP competitor, unlabeled GTP and cGMP did not 
compete with 32P-cdiGMP-binding and for several proteins containing EAL domains, 
increased the fraction bound of 32P-cdiGMP. The lack of significant 32P-cdiGMP-
binding by VCA0071 and VC2370 in this particular assay may reflect decreased protein 
expression or other differences in whole cell lysate composition. In total, these results 
suggest that most positive VC ORFs express a protein product that specifically binds  
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Figure 20. Primary DRaCALA screen of Vibrio cholerae ORF libraries. Graph of 
average fraction bound 32P-cdiGMP vs. individual V. cholerae (A) His-ORFs and (B) 
His-MBP-ORFs overexpressed in E. coli whole cell lysates. ORFs are arranged by VC 
gene number along the X-axis. Validated positive ORFs are indicated by color and 
classified by type of cdiGMP-binding protein. Other refers to proteins that have not been 
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Table 1. Fraction bound of whole cell lysate from secondary screen of positive 
ORFs. Table of fraction bound 32P-cdiGMP generated by individual clones of V.c. ORFs 
identified as positive in primary screen. The cutoff for positive binding in this assay was 
at least 3 standard deviations above the average fraction bound for a set of 8 vector 
control clones. Clones with positive fraction bound are highlighted in green. 
His-ORF CFU 1 CFU 2 CFU 3 CFU 4 CFU 5 CFU 6 CFU 7 CFU 8 
VC0072 0.48 0.42 0.48 0.43 0.42 0.42 0.46 0.43 
VC0405 0.30 0.24 0.28 0.15 0.19 0.23 0.23 0.24 
VC0658 0.52 0.53 0.56 0.54 0.55 0.56 0.52 0.51 
VC0665 0.21 0.21 0.17 0.11 0.16 0.17 0.22 0.19 
VC0703 0.14 0.14 0.12 0.11 0.12 0.14 0.19 0.14 
`VC1295 0.43 0.43 0.51 0.46 0.46 0.50 0.47 0.49 
VC1308 0.16 0.11 0.23 0.08 0.13 0.17 0.12 0.18 
VC1348 0.42 0.46 0.44 0.46 0.47 0.43 0.45 0.44 
VC1370 0.32 0.34 0.42 0.41 0.38 0.41 0.43 0.35 
VC1641 0.53 0.53 0.57 0.56 0.57 0.58 0.59 0.53 
VC1652 0.30 0.29 0.32 0.33 0.34 0.34 0.35 0.30 
VC1710 0.35 0.38 0.44 0.43 0.42 0.44 0.40 0.36 
VC1934 0.12 0.11 0.11 0.11 0.10 0.08 0.10 0.10 
VC2344 0.56 0.52 0.58 0.56 0.57 0.56 0.54 0.55 
VC2370 0.21 0.17 0.26 0.19 0.17 0.19 0.23 0.23 
VC2529 0.14 0.16 0.13 0.12 0.13 0.11 0.14 0.16 
VCA0042 0.57 0.53 0.55 0.58 0.59 0.59 0.58 0.58 
VCA0210 0.18 0.16 0.17 0.19 0.17 0.20 0.18 0.18 
VCA0593 0.64 0.61 0.51 0.53 0.56 0.65 0.61 0.63 
VCA0681 No Growth 0.53 0.57 0.58 0.59 0.59 0.55 0.56 
VCA0931 0.28 0.20 0.38 0.38 0.37 0.40 0.39 0.37 
VCA0952 0.11 0.10 0.10 0.10 0.10 0.13 0.13 0.11 
VCA1083 0.55 0.51 0.50 0.52 0.49 0.53 0.53 0.55 
His-MBP-ORF 
       VC0072 0.51 0.50 0.49 0.49 0.47 0.47 0.48 0.46 
VC0405 0.22 0.17 0.19 0.16 0.12 0.14 0.16 0.16 
VC0658 0.55 0.51 0.52 0.50 0.48 0.50 0.50 0.48 
VC0703 0.16 0.15 0.19 0.16 0.16 0.13 0.14 0.12 
VC1295 0.56 0.55 0.55 0.57 0.58 0.50 0.53 0.51 
VC1348 0.55 0.54 0.54 0.55 0.55 0.52 0.52 0.52 
VC1370 0.17 0.19 0.26 0.20 0.21 0.19 0.24 0.21 
VC1641 0.51 0.48 0.50 0.48 0.49 0.50 0.53 0.50 
VC1710 0.37 0.30 0.35 0.35 0.38 0.37 0.37 0.35 
VC2066 0.21 0.16 0.16 0.12 0.17 0.14 0.15 0.17 
VC2344 0.53 0.47 0.51 0.50 0.47 0.49 0.50 0.49 
VC2370 0.30 0.27 0.28 0.25 0.24 0.25 0.22 0.23 
VCA0042 0.43 0.42 0.46 0.44 0.42 0.46 0.46 0.44 
VCA0071 0.14 0.13 0.15 0.13 0.15 0.14 0.16 0.15 
VCA0210 0.31 0.27 0.26 0.30 0.32 0.28 0.28 0.24 
VCA0593 0.54 0.53 0.50 0.40 0.46 0.48 0.54 0.46 
VCA0681 0.56 0.49 0.47 0.51 0.50 0.50 0.51 0.52 
VCA0735 0.25 0.28 0.28 0.29 0.30 0.27 0.31 0.36 
VCA0931 0.40 0.40 0.39 0.38 0.38 0.39 0.36 0.36 
VCA0965 0.25 0.21 0.23 0.25 0.27 0.20 0.19 0.21 
VCA1083 0.57 0.54 0.55 0.52 0.53 0.50 0.50 0.49 
  
	  







cdiGMP-binding4  VC Gene # NC cdiGMP1 cGMP2 GTP3  NC cdiGMP
1 cGMP2 GTP3 
VC0405 0.29 0.07*** 0.30*** 0.39*** 
 
0.36 0.03 *** 0.32*** 0.38*** MshE N/A 
VC1308 0.34 0.06*** 0.26*** 0.35*** 
 
- - - - TyrR N/A 
VC2066 - - - - 0.12 0.02 *** 0.08** 0.12*** FliA N/A 
VC2529 0.08 0.01*** 0.07* 0.09***  - - - - RpoN N/A 
VCA0071 - - - -  0.05 0.02 0.05 0.05 PstC N/A 
VCA0593 0.55 0.02 *** 0.62*** 0.61*** 
 
0.53 0.03 *** 0.59*** 0.57*** hypothetical protein N/A 
VC0665 0.15 0.02 *** 0.15*** 0.14*** 
 
- - - - VpsR  (165) 
VCA0952 0.17 0.04 *** 0.18*** 0.24*** 
 
- - - - VpsT  (166) 
VCA0042 0.58 0.03 *** 0.65*** 0.61*** 
 
0.48 0.07 *** 0.50*** 0.52*** PlzD (PilZ) (127) 
VC2344 0.57 0.04 *** 0.61*** 0.62*** 
 
0.53 0.03 *** 0.55*** 0.55*** PlzC (PilZ) (127) 
VCA0735 - - - - 
 
0.28 0.03 *** 0.27*** 0.31*** PlzE (PilZ) (127) 
VC1370 0.45 0.03 *** 0.51*** 0.47*** 
 
0.30 0.02 *** 0.34*** 0.37*** (GGDEF) N/A 
VC2370 0.16 0.04 *** 0.20*** 0.15*** 
 
0.07 0.04  0.13** 0.08*** (GGDEF) N/A 
VCA0965 - - - - 
 
0.17 0.02 *** 0.14*** 0.13*** CdgF (GGDEF) DGC (216) 
VC0658 0.55 0.02 *** 0.60*** 0.61*** 
 
0.56 0.02 *** 0.58*** 0.59*** (GGDEF + EAL) N/A 
VC0072 0.36 0.00 *** 0.49*** 0.48*** 
 
0.47 0.02 *** 0.51*** 0.55*** (GGDEF + EAL) N/A 
VC0703 0.19 0.05 *** 0.19*** 0.23*** 
 
0.23 0.01 *** 0.19*** 0.20*** MbaA (GGDEF + EAL) N/A 
VC1934 0.24 0.02 *** 0.21*** 0.22*** 
 
- - - - (GGDEF + EAL) N/A 
VC1641 0.58 0.02 *** 0.66*** 0.63*** 
 
0.30 0.04 *** 0.32*** 0.36*** (EAL) N/A 
VC1710 0.42 0.06 *** 0.50*** 0.58*** 
 
0.42 0.02 *** 0.47*** 0.56*** (EAL) N/A 
VCA1083 0.57 0.04 *** 0.64*** 0.61*** 
 
0.53 0.04 *** 0.53*** 0.58*** (EAL) N/A 
VC1652 0.36 0.08 *** 0.47*** 0.52*** 
 
- - - - VieA (EAL) PDE (95) 
VCA0681 0.51 0.01 *** 0.50*** 0.58*** 
 
0.50 0.01 *** 0.48*** 0.55*** (HD-GYP) PDE (217) 
VCA0210 0.17 0.03 *** 0.17*** 0.15*** 
 
0.33 0.04 *** 0.41*** 0.34*** (HD-GYP) N/A 
VC1295 0.46 0.02 *** 0.55*** 0.52*** 
 
0.51 0.02 *** 0.55*** 0.57*** (HD-GYP) N/A 
VCA0931 0.33 0.01 *** 0.36*** 0.42*** 
 
0.36 0.02 *** 0.41*** 0.48*** (HD-GYP) N/A 
VC1348 0.49 0.02 *** 0.55*** 0.52*** 
 
0.54 0.02 *** 0.54*** 0.56*** (HD-GYP) N/A 
VCA0895 - - - - 
 
0.28 0.01 *** 0.27*** 0.26*** (HD-GYP) N/A 
1Two-way ANOVA of Fb cdiGMP vs. No Competitor (NC). 2 Two-way ANOVA of Fb cdiGMP vs. cGMP. 3  Two-way ANOVA of Fb cdiGMP vs. GTP. * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, No asterisk = p > 0.05. 4 Binding and enzymatic activity is deemed positive if activity has been demonstrated for the 
purified protein or if mutation of residues required for cdiGMP-binding or enyzmatic activity regulate a cdiGMP-dependent phenotype. DGC = diguanylate 
cyclase activity reported, PDE = phosphodiesterase activity reported.
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cdiGMP, and that guanosine nucleotides may regulate the availability or affinity of some 
cdiGMP-binding sites (96). 
3.3 Positive ORFs Encode cdiGMP-binding Proteins  
 Several V. cholerae proteins have been predicted or demonstrated to have 
cdiGMP binding activity and some of these proteins were among the validated positive 
ORFs (Table 3, Table 4). Four cdiGMP-binding domains can be predicted from sequence 
information including the I-site of GGDEF domains, PilZ domain proteins, and the active 
sites of EAL and HD-GYP domains. In addition to genes with conserved cdiGMP-
binding domains, 3 cdiGMP-binding transcription factors lacking a defined cdiGMP-
binding domain have been described and are present in the V. cholerae ORFeome 
(160,165,166). The ability of the DRaCALA ORFeome screen to identify cdiGMP-
binding proteins can be assessed by the hit rate of ORFs encoding predicted and 
empirically demonstrated cdiGMP-binding activity.  
GGDEF Domain Proteins  
 The V. cholerae ORFeome contains 38 of 41 genes encoding a GGDEF domain 
(excluding VCA1082, VC1376, and VC0398), with 9 of 10 genes encoding both a 
GGDEF and EAL domain (excluding VC0398). The RxxD motif required for cdiGMP-
binding is conserved in 10 of these genes, but cdiGMP binding has not been 
demonstrated for their protein products (86). 3 of 10 GGDEF domains with a conserved 
RxxD motif were identified as positive ORFs, suggesting that these proteins have 
cdiGMP-binding activity (Table 1, Table 3). The remaining 7 GGDEF domain ORFs may 
either lack cdiGMP-binding activity, not have been expressed, or produce unlabeled 
cdiGMP which can compete radiolabeled cdiGMP from cdiGMP-binding proteins. 
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Table 3. Hit rate of VC ORFs encoding proteins with predicted cdiGMP-binding 
domains. This table lists proteins with conserved domains predicted to bind cdiGMP. 
Residues required for cdiGMP-binding are defined for GGDEF (86), EAL (218), HD-



















GGDEF only 31 11 10 3 (30%) 
EAL only 12 11 10 4 (40% 
GGDEF+EAL 10 9 9 4 (44%) 
HD-GYP 9 7 7 6 (86%) 
PilZ 5 4 4 3 (75%) 
Total 67 42 40 20 (50%) 
 
 
Table 4. Hit rate of VC ORFs encoding proteins with demonstrated cdiGMP-
binding activity. This table lists proteins that have been purified and shown to bind 
cdiGMP directly. References for PDE (EAL) (94,219-222), (HD-GYP) (217), and 









GGDEF only 0 N/A N/A 
EAL only 4 4 1 
GGDEF+EAL 1 1 0 
HD-GYP 1 1 1 
PilZ 2 2 2 
Transcription Factors 3 3 2 
Total 11 11 6 (55%) 
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EAL Domain Proteins 
 The V. cholerae ORFeome contains 20 of 22 genes encoding a EAL domain 
(excluding VCA0536 and VC0398). Residues required for PDE activity are completely 
conserved in 19 of 20 EAL domains (excluding VCA1083), which predicts that the 
protein products of these genes may bind cdiGMP. The EAL domain of VCA1083 
encodes a serine instead of the conserved glutamate corresponding to residue 208 of P. 
aeruginosa RocR, but is annotated as a pseudogene in NCBI and is likely not expressed 
in V. cholerae (218). 6 of 19 EAL domains with conserved active were identified as 
positive ORFs (Table 3). 4 of the positive ORFs with EAL domains also contain a 
GGDEF domain, but none retained the conserved RxxD motif, suggesting that cdiGMP-
binding activity is due to binding at the EAL domain active site. VCA1083 was also 
identified as positive, suggesting the protein product of this pseudogene retains cdiGMP-
binding activity. Of the 19 EAL domains with predicted cdiGMP-binding activity, 5 have 
been demonstrated to have PDE activity, including VC1652 (VieA), VC0130 (CdpA), 
VC1592, VC1086, and VC0137 (CdgJ) (95,218-222). Positive ORFs containing EAL 
domains include 1 of these 5 EAL domain proteins (VieA). EAL-domain proteins that 
were not identified may not bind cdiGMP, not be sufficiently expressed, or hydrolyze 
cdiGMP to pGpG before DRaCALA is complete. These results suggest that some, but not 
all cdiGMP-binding EAL-domain proteins were identified by this screen. 
HD-GYP Domain Proteins 
 The V. cholerae ORFeome contains 9 out of 9 V. cholerae proteins with an HD-
GYP domain, of which only VCA0681 has been purified and shown to have PDE activity 
(217). HD-GYP domains require conserved residues for PDE activity and these residues 
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are conserved in 7 of 9 HD-GYP domains (excluding VC1087 and VC2497) (206,217). 
Positive ORFs include 6 of 7 ORFs encoding HD-GYP domains with conserved residues 
for PDE activity, including VCA0681 with demonstrated binding activity. Thus, most 
HD-GYP domain proteins with predicted PDE activity were identified by the DRaCALA 
ORFeome screen. 
PilZ Domain Proteins 
 The V. cholerae ORFeome contains 5 of 5 V. cholerae genes encoding PilZ 
domain proteins. 4 of 5 PilZ proteins contain the the conserved RxxxR and DxSxxG 
residues required for cdiGMP-binding, with the exception of PlzB (VC1885) (127). A 
previous study has demonstrated cdiGMP-binding to PlzC (VC2344) and PlzD 
(VCA0042), but failed to identify cdiGMP-binding for PlzA (VC0697) or PlzE 
(VCA0735) (127). PlzC and PlzD were identified as positive in both His-ORF and His-
MBP-ORF libraries, while PlzE was identified as positive only in the His-MBP-ORF 
library. CdiGMP-binding was not previously detected for a purified His-PlzE fusion, 
suggesting that maltose binding protein may be required for cdiGMP-binding activity of 
heterologously expressed PlzE (127). 
CdiGMP Binding Transcription Factors 
 3 cdiGMP-binding transcription factors lacking a defined cdiGMP-binding 
domain have been described and are present in the V. cholerae ORFeome (160,165,166). 
Positive ORFs include 2 of the 3 known cdiGMP-binding transcription factors VpsT and 
VpsR, but not FlrA.  
 In total, we identified 19 of 40 ORFs with predicted cdiGMP-binding domains 
(Table 3) and 5 of 10 ORFs encoding proteins with empirically demonstrated cdiGMP-
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binding activity (Table 4). These results indicate that positive ORFs encode cdiGMP-
binding proteins and that our DRaCALA ORFeome screen positively identified 
approximately 50% of both predicted and empirically demonstrated cdiGMP-binding 
proteins.  
 The DRaCALA screen also revealed 6 positive ORFs encoding proteins that are 
not predicted to bind cdiGMP. These proteins represent putative new classes of non-
canonical cdiGMP-binding proteins. One of these ORFs encodes MshE (VC0405), an 
ATPase that is required for biogenesis of the MSHA type IV pilus (223). The msh operon 
encodes an uncharacterized GGDEF/EAL-domain protein (VC0398) and the MSHA 
pilus plays a role in cdiGMP regulated phenotypes including surface attachment, biofilm 
formation, and host colonization (224-228). This suggests that cdiGMP may regulate the 
MSHA pilus, possibly through direct binding to MshE. Two other cdiGMP-binding 
ORFs encode highly conserved sigma factors FliA (sigma28, VC2066) and RpoN 
(sigma54, VC2529). These sigma factors are highly conserved global transcriptional 
regulators in multiple organisms and their role in the transcriptional regulation of V. 
cholerae flagellar biosynthesis has been well characterized (229-231). Several enhancer-
binding protein transcription factors with cdiGMP-binding activity are predicted to 
interact with sigma54 including FlrA and FleQ. Furthermore, cdiGMP is known to 
regulate flagellar transcription in V. cholerae, suggesting that these sigma factors may 
have cdiGMP regulated activities. A fourth positive ORF encodes PstC (VCA0071), a 
component of a conserved phosphate transport system that is well-studied in E. coli 
(232,233). A genetic screen for suppressors of cdiGMP-dependent repression of V. 
cholerae motility identified 8 unique transposon insertions in PstC, but a direct role of 
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PstC in cdiGMP-binding was not investigated (221). The fifth positive ORF encodes 
VCA0593, which is annotated as an exopolyphosphatase-related protein. 
Exopolyphosphatases hydrolyze polymers of inorganic phosphatase (polyP), and 
regulation of polyP has been shown to affect cdiGMP-dependent phenotypes including 
biofilm formation and motility in numerous prokaryotic organisms (234-238). However, 
VCA0593 has low homology to E. coli exoployphosphatase, and is not reciprocal best 
BLAST hit for E. coli exopolyphosphatase in V. cholerae, suggesting that VCA0593 may 
represent a novel class of exopolyphosphatase-related proteins that bind cdiGMP. A final 
positive ORF encodes TyrR, which is a member of the NtrC class enhancer-binding 
protein similar to FleQ, FlrA, and VpsR. The identification of these putative cdiGMP-
binding proteins as positive ORFs in our DRaCALA ORFeome screen suggests several 
novel mechanism for cdiGMP-dependent regulation in V. cholerae. 
 To determine if FliA and RpoN bind cdiGMP directly, we purified N-terminal 
His-MBP fusions of FliA and RpoN. We failed to detect binding to purified FliA and 
RpoN by DRaCALA, suggesting that cdiGMP-binding activity was lost during 
purification (Figure 21). This could represent the loss of intrinsic binding activity of FliA 
and RpoN, or loss of E. coli cdiGMP-binding proteins that are removed during 
purification. 
3.4 MshE Specifically Binds cdiGMP with High Affinity 
 Type IV pili are ubiquitious multi-functional pili that participate in cdiGMP-
dependent phenotypes including twitching and swarming motility, biofilm formation, and 
pathogenesis (112,239-241). Conserved ATPases required for type IV pilus assembly and 
retraction have been shown to interact with cdiGMP-binding proteins in P. aeruginosa  




Figure 21. Binding of cdiGMP to purified FliA and RpoN. DRaCALA spots of 
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and X. campestris, but direct binding of cdiGMP to T2SE ATPases has not been 
demonstrated (103,242-244). Identification of the ATPase MshE in both His- and His-
MBP-ORF libraries suggested a potential role for cdiGMP in the regulation of the MSHA 
type IV pilus in V. cholerae. 
 To determine the affinity and specificity of cdiGMP-binding to MshE, we purified 
His-MBP-MshE and assayed binding to 32P-cdiGMP by DRaCALA. The affinity of 
cdiGMP-binding to MshE was determined by quantifying fraction bound 32P-cdiGMP to 
serial dilutions of purified MshE. Non-linear regression analysis of cdiGMP-binding vs. 
protein concentration using a one site binding model estimated the dissociation constant 
(Kd) for cdiGMP to be 830 ± 80 nM (Figure 22A). To determine the specificity of 
cdiGMP-binding to MshE, we measured fraction bound 32P-cdiGMP in the presence of 
unlabeled nucleotide competitors. 32P-cdiGMP-binding to His-MBP-MshE was 
significantly decreased by unlabeled cdiGMP and GDP, but not by cGMP, GMP, GTP, 
ATP, CTP, or UTP (Figure 22B). These results indicate that MshE specifically binds 
cdiGMP with high affinity. 
 cdiGMP effector proteins bind cdiGMP to allosterically regulate protein activity. 
To determine if cdiGMP-binding regulates MshE ATPase activity, purified His-MBP-
MshE was incubated with radiolabeled ATP in the presence and absence of cdiGMP and 
ATP hydrolysis was measured over time by thin layer chromatography. We observed a 
similar rate of ATP hydrolysis in the presence and absence of cdiGMP, suggesting that 
cdiGMP binding does not regulate the ATPase activity of purified His-MBP-MshE 
(Figure 23). 
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Figure 22. Affinity and specificity of cdiGMP-binding to MshE. (A) Graph of fraction 
bound 32P-cdiGMP of 2-fold serial dilutions of purified His-MBP-MshE. The 
dissociation constant (Kd) is indicated. (B) Graph of fraction bound 32P-cdiGMP-binding 
to 4µM His-MBP-MshE in the presence of 1 mM nucleotide competitors. 1-Way 
ANOVA with Dunnet’s Post Test indicates a significant difference in fraction bound for 
cdGMP and GDP compared to no competitor (NC), * indicates p < 0.001. 
  






















































































































Figure 23. ATPase activity of MshE is not regulated by cdiGMP. (A) Graph of 
fraction 32P-ATP hydrolyzed over time by 4 µM His-MBP-MshE in the presence and 
absence of 50 µM unlabeled cdiGMP.  
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3.5 The N-terminus of MshE Defines a Subset of cdiGMP-binding ATPases that 
Regulate Type IV Pili and Type II Secretion Systems 
 MshE belongs to a family of ATPases associated with the biosynthesis and 
retraction of type IV pili and secretion by type II secretion systems. Although 
phylogenetically related, these ATPases do not have a common nomenclature and are 
referred to here as T2SE ATPases based on the common “E” assignment of ATPases 
among genes encoding type II secretion components (245). To determine if cdiGMP-
binding is a conserved feature of T2SE ATPases, we identified homologs of MshE and 
assayed them for cdiGMP-binding. P-Blast with the full length MshE amino acid 
sequence identified 5 related ATPases in V. cholerae and 8 in P. aeruginosa, including 
several ATPases that regulate type IV pili function (PilB, PilT, and PilU) and type II 
secretion (GspE, EpsE, and XcpR) (241,246-252). We constructed His-ORF fusions for 
each V. cholerae and P. aeruginosa MshE homolog and assayed cdiGMP-binding by 
DRaCALA in E. coli whole cell lysate (Figure 24A). Expression of PA14_29490 
significantly increased fraction bound 32P-cdiGMP, suggesting that PA14_29490 is a 
cdiGMP-binding protein. These results suggest that a subset of T2SE ATPases 
represented by MshE and PA14_29490 are cdiGMP-binding proteins. 
 T2SE ATPases encode a N-terminal T2SE domain and a highly conserved C-
terminal domain containing the Walker A/B ATPase motif (Figure 25A). To localize the 
cdiGMP-binding site of MshE, we created N- and C-terminal truncations of MshE 
(Figure 25B). These truncations were overexpressed as N-terminal His fusion proteins in 
E. coli and assayed for cdiGMP-binding. Expression of each fragment was visualized by 
coomassie staining of whole cell lysates separated by SDS PAGE (Figure 25C).  
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Figure 24. cdiGMP binding to Vibrio cholerae and Pseudomonas aeruginosa 
homologs of MshE in whole cell lysate. (A) Graph of fraction bound 32P-cdiGMP of 
whole cell lysate expressing Vibrio cholerae and Pseudomonas aeruginosa homologs of 
MshE. The dashed red line indicates background binding for a vector control strain. (B) 
Clustal-W alignment of the N-terminal fragments of MshE homologs corresponding to 
residues 1-242 of MshE. The monophyletic cluster of MshE and PA14_29490 is 
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Figure 25. cdiGMP binds to an N-terminal fragment of MshE. (A) Cartoon of 
conserved domains in MshE. (B) Fragments generated for binding analysis are numbered 
with and the N- and C-terminal amino acid are indicated. (C) Fragments of MshEVC were 
overexpressed in E. coli and whole cell lysate was assayed by DRaCALA. (D) Image of 
coomassie-stained PAGE of E. coli whole cell lysate analyzed by DRaCALA in  (C). 
Arrowheads indicate overexpressed fragments of MshE and predicted size of protein 
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DRaCALA of the same lysates demonstrated that fraction bound 32P-cdiGMP was 
significantly increased in whole cell lysates expressing the N-terminal 242 residues of 
MshE (Fragment 2) as compared to an empty vector control (Figure 25D). Fragment 3 
was also expressed, but failed to significantly elevate fraction bound 32P-cdiGMP despite 
containing all of Fragment 2. This suggests that the additional amino acids in Fragment 3 
may prevent proper folding of a N-terminal cdiGMP-binding site in MshE. In agreement 
with a previous phylogenetic analysis of T2SE ATPases, Clustal-W alignment of the N-
termini of the P.a. and V.c. MshE homologs revealed a monophyletic cluster for 
PA14_29490 and MshE (Figure 24B) (245). Thus, the N-terminus of MshE contains a 
cdiGMP-binding site, and conserved features in the N-terminus of MshE and 
PA14_29490 may define a subset of cdiGMP-binding T2SE ATPases. 
3.6 Identification of Conserved Residues in the N-terminal cdiGMP-binding 
Fragment of MshE 
 To determine the specific residues in the N-terminus of MshE that mediate 
cdiGMP-binding, conserved charged residues were targeted for mutation to alanine. 
cdiGMP-binding sites in PilZ, GGDEF, EAL, and HD-GYP domains contain charged 
residues that make contact with the cdiGMP molecule and are required for cdiGMP-
binding (86,105,218,253). To identify residues that mediate cdiGMP-binding to MshE, 
charged residues in the N-terminal 242 amino acids were identified by clustal-W 
alignment of MshE, PA14_29490, and the top 12 P-BLAST hits of MshE excluding the 
Vibrio genus (Figure 26A). 13 conserved charged residues were identified, including a 
cluster of 9 residues in the T2SE domain. These 9 residues are conserved in alignments of 
PilB and GspE homologs that did not bind cdiGMP in our DRaCALA experiments  
	  
 
Figure 26. Conserved residues required for cdiGMP-binding by MshE. (A) Clustal-W alignment of amino acid sequences of VC 
MshE homologs. Grey bars highlight conserved residues. Asterisks indicate charged residues. The cluster of charged residues 
conserved in alignments of PilB and GspE homologs are indicated by a horizontal line. (B) DRaCALA quantification of fraction 


































Vibrio            1 ---------MPINKLRKRLGDLLVEEGIVSEAQLEQALNAQKNTGRRLGDTLISLGFLSETQLLNFLAQQLSLPVI--DLSRAHVDIDAVPLLPEVHAR---RLRALVIGRSGDTLRIAMSDPADLFAQE 116
Pseudomonas       1 MSSEAVSPGPQVTAEWIPLGQRLLERGLVSGQELERALDLQRRLGGRLGGILVRSGAISENTLMQVLAEQLRLPLVGDDLRKPSEESIAAFLLSTPINTDWFVEEQLVVWEEGEQLLFAARDPLSPSIRE 130
Pseudoalteromonas 1 ----------MRPSLKMRLGDLLVHEHMITEAQLSEALNVQAATGRKLGSTLITLEFISEPQLLRFLAQQLQVPFL--DISQRKISHDVSKLLSEVYAR---RYRALVIEDNGDSVLVGMSDPADLRGLD 115
Photobacterium    1 ---------MQI-RLRKRLGDLLVEEGIVAQDQLEQALDKQRSTGRKLGDTLISMGFLTEQQLLSFLSRQLDIPLV--DLTRVSVDIESVSLLSEVHAR---RLRALVIGCRGDTVRVAMSDPADLAAQE 115
Neptuniibacter    1 ---------MAAPKMKIRIGDLLVQNGVISEQQLMEALDKQKQTRQKLGKALVTMGYVQEQQFLEFLSQQLNIPLV--ELTHYSFNQEDVLRLPETQAR---RFRALVLKEEPDHFLVGMSDPMDIFAFD 116
Moritella         1 ---------MAQLKLKQRLGDLLVGEGIISDEQLGLALKEQRSSGRKLGATLTHLGFITEEQLLNFLSQQLDIPFL--NIATLTIDPQSVMKLPEVHAR---RHRALVVKAEHDVLTIALSDPADLNAVE 116
Idiomarina        1 ---------MKRPRLKMRLGDLLVHEQIISEEQLQKALEQQRISGRKLGATLTDLGYISEQQLLEFLAQQLKLPLI--SISERKIPAEAFKLLPEVQAR---RHRALVIEASEEQALVGMSDPADLSSID 116
Grimontia         1 ---------MAV-KLRKRLGDLLVEEHIITDAHLNAALARQSETGRKLGDTLMEMGILTESQMLDFLARQLGVPLI--DLSLTQVDPSAVSLLPEVHAR---RLRALVIGRIGNTVRVAMSDPADLASQE 115
Glaciecola        1 ----------MKPRTKIRLGDLLVQEGIISEEQLMQTLSAQKQSGRKLGHMLIELGFVSENQLLTFLSQHLGVPLV--DVTQYQVSVEAVLLLPEVQAR---RYRALVLDDKGDHLLVGMSDPADLAAID 115
Gallaecimonas     1 ---------MTQPRLKMRLGDLLVSERIITDSQLQDALASQKRLGRKLGRTLVELGYLSEHQLLTFLSQQLKIPYL--DIAERRLDPQVAKLVPEVLAR---RYRALVLEADQDSALIGMSDPADLQALD 116
Ferrimonas        1 ----------MKAKLKQRLGDLLVSEGIISEAQLMEALAAQKQSGRKLGRTLIDLHLISEEQLLSFLAQQMNIEFL--DLSAHRIKPELVQLLPEVHAR---RYRALVVAGDDNELTVAMSDPADLAAID 115
Colwellia         1 ---------MAAPKLKMRLGDLLVDKDIISNDQLMQALSSQKQTGRKLGDTLIELNYLSERQLLEFLAQQLNVPFM--DISQFKISPAVSSLLPEVHAR---RLRALIIEDRGASVLLGMSDPADLSGLD 116
Alteromonas       1 ----------MN-KPRVRLGDLLVQHNLISADELMTALSEQKSTGRKLGATLISMGLVTEHQMLELLSRHLNVPLI--DIDQYRVNQQAVLLLPEIQAR---RYRALVIDDKGDSLLVAMSDPADLTAVD 114
Agarivorans       1 ---------MAQPKLRMRLGDLLVSEQVISEADLMSALAQQKQSGRKLGATLIELGVIAEVQLLEFLARQLGIPFV--DLAQISVDANAVVLLGEVHAR---RLRALVIHKDGDVLTVAISDPADLSAID 116
Vibrio          117 ALLNQLPDYGFEFVIAPEKQLVDGFDRYYRRTKEIVSFAEQLHAEHKTNDSFD--FEITDSDSDEVTVVKLINSLFEDAIQVGASDIHIEPDANVLRLRQRIDGVLHETLLHEVNIASALVLRLKLMANL 244
Pseudomonas     131 TLGYFYPERSIQAVLCRS----QDLDGWLEHSLDLARQGADRHAYGSEDIRYLR------ELAEEAPVVELVNNVMSQAMEKRSSDIHIEPREFDFRIRFRVDGVLHDQLSLPRERFAAVVSRIKLISAI 250
Pseudoalterom.  116 QLATMLAPKRIDLAVVQESQIMAAFDNVYRRTDEITNFAAQLHEEYQDVEEFDLN--SLGDETSDATVVKLLQSIFEDAVQVRASDIHIEPDEGLLRIRQRVDGILQEHTLNQVKIASALVLRLKLMSGL 243
Photobacterium  116 AVYNQLAQYRVELVIAPERHLIAAFDRYYRRTQEIVSFAEQLQAEHQDSSDFS--FGFDDNDNEEVTVVKLINSLFEDAIQVGASDIHIEPDADVLRIRQRIDGVLHETLLNETSVSAALVLRLKLMSGL 243
Neptuniibacter  117 ELQRTLP-KPIELAVVSESQLLQSMDLLYRKTSDIEDLADQLNEE-IADDAFDL-AALTATDEVDVPVVKLLKSLFEDAVQVGASDIHIEPDENVLRIRQRIDGVLHEHVMKEKRIASALVLRLKLMASL 243
Moritella       117 AISNVLSAYQLEFAIVRESELLPAYDRLYRRTKDIEAFAGQLEDEHRPAQEFDI-FRDVDDASSEATVVKFLNSVFEDAVQVGASDIHIEPDENALRIRLRVDGVLQENVLNEVAIVPALVLRLKLMAGL 245
Idiomarina      117 AINQLLAPRQVELAVVPEGELMQAFDNLYRRTKEIETFASQLQDEYEDTSEFELGQLSLDDDTDEATVAKLLQSIFEDAVQVRASDIHIEPDDRKLRIRQRVDGVLQENVLEETNIANALVLRLKLMAGL 246
Grimontia       116 SVLNQLHQYQVELLITAEQPLIDAFDRYYRRTSEIASFAERLQAEHGVKLEQN--FGADEEQSEEVTVVKLINSLFEDAVQVNASDIHIEPDADALRIRQRIDGVLHETLLKERAIASALVLRLKLMSGM 243
Glaciecola      116 ILSGVLP-KPVKVAVVSDAQLFQAYDRFYRRTEDIASFAQELAEEYQDDEEFD--FDTGVDDEQDTAVARLLQSIFEDALQTKASDIHIEPDNELLRIRLRVDGVLQENVIKEKNIASALVLRLKLMSGL 242
Gallaecimonas   117 ALEQRLAPRQLRLAVVEEAQLLHAFDGLYRRTQEIASYASQLEEEHQETADFDFGALVRDEGEGGATVARLLQSLFEDAVQMRASDIHIEPEQNQLRIRQRIDGVLQENVLKEARVAGALVLRLKLMAGL 246
Ferrimonas      116 TLETLLAPRHVNLAVATEGQLLDAFDNLYRHTDKIASIAGELHEEYSAQSDFSLDALVAEDADNDTTVVRLLQSIFEDAVQVRASDIHIEPDEKLLRIRYRVDGQLMETTLSEYRVANALVLRIKLMAGL 245
Colwellia       117 QLERMLSPKRIELAVVMESQIFDAFDSLYRRTAEIESFASQLEEEYEESSSFDLAT-TFLDEGGDATVGKLLQSVFEDAVQMRASDIHIEPEEHQLRIRQRIDGVLQEKILKENKIASAMVLRLKLMAGL 245
Alteromonas     115 HLSETLN-RQIELAVVSEQQLFTAYDTFYRKTQEIASFAQELAEEYDTEDNFN--IELGGAGDQDTTVARLLQSIFEDAVIAKASDIHIEPDENQLRIRQRVDGVLQETVIPEKSIAAALVLRLKLMAGL 241
Agarivorans     117 TLASLLAPHQLKYVVARESQVVEAFDRFYRRTREIEGFAQELKEEYASSDEFDIGLATADDESNETTVVKLLQSLFEDAVQVGASDIHIEPDEKVLRIRQRVDGVLQESVLNEVQIASAMVLRLKLMSGL 246
A * * *
*
Pfam: T2SE
Conserved in GspE and PilB Homologs
** ** ** ***
B
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(Figure 25A). Residues required for cdiGMP-binding by T2SE ATPases are probably 
uniquely conserved in cdiGMP-binding homologs, prompting the elimination of the C-
terminal cluster of conserved residues from consideration. Thus, the remaining four 
charged residues (Q32, E51, D108 and D142) are conserved by MshE and PA14_29490, 
but not in closely related T2SE ATPases lacking cdiGMP-binding. These residues may 
be required for cdiGMP-binding. 
 To test this hypothesis, the mutations Q32A, E51A, D108A, and D142A were 
introduced into full length MshE. These MshE mutants were expressed as N-terminal 
His-MshE fusions in E. coli and assayed for cdiGMP-binding in whole cell lysates. The 
mutant alleles displayed decreased cdiGMP-binding compared to wild type mshE, but 
were still able to significantly increase fraction bound 32P-cdiGMP as compared to a 
vector control (Figure 26B). These results suggest that these residues are not absolutely 
required for cdiGMP-binding by MshE. However, these experiments are not conclusive 
about the potential role of these charged residues in cdiGMP-binding by MshE. Mutation 
of these residues may have subtle effects on the affinity of MshE for cdiGMP which 
might not be apparent from a single measurement of fraction bound cdiGMP with 
undefined protein concentrations. Alternatively, MshE may have multiple cdiGMP-
binding sites and loss of residues required for cdiGMP-binding at one site may be masked 
by cdiGMP-binding at a second site. In the future, determining the stoichiometry of 
cdiGMP-binding to MshE and quantifying the dissociation constant of individual mutants 
may address these possibilities  
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3.7 Discussion 
 Here we have reported the systematic identification of cdiGMP-binding proteins 
from a V. cholerae ORFeome based on a high-throughput biochemical assay of cdiGMP-
binding activity. Work in other laboratories has developed several other approaches for 
identification of protein effectors based on their affinity for signaling molecules. In one 
approach, an affinity-tagged signaling molecule is used as a molecular bait to “fish out” 
interacting proteins that are subsequently identified by liquid chromatoraphy-mass 
spectrometry (LC-MS). For example, biotin-conjugated cyclic di-AMP (cdiAMP) mixed 
with streptavidin coated beads enabled the pull down and identification of the S. aureus 
cdiAMP binding protein KtrA (254). This approach can identify binding interactions to 
proteins expressed in their native organism, which may possess unique post-
transcriptional and post-translational regulation of protein activity. However, 
identification of low affinity effectors is limited by wash steps that remove non-
specifically bound proteins. To overcome this limitation, the pull-down approach has 
been modified to include a protein capture step. For example, a cdiGMP capture 
compound has been developed that contains an aromatic group that forms a highly 
reactive nitrene upon UV-irradiation. This aromatic group is linked to cdiGMP and biotin 
via an acyl carrier, and proteins that interact with cdiGMP are irreversibly cross-linked to 
the capture compound by UV-irradiation (208). Capture compounds allows improved 
stringency in protein purification, but proteins that interact with cdiGMP, the aromatic 
group, or the acyl chain may be pulled down by this approach. In total, affinity-pull down 
approaches enable effector identification from a wide variety of biological samples, but 
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are not systematic due to the requirement of effector expression under laboratory 
conditions.  
 Alternatively, ORF libraries have enabled the systematic overexpression and 
analysis of individual proteins (255). Most biochemical assays typically require protein 
purification and thus ORFs are expressed as fusion proteins with affinity tags for 
purification. For example, a study of the Saccharomyces cerevisiae proteome expressed 
GST-ORF fusions cloned from an open reading frame library, purified proteins in pools, 
and assayed the pools for various biochemical activities (256). Positive pools were 
deconvoluted enabling the identification of open reading frames encoding proteins with 
specific biochemical activity. This approach has been extended by covalently attaching 
purified proteins to glass slides, enabling the production of high-density protein 
microarrays that have been used to systematically screen protein-protein and protein-
ligand interactions (188,189,257,258). However, both affinity pulldown and screening of 
purified proteins use chemically modified ligands that may alter protein-ligand 
interactions. DRaCALA uses radiolabeled probes that are synthesized enzymatically from 
common radiolabeled precursors such as ATP and GTP. However, not all ligands can be 
easily radiolabeled and the use of radiolabeled compounds requires specialized 
equipment and monitoring. DRaCALA can also detect specific binding activity of both 
soluble and insoluble proteins in whole cell lysate, and thus bypass the requirement for 
protein purification (Figure 15). While DRaCALA screening of whole cell lysates is 
rapid, confirmation of direct binding still requires protein purification or identification 
and mutation of the ligand binding site. In summary, DRaCALA ORFeome screens 
represent a low-cost, high-throughput method for identifying protein-ligand interactions 
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that combines systematic protein overexpression with direct detection protein-ligand 
interactions in whole cell lysate.  
 A previously reported DRaCALA ORFeome screen identified 3 cdiAMP binding 
proteins from a Staphyloccus aureus His-ORF library. A cdiAMP-based affinity pull 
down from a S. aureus whole cell lysate had previously identified KtrA, suggesting that 
the other two cdiAMP binding proteins may not have been sufficiently expressed by S. 
aureus for detection by affinity pull-down. However, the cdiAMP binding protein, CpaA, 
was not present in the S. aurues ORFeome, and was thus not identified by DRaCALA 
screening. CdiAMP signaling is not well-studied and thus the hit rate of the S. aureus 
ORFeome screen was unable to be evaluated. 
 In this study, several predicted and empirically demonstrated cdiGMP binding 
proteins from V. cholerae were not identified in the ORFeome screen. There are both 
general and protein-specific reasons that potentially explain why some cdiGMP binding 
proteins were not identified as positive ORFs. In general, ORFs encoding cdiGMP-
binding proteins may not be identified due to insufficient protein expression, improper 
folding of cdiGMP-binding sites, or low affinity for cdiGMP. We attempted to overcome 
the limitations of low protein expression and inactive ORF fusions by the use of both 
His-ORF and His-MBP-ORF libraries. From a total of 28 positive ORFs, 6 were 
identified exclusively in the His-ORF library and 5 in the His-MBP-ORF library. Thus, 
screening two ORF libraries improved our detection rate by approximately 20-30% and 
resulted in a total hit rate of approximately 50% of known and 50% of predicted 
cdiGMP-binding proteins. In addition to these general issues, proteins with both 
cdiGMP-binding and DGC activity may be difficult to identify. Previous experiments 
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with the P. aeruginosa DGC WspR indicated that excess cdiGMP decreases fraction 
bound 32P-cdiGMP, suggesting that DGC activity may have decreased the hit rate of 
ORFs encoding GGDEF domains (Figure 13A). In total, these results suggest that 
DRaCALA ORFeome screens are a powerful method for identifying many, but not all 
genomically-encoded cyclic di-nucleotide binding proteins.  
 The most exciting results of our V. cholerae screen was the identification of 6 
positive ORFs lacking canonical cdiGMP-binding domains. These ORFs represent 
putative novel cdiGMP effectors and may regulate cdiGMP-dependent phenotypes in V. 
cholerae. For example, studies of the MSHA pilus demonstrate a positive role in 
attachment to chitinous surfaces and biofilm formation, but MSHA must be 
downregulated for mucus penetration during host infection (224,226,228). cdiGMP 
regulates V. cholerae colonization of an infant mouse model and multiple DGCs and 
PDEs are differentially-regulated during host infection and environmental persistence 
(173,221,222,259). Thus cdiGMP-binding by MshE may provide a mechanism for the 
differential regulation of the MSHA pilus as Vibrio cholerae transitions between host 
infection and aquatic reservoirs.  
 CdiGMP also regulates swimming motility in numerous organisms including V. 
cholerae. A second positive ORF encoding PstC was previously identified in a V. 
cholerae transposon mutagenesis screen where it was required for a decreased swimming 
motility phenotype observed in a V. cholerae PDE mutant with increased cellular 
cdiGMP concentrations (221). PstC is a component of a conserved phosphate transporter 
that regulates transcription by the two component response regulator PhoB. Loss of phoB 
or pst restored motility in the cdiGMP-high background, suggesting that cdiGMP may 
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bind PstC to regulate PhoB activity. A third positive ORF, VCA0593, encodes a 
hypothetical protein with weak homology to exopolyphosphatases. The low homology of 
VCA0593 with known exopolyphosphatases and the presence of a second bona fide 
exopolyphosphatase in the V. cholerae genome suggests that VCA0593 may not function 
as an exopolyphosphatase. 
 Finally, we identified 3 positive ORFs encoding transcriptional regulators. FliA 
and RpoN are sigma factors, while TyrR is an NtrC-type enhancer-binding protein 
similar to FleQ, VspR, and FlrA. A V. cholerae transcriptional microarray has revealed 
that cdiGMP regulates transcription of over 100 genes in V. cholerae including several 
operons for flagellar biosynthesis, which are regulated by FliA and RpoN (260). 
Expression of FliA and RpoN consistently resulted in elevated cdiGMP-binding in E. coli 
whole cell lysates, but the lack of cdiGMP-binding to purified FliA and RpoN suggests 
that cdiGMP-binding activity was lost during purification. This loss of activity could 
reflect loss of of FliA and RpoN activity during purification. Alternatively, these highly 
conserved sigma factors may be regulating transcription of endogenous E. coli cdiGMP-
binding proteins or altering the affinity of E. coli cdiGMP-binding proteins which would 
be removed during purification. These possibilities were not investigated, and the role of 
FliA and RpoN in direct cdiGMP-binding remains inconclusive. TyrR has not been 
characterized in V. cholerae, but its homolog in E. coli has been well-studied as a 
transcriptional regulator of aromatic amino acid metabolism and transport (261). Genes 
involved in aromatic amino acid metabolism of V. cholerae were not differentially 
transcribed in response to elevated cdiGMP, but it is not clear if TyrR is expressed by V. 
cholerae in laboratory conditions (260). In total, the identification of positive ORFs 
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lacking conserved cdiGMP-binding domains has suggested new regulatory roles for 
cdiGMP signaling. Demonstration of direct cdiGMP-binding and cdiGMP-dependent 
regulation of protein activity is required to determine if these proteins are indeed cdiGMP 
effectors. 
 CdiGMP-dependent regulation of type IV pili have been demonstrated in P. 
aeruginosa and Xanthomonas species, and several GGDEF, HD-GYP, and PilZ proteins 
have been shown to interact with the extension ATPase PilB and retraction ATPases PilT 
and PilU in Xanthomonas (103,112,114,244,262,263). However, a precise mechanism for 
cdiGMP-dependent regulation of type IV pili has not been defined. The identification of 
MshE as a cdiGMP-binding protein prompted us to investigate homologous ATPases to 
determine whether they too might bind cdiGMP. MshE belongs to a broad family of 
T2SE ATPases required for extension and retraction of type IV pili and membrane 
translocation of type II secreted proteins (245,264). We tested several T2SE ATPases 
from V. cholerae and P. aeruginosa for cdiGMP-binding, but only detected cdiGMP-
binding activity for PA14_29490. MshE and PA14_29490 form a monophyletic cluster of 
T2SE ATPases suggesting that a subset of T2SE ATPases may be regulated by cdiGMP. 
However, we were not able to observe cdiGMP-dependent regulation of ATPase activity 
in purified MshE (Figure 23). This suggests that cdiGMP binding may regulate other 
activities of MshE such as protein interactions within the MSHA biosynthetic complex. 
that phylogenetic clustering was correlated with the biological roles of T2SE ATPases 
(245). In the future, identification of a conserved cdiGMP-binding site in MshE and 
PA14_29490 may allow prediction of cdiGMP binding for other T2SE ATPases and 
reveal the regulatory effects of cdiGMP binding.  
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3.8 Materials and Methods 
cdiGMP-binding Buffer 
Whole cell lysate resuspensions, DRaCALA, and ATPase assays were carried out in 
cdiGMP-binding buffer containing 10 mM Tris pH = 8.0, 100 mM KCl, 5 mM MgCl2. 
Gateway Destination Vector Construction 
 pVL791 Cb GW and pVL847 Gn GW were constructed as destination vectors in 
LR reactions for cloning VC ORFs. pVL791 Cb and pVL847 Gn are pET-19 derivatives 
that are carbenecillin or gentamycin resistant and produce N-terminal His- and His-MBP 
fusions respectively. The gateway destination casette was amplified from pRFA and 
cloned in frame with the N-terminal fusions to produce the gateway adapted vectors. 
ORFeome Library Construction 
 The V. cholerae N16961 ORF library was obtained from BEI. LR Clonase 
reactions were performed per NEB protocol using miniprepped pDONR vectors from the 
V. cholerea ORFeome in combination with pVL791 Cb GW and pVL847 Gn GW 
destination vectors. Gateway reactions were transformed into an E. coli T7IQ strain 
(NEB) and recombinants were selected on LB agar plates containing either carbenecillin 
or gentamycin. Multiple colonies from individual transformations were inoculated in LB 
M9 rich media in 96-well plate format and grown overnight with shaking at 30 ˚C. 
Overnight cultures were subcultured 1:50 into fresh media and grown for 4 hours at 30 ˚C 
with shaking. VC ORF expression was induced by addition of 1 mM IPTG and grown for 
an additional 4 hours. 1.5 mL of induced culture was centrifuged and cells were 
resuspended in 150 µL of cdiGMP-binding buffer supplemented with DNAse , Lysozyme 
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and the protease inhibitor PMSF. 20 µL aliquots were transferred to 96-well microtiter 
plates and stored at -80 ˚C. 
DRaCALA  
 Whole cell lysates for DRaCALA screening were prepared by freeze-thawing 
resuspended cells in microtiter plates a total of 3 times. After the final thaw, 20 µL of 
cdiGMP-binding buffer supplemented with 16 pM 32P-cdiGMP and 500 mM unlabeled 
GTP was added to whole cell lysate plates. 2 µL of this mixture was then spotted in 
duplicate on nitrocellulose using a 96-well pin tool. DRaCALA of purified proteins was 
performed with concentrations of protein and unlabeled competitor as indicated. Spots 
were allowed to dry completely (about 20 minutes) before exposing a phosphorimager 
screen and capturing with a Fujifilm FLA-7000. Photostimulated luminescence (PSL) 
from the inner spot and total PSL of the spot were quantitated with Fuji Image Gauge 
software. The fraction bound (Fb) (209) was calculated using measurements of the total 
area (Aouter), the area of the inner circle (Ainner), the total PSL intensity (Itotal), and the 
inner intensity (Iinner) as follows: 
€ 
FB =











His-MBP-MshE, His-MBP-FliA, and His-MBP-RpoN were purified from strains 
constructed in the ORFeome library. E. coli strain NEB-T7IQ harboring recombined 
pVL847 Gn GW - ORF vectors expressing N-terminal His-MBP-ORFs were induced for 
4 hours at 30 ˚C with 1 mM IPTG. Induced bacteria were collected by centrifugation and 
resuspended in His Buffer A (10 mM Tris, 100 mM NaCl and 25 mM imidazole, pH = 
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8.0) and frozen at -80 ˚C until purification. Thawed bacteria were lysed by sonication 
after addition of DNase I (Roche), lysozyme (Roche), and PMSF (1 mM final 
concentation). Insoluble material was removed by centrifugation and the His-fusion 
protein was purified from the clarified whole cell lysate by separation over an Ni-NTA 
column. Proteins were subsequently purified and concentrated using anion exchange to a 
concentration of at least 20 µM, supplemented with 25% glycerol, and frozen at -80°C 
until thawed for use.  
ATPase Assay 
24 nM 32P-ATP was incubated with 4 µM His-MBP-MshE in the presence or absence of 
50 µM cdiGMP in cdiGMP-binding buffer. ATP hydrolysis was monitored by thin layer 
chromatography using PEI cellulose plates and a buffer containing 15 mL 1.5 M KCl and 
10 mL saturated (NH4)2SO4. Aliquots of the ATPase reaction were spotted on the PEI 
cellulose plate at indicated time points and fraction of radiolabel associated with free 
phosphate was quantified by exposure to phosphorimager.  
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Chapter 4: DRaCALA For Affinity and Kinetic Determination of 
Protein-Oligonucleotide Interactions  
4.1 Introduction 
 Previous studies have shown that DRaCALA can accurately measure protein–
ligand interactions for purified proteins and whole-cell extracts expressing recombinant 
proteins. The simplicity of DRaCALA gives it potential for general applicability. Ligand 
mobility in DRaCALA is a necessity, but the possibility that ligands partition out of the 
mobile liquid phase during capillary action, and are therefore not mobile, has not yet been 
investigated. 
 Because mononucleotides and dinucleotides have been shown to be mobile, it is 
reasonable to expect that double stranded DNA would be mobile as well. This led us to 
apply the method to DNA–protein interactions using the well-characterized interaction 
between E. coli cyclic AMP receptor protein (CRP) and its DNA binding site ICAP. CRP 
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is a transcription factor that has regulatory function at approximately 200 sites on the E. 
coli genome (16,192,265). CRP binds cAMP and cGMP (266), but DNA binding and 
transcriptional activation by CRP is solely dependent on cAMP binding (14). A 28-bp 
symmetrical synthetic consensus sequence, called ICAP, binds CRP with the greatest 
affinity (15). Through filter-binding assays, the affinity of the CRP–ICAP interactions 
and the contributions of specific nucleotides (such as guanines at positions 8 and 10 and 
the cytosines at positions 19 and 21) have been defined (267). 
 In this study, DRaCALA is shown to allow quantification of CRP–ICAP 
interactions using 32P-end-labeled oligonucleotides. Specificity of binding and 
competition studies were performed to establish this proof of principle. Furthermore, the 
method was used to obtain measurements of both affinity and kinetics. Much larger DNA 
probes derived from whole plasmids were tested in the same way. DNA could function as 
a carrier molecule for studying interactions between a protein and a molecule covalently 
linked to DNA. This also allows easy indirect 32P-labelling of molecules that are more 
difficult to label than DNA. Finally, immobilization of nucleic acids with the biotin-
streptavidin system is shown to allow study of small molecule interactions with RNA 
(riboswitches). We show here the different ways DRaCALA can be used to study 
molecular interactions with nucleic acids including protein–nucleic acid and riboswitch-
small ligand interactions. 
4.2 DNA Oligonucleotides are Mobile in DRaCALA and Sequestered by Protein 
Binding 
 Because radiolabeled mononucleotides and dinucleotides are mobile on 
nitrocellulose by capillary action (209), we reasoned this would be a property of double-
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stranded DNA as well. If confirmed, this would allow study of DNA using the 
DRaCALA technique. Double-stranded mobility on nitrocellulose was tested using 5’-
end-labeled duplex DNA formed by annealing a pair of 40-bp oligonucleotides that 
generate the CRP consensus binding site, ICAP (gd126 and gd127 in Table 6, Chapter 
4.10 Materials and Methods). When the 32P-labeled DNA was spotted on dry 
nitrocellulose, the 32P radiolabel was mobilized by radial capillary action resulting in a 
homogenous signal across the total sample area (Figure 27A) similar to results previously 
obtained for cAMP and ATP (209). Addition of 100 nM CRP and 200 mM cAMP to the 
ICAP probe is known to promote DNA–protein complexes (267). Spotting of the CRP–
ICAP mixture at equilibrium resulted in sequestration of the soluble probe by the 
immobilized protein. Maltose binding protein (MBP), which does not bind DNA, did not 
sequester the probe, resulting in a uniform distribution of the radiolabel as in the control 
without any protein. This shows that specific molecular interaction is required for probe 
sequestration. Quantification of the fraction bound revealed that probe alone and probe 
mixed with non-specific protein have no fraction bound (Figure 27B). These results 
demonstrate the ability of DRaCALA to detect interactions between proteins and double-
stranded DNA.  
4.3 Oligonucleotide–Protein Interactions Are Specific in DRaCALA 
 CRP interaction with ICAP requires sequence-specific inverted repeats (267). To 
test if DRaCALA can detect changes in DNA–protein interaction with single base pair 
changes, point mutants were generated in the ICAP site at positions that are known to 
abolish binding (267). Specifically, the guanosines at position 8 and position 10 were 
changed to cytosines. Because the site is symmetrical, the corresponding cytosines at  
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Figure 27. Detection of Protein–DNA Interaction by DRaCALA. (A) Phosphorimager 
visualization of DRaCALA spots of indicated proteins at 100 nM mixed with 4 nM 32P-
labeled ICAP fragments and 200 mM cAMP show distributions of the radioligand, which 
are diffused and homogenous (no protein, MBP) or sequestered (CRP). (B) The fraction 
bound was quantified using the formula in the ‘Methods’ section and error bars indicate 
the SD for three spots. 
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positions 19 and 21 were changed to guanosines (Figure 28A). These various probes were  
tested, at 4 nM, for binding to CRP by DRaCALA. The wild-type ICAP was sequestered 
by 100 nM CRP as before. The 8:GC mutant (G to C at position 8 and C to G at position 
21) showed a very low level of binding to CRP while the10:GC mutant (G to C at 10 and 
C to G at 19) and the 8,10:GC double mutant exhibited no binding (Figure 28B). To 
confirm specificity, the binding between wild-type ICAP and 100 nM CRP was subjected 
to competition by wild-type and mutant-unlabeled DNA at 10, 100, or 1000 times the 
concentration of the labeled DNA. The wild-type competitor partially competed at 10-
fold excess and competed more significantly with increased amount of competitor 
(Figure 28C). The 8:GC competitor showed no competition at 10- or 100-fold excess but 
did display some minor competition at 1000-fold. The 10:GC and 8,10:GC failed to 
compete regardless of their concentration. These results collectively show that 
DRaCALA measures sequence-specific DNA binding. 
4.4 DNA-Binding Affinity and Kinetics Can Be Measured by DRaCALA 
 In order to accurately describe the activity of a transcription factor or other protein 
on a DNA binding site, it is desirable to determine the affinity and kinetics of the DNA–
protein interaction. Because radionuclides can be detected with high sensitivity, 
DRaCALA can be used to make such measurements for high-affinity interactions. Serial 
2-fold dilutions of CRP were mixed with limiting 32P-labeled ICAP probe (5 pM) to find 
the affinity of CRP for ICAP. CRP bound ICAP with maximum affinity when it was 
saturated with 200 mM cAMP. Analysis of these results indicated a dissociation constant 
(Kd) of 3.6 ± 0.4 x10-11 M (SE) (Figure 29A). This is consistent with previously reported 
values for ICAP (266) (Table 5). In the absence of cAMP, the affinity of CRP for ICAP  
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Figure 28. CRP binding to specific DNA sequences detected by DRaCALA. (A) The 
sequence of the 28-bp ICAP site. The positions perturbed in this study are marked in red. 
Names of mutant versions are listed next to the point mutations that define them. 
Equivalent nomenclature for mutants from Gunasekera et al. (267) is indicated in 
parentheses. (B) DRaCALA spots for direct binding of 100 nM CRP to 4 nM of ICAP, 
8:G-C, 10:G-C and 8, 10:G-C probes with 200 mM cAMP are shown above the graphed 
quantification of fraction bound. (C) Binding of the ICAP probe to CRP was subjected to 
competition by unlabeled probes at 10, 100 or 1000 times the concentration of the 
radioligand. All error bars represent SD of three spots. DRaCALA spots shown above 
their respective conditions are separate images consolidated to fit the graph. 
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Figure 29. DRaCALA allows determination of affinity and kinetics of protein–DNA 
interaction. The affinity of CRP to the ICAP binding site reconstituted from annealed 
oligonucleotides (vl1427 and vl1428) was determined by the ability of serially diluted 
CRP to sequester 4 pM 32P-labeled ICAP probe in the presence of 200 mM cAMP by (A) 
DRaCALA and (B) EMSA. (C) The fraction bound is plotted against each concentration 
of CRP as detected by EMSA in the presence of 200 mM cAMP or DRaCALA at 0 or 
200 mM cAMP. Plot represents a single replicate for EMSA and three replicates for 
DRaCALA. All Kd values are reported in Table 5. (D) The observed off-rate, koff = 2.6 ± 
0.40 x 10-3 s-1 (SD), was measured by adding 1000-fold unlabeled competitor to 5 nM 
CRP with 5 pM ICAP oligonucleotide probe and spotting at different time points. All 
error bars represent the SD of three spots. 
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Table 5. Observed affinity of CRP to various ICAP probes from this and previous 
studies with indicated amounts of cAMP. All reported Kd values from this study were 
determined by DRaCALA and the standard error of three trials is reported. 
 
Source Method Probe [cAMP] (M) Kd (M)(± SEM) 
(267) Filter binding ICAP oligo 32P 2 x 10-4 1.4 ± 0.3 x 10-11a 
(267) Filter binding ICAP oligo 32P 0 > 1.0 x 10-7a 
This study DRaCALA ICAP oligo 32P 2 x 10-4 3.6 ± 0.4 x 10-11 
This study DRaCALA ICAP oligo 32P 0 > 1.0 x 10-6 
This study DRaCALA ICAP* plasmid 32P 2 x 10-4 4.1 ± 1.0 x 10-11 
This study DRaCALA ICAP* plasmid 32P 0 > 1.0 x 10-6 
This study EMSA ICAP oligo 32P 2 x 10-4 8.1 ± 0.8 x 10-11 
 
aThe affinity reported in the Gunasekera et al. paper is the binding constant or association 
constant Ka. We have taken the inverse of those values to give the Kd reported in Table 5 
to match our Kd measurements. 
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was at least 10,000-fold lower (Kd > 1.0 x 10-6 M) (Figure 29C). To confirm our 
DRaCALA results, we applied the same sample to an EMSA to determine the fraction 
bound (Figure 29B). The autoradiogram of the EMSA shows that the mobility of the free 
annealed oligonucleotide is retarded in the presence of CRP while the free the single-
stranded oligonucleotide is not (Figure 29 and Figure 30). The results from the EMSA 
assay yielded a similar dissociation constant Kd of 8.1 ± 0.8 x 10-11 M (Figure 29C). 
 We also used the CRP–ICAP binding interaction to test whether DRaCALA can be 
used to easily monitor the dissociation kinetics for protein–DNA complexes. A limiting 
amount of 32P-labeled ICAP (5 pM) was mixed with a protein concentration just above 
the Kd (5 nM). Then, unlabeled competitor ICAP was added in 1000-fold excess of 
radiolabeled ligand and spots were made over time, and these spots were analyzed to 
monitor the fraction of ICAP bound as a function of time. Our analysis indicated a 
dissociation rate (koff) of 2.6 ± 0.40 x 10-3 s-1 (SD) for the CRP–cAMP complex, 
corresponding to a half-life of 4.42 min (Figure 29D). Using the DRaCALA-observed 
off-rate and affinity, the calculated on-rate is kon = 7.2 x 107 M-1 s-1. These results show 
that DRaCALA is a rapid method for determining affinity and kinetics of protein–DNA 
interactions. 
4.5 Protein Binding of Whole-Plasmid Ligands is Detected Specifically by 
DRaCALA 
 The mobility of both nucleotides and double-stranded oligonucleotides on 
nitrocellulose suggests that molecular weight is not a critical limiting factor for what 
types of molecules can be used as the mobile, detectable ligand. The size limit of DNA 
ligands in DRaCALA was tested by cloning the same ICAP binding site and mutant sites  
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Figure 30. EMSA detection of single-stranded oligonucleotide and annealed ICAP 
site in the absence and presence of CRP. The oligonucleotides (vl1427 and vl1428) are 
5’ end-labeled with 32P by PNK. The labeled oligonucleotides are annealed individually 
or in combination as indicated. Labeled oligonucleotides are incubated with and without 
CRP and separated by PAGE. (A) Autoradiogram of EMSA. (B) Quantification of the 
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onto a 3.5 kb pVL-Blunt plasmid, and using the entire linearized vector as a ligand. Each  
of the linearized plasmids was labeled with 32P and shown to be mobile in DRaCALA 
(plasmids listed in Table 7, Chapter 4.10 Materials and Methods). Plasmids (50 pM) with 
ICAP sites bound 100 nM CRP. In contrast, plasmids with 8:GC bound weakly and 
10:GC or 8,10:GC sites did not bind at all (Figure 31A). 
 Binding of a single ICAP insert on a plasmid probe (50 pM) to 100 nM CRP was 
next subjected to competition. Competitors in this case were made by PCR amplification 
of a 600-bp region of the plasmids containing wild-type and mutant ICAP sites. The 
wild-type PCR competitor partially inhibited radiolabeled plasmid binding to CRP at 10-
fold excess of the radiolabeled ligand and fully competed at 1000-fold excess (Figure 
31B). PCR products containing 8:GC, 10:GC, or 8,10:GC did not compete away binding 
even at 1000-fold excess concentration. Detected binding of CRP to whole-plasmid 
probes is therefore also site-specific in DRaCALA. These results show that the critical 
parameter for detection of protein–DNA interaction by DRaCALA is the mobility of the 
ligand on the solid support and not the molecular weight of the ligand. 
4.6 Affinity and Kinetics Determined For Whole Plasmid Ligand 
 Whole plasmids can also be used in affinity and kinetic studies. With 200 mM 
cAMP, the observed Kd of CRP and a plasmid with a single ICAP site was 4.1 ± 0.3 x  
10-11 M (SD) (Figure 32A). Without cAMP the Kd was > 1.0 x 10-6 M. These values are 
similar to those obtained for the labeled oligonucleotides and those from previous studies 
(Table 5). The off-rate for the plasmid was observed at koff = 4.8 ± 0.17 x 10-4 s-1, 
corresponding to a half-life of 23.9 min (Figure 32B). The calculated on-rate for the 
plasmid was kon = 1.2 x 107 M-1 s-1, which is 6-fold lower than that of the annealed  
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Figure 31. DRaCALA allows detection of specific interaction of CRP with plasmid 
carrying the ICAP site. (A) 50 pM individual plasmids with 1x, 3x or 5x wild-type 
binding sites or 3x mutant-binding sites cloned in series were tested for binding in the 
presence of 100 nM CRP and 200 mM cAMP. (B) Specificity was determined by 
competition of binding to 32P-labeled 1x wild-type plasmid with unlabeled PCR products. 
Competitors used were 1x ICAP, 3x 8:G-C, 3x 10:G-C, 3x 8,10:G-C. All error bars 
represent SD of three spots with a representative spot (spot images consolidated to fit 
graph) shown above each column. 
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Figure 32. Affinity and kinetics of DNA-binding determined using 5 pM whole-
plasmid probe with a single ICAP site. (A) Graphs of fraction of ICAP plasmid bound 
by various concentrations of CRP with indicated levels of cAMP (Kd reported in Table 
5). (B) Graph of observed off-rate of koff = 4.8 ± 0.17 x 10-4 s-1 (SD) for ICAP plasmid 
generated by adding 1000-fold unlabeled PCR product (1x ICAP) competitor to 5 nM 
CRP with plasmid probe and spotting at time points > 3 h. All error bars represent SDs of 
three spots. 
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oligonucleotides, likely due to the large excess of non-specific DNA in the plasmid  
probe. Affinity and kinetics can thus also be measured for sites contained on a plasmid. 
4.7 Use of DNA As a Carrier/Label Molecule 
 Because such large pieces of DNA can be used in DRaCALA without altering 
specificity, we hypothesized that DNA could be used as a label and carrier for molecules 
that are not ordinarily mobile in DRaCALA and/or not easily labeled. Because ligand 
mobility and ligand detection are the only requirements for the mobile binding partner, 
DNA-conjugation could potentially make any molecule adaptable for use as a DRaCALA 
probe. A DNA component to the probe allows for easy labeling with 32P. Many small, 
soluble molecules are not mobile in DRaCALA suggesting that fluorescently labeled low 
molecular weight ligands are not suitable for DRaCALA technique (Figure 33). 
However, addition of DNA to immobile ethidium bromide conferred mobility to the 
interacting dye (Figure 33) implying that conjugation to DNA can overcome the 
immobility of some dye molecules. DNA can also be covalently linked to molecules 
through bioconjugate PCR with modified primers. This technique was tested using the 
biotin–streptavidin system. PCR products including the binding sites of the 3x ICAP 
plasmid and 3x 8,10:GC plasmid were generated with a 5’-biotinylated primer and 
labeled with 32P on the free 5’-end. These bioconjugate probes were tested with 
DRaCALA for binding to CRP, streptavidin and MBP. The wild-type probe without 
biotin-bound CRP but not streptavidin or MBP (Figure 34A). The biotinylated wild-type 
probe bound both CRP and streptavidin but not MBP. The 8,10:GC probe without biotin 
bound none of the proteins, whereas the biotinylated version bound only streptavidin. 
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Figure 33. Small detectable molecules exhibit variable mobility by capillary action 
through nitrocellulose. 5 µl of given concentration of each molecule was spotted: 3 nM 
32P-ATP, 10 µM TNP-ATP, 200 µM FITC-NP, 250 µM crystal violet, 300 µM 
Coomassie, 200 µM TRITC, 500 µM propidium iodide, 250 µM EtBr, 250 µM EtBr with 
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Figure 34. Bioconjugate DNA probes. Bioconjugate probes were generated by PCR 
with 5’-biotinylated primers. (A) Four probes (ICAP and 8,10:GC with and without 
biotin) were tested for binding to CRP, streptavidin and MBP. A mix of 50 pM 32P-
labeled probe, 100 nM protein and 200 mM cAMP was spotted on 0.8 m nitrocellulose 
and phosphor images of the spots are shown. (B) The ICAP–biotin probe affinity for 
streptavidin in PBS was determined by DRaCALA with 100 pM probe (Kd = 4.0 ± 0.6 x 
10-10 M). (C) Binding of 10 nM streptavidin to the ICAP–biotin probe was competed with 
serial dilutions of free biotin (IC50 = 3.3 x 10-8 M).  
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 The affinity of the biotinylated ICAP probe was determined using DRaCALA by 
diluting streptavidin (Figure 34B). The ability to assess affinity was limited by the 
concentration of the probe that could not be diluted below tens of pM without loss of 
signal. The limit of DRaCALA detecting binding seems to be therefore the limit of 
detection of the probe. The IC50 of free biotin was determined by competing against the 
probe with different concentrations of free biotin (Figure 34C). Here the IC50 of 33 nM is 
approximately enough to occupy the four sites of the 10 nM streptavidin. The observed 
affinity is lower than the previous published values for free biotin probably because the 
biotin molecule was conjugated to DNA (138). We were also able to measure the off-rate 
of the conjugated biotin by observing the exchange with excess free biotin (Figure 35). 
The exchange occurred in two steps, with an initial rapid off-rate and then a second 
slower rate corresponding to a half-life of 112 h and exchange-rate of koff = 1.7 x 10-6 s-1. 
The biphasic disscoation timecourse has been previously reported in a study of avidin and 
unconjugated biotin and is likely due to the tetramer protein having different affinites for 
biotin depending on the number of occupied sites (268). These results demonstrate that 
PCR conjugation can be used to link a molecule/ligand of interest to DNA, which allows 
facile 32P-labeling and can confer mobility (in DRaCALA), allowing rapid determination 
of affinity and kinetics of the protein–ligand interaction. 
4.8 Riboswitch-Binding cdiGMP 
 We have shown that protein interaction with DNA can be detected by DRaCALA. 
We wondered whether this technique could be applied to monitor RNA-ligand binding 
interactions. In particular, can the DRaCALA technology be used to detect the interaction 
of riboswitches with their small molecule ligands? One example of such an interaction  
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Figure 35: Off Rate of Streptavidin-Biotin Interaction. Binding of 10 nM streptavidin 
to 100 pM 32P-ICAP-biotin probe measured over time after addition of 100 µM free 
biotin.  
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that has been of recent interest is the cdiGMP responsive Vc2 riboswitch identified in 
bacteria (138). To study such an interaction with DRaCALA, one of the binding partners 
must be immobilized. We achieved this through biotinylation of Vc2* riboswitch RNA 
(with a modified tetraloop and shortened 5’- and 3’-ends compared to the original Vc2) at 
the 3’-end by periodate cleavage of the terminal ribose and reductive amination to 
conjugate the biotin moiety. The biotinylated riboswitch was sequestered by streptavidin, 
allowing the nucleic acid to take the place of protein as the immobile partner in the 
binding assay (Figure X8). Vc2* was tested directly for sequestration of cdiGMP and 
also biotinylated and tested for binding to cdiGMP in the presence or absence of 
streptavidin. The 4 nM radiolabeled cdiGMP was mobile alone and in the presence of the 
Vc2* or biotinylated Vc2* RNA (Figure 36A, lanes 1–3). This suggests that RNA, like 
DNA, is mobile in this system, and therefore could be used as a labeled probe as well. 
Streptavidin did not sequester radiolabeled cdiGMP alone or with Vc2* RNA, so there is 
no detectable interaction between streptavidin and Vc2* RNA (lanes 4–5). Biotinylated 
Vc2* RNA and bound cdiGMP were immobilized by streptavidin as expected (lane 6). 
The affinity of Vc2* for cdiGMP was tested using both DRaCALA and an EMSA (or gel 
shift). These measurements were made in a Vc2 binding buffer (10 mM sodium 
cacodylate, 10 mM MgCl2, 10 mM KCl) by heating the binding reaction to 70 ˚ C for 3 
min, slowly cooling to room temperature, and then incubating at room temperature for 48 
h (142). Remarkably similar results were obtained using DRaCALA and gel shift (Figure 
36B). The affinity of the Vc2* RNA for cdiGMP was observed to be Kd = 7.8 ± 1.9 10-9 
M with DRaCALA and Kd = 9.8 ± 1.6 x 10-9 M with EMSA. These results show that 
DRaCALA works as well as EMSA for studying the molecular interactions of  
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Figure 36. Vc2* RNA binding to 32P-cdiGMP is detected by DRaCALA. (A) Spots 
visualized by phosphorimager with streptavidin used to immobilize biotinylated RNA. 
The binding reaction contained 4 nM 32P-cdiGMP, 1 mM RNA and 200 nM streptavidin 
in buffer (10 mM KCl, 10 mM sodium cacodylate, 3 mM MgCl2). (B) The affinity of 
Vc2*-biotin RNA for cdiGMP was determined with both EMSA and DRaCALA by 
diluting RNA in the binding reaction. The fraction bound is normalized such that 1.0 
represents maximal binding. The DRaCALA-obtained affinity was Kd = 7.8 ± 1.9 x 10-9 
M and the apparent affinity in EMSA was Kd = 9.8 ± 1.6 x 10-9 M 
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riboswitches. This strategy can be adapted to study interactions between the biotinylated 
nucleic acids and a mobile ligand (another nucleic acid or nucleotide). 
4.9 Discussion 
 Nucleic acid interactions with proteins and low molecular weight ligands are 
fundamental for biological function. This has inspired the development of a number of 
assays to measure these interactions. We will compare and contrast the merits of 
DRaCALA with these various assay systems using CRP–cAMP as the classic example of 
a signal-responsive transcription factor and a model system for protein interaction with 
both a large nucleic acid and a mononucleotide. Study of the CRP system led to the 
establishment of some fundamental concepts related to transcription, such as regulation 
by second messengers (269), multiple promoter control of a single operon (270-272) and 
promoter control of RNA polymerase binding (273). Because of this foundational work, 
CRP and the lac repressor have been traditionally used to demonstrate proof of principal 
for various methods to detect DNA–protein interactions. 
 Nucleic acid–protein DRaCALA utilizes the differential mobility of nucleic acids 
through nitrocellulose to separate DNA that is bound to a protein from that which is 
unbound. The interactions measured in this way were specific to the nucleic acid 
sequences because point mutations at previously identified critical nucleic acids 
abolished specific binding of CRP to ICAP in both annealed oligonucleotides and 
plasmids (274). The affinity of the interaction was measured by diluting the protein 
before adding it to limiting amounts of probe and spotting on nitrocellulose. The Kd 
measured for the annealed oligonucleotide and plasmid closely matched what was 
reported in a previous study that used a filter-binding assay (267) as well as a study that 
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used gel shift (275) (Table 5). The off-rate determined with DRaCALA was slower for 
the plasmid than for the oligonucleotide probe, which is consistent with the finding that 
non-specific DNA concentration can affect the kinetics of specific DNA binding with 
protein (276). The off-rate for the plasmid (koff = 4.84 ± 0.17 x 10-4 s-1) was similar to that 
reported in a gel shift study (koff = 1.2 x 10-4 s-1) (276). This corresponds to an observed 
half lives of 23.9 min for DRaCALA and about an hour for gel shift. This difference may 
be explained by the amount of unlabeled competitor used to chase off the probe, which 
was at 25 times molar excess for the gel shift and 1000 times for DRaCALA. For 
DRaCALA with plasmid probes, another advantage is that high concentrations of 
competitor can easily be obtained by PCR amplification. The on-rate cannot be measured 
using DRaCALA, but it can be approximated by assuming a simple one-step binding 
mechanism with a calculation based on the affinity and off-rate. Using DRaCALA with 
plasmid probes allows for easy testing of direct binding and specific competition of any 
potential DNA-binding site simply by cloning into a plasmid that can be labeled for 
detection. One could make the case that studying kinetics in this system more accurately 
reflects DNA-binding activity in a cell compared to protein-oligo binding, because there 
is a great excess of DNA to which the protein can bind non-specifically. 
 Comparing DRaCALA to the traditional separation-based methods reveals the 
advantages of the new technique. The filter-binding assay was the first popular method 
that depended on separation of bound and unbound ligands based on differential mobility 
through a support (181). This technique was used for the first study of the interaction of 
CRP with DNA (274). One key difference between DRaCALA and filter-binding assays 
is that for DRaCALA, both the bound ligand and the total amount of ligand are always 
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measured. In contrast, the traditional filter-binding assay typically only measures the 
bound ligand. Thus, results of filter-binding assays are typically normalized to 1.0 
fraction bound for the highest concentration of protein or ligand. In contrast, results for 
DRaCALA for the highest concentration of protein is often < 1.0. There are three 
potential reasons for the fraction bound detected by DRaCALA to be less than the 
theoretical 1.0. First, the off-rate of the protein–ligand interaction dictate that, during the 
assay time, a population of the bound ligand is dissociated, mobilized and cannot rebind 
the protein. Second, for all 5’-end-labeled nucleotide, a small fraction of labeled free 
phosphate can be hydrolyzed and appear as free ligand. Third, oligonucleotide probes can 
fold into non-native conformations. For example, the inverted repeat of the ICAP oligo 
can lead to the folding into hairpins that cannot be bound by CRP. Because DRaCALA 
measures both free and bound ligand, the determined fraction bound is far more accurate 
despite the detection of fraction bound of < 1.0. We do not think this is a concern as the 
Kd and koff that we measured for CRP–ICAP interactions are similar to previously 
reported results. A similarity shared by DRaCALA and filter-binding assays is the 
interaction of proteins with nitrocellulose may alter the behavior of proteins. For 
DRaCALA, this effect is likely protein-specific since soluble and insoluble forms of 
Alg44 and PelD behave similarly when assayed for binding to cdiGMP by DRaCALA 
(209). 
 The EMSA (or gel shift), which detects interactions because they cause retardation 
in DNA mobility through a gel, was first introduced as an alternative to the filter-binding 
assay using the lac repressor as an example (277,278). Later it was used to study CRP in 
greater detail (275,276). The major strengths of the gel shift are that both bound and 
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unbound ligands are measured and supershifts provide information about binding 
structure. A potential issue is the length of time required to run the gel, during which time 
the protein and DNA can dissociate, which is a particular concern for lower affinity 
interactions (279). DRaCALA does not have a wash step and it measures total signal in 
every sample with a visual readout, making it preferable to the filter-binding assay. 
EMSA also measures total signal with a visual readout, but requires a much greater assay 
time than DRaCALA. Although DRaCALA is more rapid, EMSA still retains an 
advantage in the detection of supershifts that result from an antibody binding to a DNA-
bound protein or multiple proteins binding to DNA. The ability of DRaCALA to detect 
interactions on plasmid DNA is a significant improvement over EMSA, which is most 
sensitive with probes <300-bp long (280). 
 More modern techniques include chromatin immunoprecipitation on a microarray 
chip (ChIP-chip) and sequencing of chromatin immunoprecipitated DNA (ChIP-Seq). 
These assays allow for a high-throughput approach to identify binding sites on the 
chromosome but provide no measure of affinity and cannot rule out indirect interactions 
(281,282). Because the readout of ChIP-chip is precipitation or a lack thereof, studies of 
transcription factors such as CRP often have false negatives and include a lot of 
background noise attributable to low-affinity binding sites (283). The most accurate 
analytical assays include isothermal titration calorimetry (ITC) and surface plasmon 
resonance (SPR). ITC uses a controlled chamber to assess heat changes as DNA binds 
protein, allowing for thermodynamic and kinetic measurements (284). SPR detects 
molecular weight changes on a metal surface in real time and can determine affinity and 
kinetics with remarkable sensitivity (285). The proof of principle for SPR studies of 
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DNA–protein interaction was first demonstrated using the lac repressor (286). ITC and 
SPR have the advantage over DRaCALA in that neither technique requires labeling of the 
ligand of interest. However, the common drawbacks of ChIP-chip, ITC and SPR are the 
relatively high associated costs and need for specialized equipment. DRaCALA uses 
small amounts of inexpensive materials and requires no special equipment, making 
biochemistry accessible to molecular biologists. DRaCALA is precise, with standard 
deviations (SDs) of measurements that are typically <5% of the mean. The value of 
DRaCALA lies in the simplicity of the technique. The only special tool required is a 
detector of the label on the probe. Only a small amount of sample and nitrocellulose are 
needed, making it inexpensive and easy to scale up. Capillary action of small volumes is 
fast, so separation of bound and unbound ligand takes only seconds. Together, these traits 
make DRaCALA especially cost and time efficient in comparison to established methods. 
 The simplicity of DRaCALA allows adaptation of the technique to study other 
molecular interactions. PCR conjugation of DNA to a variety of molecules can be 
achieved using commercially available modified primers that can have 5’ reactive groups 
such as aldehydes, amines and thiols. This can serve the dual function of keeping the 
molecule mobile through nitrocellulose and providing a mechanism to label the probe in 
different ways. Radiolabelling small molecules directly is often impractical due to costs 
associated with chemical synthesis with radiolabeled chemicals, so DNA conjugation 
could be a good alternative. The free 5’-end of the DNA can be 32P-labeled as in this 
study or occupied with a fluorescent dye from a second modified primer in the original 
PCR reaction. While fluorescence may be desirable for its ease of use, it cannot match 
the sensitivity of 32P. Bioconjugate PCR was used in this study with the simple 
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streptavidin– biotin system. Biotinylated PCR products were mobile, detectable and 
showed specific interactions with CRP and streptavidin. This also allows selective 
immobilization of biotinylated nucleic acids so that they can take the role of the immobile 
binding partner in DRaCALA. 
 As shown in this study, immobilization of RNA allowed detection of RNA 
interaction with a small ligand. This area has been of great interest since the discovery of 
riboswitches, cis-acting RNA sequences on mRNAs that directly interact with small 
molecules and consequently self-regulate their transcriptional termination and/or 
translation (287,288). Such RNAs have been found to bind a variety of small molecules, 
including amino acid derivatives, coenzyme B12 and the bacterial second messenger 
cdiGMP (138,289,290). Studies of riboswitches have primarily used in-line probing and 
equilibrium dialysis to analyze direct RNA binding to its target molecule. These methods 
require long incubations that limit their accuracy in determining biochemical parameters. 
Others have used gel shift assays to measure the affinity and kinetics for riboswitches 
(142). By comparing DRaCALA to gel shift assays using a Vc2* RNA to establish a 
proof of principle, we have demonstrated that DRaCALA is a powerful alternative to 
these methods, which is much faster with at least equal accuracy and precision (Figure 
36). In this study, RNA was immobilized using biotinylation, but RNA could also be 
immobilized by other means such as with a known binding protein or an additional 
sequence on the RNA that specifically binds a protein. Another alternative strategy is to 
use a biotinylated DNA oligonucleotide that can hybridize with the RNA molecule (3’-
end of riboswitch) to provide a method for immobilization. The same technique could 
also be used to study RNA–RNA interactions in the context of regulatory RNAs, which 
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are ubiquitous in prokaryotes and eukaryotes and have therapeutic potential (291,292). 
As more research is done involving RNA interactions with a variety of other molecules, it 
is critical to have a rapid, quantitative and cost-effective method for directly testing these 
interactions. 
 DRaCALA requires one immobile binding partner and a ligand that is detectable 
and mobile by capillary action. This study provides a foundation for universal 
applicability of DRaCALA for studying any molecular interaction. There is evidence that 
DNA could serve as a label and carrier for any molecule that can be conjugated to it. 
Because bioconjugate PCR allows specific immobilization of biotinylated nucleic acids, 
the assay can be used with nucleic acids as the immobile and/or the mobile piece in 
binding studies. These manipulations of the mobility of molecules provide a window to 
the many potential uses of this assay. Additionally, the ease of running DRaCALA (little 
volume needed, no wash step, inexpensive materials and visual readout) makes it 
possibly amenable to usage as a portable rapid diagnostic tool in a ‘lab-on-paper’ design 
(293). 
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4.10 Chapter 4 Methods 
Table 6. Primers used in Chapter 4. ICAP and mutant ICAP sites are indicated (RC = 
reverse complement).  
Name Contenta Use Sequence (5’-3’) Reference 
gd126 ICAP* oligonucleotide probe AGGAGGAATAAATGTGATCT
AGATCACATTTTAGAGGAGG 
This study 
gd127 ICAP* RC oligonucleotide probe CCTCCTCTAAAATGTGATCT
AGATCACATTTATTCCTCCT 
This study 
gd128 ICAP* 8:G-C oligonucleotide probe AGGAGGAATAAATCTGATCT
AGATCAGATTTTAGAGGAGG 
This study 
gd129 ICAP* 8:G-C RC oligonucleotide probe CCTCCTCTAAAATCTGATCT
AGATCAGATTTATTCCTCCT 
This study 
gd130 ICAP* 10:G-C oligonucleotide probe AGGAGGAATAAATGTCATCT
AGATGACATTTTAGAGGAGG 
This study 
gd131 ICAP* 10:G-C RC oligonucleotide probe CCTCCTCTAAAATGTCATCT
AGATGACATTTATTCCTCCT 
This study 




gd133 ICAP* 8,10:G-C RC oligonucleotide probe CCTCCTCTAAAATCTCATCT
AGATGAGATTTATTCCTCCT 
This study 
kr122 ICAP* clone into plasmid AATAAATGTGATCTAGATCA
CATTTTAG 
This study 
kr123 ICAP* RC clone into plasmid CTAAAATGTGATCTAGATCA
CATTTATT 
This study 
kr124 ICAP* 8:G-C clone into plasmid AATAAATCTGATCTAGATCA
GATTTTAG 
This study 
kr125 ICAP* 8:G-C RC clone into plasmid CTAAAATCTGATCTAGATCA
GATTTATT 
This study 
kr126 ICAP*10:G-C clone into plasmid AATAAATGTCATCTAGATGA
CATTTTAG 
This study 
kr127 ICAP* 10:G-C RC clone into plasmid CTAAAATGTCATCTAGATGA
CATTTATT 
This study 
kr128 ICAP* 8,10:G-C clone into plasmid AATAAATCTCATCTAGATGA
GATTTTAG 
This study 
kr129 ICAP* 8,10:G-C RC clone into plasmid CTAAAATCTCATCTAGATGA
GATTTATT 
This study 








vl880 - PCR of insert GACCATGATTACGCCAAGCT
A 
This study 
vl881 - PCR of insert CAGCTTTCATCCCCGATATG This study 
a The original ICAP sequence described by Ebright, Ebright, and Gunasekara the same as 
vl1427 and vl1428. ICAP* sequences including gd126-133 and kr122-129 have the core 
28bp of the ICAP sequence with the indicated sequences. gd126-133 have 6 bp flanking 
sequence that is different  
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Table 7. Plasmids used in Chapter 4. ICAP and mutant ICAP sites are indicated.   
 
Name Parent Insert 
pVL-Blunt - - 
pGD7 pVL-Blunt ICAP x5 
pGD8 pVL-Blunt ICAP x3 
pGD9 pVL-Blunt ICAP x1 
pGD11 pVL-Blunt ICAP 8:G-C x3 
pGD12 pVL-Blunt ICAP 10:G-C x3 
pGD13 pVL-Blunt ICAP 8,10:G-C x3 
 
Proteins, nucleic acids, and chemicals 
 The Vc2* DNA template was ordered from Integrated DNA Technologies. Other 
DNA oligonucleotides, Nucaway size exclusion columns, and Turbo DNase were from 
Invitrogen. RNase was from Fermentas. RNase inhibitor and enzymes for restriction 
digests, PCR, and other nucleic acid manipulations were from New England Biolabs. 
Streptavidin MagneSphere Paramagnetic Particles, Wizard miniprep and PCR 
Purification kits for DNA purification were from Promega. Biotin hydrazide and 
streptavidin were from Sigma Aldrich. 
CRP was purified according to (209). Briefly, His-CRP (CRP) was expressed 
from pBAD-CRP (a gift from Dr. Sankar Adhya) and purified using a Ni-NTA column. 
Proteins were dialyzed in 10 mM Tris, pH 8.0 and 100 mM NaCl. His-CRP was 
subsequently purified and concentrated using cation exchange to a concentration of 36 
µM, frozen in liquid nitrogen, and stored at -80°C until thawing for use. The fraction of 
active CRP molecules in sequence-specific DNA binding (0.61) was determined by 
titration of DNA fragment ICAP under stoichiometric binding conditions. Specifically, 
serial dilutions of CRP were incubated with a concentration of 32P ICAP dsDNA in 
excess of the Kd (200 nM) for 10 minutes at room temperature prior to determination of 
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binding by DRaCALA and EMSA. All data are reported in terms of molar concentrations 
of active CRP dimers. 
Preparation and activity of DNA oligonucleotides and plasmid probes 
 Reverse complementary oligonucleotides gd126-133 and vl1427-1428 (Table 6) 
were used to generate probes by labeling 5 pmol of the forward primer with T4 
Polynucleotide Kinase (PNK) and 15 pmol / 5 mCi of γ-32P-labelled ATP. Five pmol of 
the reverse complementary primer were added and the PNK was heat-inactivated during 
primer annealing in a 80°C water bath for ten minutes, which was then allowed to cool to 
room temperature over 1 hour. The annealed product was separated from free 32P-ATP 
using a Nucaway column and diluted 1:10 for binding and competitions studies and 
1:1000 for affinity and kinetics studies. Plasmids with binding sites were generated by 
cloning annealed, PNK-treated primers pairs (kr122-129 of Table 6) into StuI-cut pVL-
Blunt, and sequencing for verification (Table 7). Plasmids were 5’ end-labeled by 
sequential digestion with the single cutter BamHI, dephosphorylation of the 5’ overhang 
with Calf Intestinal Alkaline Phosphatase, separation from enzymes by a Wizard PCR 
Purification column, and treatment with PNK in the presence of γ-32P-labelled ATP. The 
labeled product was purified by Wizard column and a Nucaway column and diluted 1:10 
for affinity and kinetic study. The near 5' end of these labeled plasmids is about 40 bp 
from the cloned binding sites.  Competitors for plasmid binding were PCR amplified 
from these plasmids using primers vl880-vl881, which amplify the cloned binding sites 
and 250 bp flanking on each side (Table 6). The concentration of the ICAP probes was 
determined by Nanodrop1000. The fraction of ICAP that is active for binding is 
determined by measuring the maximum fraction of 32P-labeled ICAP in excess of Kd (200 
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nM) that could be specifically bound by excess CRP by both EMSA and DRaCALA. The 
fraction was multiplied by concentration of ICAP to yield the concentration of ICAP that 
is active. 
Differential Radial Capillary Action of Ligand Assay (DRaCALA) 
 Protein, 32P-labeled DNA, and 200 µM cAMP (unless otherwise noted) were 
mixed in CRP buffer (10 mM Tris, pH 7.9, 200 mM NaCl, 0.1 mM DTT, 50 µg/ml BSA) 
(15) and incubated at room temperature for ten minutes. Five microliter of the mix was 
spotted on nitrocellulose by first pipetting the liquid out onto the tip of the pipette and 
then touching the drop to the membrane. Spots were allowed to dry completely (about 20 
minutes) before exposing a phosphorimager screen and capturing with a Fujifilm FLA-
7000. Photostimulated luminescence (PSL) from the inner spot and total PSL of the spot 
were quantitated with Fuji Image Gauge software. The fraction bound (Fb) (209) was 
calculated using measurements of the total area (Aouter), the area of the inner circle 
(Ainner), the total PSL intensity (Itotal), and the inner intensity (Iinner) as follows: 
€ 
FB =










Electrophoretic Mobility Shift Assay (EMSA) for CRP binding to ICAP oligonucleotide 
A fraction of the same mix described for the DRaCALA assay is supplemented 
with 10% glycerol and 0.001%Bromophenol Blue, and 5 µL was loaded onto an 8% 70:1 
0.5x TBE (90 mM Tris pH = 8.0, 90 mM H3BO3, 2.5 mM Na2EDTA) polyacrylamide gel 
(294). EMSA was preformed with 0.5x TBE Buffer at 4 ˚C. Gels were exposed to a 
phosphorimager screen and the image was captured with a Fujifilm FLA-7000. The 
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fraction bound was calculated as the intensity of the bound ICAP probe as a fraction of 
the total intensity of the bound and free ICAP probe.  
Non-radioactive ligands and detection 
 Fluorescent dyes were imaged with a GE Typhoon Trio. TNP was detected with 
electrochemiluminescence excitation at 555 nm emission. FITC was detected with 488 
nM excitation and 526 nM emission. Ethidium bromide was imaged under a UV light 
source. TRITC, Propidium iodide, crystal violet, and coomassie brilliant blue were 
imaged in visible light. 
Bioconjugate PCR 
 Biotinylated probes were generated by PCR using 5’-biotinylated primer vl881 
for amplification of a ~600 base pair region of plasmids pGD9 and pGD13 (Table 7). 
PCR products were extracted from an agarose gel and purified with a Wizard column. 
These were then γ-32P-labelled as described for the whole plasmids. 
Preparation and purification of Vc2* RNA 
 The Vc2* template sequence (138) including T7 promoter sequence and 
complimentary T7 promoter sequence 5′ - CTA ATA CGA CTC ACT ATA G - 3′ were 
purchased from Integrated DNA Technologies (IDT). Transcription was performed using 
1.5 µg of template, 10 µL of 4 mg/ml T7 polymerase per 200 µL of transcription volume, 
15 mM total NTP (A/C/G/UTPs), 15 mM MgCl2 in a transcription buffer of 40 mM Tris-
HCl (pH 8.1), 1 mM spermidine, 5 mM dithiothreitol (DTT), 0.01% Trixon X-100, 2 
units of RNase inhibitor, 2 unit of inorganic pyrophosphatase. After 3 h, 0.4 units of 
Turbo DNase were added and incubated for another 15 min. The crude RNA was purified 
using a 12% denaturing PAGE with 1×TBE buffer. The product band was detected via 
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UV-shadowing the gel, excised and electro-eluted in a Schleicher and Schuell Elutrap 
eletro-separation system. The purified RNA was precipitated with three volumes of 
absolute ethanol and 10% volumes of 0.3 M sodium acetate. The RNA pellet was then 
resuspended in water and dialyzed in a Nestroup Biodialyzer with a 500 MWCO 
membrane for 24 h against 100 mM potassium phosphate buffer (pH 6.4), 0.5 M KCl, 10 
mM EDTA, and then 1 and 0,1 mM EDTA, and finally against two changes of double 
distilled H2O water before it was lyophilized. 
Biotin labeling of RNA with biotin hydrazide at 3’-end 
 Seven µL of freshly prepared 0.5 M NaIO4 was added to Vc2* RNA (210 µg) in 
100 µL of water and the solution incubated at room temperature for 1 h. The excess 
NaIO4 was removed by filtration, using an Amicon ultra 0.5 mL centrifugal filter 
with10K cut-off membrane. The RNA was washed with 3×0.5 mL of water and then 
recovered by reverse spin. After that, 5µL of 1M sodium acetate, pH 4.95, and 7 ml of 35 
mM biotin hydrazide in DMSO were added to the RNA. Coupling was carried out at 37 
˚C for 1.5 hr, then 3 µL of 1 M NaCNBH3 in acetonitrile was added and the reduction 
was carried out at room temperature for 1 hr. The unused biotin hydrazide and NaCNBH3 
were removed by centrifugal filter as above. 
Testing the biotinylation efficiency with magnetic streptavidin beads 
 Four hundred µL of streptavidin MagneSphere Paramagnetic Particle solution 
(Promega; Binding capacity: greater than 0.75 nmol of biotinylated oligonucleotide (dT) 
bind per ml of particles) was taken and washed three times with 500 µL saline-sodium 
citrate (SSC) buffer (0.5X). The washing step was facilitated by applying a magnet to the 
side of the tube and the supernatant discarded during each wash. SSC buffer with 100 µl 
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of dissolved biotinylated RNA (2 µM) was added to streptavidin-coated magnetic 
particles and the tube was gently tapped to suspend the beads. The suspended beads were 
incubated at room temperature for 30 minutes, with occasional agitation by hand. A 
magnet was applied to the side of the tube and the supernatant was collected. The beads 
were washed with 100 µL SSC buffer (0.5X) two more times and the supernatant was 
collected and combined and UV260nm measurement was made (OD260 = 0.123; 300µL of 
supernatant wash). Because the supernatant was diluted three times, the OD of the 
original supernatant must be 0.531. This OD value was compared to the OD of the 
biotinylated RNA before incubation with streptavidin-coated beads. The yield of the 
biotnylated RNA was calculated to be 76.8%. 
 To confirm that the biotinylated RNA was bound to the streptavidin magnetic 
beads, 0.5 µL of RNAse A/T1 Mix was added to the washed beads in 100 µL of SSC 
buffer (0.5X). The beads were incubated at 37 ˚C for 30 mins before the supernatant was 
collected by applying a magnet. The OD260 for the eluted nucleotides was 0.560. The 
slight increase in absorbance at 260 nm (compare OD of 0.531 for the RNA with an OD 
of 0.56 for the nucleotides generated from the RNA hydrolysis) is expected as free 
nucleotides have higher absorption than when in a polynucleotide (hypochromic effect).  
Electrophoretic Mobility Shift Assay for RNA binding to cdiGMP 
 Gel shift assays were performed using 8% acrylamide gels with 100 mM 
Tris/HEPES, pH = 7.5, 10 mM MgCl2, and 0.1 mM EDTA in the gel and running buffer. 
Gels were run at 4°C at 100V for 2 hours. Gels were imaged with a phosphorimager and 
fraction bound quantified with Fuji Image Guage software. The 32P cdiGMP probe was 
synthesized from α-32P-GTP by incubating overnight with purified diguanylate cyclase 
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WspR (PA3702 from Pseudomonas aeruginosa) in 10 mM Tris, pH = 8, 100 mM NaCl, 
and 5 mM MgCl2 at 37°C. 
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Chapter 5: Conclusions and Perspective 
5.1 Evaluation of DRaCALA ORFeome Screens for the Identification of cdiGMP-
binding Proteins 
 The primary goal of my doctoral research has been to characterize the genetic 
basis of cdiGMP signaling in prokaryotes. Similar to eukaryotic cAMP signaling, 
prokaryotic cdiGMP signaling is complex with individual organisms containing dozens 
of DGCs and PDEs and multiple cdiGMP-dependent effectors (79). Genetic screens of 
cdiGMP-dependent phenotypes suffer from the intricate nature of cdiGMP regulated 
processes, which are diverse, multifactorial, and not necessarily observable under 
laboratory conditions. Despite these challenges, all cdiGMP-dependent processes rely on 
the allosteric regulation of effector proteins and RNAs by cdiGMP-binding. Therefore, to 
discover the molecular targets of cdiGMP signaling, I sought to systematically identify 
all proteins with cdiGMP-binding activity encoded within a bacterial genome. The 
identification of a complete set of cdiGMP effectors would reveal the potential regulatory 
activities of cdiGMP within a cell and provide a system level understanding of the 
cdiGMP regulatory network. 
 Several systematic methods for the identification of protein-ligand interactions 
have been applied to the identification cdiGMP-binding proteins. Most notably, the 
identification of conserved cdiGMP-binding domains (PilZ, GGDEF, EAL, HD-GYP) 
has allowed bioinformatic prediction of cdiGMP-binding proteins from sequenced 
genomes (109,112,126). However, several cdiGMP-binding proteins have been described 
that lack these domains (148,157,160,165,166). In the absence of conserved binding 
domains, cdiGMP-binding proteins have been identified based on their affinity for 
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cdiGMP. Several studies have attempted to identify cdiGMP effectors by affinity 
pulldown coupled with LC-MS for protein identification (208,295). However, affinity 
pull downs are limited by the requirement for expression of cdiGMP-binding proteins 
under laboratory conditions. Additionally, chemically derivatized cdiGMP probes may 
not interact with all cdiGMP-binding proteins (296-298). These limitations are overcome 
by DRaCALA through the use of radiolabeled cdiGMP probes and heterologous 
expression of fusion proteins in whole cell lysate. Thus, DRaCALA provides an 
alternative method for cdiGMP-binding protein identification that can be applied on a 
genomic scale. By systematically testing every individual open reading frame present 
within a genome for the expression of a cdiGMP-binding protein, DRaCALA may allow 
identification of a complete set of genomically-encoded cdiGMP effectors. 
 The DRaCALA ORFeome screen of the Vibrio cholearae open reading frame 
library had considerable success in identifying predicted, empirically characterized, and 
novel cdiGMP effector proteins. However, several proteins with demonstrated cdiGMP-
binding proteins were not identified (Chapter 3.3). While positive ORFs generally encode 
cdiGMP-binding proteins, negative ORFs may not be active as fusion proteins, 
improperly folded during heterologous expression, have low affinity for cdiGMP, require 
multi-protein complexes for binding, or not be expressed at sufficiently high levels for 
detection. Furthermore, DGC activity may affect the ability to detect binding to cdiGMP. 
Overexpression of GGDEF-domain proteins with DGC activity produces excess 
unlabeled cdiGMP thereby lowering fraction bound 32P-cdiGMP (Figure 16). In total, we 
identified 28 ORFs encoding putative cdiGMP-binding proteins, including 5 of 10 ORFs 
encoding proteins with empirically demonstrated cdiGMP-binding activity (Chapter 4.9). 
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A DRaCALA ORFeome screen to identify cdiAMP binding proteins from a 
Staphylococcus aureus open reading frame library obtained similar results. In 
collaboration with our lab, a report by Corrigan et al. identified 4 novel cdiAMP binding 
proteins and 3 of these proteins were identified in the DRaCALA screen (254). The 
fourth protein CpaA was not present in the S. aureus ORFeome. Together, these studies 
show that DRaCALA ORFeome screens are a systematic method for the identification of 
cyclic di-nucleotide binding proteins. However, DRaCALA alone is not sufficient to 
determine a complete set of binding proteins within a given genome. Nonetheless, the 
characterization of new binding proteins will allow identification of evolutionarily 
conserved cdiGMP-binding motifs, thereby enabling prediction of new cdiGMP-binding 
proteins in sequenced organisms. Subsequent genetic and biochemical characterization 
can determine if these cdiGMP-binding proteins are sufficient to mediate cdiGMP-
dependent phenotypes. A combination of these approaches may enable identification of a 
complete set of genomically-encoded cdiGMP-binding proteins. 
5.2 Linking cdiGMP-binding Proteins to cdiGMP Regulated Phenotypes 
  Previous identification of cdiGMP-binding proteins has provided insight into the 
cellular targets and molecular mechanisms of cdiGMP-dependent regulation. For 
example, YcgR is a regulator of flagellar motility that interacts with the flagellar motor 
complex. Identification of a PilZ domain in YcgR suggested that cdiGMP regulates 
flagellar motility by binding to YcgR (122). Subsequent studies on the molecular 
mechanism of cdiGMP regulation by YcgR have revealed that cdiGMP-binding to YcgR 
alters protein-protein interactions between YcgR and the flagellar motor complex 
(195,299,300). This causes a decrease in flagellar velocity and induces a counter-
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clockwise bias in flagellar rotation. Counterclock-wise rotation produces long runs and 
decreased tumbling, preventing bacteria from changing direction upon encountering 
microscopic obstructions (301). In a second example, the Alg44 protein was identified as 
a unique regulator of alginate biosynthesis in P. aeruginosa (125). Subsequent 
identification of a PilZ domain in the Alg44 protein led to the discovery that cdiGMP-
binding to Alg44 regulates alginate biosynthesis (121,126).Thus, the discovery of 
cdiGMP-binding to proteins with previously characterized regulatory activity has 
provided valuable insight into the specific cellular processes regulated by cdiGMP. 
 In the absence of known phenotypes and biochemical activities, identification of 
specific regulatory targets and mechanisms for individual cdiGMP-binding proteins can 
be challenging. For example, V. cholerae encodes 3 PilZ domain proteins that bind 
cdiGMP and contain no other identifiable domain (127). Genetic analysis of their 
requirement for cdiGMP-dependent phenotypes revealed pleiotropic effects on motility, 
biofilm formation and intestinal colonization (127). The specific molecular activities of 
these proteins have yet to be described. Similarly, P. aeruginosa contains 7 PilZ domain 
proteins that bind cdiGMP, but the biological effects of cdiGMP-binding to these proteins 
have only been described for Alg44 (126). Thus, connecting cdiGMP-binding proteins to 
specific cdiGMP regulated processes remains a challenge. To determine the specific 
activities of cdiGMP-binding proteins, genetic and biochemical dissection of the specific 
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5.3 MshE and cdiGMP-dependent Regulation of Type IV Pili 
 The identification of cdiGMP-binding to MshE has suggested a new mechanism 
for cdiGMP-dependent regulation of MSHA type IV pili in Vibrio cholerae. MshE is a 
member of a family of hexameric ATPases (here referred to as T2SE ATPases) that are 
required for both biosynthesis and retraction of type IV pili (245). Previous work has 
demonstrated that cdiGMP regulates type IV pili-dependent motility in Pseudomonas 
aeruginosa and pathogenesis in Xanthomonas campestris. Some genetic requirements 
have been identified for this cdiGMP dependent regulation, but the precise mechanism by 
which cdiGMP regulates pili function is unknown. 
Regulation in Pseudomonas aeruginosa 
 In P. aeruginosa, the PilZ protein is required for type IV pili biogenesis but does 
not bind cdiGMP directly (126,302). Instead, a cdiGMP-binding protein FimX was 
shown to regulate type IV pili formation (112,114,116). However, FimX and PilZ do not 
interact in P. aeruginosa, and the mechanism of FimX regulation of type IV pili is not 
known. Furthermore, a recent screen of type IV pili formation in a fimX mutant revealed 
that high cdiGMP levels allow pilus formation in the a fimX independent manner, 
suggesting that other cdiGMP-binding proteins may be involved in type IV pili regulation 
(263).  
Regulation in Xanthomonas campestris sp. 
 cdiGMP-dependent regulation of type IV pili has been studied in two 
Xanthomonas species, X. campestris citri, and X. campestris campestris. In both 
organisms, cdiGMP signaling components interact with either the PilB extension ATPase 
or PilT/PilU retraction ATPases of type IV pili. In X. campestris citri, a FimX homolog 
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has been shown to directly interact with a PilZ protein deficient in cdiGMP-binding to 
regulate type IV pili (244). The FimX and PilZ protein of X. campestris citri have been 
crystallized in complex with a MshE homolog, PilB, suggesting that cdiGMP may 
regulate type IV pili via protein-protein interactions with PilB (262). In the related 
organism X. campestris campestris, studies have shown that an HD-GYP domain protein, 
RpfG, interacts with a GGDEF-domain protein to recruit a PilZ domain protein that has 
cdiGMP-binding activity (103,242). This RpfG/GGDEF/PilZ protein complex interacts 
with a different set of conserved MshE homologs, PilT and PilU which function in type 
IV pili retraction (242).  
 In this work, purified MshE was shown to bind cdiGMP and have ATPase activity 
(Chapter 3.4). However, cdiGMP-binding did not alter the rate of ATP hydrolysis, 
suggesting that cdiGMP binding may alter other activties of MshE such as protein-protein 
interactions. Thus, cdiGMP-dependent regulation of type IV pili appears to converge on 
the regulatory ATPases, but the molecular mechanisms of this regulation appear to have 
diverged. Studies in X. campestris demonstrate multiple cdiGMP effector interactions 
with MshE homologs and direct cdiGMP-binding to MshE may represent a V. cholerae 
specific mechanism for cdiGMP-dependent regulation of type IV pili.  
 Alternatively, the identification of cdiGMP-binding activity for the P aeruginosa 
MshE homolog PA14_29490 indicates that direct cdiGMP-binding may be a conserved 
regulatory feature. MshE and PA14_29490 represent a monophyletic cluster among the 
T2SE ATPases that that regulate type IV pili and type II secretion systems (245). Type II 
secretion systems and type IV pili assembly apparatus are evolved from a common 
ancestor and composed of proteins with similar structure and function, suggesting a 
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conserved mechanism for type IV pilus assembly and type II secretion (303). For 
example, both systems contain pilin-like proteins that are assembled by T2SE ATPases to 
form the type IV pili or a piston like pseudopilus required for secretion of type II 
secretion substrates (304). Several T2SE ATPases have been structurally and genetically 
characterized including PilB homologs required for type IV pili polymerization, 
PilT/PilU homologs required for type IV pili retraction, and EspE and XcpR required for 
type II secretion in V. cholerae and P. aeruginosa respectively (246-249,305-309). 
cdiGMP-binding was not detected for these and other T2SE ATPase homologs, 
suggesting that MshE and PA14_29490 represent a subset of T2SE ATPases that evolved 
cdiGMP-binding (Figure 24). The identification of conserved residues for cdiGMP-
binding in MshE and PA14_29490 will allow prediction of cdiGMP-binding for a subset 
of T2SE ATPases and reveal if this subset of type II secretion is a target of cdiGMP 
regulation.  
5.4 Future Applications for DRaCALA 
 DRaCALA has proven to be a valuable tool for identifying cdiGMP and cdiAMP 
binding proteins. Identification has relied on the use of large open reading frame libraries 
that were cloned to represent the majority of ORFs within a genome. DRaCALA 
ORFeome screens are useful for the identification of novel cyclic di-nucloeitde binding 
proteins, and targeted screens of positive ORF homologs can allow rapid identification of 
conserved cyclic di-nucleotide binding sites. For example, the identification of MshE 
prompted the cloning and testing of a set of homologous ATPases from P. aeruginosa 
leading to the discovery of PA14_29490 as a cdiGMP-binding protein. Similarly, the 
identification of cdiAMP binding to the RCK_C domain of KtrA prompted the testing 
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and discovery of CpaA, which also contains an RCK_C domain (254). While a lack of 
binding in the DRaCALA ORFeome screens is not definitive, verification of fusion 
protein expression is useful for discriminating between non-binding and lack of protein 
production. However, false positives may be produced if heterologous protein expression 
alters levels of the endogenous signaling system. Thus, cdiGMP binding should be 
verified for the positive ORFs that lack non-canonical cdiGMP binding sites including 
PstC, VCA0593, and TyrR. If verified, targeted DRaCALA screens of homologous 
proteins in other organisms with cdiGMP signaling systems could be performed. Several 
cdiGMP-binding homologs of the NtrC-class enhancer binding protein TyrR have already 
been identified including FleQ in P. aeruginosa and VpsR and FlrA in V. cholerae 
(148,160,165). Other NtrC class enhancer-binding proteins, such as AlgB of P. 
aeruginosa which regulates transcription of the cdiGMP-regulated alginate biosynthetic 
operon, should be tested for cdiGMP-binding (310,311). The results of these screens will 
rapidly determine if cdiGMP-binding activity is conserved among homologous groups of 
proteins. The identification of cdiGMP-binding for only a subset of homologs may reveal 
specific features that are required for cdiGMP-binding. 
 In addition to measuring protein-nucleotide interactions, DRaCALA has been 
adapted for quantification of RNA-ligand interactions using purified RNA aptamers 
(Figure 36). To date, two classes of cdiGMP-binding RNAs have been identified by 
computationally prediction of structured RNA aptamers (138,139). Potentially, 
DRaCALA could be used to systematically identify cdiGMP-binding RNAs. One of the 
first challenges of such a screen would be the construction of a library of candidate RNA 
molecules. Such a library could be constructed from cDNA clones of endogenously 
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produced RNA. Alternatively, intergenic regions and 5’ UTRs above a certain length 
could be systematically cloned for screening. An RNA library would also require a 
general method for RNA immobilization to detect binding of radiolabeled cdiGMP. For 
purified RNAs, immobilization in DRaCALA has been accomplished by the use of 
streptavidin and conjugation of biotin to purified RNA aptamers. The high affinity of 
streptavidin and biotin allows the majority of RNA to be immobilized during DRaCALA, 
but biotin conjugation to a library of RNAs expressed in whole cell lysates is not 
practical (298). However, the coat protein of the MS2 bacteriophage has been used to 
bind RNAs containing a series of stem loop structures that are specifically recognized by 
the coat protein (312,313). The MS2 RNA binding motif is not common in E. coli and 
would thus allow specific immobilization of RNAs transcripts that include the MS2-
binding motifs in whole cell lysates (314). A library of whole cell lysates expressing MS2 
labeled RNA transcripts could be screened by DRaCALA for binding to radiolabeled 
molecules. Binding specifically in the presence of the MS2 coat protein would reveal the 
presence of specific activity for putative RNA aptamers. Currently, the regulatory 
activities of RNA binding to cdiGMP are not well understood in comparison to regulation 
by cdiGMP-binding proteins. The systematic identification of cdiGMP-binding RNA 
aptamers would provide valuable insight into the role of RNA effectors in the regulation 
of cyclic di-nucleotide dependent phenotypes. 
 Finally, the simplicity and versatility of DRaCALA suggests that it may be useful 
for studying a variety of nucleotide signaling molecules. In addition to cdiGMP and 
cdiAMP, several other small nucleotide signaling molecules are known to participate in 
biological signaling including cAMP, cGMP and (p)ppGpp (315,316). Furthermore, a 
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novel class of cGMP/AMP hybrid molecules has been identified in both V. cholerae and 
eukaryotic innate immune signaling (317-321). These nucleotide signaling molecules 
have similar physical properties, indicating that they are suitable for DRaCALA 
ORFeome screens. Systematic identification of the binding proteins for these nucleotides 
could reveal their regulatory targets and provide insight into the molecular mechanisms 
of biological regulation by low molecular weight signaling molecules.  
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Appendix A 
 
Table 9. PSL Quantification for Figure 3A. Average and standard deviation of total 
signal intensity for the triplicate DRaCALA spots depicted in Figure 3A. 
 
 Total Signal Intensity cAMP ATP cdiGMP 
MBP Average 1533 40980 110179 
  Standard Deviation  132 1159 2138 
CRP Average 2479 38352 112918 
 Standard Deviation  177 5277 4038 
NtrB Average 2143 23465 99336 
  Standard Deviation  73 1836 3145 
Alg44 Average 2291 40277 116184 
  Standard Deviation  217 2307 1458 
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Table 10. PSL Quantification for Figure 3B. Average and standard deviation of total 
signal intensity for the triplicate DRaCALA spots depicted in Figure 3B. 
  
 Total Signal Intensity 
1 mM Competitor 1st Triplicate 2nd Triplicate 3rd Triplicate 
NC 47293 46379 43335 
cdiGMP 30609 31213 34001 
GTP 42359 45655 41391 
GDP 42526 40561 42042 
GMP 40367 48893 46280 
cGMP 39354 40539 43532 
ATP 39782 49712 37376 
CTP 42686 42958 33382 
UTP 41575 43598 35762 
Average 40728 43279 39678 
Standard Deviation 4456 5577 4648 
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Table 11. PSL Quantification for Figure 10A. Average and standard deviation of total 
signal intensity for the triplicate DRaCALA spots depicted in Figure 10A. 
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Table 12. PSL Quantification for Figure 10C. Average and standard deviation of total 
signal intensity for the triplicate DRaCALA spots depicted in Figure 10C. 
 
Time (s) 1st Triplicate 2nd Triplicate 3rd Triplicate 
0 109607 82354 83547 
10 83366 72748 70773 
15 84462 70645 73335 
20 82922 69334 70831 
30 80647 68939 68335 
45 81803 68864 67199 
60 81468 66620 66282 
90 83626 69013 66519 
120 77729 66088 65528 
180 78442 65317 63472 
Average 84407 69992 69582 
Standard Deviation 9121 4866 5709 
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Table 13. PSL Quantification for Figure 13A. Average and standard deviation of total 
signal intensity for the triplicate DRaCALA spots of whole cell lysates depicted in Figure 
13A. 
 
BL21(DE3) Whole Cell Lysates 
  Total Signal Intensity 
Alg44PilZ Competitor (1 mM) 1st Triplicate 2nd Triplicate 3rd Triplicate 
WT cdiGMP 15895 18914 16999 
 GTP 17215 25180 20686 
R21A cdiGMP 18611 22763 19111 
  GTP 23957 25116 23905 
S46A cdiGMP 17251 23318 20944 
 GTP 15022 24176 21991 
D44A cdiGMP 14558 20624 19909 
  GTP 16684 22550 19379 
R17A,R21A cdiGMP 20636 22338 21226 
  GTP 21244 23423 18439 
 Average 18107 22840 20259 
 Standard Deviation 3005 1934 1945 
 
 
Table 14. PSL Quantification for Figure 13A. Average and standard deviation of total 




Alg44PilZ Competitor (1 mM) Total Signal Intensity 
WT cdiGMP 14315 
 GTP 16387 
R21A cdiGMP 13676 
  GTP 14499 
S46A cdiGMP 13636 
 GTP 13921 
D44A cdiGMP 15080 
  GTP 15897 
R17A,R21A cdiGMP 14553 
  GTP 14840 
 Average 14680 
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Well Strain Name Source a BG b BC c BSp d A280e 
1_A1 PA15 UTI 0.213 0.169 1.26 51.3 
1_B1 PA14 UTI 0.151 0.148 1.02 19.4 
1_C1 PA13 UTI 0.241 0.166 1.45 52.8 
1_D1 PA8 UTI 0.232 0.183 1.27 54.2 
1_E1 CPs 433 CF 0.175 0.165 1.06 45.3 
1_F1 CPs 433 CF 0.228 0.162 1.41 38.8 
1_G1 CPs 231 CF 0.285 0.176 1.62 53.1 
1_H1 CPs 204 CF 0.259 0.160 1.62 50.0 
1_A2 PAK Hospital/laboratory 0.295 0.182 1.62 55.4 
1_B2 IT-01 ATCC type strain 0.248 0.198 1.25 59.2 
1_C2 IT-02 ATCC type strain 0.193 0.163 1.18 43.3 
1_D2 IT-03 ATCC type strain 0.310 0.185 1.68 60.6 
1_E2 IT-04 ATCC type strain 0.289 0.171 1.69 50.1 
1_F2 IT-05 ATCC type strain 0.271 0.184 1.47 53.7 
1_G2 IT-06 ATCC type strain 0.273 0.171 1.60 41.3 
1_H2 IT-07 ATCC type strain 0.288 0.169 1.70 43.6 
1_A3 IT-08 ATCC type strain 0.273 0.171 1.60 54.1 
1_B3 IT-09 ATCC type strain 0.208 0.161 1.30 38.1 
1_C3 IT-010 ATCC type strain 0.263 0.172 1.53 51.4 
1_D3 IT-011 ATCC type strain 0.246 0.165 1.49 47.1 
1_E3 IT-013 ATCC type strain 0.267 0.164 1.63 44.4 
1_F3 IT-015 ATCC type strain 0.280 0.169 1.65 50.4 
1_G3 IT-016 ATCC type strain 0.257 0.167 1.54 54.1 
1_H3 IT-017 ATCC type strain 0.246 0.180 1.37 59.0 
1_A4 IT-018 ATCC type strain 0.256 0.174 1.47 40.3 
1_B4 IT-019 ATCC type strain 0.188 0.174 1.08 35.5 
1_C4 IT-020 ATCC type strain 0.250 0.177 1.41 49.2 
1_D4 A 2 A CF 0.242 0.165 1.46 50.0 
1_E4 A 2 B CF 0.206 0.157 1.31 37.4 
1_F4 A 3 CF 0.214 0.155 1.38 42.6 
1_G4 A 7 CF 0.266 0.171 1.55 53.5 
1_H4 A 8 CF 0.207 0.156 1.33 35.9 
1_A5 A 9B CF 0.193 0.161 1.20 28.3 
1_B5 A 10A CF 0.235 0.174 1.35 34.1 
1_C5 A 15A CF 0.275 0.173 1.59 46.9 
1_D5 A 15B CF 0.251 0.173 1.45 44.5 
1_E5 SE1 CF 0.218 0.162 1.34 55.2 
1_F5 SE4 CF 0.253 0.173 1.47 45.6 
1_G5 SE5 CF 0.215 0.178 1.21 39.9 
1_H5 SE8 CF 0.198 0.159 1.25 37.4 
1_A6 SE9A CF 0.215 0.201 1.07 38.9 
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1_B6 SE10A CF 0.226 0.182 1.24 42.9 
1_C6 SE11 CF 0.226 0.169 1.34 44.9 
1_D6 SE12B CF 0.200 0.157 1.27 51.4 
1_E6 SE13 CF 0.217 0.174 1.25 37.5 
1_F6 SE14 CF 0.220 0.174 1.26 44.3 
1_G6 SE16 CF 0.193 0.170 1.14 36.3 
1_H6 SE17 CF 0.201 0.164 1.23 40.3 
1_A7 SE19 CF 0.202 0.172 1.17 19.9 
1_B7 SE21A CF 0.204 0.168 1.21 16.5 
1_C7 SE21C CF 0.202 0.172 1.17 18.1 
1_D7 SE22B CF 0.205 0.178 1.15 14.4 
1_E7 MI3A CF 0.240 0.171 1.41 22.2 
1_F7 MI3B CF 0.246 0.180 1.36 20.2 
1_G7 MI4A CF 0.277 0.180 1.54 21.9 
1_H7 MI4B CF 0.272 0.184 1.48 22.7 
1_A8 MI5A CF 0.249 0.177 1.41 58.6 
1_B8 MI5B CF 0.270 0.175 1.54 51.7 
1_C8 MI6 CF 0.269 0.181 1.49 59.7 
1_D8 MI8 CF 0.242 0.166 1.46 48.3 
1_E8 MI9A CF 0.215 0.158 1.36 40.8 
1_F8 MI9B CF 0.218 0.171 1.27 37.5 
1_G8 MI9C CF 0.231 0.173 1.34 37.7 
1_H8 MI11A CF 0.277 0.172 1.61 30.2 
1_A9 MI11C CF 0.225 0.176 1.28 42.1 
1_B9 6073 Corneal 0.267 0.184 1.45 54.9 
1_C9 6206 Corneal 0.310 0.182 1.70 56.2 
1_D9 6382 Corneal 0.301 0.183 1.64 57.0 
1_E9 6389 Corneal 0.272 0.175 1.56 48.7 
1_F9 6452 Corneal 0.238 0.178 1.34 42.9 
1_G9 PAO1 Wound/laboratory 0.281 0.187 1.51 53.4 
1_H9 696 ATCC 0.204 0.167 1.22 32.8 
1_A10 762 ATCC 0.293 0.172 1.70 60.0 
1_B10 769 ATCC 0.233 0.170 1.37 53.0 
1_C10 27853 ATCC 0.257 0.169 1.52 57.4 
1_D10 6354 Corneal 0.331 0.173 1.92 57.2 
1_E10 6487 Corneal 0.256 0.170 1.50 42.8 
1_F10 PAO381 CF 0.304 0.173 1.76 45.8 
1_G10 PAO578I Mucoid 0.322 0.167 1.93 48.8 
1_H10 PAO578II Mucoid 0.320 0.165 1.94 52.2 
1_A11 PAO579 Mucoid 0.292 0.166 1.77 43.0 
1_B11 PA27853 ATCC 0.295 0.180 1.63 55.1 
1_C11 MCW0001 CF 0.281 0.176 1.60 49.8 
1_D11 725 CF 0.294 0.172 1.71 45.8 
1_E11 1328 CF 0.294 0.167 1.76 42.0 
1_F11 1641 CF 0.312 0.173 1.81 51.8 
1_G11 381 CF 0.382 0.164 2.32 37.5 
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1_H11 578I CF 0.280 0.167 1.68 47.8 
1_A12 PA14 pMMB-RocR 0.605 0.173 3.51 30.5 
1_B12 PA14 ΔpelD pmmB:RocR 0.501 0.186 2.70 34.9 
1_C12 CF27  0.211 0.164 1.29 32.6 
1_D12 PA14 pmmB-WspR 0.205 0.172 1.19 29.6 
1_E12 PA14 ΔretS  0.219 0.171 1.28 27.0 
1_F12 PA14 Hospital/laboratory 0.228 0.180 1.27 37.9 
1_G12 PAO1 Wound/ laboratory 0.256 0.180 1.42 44.0 
1_H12 PAK Hospital/laboratory 0.295 0.185 1.59 50.9 
2_A1 MSH18 Environmental 0.341 0.200 1.71 16.5 
2_B1 MSH12 Environmental 0.310 0.197 1.57 20.8 
2_C1 MSH13 Environmental 0.259 0.195 1.33 18.1 
2_D1 MSH  Environmental 0.328 0.200 1.64 26.4 
2_E1 H14 Hospital 0.369 0.200 1.85 26.1 
2_F1 H12 Hospital 0.392 0.209 1.87 17.7 
2_G1 H19 Hospital 0.377 0.200 1.89 14.5 
2_H1 H25 Hospital 0.214 0.112 1.90 23.9 
2_A2 H26 Hospital 0.379 0.203 1.87 20.2 
2_B2 MSH3 Environmental 0.349 0.189 1.85 29.0 
2_C2 H28 Hospital 0.307 0.194 1.59 16.0 
2_D2 H17 Hospital 0.292 0.191 1.53 30.3 
2_E2 H27 Hospital 0.329 0.195 1.69 27.9 
2_F2 MSH1 Environmental 0.373 0.193 1.93 28.0 
2_G2 H15 Hospital 0.345 0.198 1.74 30.0 
2_H2 H21 Hospital 0.327 0.186 1.76 22.0 
2_A3 MSH5 Environmental 0.377 0.182 2.07 16.9 
2_B3 H24 Hospital 0.235 0.175 1.34 6.0 
2_C3 H22 Hospital 0.374 0.192 1.95 24.3 
2_D3 H29 Hospital 0.312 0.205 1.53 24.8 
2_E3 H2 Hospital 0.394 0.199 1.98 22.5 
2_F3 Pa Hospital 0.409 0.208 1.97 21.5 
2_G3 MSH17 Environmental 0.353 0.200 1.76 21.3 
2_H3 MSH12 Environmental 0.371 0.196 1.89 19.9 
2_A4 H1 Hospital 0.376 0.194 1.93 21.2 
2_B4 PB2036  0.411 0.200 2.06 20.9 
2_C4 WR5 Hospital 0.294 0.195 1.50 13.1 
2_D4 PA103  0.368 0.213 1.72 28.0 
2_E4 MSH11 Environmental 0.281 0.181 1.56 26.9 
2_F4 MSH16 Environmental 0.345 0.192 1.80 15.8 
2_G4 MSH10 Environmental 0.315 0.188 1.67 13.4 
2_H4 H30 Hospital 0.309 0.187 1.65 12.9 
2_A5 H23 Hospital 0.290 0.205 1.41 11.6 
2_B5 H16 Hospital 0.306 0.185 1.65 16.9 
2_C5 S11 Soil 0.310 0.208 1.49 22.4 
2_D5 Nathan II  0.344 0.192 1.79 20.0 
2_E5 PAK Hospital/laboratory 0.397 0.192 2.06 22.1 
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2_F5 S11 Soil 0.298 0.205 1.45 20.4 
2_G5 Pa  0.413 0.203 2.04 24.6 
2_H5 Pa  0.333 0.198 1.68 21.8 
2_A6 PAK* EMS mutant 0.378 0.201 1.88 19.8 
2_B6 PAO2003  0.230 0.192 1.20 14.5 
2_C6 PA103 CF 0.337 0.199 1.69 21.4 
2_D6 8823 CF 0.300 0.192 1.56 16.6 
2_E6 BHE08 Brazil 0.282 0.188 1.50 17.9 
2_F6 BHE07 Brazil 0.265 0.186 1.42 19.0 
2_G6 BHE06 Brazil 0.326 0.197 1.66 22.8 
2_H6 BHE05 Brazil 0.342 0.203 1.69 18.9 
2_A7 BHE04 Brazil 0.192 0.186 1.03 17.3 
2_B7 BHE03 Brazil 0.268 0.190 1.41 14.7 
2_C7 B27 Brazil 0.308 0.205 1.51 27.5 
2_D7 V209 (Alg +) CF 0.278 0.196 1.42 22.6 
2_E7 V209 (Alg -) CF 0.304 0.194 1.57 22.9 
2_F7 isolate CF 0.373 0.192 1.94 20.5 
2_G7 isolate CF 0.383 0.188 2.03 19.0 
2_H7 CF1 CF 0.309 0.201 1.54 18.8 
2_A8 CF2 CF 0.310 0.191 1.62 21.8 
2_B8 CF3 CF 0.231 0.188 1.23 13.9 
2_C8 CF4 CF 0.243 0.186 1.31 19.7 
2_D8 CF5 CF 0.295 0.194 1.52 28.0 
2_E8 CF6 CF 0.327 0.197 1.66 29.5 
2_F8 CF26 CF 0.281 0.184 1.53 6.6 
2_G8 CF27 CF 0.318 0.181 1.75 18.0 
2_H8 CF28 CF 0.503 0.188 2.68 19.5 
2_A9 CF29 CF 0.298 0.189 1.57 20.2 
2_B9 R37 CF 0.376 0.183 2.06 8.0 
2_C9 R71 CF 0.276 0.193 1.43 11.6 
2_D9 6077 Corneal 0.357 0.206 1.74 18.7 
2_E9 6294 Corneal 0.368 0.199 1.86 11.1 
2_F9 19660 Corneal 0.327 0.199 1.65 24.6 
2_G9 F34842 UTI 0.362 0.206 1.75 18.6 
2_H9 F35896 UTI 0.356 0.209 1.71 24.5 
2_A10 H38036 UTI 0.282 0.197 1.43 20.6 
2_B10 M28497 UTI 0.263 0.205 1.29 19.2 
2_C10 W57761 UTI 0.300 0.214 1.40 25.1 
2_D10 X24509 UTI 0.402 0.215 1.87 25.0 
2_E10 UTI121 UTI 0.331 0.204 1.62 19.7 
2_F10 UTI122 UTI 0.339 0.200 1.69 15.5 
2_G10 UTI123 UTI 0.277 0.200 1.38 14.5 
2_H10 UTI124 UTI 0.366 0.203 1.80 25.4 
2_A11 UTI125 UTI 0.307 0.193 1.59 10.8 
2_B11 UTI126 UTI 0.267 0.201 1.33 12.2 
2_C11 UTI127 UTI 0.287 0.200 1.44 19.3 
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2_D11 B312 Blood 0.313 0.204 1.53 17.1 
2_E11 B1460A Blood 0.321 0.203 1.58 21.4 
2_F11 B1874-2 Blood 0.335 0.203 1.65 19.9 
2_G11 CF32 CF 0.328 0.215 1.53 21.6 
2_H11 U130 UTI 0.365 0.210 1.74 15.3 
2_A12 U169 UTI 0.255 0.190 1.34 25.5 
2_B12 U779 UTI 0.340 0.218 1.56 36.0 
2_C12 U2504 UTI 0.303 0.206 1.47 35.5 
2_D12 H21651 Blood 0.323 0.212 1.53 33.6 
2_E12 X13397 Blood 0.310 0.207 1.50 39.4 
2_F12 X16259 Blood 0.276 0.202 1.37 26.6 
2_G12 S29712 Blood 0.331 0.208 1.59 24.0 
2_H12 S35004 Blood 0.347 0.225 1.54 35.6 
       
  Average BC =  0.185    
       
  
Standard 
Deviation BC =  0.016  
 
 
       
  
2 *Standard 
Deviation BC  =  0.031  
 
 
       
  
BSp Positive-
Cutoff =  1.17  
 
 
       
 
a Strains are classified as indicated. “CF” denotes cystic fibrosis isolate and “UTI” 
denotes urinary tract infection isolate. 
b 32P-cdiGMP bound during 1 mM GTP competition. 
c 32P-cdiGMP bound during 1 mM cdiGMP competition. 
d Specific binding of whole cell lysate (BG / BC). 
e Total protein concentration of whole cell lysate measured by absorbance at 280 nM by 
Thermo Fischer Nanodrop 8000 using 0.2 µM path length. Absorbance units are reported 
as if measured with 10 mm path length (actual path length of 0.2 mm). 
	  
Table 16. DRaCALA analysis of cdiGMP-binding by lysates from various organisms or tissues. 
 
Plate Well Genus Species Strain / tissue / cell type BG 
a BC b BSp c 
Predicted 
DGC d Reference for cdiGMP signaling 
e 
3_A1 Aeromonas hydrophila SJ11R 0.248 0.162 1.53 * Yes None 
3_B1 Salmonella typhimurium SL1334 0.164 0.153 1.07 Yes (124) 
3_C1 Escherichia coli ZK57 0.149 0.141 1.06 Yes (124) 
3_D1 Yersinia enterocolitica W22703 0.161 0.147 1.10 Yes None 
3_E1 Yersinia enterocolitica 8081 0.181 0.155 1.17 * Yes None 
3_F1 Yersinia pseudotuberculosis pIB1 0.155 0.158 0.99 Yes None 
3_G1 Yersinia pseudotuberculosis pYPIII 0.152 0.150 1.01 Yes None 
3_H1 Escherichia coli JM109 0.171 0.165 1.03 Yes (124) 
3_A2 Vibrio cholerae N16961 0.354 0.179 1.98 * Yes (94) 
3_B2 Burkholderia dolosa HI2914 0.301 0.166 1.82 * Yes None 
3_C2 Burkholderia dolosa AU3960 0.278 0.178 1.56 * Yes None 
3_D2 Bacillus subtilus 3160  0.185 0.162 1.14 Yes (118) 
3_E2 Bacillus subtilus 168  0.189 0.157 1.20 * Yes (118) 
3_F2 Bacillus subtilus PY79  0.206 0.152 1.36 * Yes (118) 
3_G2 Actinomyces naeslundii MG1 0.162 0.159 1.02 No sequence None 
3_H2 Staphylococcus aureus Newman 0.148 0.141 1.05 Yes cdiGMP-independent (322,323) 
3_A3 Streptococcus agalactiae 2603 0.156 0.152 1.03 No None 
3_B3 Pseudomonas putida pB2440 0.143 0.133 1.07 Yes (324) 
3_C3 Proteus mirabilis SC81c M1061 0.158 0.165 0.96 Yes None 
3_D3 Caenorhabditis elegans  0.151 0.157 0.96 No None 
3_E3 Pseudomonas stutzeri K2186 0.244 0.150 1.62 * Yes None 
3_F3 Pseudomonas stutzeri K1412 M1035 0.224 0.158 1.42 * Yes None 
3_G3 Pseudomonas stutzeri K79 0.287 0.155 1.85 * Yes None 
3_H3 Pseudomonas fluorescens K2122 0.277 0.159 1.74 * Yes (324) 
3_A4 Stenotrophomonas maltophilia K2227 0.279 0.167 1.67 * Yes None 
3_B4 Brevundimonas vesicularis K136 0.298 0.175 1.71 * No sequence None 
3_C4 Providencia stuartii SC145 M1062 0.156 0.170 0.92 Yes None 
3_D4 Pseudomonas fluorescens K2017 M1088 0.207 0.169 1.23 * Yes (324) 
3_E4 Burkholderia cenocepacia K2313 0.152 0.163 0.93 Yes None 
3_F4 Moraxella osloensis K1980 0.144 0.145 0.99 No sequence None 
3_G4 Pseudomonas fluorescens E-38 0.185 0.144 1.29 * Yes (324) 
3_H4 Proteus mirabilis H-62 0.156 0.163 0.95 Yes None 
3_A5 Proteus vulgaris  0.158 0.168 0.94 No sequence None 
3_B5 Pseudomonas alcaligenes D13 0.313 0.174 1.80 * No sequence None 
3_C5 Delftia acidovorans D12 0.324 0.177 1.83 * Yes None 
3_D5 Comamonas testosteroni D14 0.279 0.164 1.70 * Yes None 
3_E5 Pseudomonas mendocina D57 0.134 0.141 0.95 Yes None 
3_F5 Stenotrophomonas maltophilia C40 0.277 0.199 1.39 * Yes None 
3_G5 Pseudomonas putida C14 0.192 0.171 1.12 Yes (324) 
3_H5 Shewanella putrefaciens F17 0.300 0.165 1.82 * Yes None 
3_A6 Pseudomonas stutzeri H24 0.192 0.157 1.22 * Yes None 
	  
3_B6 Nicotiana benthamiana  0.199 0.170 1.17 * No sequence None 
3_C6 Burkholderia cenocepacia F2 0.218 0.174 1.25 * Yes None 
3_D6 Burkholderia cenocepacia F27 0.188 0.158 1.19 * Yes None 
3_E6 Pseudomonas diminuta  0.211 0.162 1.30 * No sequence None 
3_F6 Mus musculus Brain 0.315 0.243 1.29 * No (325) 
3_G6 Vibrio cholerae IRA J13 0.328 0.169 1.94 * Yes (94) 
3_H6 Klebsiella pneumoniae W63917 0.160 0.155 1.03 Yes (326) 
3_A7 Sinorhizobium meliloti Rm1021 0.164 0.162 1.02 Yes None 
3_B7 Mus musculus RAW Cells 0.151 0.169 0.89 No (325) 
3_C7 Vibrio harveyi MM32 0.207 0.162 1.28 * Yes None 
3_D7 Salmonella typhimurium  0.160 0.163 0.98 Yes (124) 
3_E7 Escherichia coli  0.256 0.173 1.48 * Yes (124) 
3_F7 Citrobacter freundii  0.154 0.156 0.99 No sequence None 
3_G7 Serratia marcescens  0.204 0.170 1.20 * No sequence None 
3_H7 Hafnia alvei  0.172 0.152 1.13 No sequence None 
3_A8 Micrococcus luteus  0.136 0.140 0.98 No None 
3_B8 Staphylococcus epidermidis  0.145 0.155 0.94 Yes cdiGMP-independent (322,323) 
3_C8 Enterobacter aerogenes  0.169 0.152 1.11 No sequence None 
3_D8 Bacillus megaterium  0.164 0.147 1.12 Yes None 
3_E8 Pseudomonas putida NCIMB 0.155 0.157 0.99 Yes (324) 
3_F8 Ochrobactrum anthropi NCIMB 8686 0.222 0.168 1.32 * Yes None 
3_G8 Moraxella catarrhalis  0.155 0.161 0.96 No None 
3_H8 Acinetobacter spp MD4 0.157 0.158 0.99 Yes None 
3_A9 Moraxella spp  B88 0.154 0.149 1.03 No None 
3_B9 Lactococcus lactis  0.243 0.166 1.46 * Yes None 
3_C9 Staphylococcus aureus  0.197 0.162 1.21 * Yes cdiGMP-independent (322,323) 
3_D9 Alcaligenes faecalis  0.172 0.164 1.05 No sequence None 
3_E9 Corynebacterium xerosis  0.145 0.152 0.95 No sequence None 
3_F9 Staphylococcus sciuri  0.148 0.154 0.96 No sequence None 
3_G9 Proteus mirabilis  0.168 0.176 0.96 Yes None 
3_H9 Enterococcus durans  0.155 0.154 1.01 No sequence None 
3_A10 Marinococcus halophilus  0.169 0.147 1.14 No sequence None 
3_B10 Clostridium sporogenes  0.171 0.195 0.87 Yes None 
3_C10 Saccharomyces cerevisiae  0.160 0.159 1.01 No None 
3_D10 Providencia stuartii  0.157 0.166 0.95 Yes None 
3_E10 Bacillus cereus  0.161 0.152 1.06 Yes (138) 
3_F10 Enterococcus faecalis  0.175 0.160 1.10 No None 
3_G10 Staphylococcus aureus MRSA 0.152 0.156 0.97 Yes cdiGMP-independent (322,323) 
3_H10 Neisseria gonorrhoeae MS11 0.151 0.150 1.01 No None 
3_A11 Neisseria gonorrhoeae F11090 0.149 0.155 0.96 No None 
3_B11 Neisseria sicca  0.173 0.158 1.09 No None 
3_C11 Streptococcus pyogenes GA40634 0.145 0.146 1.00 Yes None 
3_D11 Streptococcus pyogenes NZ131 0.160 0.144 1.12 Yes None 
3_E11 Streptococcus pyogenes 5448-AN 0.151 0.152 0.99 Yes None 
3_F11 Streptococcus pyogenes GA19681 0.153 0.149 1.03 Yes None 
3_G11 Mycobacterium smegmatis  0.156 0.156 1.00 Yes None 
	  
3_H11 Aspergillus niger  0.156 0.157 0.99 No None 
3_A12 Mus musculus Heart 0.213 0.196 1.09 No (325) 
3_B12 Saccharomyces cerevisiae cry1-2 0.168 0.170 0.99 No None 
3_C12 Saccharomyces cerevisiae AH109 0.161 0.158 1.02 No None 
3_D12 Leishmania major  0.154 0.170 0.91 No None 
3_E12 Homo sapiens U397 cells 0.181 0.271 0.67 No (327) 
3_F12 Homo sapiens HuH7 cells 0.149 0.151 0.99 No (327) 
3_G12 Cricetulus griseus CHO cells 0.179 0.273 0.66 No sequence None 
3_H12 Mus musculus Spleen 0.227 0.299 0.76 No (325) 
 
   
      
a BG indicates 32P-cdiGMP bound in the presence of the non-specific competitor GTP at 1 mM. 
b BC indicates 32P-cdiGMP bound in the presence of the specific competitor cdiGMP at 1 mM. 
c Specific binding of whole cell lysate (BG / BC). Organisms with values above the 1.17 cut-off are indicated by asterisks (*). 
d Genomes that encode DGC were identified on October 7th, 2010 by a search at http://www.ncbi.nlm.nih.gov/protein using a search 
term consisting of the genus and species of each organism along with “DGC”, “GGDEF” or “diguanylate”. Organisms positive for 
DGC are indicated by “Yes”. Organisms negative for DGC are indicated by “No”. Those without a sequenced genome are indicated 
by “No sequence”. 
e References for organisms using cdiGMP signaling were identified by a PubMed search using a search term consisting of the genus 
and species of each organism and “cyclic-di-GMP” on October 7th, 2010. Earliest reference reporting cdiGMP signaling in each 
species is shown. Organisms for which no citations were available are indicated by “None”. “cdiGMP independent” is noted for those 
strains that have a protein with a DGC domain and observed regulation that is independent of cdiGMP. 
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Table 17: Fraction bound 32P-cdiGMP in primary DRaCALA screen of V. cholerae 
ORFs 
 
VC Gene # His-ORF Fraction Bound 
 
His-MBP-ORF Fraction Bound 
 
Replicate 1 Replicate 2   Replicate 1 Replicate 2 
VC0001 0.09 0.07 
 
0.02 0.00 
VC0002 0.04 0.05 
 
0.06 0.06 
VC0003 0.04 0.03 
 
0.07 0.08 
VC0004 0.04 0.06 
 
0.06 0.08 
VC0005 0.09 0.05 
 
0.05 0.07 
VC0006 0.03 0.04 
 
0.06 0.05 
VC0007 0.00 0.04 
 
0.05 0.06 
VC0008 0.03 0.04 
 
0.06 0.04 
VC0009 0.05 0.06 
 
0.06 0.07 
VC0010 0.05 0.05 
 
0.05 0.06 
VC0011 0.05 0.05 
 
0.03 0.03 
VC0012 0.01 0.02 
 
0.01 0.02 
VC0013 0.01 0.01 
 
0.02 0.00 
VC0014 0.03 0.04 
 
0.04 0.03 
VC0015 0.05 0.08 
 
0.05 0.05 
VC0016 0.04 0.06 
 
0.05 0.04 
VC0017 0.09 0.09 
 
0.03 0.05 
VC0018 0.02 0.02 
 
0.06 0.09 
VC0019 0.06 0.06 
 
0.05 0.06 
VC0020 0.09 0.10 
 
0.02 0.02 
VC0021 0.04 0.03 
 
0.09 0.13 
VC0022 0.04 0.04 
 
0.04 0.02 
VC0023 0.10 0.10 
 
0.01 0.03 
VC0024 0.04 0.05 
 
0.08 0.06 
VC0025 0.10 0.10 
 
0.03 0.05 
VC0026 0.04 0.05 
 
0.08 0.06 
VC0027 0.03 0.05 
 
0.07 0.04 
VC0028 0.03 0.03 
 
0.10 0.06 
VC0029 0.03 0.02 
 
0.06 0.08 
VC0030 0.06 0.06 
 
0.06 0.08 
VC0031 0.05 0.06 
 
0.04 0.04 
VC0032 0.08 0.08 
 
0.03 0.03 
VC0033 0.08 0.08 
 
0.04 0.09 
VC0034 0.05 0.04 
 
0.04 0.05 
VC0035 0.05 0.05 
 
0.05 0.04 
VC0036 0.03 0.04 
 
0.04 0.05 
VC0037 0.07 0.10 
 
0.06 0.07 
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VC0038 0.09 0.06 
 
0.06 0.05 
VC0039 0.04 0.04 
 
0.04 0.05 
VC0040 0.04 0.07 
 
0.06 0.06 
VC0041 0.03 0.05 
 
0.06 0.06 
VC0042 -0.01 0.00 
 
0.06 0.06 
VC0043 0.01 0.03 
 
0.05 0.04 
VC0044 0.04 0.06 
 
0.04 0.05 
VC0045 0.04 0.06 
 
0.04 0.06 
VC0046 0.03 0.03 
 
0.00 0.00 
VC0047 0.02 0.01 
 
0.01 0.02 
VC0048 0.03 0.03 
 
0.04 0.04 
VC0049 0.04 0.05 
 
0.05 0.05 
VC0050 0.04 0.06 
 
0.06 0.07 
VC0051 0.05 0.04 
 
0.07 0.05 
VC0052 0.06 0.06 
 
0.07 0.07 
VC0053 0.05 0.06 
 
0.07 0.05 
VC0054 0.03 0.05 
 
0.07 0.07 
VC0055 0.04 0.06 
 
0.06 0.05 
VC0056 0.02 0.05 
 
0.04 0.04 
VC0057 0.05 0.05 
 
0.05 0.06 
VC0058 0.06 0.07 
 
0.09 0.07 
VC0060 0.05 0.06 
 
0.05 0.05 
VC0061 0.05 0.05 
 
0.04 0.06 
VC0062 0.06 0.09 
 
0.06 0.05 
VC0063 0.10 0.13 
 
0.08 0.07 
VC0064 0.06 0.08 
 
0.04 0.06 
VC0065 0.05 0.05 
 
0.05 0.06 
VC0066 0.01 0.03 
 
0.05 0.06 
VC0067 0.05 0.05 
 
0.06 0.06 
VC0068 0.04 0.05 
 
0.03 0.03 
VC0069 0.04 0.05 
 
0.05 0.05 
VC0070 0.09 0.10 
 
0.03 0.04 
VC0071 0.02 0.03 
 
0.10 0.12 
VC0072 0.55 0.53 
 
0.48 0.53 
VC0072 0.01 0.04 
 
0.05 0.06 
VC0073 0.05 0.04 
 
0.13 0.17 
VC0074 0.06 0.06 
 
0.02 0.04 
VC0075 0.05 0.06 
 
0.08 0.09 
VC0076 0.06 0.06 
 
0.05 0.05 
VC0077 0.07 0.10 
 
0.02 0.03 
VC0078 0.00 0.00 
 
0.05 0.09 
VC0079 0.08 0.08 
 
0.10 0.03 
VC0080 0.03 0.03 
 
0.03 0.04 
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VC0081 0.05 0.06 
 
0.07 0.05 
VC0082 0.00 0.02 
 
0.01 0.02 
VC0083 0.07 0.07 
 
0.04 0.03 
VC0084 0.04 0.03 
 
0.06 -0.01 
VC0085 0.04 0.04 
 
0.04 0.04 
VC0086 0.05 0.06 
 
0.01 0.02 
VC0087 0.04 0.02 
 
0.05 0.06 
VC0088 -0.02 0.01 
 
0.05 0.04 
VC0089 0.03 0.02 
 
0.04 0.05 
VC0090 0.04 0.03 
 
0.05 0.05 
VC0091 0.02 0.02 
 
0.06 0.08 
VC0092 0.07 0.08 
 
0.03 0.03 
VC0093 0.05 0.06 
 
0.06 0.06 
VC0094 0.06 0.06 
 
0.05 0.04 
VC0095 0.04 0.04 
 
0.05 0.04 
VC0096 0.09 0.06 
 
0.06 0.07 
VC0097 0.04 0.03 
 
0.13 0.10 
VC0098 0.13 0.14 
 
0.05 0.05 
VC0099 0.05 0.05 
 
0.02 0.02 
VC0100 0.10 0.11 
 
0.06 0.06 
VC0101 0.09 0.07 
 
0.04 0.04 
VC0102 0.04 0.07 
 
0.06 0.07 
VC0103 0.07 0.08 
 
0.06 0.04 
VC0104 0.05 0.05 
 
0.04 0.03 
VC0105 0.05 0.04 
 
0.05 0.02 
VC0106 0.06 0.07 
 
0.09 0.08 
VC0107 0.04 0.05 
 
0.05 0.05 
VC0108 0.02 0.03 
 
0.03 0.02 
VC0109 0.02 0.06 
 
0.04 0.05 
VC0110 0.05 0.08 
 
0.04 0.04 
VC0111 0.09 0.10 
 
0.06 0.06 
VC0112 0.09 0.11 
 
0.07 0.07 
VC0113 0.12 0.10 
 
0.09 0.09 
VC0114 0.09 0.08 
 
0.07 0.06 
VC0115 0.12 0.12 
 
0.07 0.08 
VC0116 0.04 0.05 
 
0.02 0.03 
VC0117 0.13 0.14 
 
0.06 0.06 
VC0118 0.05 0.05 
 
0.03 0.04 
VC0119 0.09 0.09 
 
0.02 0.03 
VC0120 0.06 0.08 
 
0.00 0.04 
VC0121 0.08 0.07 
 
0.04 0.04 
VC0123 0.07 0.07 
 
0.04 0.03 
VC0124 0.09 0.11 
 
0.05 0.04 
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VC0125 0.07 0.08 
 
0.05 0.06 
VC0126 0.09 0.08 
 
0.03 0.03 
VC0127 0.09 0.10 
 
0.04 0.04 
VC0128 0.09 0.09 
 
0.04 0.04 
VC0129 0.07 0.07 
 
0.06 0.04 
VC0130 0.00 0.01 
 
0.01 0.02 
VC0131 0.11 0.12 
 
0.07 0.06 
VC0132 0.09 0.08 
 
0.06 0.06 
VC0133 0.05 0.05 
 
0.04 0.04 
VC0133 0.06 0.06 
 
0.04 0.05 
VC0134 0.06 0.05 
 
0.04 0.04 
VC0135 0.05 0.06 
 
0.07 0.06 
VC0136 0.06 0.06 
 
0.03 0.04 
VC0137 0.01 0.03 
 
0.00 -0.01 
VC0138 0.05 0.06 
 
0.06 0.07 
VC0139 0.11 0.11 
 
0.07 0.07 
VC0140 0.11 0.12 
 
0.06 0.06 
VC0141 0.03 0.06 
 
0.04 0.08 
VC0142 0.07 0.05 
 
0.03 0.03 
VC0143 0.01 0.02 
 
0.00 0.01 
VC0144 0.08 0.08 
 
0.07 0.07 
VC0145 0.02 0.04 
 
0.05 0.05 
VC0146 0.03 0.03 
 
0.02 0.03 
VC0147 0.05 0.06 
 
0.03 0.04 
VC0148 0.01 0.02 
 
0.00 0.00 
VC0149 0.02 0.03 
 
0.01 0.01 
VC0150 0.08 0.06 
 
0.05 0.07 
VC0151 0.02 0.02 
 
0.01 0.01 
VC0152 0.07 0.06 
 
0.04 0.04 
VC0153 0.02 0.02 
 
0.01 0.01 
VC0154 0.02 0.00 
 
0.00 0.00 
VC0156 0.04 0.05 
 
-0.02 -0.02 
VC0157 0.03 0.04 
 
0.05 0.03 
VC0158 0.06 0.10 
 
0.06 0.06 
VC0159 0.02 0.03 
 
0.01 0.02 
VC0160 0.07 0.07 
 
0.04 0.05 
VC0161 0.03 0.03 
 
0.04 0.03 
VC0162 0.09 0.09 
 
0.05 0.08 
VC0163 0.05 0.13 
 
0.06 0.06 
VC0164 0.05 0.06 
 
0.04 0.03 
VC0165 0.02 0.03 
 
0.00 0.00 
VC0166 0.02 0.02 
 
0.01 0.02 
VC0167 0.03 0.05 
 
0.03 0.03 
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VC0168 0.05 0.04 
 
0.07 0.07 
VC0169 0.07 0.07 
 
0.02 0.03 
VC0170 0.08 0.10 
 
0.04 0.08 
VC0171 0.03 0.05 
 
0.03 0.03 
VC0172 0.09 0.08 
 
0.02 0.03 
VC0173 0.04 0.04 
 
0.00 0.02 
VC0174 0.02 0.02 
 
0.01 0.02 
VC0175 0.04 0.05 
 
0.04 0.04 
VC0176 0.11 0.08 
 
0.03 0.05 
VC0177 0.03 0.04 
 
0.02 0.02 
VC0178 0.03 0.03 
 
0.01 0.02 
VC0179 0.04 0.03 
 
0.04 0.04 
VC0180 0.07 0.08 
 
0.07 0.05 
VC0181 0.01 0.02 
 
0.01 0.02 
VC0182 0.01 0.02 
 
0.02 0.03 
VC0183 0.03 0.03 
 
0.05 0.05 
VC0184 0.08 0.09 
 
0.05 0.05 
VC0185 0.02 0.02 
 
0.01 0.01 
VC0186 0.07 0.07 
 
0.05 0.06 
VC0187 0.01 0.02 
 
0.01 0.02 
VC0188 0.06 0.07 
 
0.03 0.03 
VC0189 0.05 0.05 
 
0.03 0.03 
VC0189 0.04 0.05 
 
0.03 0.04 
VC0190 0.01 0.02 
 
0.08 0.08 
VC0191 0.06 0.06 
 
0.04 0.04 
VC0192 0.01 0.02 
 
0.01 0.01 
VC0193 0.08 0.09 
 
0.05 0.08 
VC0194 0.09 0.08 
 
0.08 0.12 
VC0195 0.04 0.05 
 
0.01 0.01 
VC0196 0.08 0.06 
 
0.08 0.07 
VC0197 0.05 0.05 
 
0.01 0.01 
VC0198 0.01 0.02 
 
-0.01 0.00 
VC0199 0.09 0.09 
 
0.14 0.10 
VC0200 0.01 0.01 
 
0.02 0.02 
VC0201 0.02 0.06 
 
0.06 0.05 
VC0202 0.08 0.10 
 
0.04 0.03 
VC0203 0.01 0.03 
 
0.04 0.04 
VC0204 0.00 0.00 
 
0.10 0.06 
VC0205 0.08 0.07 
 
0.06 0.03 
VC0206 0.01 0.02 
 
0.16 0.13 
VC0207 0.02 0.04 
 
0.03 0.03 
VC0208 0.01 0.03 
 
0.03 0.02 
VC0209 0.05 0.05 
 
0.06 0.04 
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VC0210 0.00 0.02 
 
0.11 0.10 
VC0211 0.06 0.06 
 
0.04 0.04 
VC0212 0.01 0.00 
 
0.12 0.09 
VC0213 0.00 0.00 
 
0.12 0.08 
VC0214 0.06 0.05 
 
0.07 0.02 
VC0215 0.03 0.03 
 
0.03 0.03 
VC0216 0.04 0.06 
 
0.04 0.02 
VC0217 0.03 0.06 
 
0.04 0.04 
VC0218 0.06 0.04 
 
0.04 0.03 
VC0219 0.04 0.05 
 
0.06 0.04 
VC0220 0.05 0.05 
 
0.02 0.02 
VC0221 0.00 0.00 
 
0.07 0.05 
VC0222 0.06 0.06 
 
0.06 0.04 
VC0223 0.02 0.03 
 
0.08 0.07 
VC0224 0.01 0.02 
 
0.09 0.06 
VC0225 0.04 0.07 
 
0.04 0.04 
VC0226 0.07 0.10 
 
0.04 0.04 
VC0227 0.01 0.00 
 
0.04 0.04 
VC0228 0.06 0.06 
 
0.07 0.05 
VC0229 -0.01 0.00 
 
0.08 0.06 
VC0230 0.02 0.01 
 
0.02 0.03 
VC0231 0.06 0.06 
 
0.06 0.06 
VC0232 0.04 0.05 
 
0.06 0.02 
VC0233 0.00 0.03 
 
0.07 0.06 
VC0234 0.00 0.01 
 
0.05 0.04 
VC0235 0.05 0.10 
 
0.04 0.04 
VC0236 0.00 0.00 
 
0.08 0.05 
VC0237 -0.01 0.01 
 
0.12 0.11 
VC0238 0.01 0.01 
 
0.09 0.06 
VC0239 0.01 0.04 
 
0.06 0.05 
VC0240 0.10 0.08 
 
0.02 0.02 
VC0241 -0.01 0.00 
 
0.12 0.11 
VC0242 0.00 0.01 
 
0.15 0.13 
VC0243 0.02 0.04 
 
0.03 0.03 
VC0244 0.00 0.02 
 
0.09 0.05 
VC0245 0.01 0.03 
 
0.04 0.04 
VC0246 0.04 0.05 
 
0.03 0.03 
VC0247 0.02 0.02 
 
0.07 0.06 
VC0248 0.06 0.06 
 
0.06 0.02 
VC0249 0.01 0.02 
 
0.05 0.04 
VC0250 0.00 0.03 
 
0.02 0.01 
VC0251 0.03 0.04 
 
0.05 0.05 
VC0252 0.01 0.01 
 
0.17 0.17 
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VC0253 0.06 0.06 
 
0.03 0.04 
VC0254 0.02 0.02 
 
0.08 0.08 
VC0254 0.01 0.02 
 
0.05 0.05 
VC0255 0.04 0.04 
 
0.03 0.03 
VC0256 0.01 0.01 
 
0.09 0.07 
VC0257 0.02 0.02 
 
0.05 0.05 
VC0258 0.01 0.00 
 
0.02 0.03 
VC0259 0.00 0.01 
 
0.05 0.04 
VC0260 0.04 0.06 
 
0.07 0.06 
VC0261 0.04 0.03 
 
0.06 0.05 
VC0262 0.00 0.02 
 
0.03 0.02 
VC0263 0.05 0.07 
 
0.02 0.05 
VC0264 0.09 0.08 
 
0.05 0.07 
VC0265 0.04 0.03 
 
0.05 0.04 
VC0266 0.03 0.06 
 
0.04 0.07 
VC0267 0.03 0.05 
 
0.11 0.09 
VC0268 0.07 0.04 
 
0.02 0.07 
VC0269 0.03 0.03 
 
0.08 0.06 
VC0270 0.08 0.04 
 
0.08 0.09 
VC0271 0.01 0.04 
 
0.08 0.07 
VC0272 0.09 0.07 
 
0.07 0.03 
VC0273 0.04 0.04 
 
0.06 0.06 
VC0274 0.05 0.04 
 
0.07 0.09 
VC0275 0.03 0.03 
 
0.06 0.06 
VC0276 0.08 0.09 
 
0.06 0.06 
VC0277 0.11 0.11 
 
0.07 0.06 
VC0278 0.07 0.04 
 
0.04 0.03 
VC0279 0.05 0.04 
 
0.04 0.05 
VC0280 0.03 0.03 
 
0.05 0.04 
VC0281 0.05 0.02 
 
0.03 0.03 
VC0282 0.06 0.06 
 
0.08 0.06 
VC0283 0.06 0.07 
 
0.06 0.06 
VC0284 0.05 0.04 
 
0.05 0.06 
VC0285 0.06 0.06 
 
0.06 0.09 
VC0286 0.03 0.03 
 
0.01 0.03 
VC0286 0.00 0.00 
 
0.04 0.05 
VC0287 0.02 0.02 
 
0.04 0.04 
VC0287 0.01 0.05 
 
0.05 0.05 
VC0288 0.06 0.07 
 
0.04 0.07 
VC0289 0.07 0.07 
 
0.10 0.09 
VC0290 0.07 0.07 
 
0.08 0.13 
VC0291 0.07 0.05 
 
0.09 0.07 
VC0292 0.07 0.06 
 
0.02 0.03 
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VC0293 0.06 0.06 
 
0.03 0.04 
VC0294 0.08 0.10 
 
0.10 0.11 
VC0295 0.11 0.09 
 
0.08 0.07 
VC0297 0.10 0.08 
 
0.07 0.04 
VC0298 -0.01 0.03 
 
0.07 0.06 
VC0299 0.05 0.08 
 
0.03 0.04 
VC0300 0.07 0.07 
 
0.04 0.04 
VC0301 0.06 0.06 
 
0.07 0.05 
VC0302 0.06 0.06 
 
0.03 0.05 
VC0303 0.05 0.08 
 
0.06 0.08 
VC0304 0.03 0.02 
 
0.11 0.07 
VC0305 0.03 0.06 
 
0.12 0.12 
VC0306 0.05 0.05 
 
0.04 0.06 
VC0307 0.08 0.10 
 
0.07 0.07 
VC0308 0.02 0.06 
 
0.04 0.03 
VC0309 0.01 0.02 
 
0.04 0.04 
VC0311 0.03 0.04 
 
0.04 0.05 
VC0312 0.05 0.08 
 
0.03 0.03 
VC0313 0.05 0.05 
 
0.06 0.06 
VC0314 0.06 0.06 
 
0.07 0.06 
VC0316 0.05 0.06 
 
0.02 0.03 
VC0317 0.06 0.08 
 
0.05 0.11 
VC0318 0.03 0.04 
 
0.07 0.07 
VC0319 0.07 0.08 
 
0.07 0.05 
VC0320 0.04 0.03 
 
0.04 0.04 
VC0321 0.02 0.02 
 
0.00 0.00 
VC0322 0.05 0.07 
 
0.05 0.04 
VC0323 0.11 0.10 
 
0.06 0.06 
VC0324 0.03 0.03 
 
0.01 0.02 
VC0326 0.01 0.03 
 
0.01 0.01 
VC0327 0.10 0.06 
 
0.05 0.07 
VC0328 0.03 0.03 
 
0.05 0.06 
VC0329 0.06 0.07 
 
0.06 0.04 
VC0330 0.02 0.03 
 
0.06 0.07 
VC0331 0.04 0.04 
 
0.09 0.08 
VC0332 0.03 0.03 
 
0.00 0.01 
VC0333 0.04 0.04 
 
0.08 0.07 
VC0334 0.04 0.04 
 
0.03 0.03 
VC0335 0.08 0.08 
 
0.05 0.05 
VC0336 0.06 0.07 
 
0.06 0.05 
VC0337 0.05 0.04 
 
0.03 0.01 
VC0338 0.06 0.06 
 
0.06 0.06 
VC0339 0.02 0.03 
 
0.04 0.04 
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VC0341 0.08 0.08 
 
0.07 0.07 
VC0342 0.06 0.06 
 
0.03 0.04 
VC0343 0.06 0.07 
 
0.03 0.02 
VC0344 0.06 0.05 
 
0.01 0.02 
VC0345 0.08 0.10 
 
0.06 0.05 
VC0346 0.04 0.06 
 
0.05 0.05 
VC0347 0.12 0.10 
 
0.10 0.09 
VC0348 0.02 0.02 
 
0.06 0.07 
VC0349 0.04 0.03 
 
0.09 0.08 
VC0350 0.05 0.05 
 
0.03 0.03 
VC0351 0.02 0.03 
 
0.05 0.05 
VC0352 0.06 0.04 
 
0.03 0.03 
VC0353 0.03 0.02 
 
0.05 0.06 
VC0354 0.01 0.01 
 
0.02 0.02 
VC0355 0.06 0.07 
 
0.06 0.06 
VC0356 0.07 0.07 
 
0.06 0.05 
VC0357 0.05 0.05 
 
0.09 0.07 
VC0358 0.04 0.05 
 
0.04 0.07 
VC0359 0.07 0.08 
 
0.06 0.07 
VC0360 0.06 0.06 
 
0.10 0.10 
VC0361 0.06 0.07 
 
0.04 0.05 
VC0362 0.01 0.02 
 
0.00 0.00 
VC0363 0.07 0.07 
 
0.03 0.04 
VC0364 0.07 0.06 
 
0.03 0.03 
VC0365 0.06 0.05 
 
0.06 0.05 
VC0366 0.07 0.10 
 
0.03 0.04 
VC0367 0.03 0.04 
 
0.08 0.05 
VC0368 0.06 0.07 
 
0.03 0.03 
VC0369 0.04 0.04 
 
0.05 0.04 
VC0370 0.03 0.04 
 
0.04 0.04 
VC0371 0.03 0.04 
 
0.01 0.01 
VC0372 0.03 0.02 
 
0.04 0.04 
VC0373 0.06 0.07 
 
0.04 0.03 
VC0374 0.05 0.06 
 
0.11 0.10 
VC0375 0.05 0.05 
 
0.07 0.06 
VC0376 0.07 0.07 
 
0.03 0.04 
VC0377 0.02 0.02 
 
0.04 0.04 
VC0378 0.06 0.07 
 
0.06 0.04 
VC0379 0.04 0.03 
 
0.03 0.03 
VC0380 0.09 0.09 
 
0.05 0.03 
VC0381 0.02 0.02 
 
0.04 0.04 
VC0382 0.05 0.06 
 
0.06 0.06 
VC0383 0.08 0.06 
 
0.10 0.04 
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VC0384 0.04 0.04 
 
0.07 0.03 
VC0385 0.01 0.03 
 
0.05 0.05 
VC0386 0.07 0.08 
 
0.07 0.05 
VC0387 0.07 0.08 
 
0.08 0.07 
VC0388 0.07 0.06 
 
0.06 0.08 
VC0389 0.02 0.02 
 
0.03 0.05 
VC0390 0.04 0.06 
 
0.02 0.02 
VC0391 0.03 0.03 
 
0.04 0.07 
VC0392 0.03 0.05 
 
0.06 0.07 
VC0393 0.05 0.05 
 
0.08 0.07 
VC0394 0.08 0.06 
 
0.12 0.09 
VC0395 0.03 0.04 
 
0.05 0.08 
VC0396 0.06 0.09 
 
0.08 0.08 
VC0397 0.03 0.04 
 
0.06 0.06 
VC0399 0.00 0.01 
 
0.04 0.03 
VC0400 0.05 0.06 
 
0.07 0.06 
VC0401 0.01 0.02 
 
0.07 0.06 
VC0402 0.01 0.00 
 
0.01 0.02 
VC0403 0.03 0.01 
 
0.03 0.02 
VC0404 0.02 0.02 
 
0.10 0.08 
VC0405 0.17 0.19 
 
0.23 0.24 
VC0406 0.00 0.02 
 
0.05 0.04 
VC0407 0.03 0.02 
 
0.05 0.05 
VC0408 0.00 0.00 
 
0.05 0.05 
VC0409 0.05 0.05 
 
0.01 0.03 
VC0410 0.01 0.01 
 
0.04 0.04 
VC0411 0.01 0.01 
 
0.01 0.03 
VC0412 0.00 0.00 
 
0.03 0.03 
VC0413 0.05 0.04 
 
0.04 0.04 
VC0414 0.24 0.23 
 
0.04 0.04 
VC0415 0.01 0.02 
 
0.01 0.01 
VC0416 0.00 0.02 
 
0.07 0.08 
VC0417 0.06 0.05 
 
0.03 0.02 
VC0418 0.02 0.01 
 
0.03 0.04 
VC0419 -0.01 0.00 
 
0.06 0.07 
VC0420 0.04 0.03 
 
0.01 0.04 
VC0420 0.01 0.02 
 
0.04 0.05 
VC0421 0.02 0.04 
 
0.05 0.07 
VC0422 0.00 0.00 
 
0.05 0.04 
VC0423 0.02 0.03 
 
0.06 0.03 
VC0424 0.04 0.04 
 
0.08 0.06 
VC0425 0.01 0.01 
 
0.04 0.05 
VC0426 0.01 0.03 
 
0.04 0.04 
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VC0427 0.05 0.06 
 
0.03 0.03 
VC0428 0.01 0.01 
 
0.07 0.06 
VC0429 0.04 0.04 
 
0.05 0.06 
VC0430 0.04 0.02 
 
0.04 0.04 
VC0431 0.03 0.02 
 
0.05 0.07 
VC0432 0.03 0.03 
 
0.05 0.08 
VC0433 0.00 0.02 
 
0.10 0.12 
VC0435 0.14 0.13 
 
0.01 0.01 
VC0436 0.04 0.05 
 
0.03 0.04 
VC0437 0.06 0.05 
 
0.05 0.05 
VC0439 0.04 0.05 
 
0.07 0.08 
VC0440 0.07 0.07 
 
0.08 0.09 
VC0441 0.03 0.04 
 
0.05 0.04 
VC0442 0.06 0.07 
 
0.04 0.03 
VC0443 0.03 0.04 
 
0.07 0.06 
VC0444 0.03 0.03 
 
0.05 0.05 
VC0445 0.03 0.03 
 
0.07 0.07 
VC0446 0.03 0.04 
 
0.04 0.04 
VC0447 0.03 0.02 
 
0.02 0.02 
VC0448 0.02 0.03 
 
0.04 0.06 
VC0449 0.04 0.04 
 
0.06 0.05 
VC0450 0.06 0.06 
 
0.07 0.06 
VC0451 0.07 0.08 
 
0.06 0.04 
VC0452 0.03 0.04 
 
0.11 0.07 
VC0453 0.02 0.02 
 
0.12 0.10 
VC0454 0.03 0.03 
 
0.04 0.04 
VC0455 0.05 0.05 
 
0.06 0.05 
VC0456 0.03 0.04 
 
0.13 0.12 
VC0457 0.03 0.03 
 
0.09 0.07 
VC0458 0.02 0.02 
 
0.05 0.05 
VC0458 0.00 0.05 
 
0.04 0.03 
VC0459 0.03 0.02 
 
0.14 0.13 
VC0460 0.04 0.04 
 
0.05 0.05 
VC0461 0.05 0.06 
 
0.07 0.06 
VC0462 0.03 0.04 
 
0.08 0.08 
VC0463 0.02 0.02 
 
0.05 0.04 
VC0464 0.07 0.06 
 
0.06 0.07 
VC0465 0.02 0.05 
 
0.07 0.07 
VC0466 0.03 0.04 
 
0.07 0.08 
VC0467 0.02 0.02 
 
0.03 0.03 
VC0468 0.00 0.00 
 
0.07 0.05 
VC0469 0.06 0.06 
 
0.08 0.07 
VC0470 0.02 0.02 
 
0.03 0.02 
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VC0471 0.02 0.02 
 
0.07 0.09 
VC0472 0.02 0.02 
 
0.01 0.01 
VC0473 0.04 0.05 
 
0.03 0.04 
VC0474 0.02 0.02 
 
0.06 0.06 
VC0475 0.01 0.00 
 
0.02 0.02 
VC0476 0.01 0.03 
 
0.03 0.08 
VC0477 0.02 0.03 
 
0.04 0.03 
VC0477 0.01 0.02 
 
0.03 0.04 
VC0478 0.02 0.04 
 
0.05 0.06 
VC0479 0.03 0.04 
 
0.04 0.03 
VC0480 0.00 0.01 
 
0.01 0.02 
VC0481 0.04 0.04 
 
0.03 0.02 
VC0482 0.05 0.05 
 
0.05 0.05 
VC0483 0.02 0.02 
 
0.04 0.09 
VC0484 0.04 0.03 
 
0.05 0.05 
VC0485 0.02 0.01 
 
0.05 0.06 
VC0486 0.05 0.07 
 
0.07 0.06 
VC0487 0.09 0.12 
 
0.03 0.05 
VC0488 0.01 0.03 
 
0.05 0.07 
VC0489 0.06 0.07 
 
0.02 0.03 
VC0490 0.03 0.02 
 
0.05 0.05 
VC0491 0.05 0.05 
 
0.03 0.03 
VC0492 0.02 0.02 
 
0.04 0.05 
VC0492 0.01 0.01 
 
0.04 0.04 
VC0493 0.04 0.05 
 
0.04 0.05 
VC0494 0.02 0.02 
 
0.08 0.08 
VC0495 0.02 0.02 
 
0.06 0.05 
VC0496 0.02 0.03 
 
0.05 0.05 
VC0497 0.04 0.05 
 
0.04 0.05 
VC0498 0.07 0.06 
 
0.05 0.05 
VC0499 0.03 0.04 
 
0.07 0.09 
VC0500 0.04 0.06 
 
0.04 0.05 
VC0501 0.03 0.04 
 
0.06 0.06 
VC0502 0.03 0.03 
 
0.09 0.04 
VC0503 0.02 0.02 
 
0.02 0.02 
VC0504 0.02 0.06 
 
0.03 0.05 
VC0505 0.06 0.06 
 
0.06 0.06 
VC0506 0.08 0.08 
 
0.06 0.04 
VC0507 0.07 0.08 
 
0.01 0.03 
VC0508 0.05 0.06 
 
0.09 0.08 
VC0509 0.05 0.06 
 
0.08 0.07 
VC0510 0.00 0.01 
 
0.07 0.04 
VC0511 0.05 0.05 
 
0.05 0.04 
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VC0512 0.04 0.05 
 
0.08 0.05 
VC0513 0.01 0.01 
 
0.09 0.08 
VC0514 0.04 0.03 
 
0.05 0.07 
VC0515 0.01 0.01 
 
0.02 0.02 
VC0516 0.01 0.03 
 
0.06 0.06 
VC0517 0.07 0.05 
 
0.04 0.06 
VC0518 0.02 0.04 
 
0.04 0.05 
VC0519 0.05 0.06 
 
0.08 0.09 
VC0520 0.05 0.06 
 
0.04 0.05 
VC0521 0.09 0.07 
 
0.06 0.06 
VC0522 0.05 0.07 
 
0.04 0.03 
VC0523 -0.01 0.00 
 
0.07 0.06 
VC0524 0.05 0.06 
 
0.09 0.10 
VC0525 0.00 0.01 
 
0.10 0.08 
VC0526 0.03 0.03 
 
0.04 0.05 
VC0527 0.06 0.05 
 
0.01 0.02 
VC0528 -0.01 -0.01 
 
0.12 0.13 
VC0529 0.02 0.02 
 
0.06 0.05 
VC0530 0.06 0.07 
 
0.06 0.04 
VC0531 0.06 0.05 
 
0.04 0.03 
VC0532 0.00 0.00 
 
0.09 0.10 
VC0533 0.02 0.03 
 
0.02 0.01 
VC0534 0.00 0.00 
 
0.08 0.07 
VC0535 0.05 0.05 
 
0.07 0.05 
VC0536 0.05 0.05 
 
0.06 0.07 
VC0537 -0.01 -0.01 
 
0.07 0.06 
VC0538 0.06 0.05 
 
0.06 0.05 
VC0539 -0.01 0.03 
 
0.04 0.04 
VC0540 0.03 0.03 
 
0.03 0.03 
VC0541 0.02 0.02 
 
0.03 0.06 
VC0542 0.06 0.05 
 
0.07 0.06 
VC0543 0.04 0.03 
 
0.07 0.07 
VC0544 0.04 0.04 
 
0.06 0.05 
VC0545 0.10 0.10 
 
0.06 0.06 
VC0546 0.05 0.06 
 
0.03 0.02 
VC0547 0.03 0.04 
 
0.05 0.05 
VC0548 0.11 0.06 
 
0.06 0.03 
VC0549 0.06 0.06 
 
0.02 0.02 
VC0550 0.02 0.01 
 
0.06 0.05 
VC0551 0.01 0.03 
 
0.02 0.02 
VC0552 0.02 0.06 
 
0.03 0.04 
VC0553 0.04 0.04 
 
0.07 0.06 
VC0554 0.07 0.05 
 
0.08 0.10 
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VC0555 0.03 0.03 
 
0.02 0.02 
VC0556 0.04 0.05 
 
0.07 0.05 
VC0557 0.04 0.04 
 
0.06 0.08 
VC0558 0.03 0.02 
 
0.04 0.18 
VC0559 0.00 0.01 
 
0.03 0.03 
VC0560 0.07 0.05 
 
0.07 0.07 
VC0561 0.03 0.03 
 
0.02 0.03 
VC0562 0.04 0.03 
 
0.06 0.07 
VC0563 0.03 0.04 
 
0.07 0.07 
VC0564 0.04 0.10 
 
0.04 0.05 
VC0565 0.02 0.05 
 
0.04 0.04 
VC0567 0.05 0.04 
 
0.05 0.22 
VC0568 0.05 0.05 
 
0.05 0.04 
VC0569 0.07 0.07 
 
0.04 0.03 
VC0570 0.06 0.07 
 
0.07 0.03 
VC0571 0.10 0.10 
 
0.05 0.04 
VC0572 0.08 0.08 
 
0.01 0.02 
VC0573 0.02 0.02 
 
0.03 0.04 
VC0574 0.08 0.07 
 
0.03 0.03 
VC0575 0.00 0.02 
 
0.05 0.16 
VC0576 0.08 0.06 
 
0.04 0.02 
VC0577 0.00 0.01 
 
0.01 0.05 
VC0578 0.03 0.03 
 
0.01 0.01 
VC0579 0.05 0.06 
 
0.03 0.04 
VC0580 0.07 0.07 
 
0.08 0.05 
VC0581 0.04 0.04 
 
0.05 0.04 
VC0582 0.02 0.03 
 
0.03 0.04 
VC0583 0.09 0.07 
 
0.02 0.03 
VC0584 0.05 0.06 
 
0.05 0.04 
VC0585 0.07 0.06 
 
0.05 0.06 
VC0586 0.07 0.06 
 
0.01 0.02 
VC0587 0.04 0.04 
 
0.03 0.07 
VC0588 0.07 0.06 
 
0.04 0.05 
VC0589 0.04 0.04 
 
0.04 0.07 
VC0590 0.04 0.05 
 
0.03 0.04 
VC0591 0.03 0.04 
 
0.03 0.07 
VC0592 0.01 0.01 
 
0.08 0.05 
VC0593 0.03 0.05 
 
0.08 0.08 
VC0596 0.07 0.07 
 
0.08 0.06 
VC0597 0.03 0.04 
 
0.05 0.06 
VC0598 0.04 0.04 
 
0.03 0.04 
VC0599 0.07 0.06 
 
0.04 0.05 
VC0600 0.06 0.08 
 
0.03 0.03 
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VC0601 0.01 0.01 
 
0.05 0.04 
VC0602 0.01 0.02 
 
0.04 0.04 
VC0603 0.02 0.02 
 
0.04 0.02 
VC0604 0.03 0.04 
 
0.05 0.06 
VC0605 0.09 0.08 
 
0.05 0.07 
VC0606 0.07 0.07 
 
0.05 0.04 
VC0607 0.03 0.04 
 
0.00 0.04 
VC0607 0.01 0.00 
 
0.07 0.07 
VC0609 0.02 0.04 
 
0.02 0.02 
VC0610 0.02 0.02 
 
0.04 0.04 
VC0611 0.02 0.03 
 
0.02 0.05 
VC0611 0.01 0.02 
 
0.05 0.05 
VC0612 0.00 0.01 
 
0.03 0.04 
VC0613 0.05 0.07 
 
0.03 0.06 
VC0614 0.04 0.03 
 
0.12 0.12 
VC0615 0.02 0.02 
 
0.04 0.06 
VC0615 -0.01 0.07 
 
0.06 0.05 
VC0616 0.02 0.01 
 
0.04 0.06 
VC0617 0.00 0.03 
 
0.04 0.05 
VC0619 0.03 0.04 
 
0.06 0.04 
VC0620 0.02 0.03 
 
0.02 0.04 
VC0620 0.01 0.04 
 
0.03 0.04 
VC0621 0.07 0.08 
 
0.06 0.05 
VC0622 0.02 0.03 
 
0.04 0.04 
VC0623 0.03 0.03 
 
0.05 0.04 
VC0624 0.06 0.05 
 
0.10 0.10 
VC0625 0.04 0.07 
 
0.05 0.05 
VC0626 0.08 0.06 
 
0.07 0.06 
VC0627 0.05 0.06 
 
0.05 0.05 
VC0628 0.05 0.09 
 
0.05 0.05 
VC0629 0.02 0.04 
 
0.04 0.04 
VC0630 0.08 0.06 
 
0.07 0.06 
VC0631 0.07 0.05 
 
0.11 0.08 
VC0632 0.03 0.03 
 
0.05 0.05 
VC0633 0.06 0.05 
 
0.09 0.06 
VC0634 0.07 0.16 
 
0.08 0.10 
VC0635 0.06 0.05 
 
0.12 0.11 
VC0636 0.06 0.07 
 
0.09 0.08 
VC0637 0.10 0.08 
 
0.06 0.09 
VC0638 0.03 0.04 
 
0.08 0.04 
VC0639 0.06 0.06 
 
0.08 0.09 
VC0640 0.06 0.05 
 
0.09 0.06 
VC0641 0.08 0.09 
 
0.05 0.05 
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VC0642 0.04 0.05 
 
0.01 0.01 
VC0643 0.10 0.10 
 
0.04 0.06 
VC0644 0.01 0.02 
 
0.01 0.02 
VC0645 0.08 0.06 
 
0.16 0.20 
VC0646 0.08 0.06 
 
0.03 0.04 
VC0647 0.08 0.08 
 
0.05 0.06 
VC0648 0.04 0.04 
 
0.08 0.07 
VC0649 0.05 0.04 
 
0.06 0.05 
VC0650 0.04 0.05 
 
0.06 0.06 
VC0651 0.05 0.04 
 
0.08 0.07 
VC0652 0.07 0.06 
 
0.07 0.07 
VC0653 -0.02 -0.01 
 
-0.01 -0.01 
VC0654 0.04 0.06 
 
0.07 0.06 
VC0655 0.03 0.03 
 
0.01 0.02 
VC0656 0.03 0.03 
 
0.07 0.05 
VC0657 0.06 0.06 
 
0.06 0.05 
VC0658 0.60 0.64 
 
0.58 0.54 
VC0659 0.06 0.05 
 
0.05 0.06 
VC0660 0.04 0.05 
 
0.03 0.03 
VC0661 0.07 0.07 
 
0.14 0.13 
VC0662 0.04 0.05 
 
0.12 0.15 
VC0663 0.07 0.06 
 
0.09 0.10 
VC0664 0.04 0.03 
 
0.06 0.06 
VC0665 0.12 0.13 
 
0.15 0.13 
VC0666 0.04 0.04 
 
0.07 0.09 
VC0667 0.03 0.03 
 
0.03 0.04 
VC0668 0.06 0.06 
 
0.08 0.08 
VC0669 0.06 0.06 
 
0.05 0.04 
VC0670 0.08 0.08 
 
0.01 0.03 
VC0671 0.04 0.05 
 
0.05 0.05 
VC0672 0.02 0.02 
 
0.03 0.04 
VC0673 0.04 0.04 
 
0.06 0.07 
VC0674 0.05 0.05 
 
0.09 0.09 
VC0675 0.01 0.01 
 
0.00 0.01 
VC0676 0.08 0.09 
 
0.05 0.08 
VC0677 0.06 0.06 
 
0.09 0.08 
VC0678 0.02 0.04 
 
0.07 0.07 
VC0679 0.03 0.06 
 
0.05 0.04 
VC0680 0.04 0.03 
 
0.06 0.05 
VC0681 0.01 0.01 
 
0.00 0.01 
VC0682 0.11 0.14 
 
0.03 0.08 
VC0683 0.05 0.04 
 
0.08 0.07 
VC0684 0.04 0.04 
 
0.10 0.09 
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VC0685 0.04 0.05 
 
0.09 0.07 
VC0686 0.07 0.09 
 
0.05 0.06 
VC0687 0.04 0.05 
 
0.05 0.06 
VC0688 0.05 0.04 
 
0.06 0.06 
VC0689 0.08 0.07 
 
0.04 0.03 
VC0690 0.08 0.07 
 
0.13 0.08 
VC0691 0.05 0.06 
 
0.08 0.07 
VC0692 0.03 0.07 
 
0.13 0.09 
VC0693 0.09 0.08 
 
0.04 0.04 
VC0694 0.05 0.09 
 
0.03 0.05 
VC0695 0.06 0.06 
 
0.12 0.09 
VC0696 0.07 0.05 
 
0.16 0.14 
VC0697 0.04 0.04 
 
0.07 0.06 
VC0698 0.07 0.09 
 
0.03 0.09 
VC0699 0.09 0.14 
 
0.09 0.07 
VC0700 0.06 0.05 
 
0.03 0.05 
VC0701 0.08 0.07 
 
0.10 0.11 
VC0702 0.03 0.04 
 
0.02 0.03 
VC0703 0.07 0.07 
 
0.15 0.14 
VC0703 0.00 0.04 
 
0.04 0.03 
VC0704 0.02 0.02 
 
0.05 0.05 
VC0705 0.04 0.04 
 
0.05 0.05 
VC0706 0.03 0.04 
 
0.04 0.04 
VC0707 0.06 0.07 
 
0.03 0.03 
VC0708 0.04 0.03 
 
0.07 0.05 
VC0709 0.07 0.06 
 
0.05 0.06 
VC0710 0.05 0.04 
 
0.08 0.06 
VC0711 0.05 0.07 
 
0.03 0.03 
VC0712 0.05 0.06 
 
0.06 0.06 
VC0713 0.03 0.03 
 
0.07 0.05 
VC0714 0.02 0.00 
 
0.00 0.02 
VC0715 0.06 0.07 
 
0.04 0.06 
VC0716 0.02 0.02 
 
0.00 0.01 
VC0717 0.04 0.04 
 
0.02 0.02 
VC0718 0.04 0.05 
 
0.06 0.06 
VC0719 0.09 0.08 
 
0.03 0.05 
VC0720 0.02 0.02 
 
0.01 0.02 
VC0721 0.02 0.02 
 
0.04 0.01 
VC0722 0.07 0.05 
 
0.05 0.04 
VC0723 0.03 0.02 
 
0.06 0.06 
VC0724 0.01 0.01 
 
0.07 0.07 
VC0725 -0.03 0.01 
 
0.09 0.07 
VC0726 0.08 0.08 
 
0.06 0.06 
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VC0727 0.05 0.07 
 
0.06 0.06 
VC0728 0.02 0.03 
 
0.04 0.04 
VC0729 0.07 0.07 
 
0.04 0.04 
VC0729 0.06 0.06 
 
0.04 0.04 
VC0730 0.13 0.10 
 
0.06 0.06 
VC0731 0.17 0.14 
 
0.02 0.04 
VC0732 0.09 0.08 
 
0.04 0.05 
VC0733 0.05 0.05 
 
0.03 0.03 
VC0734 0.00 0.02 
 
0.06 0.04 
VC0735 0.06 0.08 
 
0.07 0.08 
VC0736 0.17 0.17 
 
0.04 0.02 
VC0737 0.08 0.09 
 
0.05 0.06 
VC0738 0.06 0.08 
 
0.08 0.08 
VC0738 0.07 0.09 
 
0.06 0.06 
VC0739 0.15 0.13 
 
0.03 0.03 
VC0740 0.05 0.05 
 
0.06 0.06 
VC0741 0.03 0.05 
 
0.05 0.05 
VC0742 0.11 0.10 
 
0.07 0.06 
VC0743 0.04 0.06 
 
0.03 0.04 
VC0744 0.03 0.03 
 
0.01 0.02 
VC0745 0.15 0.11 
 
0.01 0.00 
VC0746 0.13 0.12 
 
0.02 0.01 
VC0747 0.09 0.08 
 
0.01 0.02 
VC0748 0.15 0.14 
 
0.02 0.01 
VC0749 0.10 0.09 
 
0.00 0.01 
VC0750 0.08 0.05 
 
0.06 0.06 
VC0751 0.07 0.07 
 
0.03 0.04 
VC0752 0.07 0.08 
 
0.05 0.05 
VC0753 0.10 0.10 
 
0.01 0.04 
VC0754 0.09 0.08 
 
0.05 0.05 
VC0755 0.11 0.09 
 
0.04 0.04 
VC0756 0.05 0.05 
 
0.02 0.03 
VC0757 0.14 0.15 
 
0.03 0.03 
VC0758 0.07 0.04 
 
0.03 0.02 
VC0759 0.09 0.07 
 
0.00 0.00 
VC0760 0.04 0.05 
 
0.09 0.09 
VC0761 0.12 0.09 
 
0.01 0.00 
VC0762 0.10 0.07 
 
0.05 0.05 
VC0763 0.00 0.02 
 
0.01 0.01 
VC0764 0.02 0.03 
 
0.04 0.05 
VC0765 0.13 0.11 
 
0.03 0.01 
VC0766 0.05 0.06 
 
0.08 0.06 
VC0767 -0.01 0.02 
 
0.05 0.05 
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VC0768 0.01 0.01 
 
0.07 0.05 
VC0769 0.01 0.02 
 
0.04 0.04 
VC0770 0.07 0.10 
 
0.01 0.00 
VC0771 0.02 0.02 
 
0.06 0.01 
VC0772 -0.03 -0.03 
 
0.07 0.06 
VC0773 0.06 0.06 
 
0.07 0.06 
VC0774 0.06 0.08 
 
0.03 0.04 
VC0775 0.13 0.14 
 
0.00 0.01 
VC0776 0.02 0.03 
 
0.07 0.02 
VC0777 0.11 0.10 
 
0.01 0.02 
VC0778 0.12 0.11 
 
0.02 -0.01 
VC0779 0.03 0.04 
 
0.05 0.05 
VC0780 0.13 0.11 
 
0.00 0.01 
VC0781 0.12 0.11 
 
0.00 0.01 
VC0782 0.05 0.05 
 
0.10 0.07 
VC0783 0.06 0.05 
 
0.07 0.06 
VC0784 0.10 0.11 
 
0.03 0.03 
VC0785 0.05 0.05 
 
0.04 0.05 
VC0786 0.06 0.06 
 
0.06 0.09 
VC0787 0.03 0.04 
 
0.06 0.06 
VC0788 0.05 0.04 
 
0.04 0.04 
VC0788 0.02 0.01 
 
0.03 0.04 
VC0789 0.06 0.05 
 
0.08 0.05 
VC0790 0.05 0.03 
 
0.09 0.07 
VC0791 0.08 0.09 
 
0.04 0.04 
VC0792 0.02 0.03 
 
0.08 0.08 
VC0793 0.01 0.14 
 
0.02 0.03 
VC0793m 0.04 0.04 
 
0.06 0.06 
VC0794 0.10 0.11 
 
0.01 0.02 
VC0795 0.03 0.05 
 
0.04 0.05 
VC0796 0.05 0.06 
 
0.06 0.07 
VC0797 0.07 0.06 
 
0.07 0.06 
VC0798 0.05 0.04 
 
0.03 0.04 
VC0799 0.02 0.02 
 
0.04 0.04 
VC0800 0.08 0.07 
 
0.12 0.12 
VC0801 0.05 0.04 
 
0.08 0.06 
VC0802 0.05 0.05 
 
0.07 0.06 
VC0803 0.03 0.02 
 
0.03 0.04 
VC0805 0.02 0.02 
 
0.04 0.05 
VC0806 0.06 0.04 
 
0.05 0.04 
VC0807 0.02 0.02 
 
0.10 0.06 
VC0808 0.03 0.03 
 
0.05 0.06 
VC0809 0.04 0.05 
 
0.06 0.04 
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VC0810 0.05 0.03 
 
0.10 0.08 
VC0811 0.05 0.05 
 
0.07 0.07 
VC0812 0.03 0.04 
 
0.08 0.08 
VC0813 0.06 0.07 
 
0.06 0.06 
VC0814 0.02 0.02 
 
0.15 0.11 
VC0815 0.22 0.24 
 
0.01 0.01 
VC0816 0.09 0.08 
 
0.04 0.03 
VC0817 0.03 0.06 
 
0.08 0.07 
VC0818 0.07 0.06 
 
0.05 0.05 
VC0819 0.02 0.02 
 
0.07 0.06 
VC0820 0.03 0.03 
 
0.01 0.01 
VC0821 0.02 0.04 
 
0.05 0.04 
VC0822 0.01 0.02 
 
0.06 0.07 
VC0823 0.02 0.02 
 
0.05 0.05 
VC0824 0.02 0.02 
 
0.03 0.04 
VC0824 0.01 0.02 
 
0.06 0.05 
VC0825 0.05 0.05 
 
0.06 0.06 
VC0826 0.04 0.05 
 
0.06 0.05 
VC0827 0.02 0.02 
 
0.07 0.07 
VC0827 0.01 -0.02 
 
0.05 0.07 
VC0828 0.01 0.01 
 
0.04 0.03 
VC0829 0.08 0.06 
 
0.03 0.04 
VC0830 0.06 0.07 
 
0.07 -0.07 
VC0831 0.05 0.05 
 
0.06 0.04 
VC0832 0.01 0.02 
 
0.04 0.04 
VC0833 0.04 0.05 
 
0.07 0.07 
VC0834 0.01 0.02 
 
0.06 0.08 
VC0835 0.06 0.06 
 
0.07 0.06 
VC0836 0.03 0.04 
 
0.03 0.05 
VC0837 0.04 0.06 
 
0.11 0.12 
VC0838 0.03 0.04 
 
0.03 0.03 
VC0839 0.03 0.04 
 
0.05 0.04 
VC0840 0.01 0.04 
 
0.06 0.04 
VC0841 0.01 0.01 
 
0.01 0.02 
VC0842 0.01 0.02 
 
0.05 0.08 
VC0843 0.02 0.03 
 
0.04 0.04 
VC0846 0.01 0.02 
 
0.07 0.09 
VC0847 0.05 0.05 
 
0.05 0.04 
VC0848 0.01 0.01 
 
0.08 0.09 
VC0849 -0.01 0.01 
 
0.02 0.04 
VC0850 0.07 0.06 
 
0.06 0.10 
VC0851 0.02 0.05 
 
0.04 0.06 
VC0852 0.06 0.07 
 
0.11 0.13 
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VC0853 0.05 0.06 
 
0.07 0.07 
VC0854 0.08 0.07 
 
0.04 0.05 
VC0855 0.04 0.04 
 
0.10 0.08 
VC0856 0.03 0.06 
 
0.04 0.04 
VC0857 0.06 0.07 
 
0.05 0.04 
VC0858 0.03 0.02 
 
0.05 0.04 
VC0859 0.03 0.04 
 
0.06 0.05 
VC0860 0.04 0.04 
 
0.04 0.04 
VC0861 0.04 0.10 
 
0.08 0.07 
VC0862 0.05 0.05 
 
0.10 0.06 
VC0863 0.03 0.03 
 
0.08 0.05 
VC0864 0.05 0.07 
 
0.07 0.08 
VC0865 0.06 0.07 
 
0.03 0.03 
VC0866 0.00 0.00 
 
0.03 0.02 
VC0867 0.05 0.05 
 
0.02 0.02 
VC0868 0.04 0.03 
 
0.06 0.06 
VC0869 0.07 0.08 
 
0.09 0.07 
VC0870 0.01 0.03 
 
0.05 0.04 
VC0871 0.10 0.09 
 
0.04 0.03 
VC0872 0.08 0.08 
 
0.03 0.03 
VC0873 0.02 0.03 
 
0.06 0.08 
VC0874 0.03 0.03 
 
0.07 0.04 
VC0875 0.06 0.06 
 
0.01 0.03 
VC0876 0.02 0.02 
 
0.07 0.10 
VC0877 0.10 0.09 
 
0.04 0.05 
VC0878 0.07 0.08 
 
0.06 0.08 
VC0879 0.07 0.07 
 
0.03 0.03 
VC0880 0.04 0.03 
 
0.04 0.05 
VC0881 0.03 0.03 
 
0.08 0.06 
VC0882 0.06 0.06 
 
0.02 0.03 
VC0883 0.04 0.04 
 
0.04 0.04 
VC0884 0.01 0.02 
 
0.02 0.04 
VC0885 0.05 0.05 
 
0.02 0.02 
VC0886 0.04 0.01 
 
0.03 0.05 
VC0887 0.04 0.02 
 
0.03 0.04 
VC0888 0.09 0.06 
 
0.05 0.07 
VC0889 0.03 0.04 
 
0.05 0.04 
VC0890 0.03 0.04 
 
0.01 0.01 
VC0891 0.05 0.06 
 
0.04 0.05 
VC0892 0.03 0.03 
 
0.05 0.03 
VC0893 0.04 0.04 
 
0.03 0.04 
VC0894 0.01 0.02 
 
0.07 0.06 
VC0895 0.02 0.04 
 
0.05 0.05 
	   172	  
VC0897 0.03 0.03 
 
0.12 0.09 
VC0898 0.07 0.08 
 
0.06 0.07 
VC0899 0.00 0.02 
 
0.11 0.08 
VC0900 0.04 0.04 
 
0.04 0.04 
VC0901 0.06 0.06 
 
0.06 0.08 
VC0902 0.05 0.04 
 
0.07 0.05 
VC0903 0.14 0.06 
 
0.01 0.03 
VC0904 0.02 0.01 
 
0.10 0.08 
VC0905 0.04 0.04 
 
0.09 0.09 
VC0906 0.02 0.02 
 
0.15 0.14 
VC0907 0.06 0.07 
 
0.05 0.05 
VC0908 0.04 0.06 
 
0.05 0.03 
VC0909 0.03 0.02 
 
0.04 0.06 
VC0910 0.02 0.02 
 
0.11 0.16 
VC0911 0.08 0.09 
 
0.05 0.04 
VC0912 0.02 0.04 
 
0.04 0.05 
VC0914 0.04 0.05 
 
0.06 0.05 
VC0915 0.05 0.05 
 
0.06 0.04 
VC0916 0.05 0.05 
 
0.05 0.05 
VC0917 0.04 0.04 
 
0.06 0.06 
VC0918 0.05 0.06 
 
0.11 0.12 
VC0919 0.07 0.08 
 
0.04 0.03 
VC0920 0.03 0.03 
 
0.14 0.12 
VC0921 0.04 0.05 
 
0.18 0.16 
VC0922 0.02 0.01 
 
0.03 0.08 
VC0923 0.04 0.05 
 
0.00 0.04 
VC0924 0.04 0.01 
 
0.03 0.04 
VC0925 0.05 0.06 
 
0.04 0.04 
VC0926 0.01 0.03 
 
0.04 0.03 
VC0927 0.02 0.01 
 
0.04 0.03 
VC0928 0.03 0.05 
 
0.05 0.03 
VC0929 0.04 0.02 
 
0.03 0.03 
VC0930 0.06 0.05 
 
0.06 0.06 
VC0931 0.01 0.02 
 
0.04 0.04 
VC0932 0.01 0.01 
 
0.03 0.04 
VC0932 0.01 0.02 
 
0.03 0.02 
VC0934 0.03 0.01 
 
0.05 0.05 
VC0935 0.02 0.03 
 
0.03 0.05 
VC0936 0.03 0.04 
 
0.02 0.03 
VC0937 0.02 0.04 
 
0.07 0.06 
VC0938 0.01 0.00 
 
0.07 0.05 
VC0939 0.06 0.05 
 
0.01 0.02 
VC0940 0.06 0.06 
 
0.01 0.01 
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VC0941 0.05 0.06 
 
0.03 0.03 
VC0943 0.02 0.01 
 
0.03 0.02 
VC0944 0.04 0.05 
 
0.09 0.09 
VC0945 0.04 0.06 
 
0.05 0.05 
VC0946 0.05 0.05 
 
0.05 0.05 
VC0947 0.00 0.00 
 
0.10 0.08 
VC0948 0.03 0.03 
 
0.10 0.09 
VC0949 0.02 0.05 
 
0.03 0.03 
VC0950 0.03 0.03 
 
0.03 0.03 
VC0951 0.04 0.04 
 
0.08 0.07 
VC0952 0.03 0.01 
 
0.11 0.10 
VC0953 0.00 0.01 
 
0.00 0.01 
VC0954 0.03 0.04 
 
0.03 0.03 
VC0955 0.02 0.02 
 
0.04 0.06 
VC0957 0.07 0.06 
 
0.04 0.07 
VC0958 0.00 0.04 
 
0.02 0.02 
VC0959 0.03 0.02 
 
0.08 0.06 
VC0960 0.04 0.05 
 
0.06 0.07 
VC0961 0.05 0.06 
 
0.05 0.05 
VC0962 0.04 0.04 
 
0.07 0.06 
VC0963 0.04 0.05 
 
0.06 0.06 
VC0964 0.07 0.05 
 
0.08 0.06 
VC0965 0.07 0.07 
 
0.06 0.05 
VC0966 0.04 0.05 
 
0.07 0.05 
VC0967 -0.01 0.00 
 
0.09 0.06 
VC0968 0.00 0.02 
 
0.06 0.05 
VC0969 0.01 0.01 
 
0.08 0.07 
VC0970 -0.01 0.04 
 
0.05 0.04 
VC0972 -0.01 -0.01 
 
0.09 0.03 
VC0973 0.04 0.03 
 
0.05 0.05 
VC0974 0.07 0.05 
 
0.05 0.05 
VC0975 0.05 0.11 
 
0.05 0.08 
VC0976 -0.01 -0.01 
 
0.07 0.04 
VC0977 0.00 0.01 
 
0.04 0.04 
VC0978 0.05 0.06 
 
0.05 0.04 
VC0979 0.04 0.03 
 
0.04 0.04 
VC0980 0.00 0.00 
 
0.07 0.07 
VC0981 0.00 0.01 
 
0.09 0.09 
VC0982 0.05 0.04 
 
0.08 0.06 
VC0983 -0.01 -0.01 
 
0.04 0.04 
VC0984 0.01 0.03 
 
0.05 0.05 
VC0985 0.03 0.04 
 
0.10 0.09 
VC0986 0.05 0.07 
 
0.06 0.08 
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VC0987 0.04 0.04 
 
0.06 0.04 
VC0988 0.00 0.00 
 
0.06 0.05 
VC0989 0.04 0.05 
 
0.03 0.03 
VC0990 0.00 -0.01 
 
0.09 0.06 
VC0991 0.01 0.00 
 
0.08 0.08 
VC0992 0.00 0.01 
 
0.07 0.07 
VC0993 -0.01 -0.01 
 
0.06 0.06 
VC0994 -0.02 -0.01 
 
0.07 0.06 
VC0995 0.13 0.10 
 
0.05 0.07 
VC0996 0.05 0.02 
 
0.02 0.01 
VC0997 0.06 0.09 
 
0.04 0.05 
VC0998 0.00 0.04 
 
0.03 0.04 
VC0999 0.05 0.04 
 
0.06 0.05 
VC1000 0.05 0.06 
 
0.04 0.06 
VC1001 0.04 0.04 
 
0.06 0.07 
VC1002 0.03 0.04 
 
0.04 0.04 
VC1003 0.02 0.03 
 
0.06 0.05 
VC1004 0.02 0.04 
 
0.04 0.05 
VC1005 0.03 0.03 
 
0.05 0.05 
VC1006 0.00 0.01 
 
0.00 0.00 
VC1007 0.03 0.05 
 
0.06 0.05 
VC1008 0.02 0.13 
 
0.05 0.05 
VC1009 0.04 0.05 
 
0.05 0.04 
VC1010 0.03 0.03 
 
0.05 0.10 
VC1011 0.00 0.03 
 
0.06 0.05 
VC1012 0.04 0.03 
 
0.05 0.05 
VC1013 0.08 0.02 
 
0.02 0.04 
VC1014 0.02 0.01 
 
-0.01 -0.01 
VC1015 0.05 0.07 
 
-0.03 -0.01 
VC1016 0.02 0.02 
 
0.04 0.03 
VC1017 0.04 0.03 
 
0.04 0.05 
VC1018 0.04 0.04 
 
0.02 0.02 
VC1020 0.10 0.07 
 
0.05 0.07 
VC1021 0.03 0.02 
 
0.05 0.05 
VC1022 -0.02 -0.02 
 
0.06 0.01 
VC1023 0.03 0.04 
 
0.09 0.08 
VC1024 0.01 0.03 
 
0.02 0.02 
VC1025 0.04 0.05 
 
0.02 0.03 
VC1026 0.09 0.09 
 
0.02 0.05 
VC1027 0.06 0.06 
 
0.04 0.06 
VC1028 0.02 0.03 
 
0.04 0.04 
VC1029 0.00 -0.01 
 
-0.02 -0.01 
VC1030 0.07 0.06 
 
0.04 0.03 
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VC1031 0.04 0.06 
 
0.03 0.03 
VC1032 0.06 0.08 
 
0.05 0.02 
VC1033 0.03 0.04 
 
0.03 0.01 
VC1034 0.03 0.03 
 
0.04 0.06 
VC1035 0.07 0.05 
 
0.04 0.04 
VC1037 0.05 0.06 
 
0.06 0.05 
VC1038 0.09 0.07 
 
0.07 0.09 
VC1039 0.02 0.04 
 
0.01 0.01 
VC1040 0.04 0.04 
 
0.06 0.05 
VC1041 0.03 0.04 
 
0.02 0.03 
VC1043 0.04 0.03 
 
0.04 0.04 
VC1044 0.03 0.04 
 
0.04 0.02 
VC1045 0.03 0.03 
 
-0.01 -0.01 
VC1046 0.07 0.06 
 
0.04 0.05 
VC1047 0.03 0.03 
 
0.06 0.04 
VC1048 0.04 0.05 
 
0.04 0.03 
VC1049 0.06 0.06 
 
0.07 0.07 
VC1050 0.02 0.03 
 
0.04 0.06 
VC1051 0.08 0.07 
 
0.03 0.05 
VC1052 0.05 0.06 
 
0.03 0.03 
VC1053 0.09 0.08 
 
0.03 0.05 
VC1054 0.08 0.08 
 
0.03 0.06 
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VC1057 0.05 0.05 
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0.05 0.06 
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0.04 0.04 
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-0.02 -0.02 
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VC1070 0.13 0.09 
 
0.03 0.10 
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VC1072 0.06 0.06 
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VC1075 0.09 0.08 
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VC1077 0.06 0.09 
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VC1078 0.06 0.06 
 
0.06 0.07 
VC1079 0.02 0.02 
 
0.04 0.05 
VC1080 0.08 0.08 
 
0.06 0.04 
VC1081 0.08 0.09 
 
0.06 0.05 
VC1082 0.06 0.06 
 
0.07 0.05 
VC1083 0.04 0.06 
 
0.07 0.09 
VC1084 0.08 0.09 
 
0.06 0.05 
VC1085 0.07 0.07 
 
0.08 0.07 
VC1086 0.00 0.00 
 
0.02 0.02 
VC1087 0.05 0.05 
 
0.04 0.06 
VC1088 0.05 0.05 
 
0.04 0.05 
VC1089 0.07 0.07 
 
0.05 0.05 
VC1090 0.08 0.08 
 
0.02 0.03 
VC1091 0.04 0.05 
 
0.05 0.06 
VC1092 0.04 0.05 
 
0.07 0.08 
VC1093 0.05 0.07 
 
0.04 0.06 
VC1094 0.04 0.05 
 
0.07 0.05 
VC1095 0.05 0.04 
 
0.06 0.06 
VC1096 0.07 0.06 
 
0.10 0.08 
VC1097 0.02 0.02 
 
0.06 0.06 
VC1098 0.07 0.08 
 
0.08 0.08 
VC1099 0.05 0.04 
 
0.12 0.07 
VC1100 0.07 0.06 
 
0.16 0.12 
VC1101 0.06 0.05 
 
0.09 0.08 
VC1102 0.04 0.04 
 
0.03 0.02 
VC1103 0.04 0.05 
 
0.03 0.03 
VC1104 0.04 0.04 
 
0.00 0.00 
VC1105 0.02 0.03 
 
0.03 0.05 
VC1106 0.08 0.07 
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VC1107 0.03 0.04 
 
0.05 0.04 
VC1108 0.07 0.05 
 
0.04 0.05 
VC1109 0.04 0.06 
 
0.06 0.03 
VC1109 0.05 0.07 
 
0.05 0.06 
VC1110 0.03 0.05 
 
0.05 0.04 
VC1111 0.08 0.09 
 
0.04 0.06 
VC1112 0.10 0.07 
 
0.05 0.05 
VC1113 0.06 0.05 
 
0.07 0.08 
VC1114 0.06 0.05 
 
0.06 0.08 
VC1115 0.07 0.06 
 
0.11 0.11 
VC1116 0.04 0.04 
 
0.04 0.04 
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0.11 0.10 
VC1118 0.04 0.04 
 
0.04 0.05 
VC1119 0.04 0.06 
 
0.10 0.09 
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VC1120 0.05 0.04 
 
0.03 0.05 
VC1121 0.04 0.04 
 
0.03 0.03 
VC1122 0.06 0.06 
 
0.05 0.06 
VC1123 0.04 0.04 
 
0.07 0.06 
VC1124 0.00 0.04 
 
0.07 0.08 
VC1125 0.05 0.05 
 
0.06 0.06 
VC1126 0.05 0.08 
 
0.08 0.09 
VC1127 0.06 0.06 
 
0.07 0.14 
VC1128 0.02 0.02 
 
0.01 0.02 
VC1129 0.06 0.07 
 
0.08 0.06 
VC1130 0.07 0.07 
 
0.08 0.07 
VC1131 0.06 0.07 
 
0.09 0.09 
VC1132 0.03 0.04 
 
0.10 0.11 
VC1133 0.04 0.04 
 
0.07 0.06 
VC1134 0.03 0.03 
 
0.05 0.06 
VC1135 0.03 0.03 
 
0.08 0.09 
VC1136 0.04 0.03 
 
0.05 0.05 
VC1137 0.04 0.05 
 
0.06 0.08 
VC1138 0.06 0.05 
 
0.08 0.09 
VC1139 0.04 0.03 
 
0.07 0.06 
VC1140 0.06 0.06 
 
0.12 0.07 
VC1141 0.02 0.02 
 
0.06 0.05 
VC1142 0.05 0.05 
 
0.05 0.09 
VC1143 0.05 0.05 
 
0.15 0.08 
VC1144 0.02 0.04 
 
0.04 0.04 
VC1145 0.03 0.06 
 
0.03 0.03 
VC1146 0.06 0.05 
 
0.09 0.11 
VC1147 0.07 0.07 
 
0.10 0.15 
VC1148 0.05 0.06 
 
0.02 0.04 
VC1149 0.08 0.07 
 
0.03 0.05 
VC1150 0.03 0.03 
 
0.09 0.08 
VC1151 0.07 0.06 
 
0.10 0.06 
VC1152 0.07 0.06 
 
0.11 0.06 
VC1153 0.01 0.01 
 
0.20 0.18 
VC1154 0.05 0.05 
 
0.06 0.05 
VC1155 0.05 0.05 
 
0.09 0.10 
VC1156 0.03 0.03 
 
0.03 0.03 
VC1156 0.00 0.05 
 
0.06 0.06 
VC1158 0.00 0.00 
 
0.07 0.07 
VC1159 0.03 0.02 
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VC1160 0.07 0.05 
 
0.05 0.04 
VC1161 0.04 0.05 
 
0.08 0.07 
VC1162 0.07 0.07 
 
0.06 0.07 
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VC1163 0.04 0.04 
 
0.06 0.01 
VC1164 0.08 0.09 
 
0.05 0.05 
VC1165 0.05 0.06 
 
0.03 0.03 
VC1165 0.05 0.04 
 
0.01 0.05 
VC1166 0.01 0.04 
 
0.05 0.05 
VC1167 0.04 0.04 
 
0.04 0.04 
VC1169 0.03 0.03 
 
0.01 0.02 
VC1170 0.07 0.07 
 
0.08 0.06 
VC1171 0.09 0.08 
 
0.04 0.05 
VC1172 0.02 0.02 
 
0.01 0.02 
VC1173 0.02 0.03 
 
0.01 0.02 
VC1174 0.07 0.07 
 
0.09 0.08 
VC1175 0.07 0.05 
 
0.13 0.06 
VC1176 0.04 0.04 
 
0.04 0.07 
VC1177 0.03 0.03 
 
0.07 0.06 
VC1178 0.02 0.03 
 
0.00 0.01 
VC1179 0.06 0.06 
 
0.08 0.07 
VC1180 0.07 0.07 
 
0.04 0.04 
VC1181 0.06 0.07 
 
0.11 0.14 
VC1182 0.03 0.03 
 
0.02 0.03 
VC1183 0.16 0.15 
 
0.03 0.02 
VC1184 0.13 0.11 
 
0.03 0.04 
VC1185 0.07 0.06 
 
0.00 0.00 
VC1186 0.09 0.10 
 
0.02 0.02 
VC1187 0.08 0.07 
 
0.06 0.05 
VC1188 0.04 0.03 
 
0.05 0.07 
VC1189 0.03 0.03 
 
0.02 0.05 
VC1189 0.01 0.01 
 
0.05 0.06 
VC1190 0.15 0.12 
 
0.04 0.03 
VC1191 0.10 0.10 
 
0.02 0.04 
VC1192 0.06 0.06 
 
0.06 0.03 
VC1193 0.05 0.10 
 
0.06 0.05 
VC1194 0.12 0.11 
 
0.02 0.04 
VC1195 0.10 0.11 
 
0.07 0.10 
VC1196 0.04 0.05 
 
0.06 0.06 
VC1197 0.04 0.05 
 
0.07 0.08 
VC1198 0.02 0.01 
 
0.03 0.03 
VC1199 0.12 0.11 
 
0.02 0.01 
VC1200 0.12 0.09 
 
0.02 0.01 
VC1201 0.07 0.07 
 
0.02 0.04 
VC1202 0.14 0.17 
 
0.04 0.05 
VC1203 0.09 0.06 
 
-0.02 -0.02 
VC1204 0.08 0.06 
 
-0.02 -0.02 
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VC1205 0.09 0.08 
 
0.00 0.00 
VC1206 0.15 0.17 
 
0.07 0.06 
VC1207 0.07 0.05 
 
0.01 0.00 
VC1208 0.08 0.08 
 
0.00 0.00 
VC1209 0.12 0.09 
 
0.03 0.02 
VC1210 0.15 0.19 
 
0.07 0.06 
VC1211 -0.01 -0.01 
 
-0.01 0.15 
VC1212 0.05 0.05 
 
0.04 0.05 
VC1213 0.11 0.12 
 
0.01 0.01 
VC1214 0.05 0.03 
 
0.03 0.05 
VC1215 0.06 0.07 
 
0.07 0.08 
VC1216 0.13 0.15 
 
0.02 0.03 
VC1217 0.16 0.16 
 
0.04 0.05 
VC1218 0.06 0.06 
 
0.04 0.04 
VC1219 0.13 0.11 
 
0.02 0.01 
VC1220 0.07 0.07 
 
0.04 0.04 
VC1221 0.14 0.11 
 
0.03 0.04 
VC1222 0.11 0.10 
 
0.03 0.05 
VC1223 0.02 0.02 
 
0.06 0.04 
VC1223 0.04 0.05 
 
0.06 0.06 
VC1224 0.04 0.03 
 
0.08 0.08 
VC1225 0.08 0.08 
 
0.05 0.06 
VC1226 0.13 0.13 
 
0.03 0.04 
VC1227 0.10 0.09 
 
0.07 0.07 
VC1228 0.10 0.10 
 
0.07 0.09 
VC1229 0.07 0.07 
 
0.04 0.05 
VC1230 0.05 0.05 
 
0.10 0.10 
VC1230 0.07 0.09 
 
0.06 0.04 
VC1231 0.09 0.07 
 
0.03 0.04 
VC1232 0.03 0.05 
 
0.06 0.06 
VC1233 0.05 0.04 
 
0.07 0.07 
VC1234 0.04 0.04 
 
0.06 0.05 
VC1235 0.04 0.04 
 
0.03 0.04 
VC1236 0.06 0.08 
 
0.09 0.10 
VC1237 0.04 0.05 
 
0.11 0.08 
VC1238 0.08 0.07 
 
0.09 0.08 
VC1239 0.10 0.09 
 
0.06 0.06 
VC1240 0.10 0.06 
 
0.08 0.06 
VC1241 0.05 0.04 
 
0.08 0.05 
VC1242 0.08 0.06 
 
0.06 0.08 
VC1243 0.05 0.06 
 
0.04 0.07 
VC1244 0.03 0.03 
 
0.05 0.05 
VC1245 0.14 0.14 
 
0.05 0.04 
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VC1246 0.11 0.08 
 
0.04 0.05 
VC1247 0.06 0.04 
 
0.09 0.08 
VC1248 0.05 0.05 
 
0.05 0.04 
VC1249 0.06 0.06 
 
0.05 0.05 
VC1250 0.12 0.12 
 
0.18 0.06 
VC1251 0.06 0.08 
 
0.03 0.04 
VC1252 0.08 0.06 
 
0.08 0.09 
VC1253 0.05 0.05 
 
0.07 0.06 
VC1254 0.05 0.05 
 
0.06 0.05 
VC1255 0.02 0.02 
 
0.01 0.01 
VC1256 0.09 0.09 
 
0.04 0.04 
VC1257 0.07 0.07 
 
0.09 0.08 
VC1258 0.02 0.02 
 
0.05 0.05 
VC1259 0.06 0.05 
 
0.06 0.05 
VC1260 0.03 0.03 
 
0.08 0.07 
VC1261 0.05 0.07 
 
0.09 0.06 
VC1262 0.06 0.04 
 
0.07 0.06 
VC1263 0.03 0.03 
 
0.06 0.06 
VC1265 0.06 0.07 
 
0.03 0.06 
VC1266 0.01 0.01 
 
0.05 0.03 
VC1267 0.00 0.01 
 
0.06 0.05 
VC1268 0.01 0.02 
 
0.04 0.03 
VC1269 0.04 0.04 
 
0.06 0.05 
VC1270 0.00 0.03 
 
0.04 0.03 
VC1271 0.01 0.02 
 
0.05 0.04 
VC1272 0.02 0.02 
 
0.06 0.06 
VC1273 0.04 0.04 
 
0.06 0.09 
VC1274 0.04 0.04 
 
0.05 0.04 
VC1275 0.02 0.02 
 
0.04 0.03 
VC1276 0.03 0.03 
 
0.04 0.03 
VC1277 0.04 0.03 
 
0.07 0.06 
VC1278 0.02 0.03 
 
0.11 0.10 
VC1279 0.04 0.05 
 
0.03 0.03 
VC1280 0.02 0.02 
 
0.06 0.05 
VC1281 0.06 0.05 
 
0.04 0.03 
VC1282 0.01 0.02 
 
0.03 0.03 
VC1283 0.09 0.09 
 
0.03 0.03 
VC1284 0.03 0.03 
 
0.04 0.03 
VC1285 0.03 0.03 
 
0.06 0.05 
VC1286 0.01 0.02 
 
0.06 0.04 
VC1287 0.02 0.02 
 
0.05 0.05 
VC1288 0.03 0.04 
 
0.05 0.05 
VC1289 0.01 0.02 
 
0.05 0.05 
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VC1290 0.03 0.03 
 
0.08 0.07 
VC1291 0.03 0.03 
 
0.06 0.05 
VC1292 0.07 0.08 
 
0.07 0.07 
VC1293 0.05 0.05 
 
0.06 0.06 
VC1294 0.05 0.06 
 
0.04 0.06 
VC1295 0.46 0.47 
 
0.48 0.54 
VC1296 0.04 0.05 
 
0.05 0.06 
VC1297 0.01 0.02 
 
0.00 0.01 
VC1298 0.09 0.08 
 
0.03 0.03 
VC1299 0.05 0.04 
 
0.07 0.07 
VC1300 0.03 0.03 
 
0.05 0.06 
VC1301 0.13 0.12 
 
0.08 0.08 
VC1302 0.07 0.07 
 
0.07 0.06 
VC1303 0.04 0.05 
 
0.05 0.08 
VC1304 0.08 0.07 
 
0.06 0.06 
VC1305 0.03 0.03 
 
0.03 0.04 
VC1306 0.01 0.02 
 
0.04 0.07 
VC1307 0.02 0.06 
 
0.02 0.03 
VC1308 0.18 0.17 
 
0.09 0.09 
VC1309 0.10 0.07 
 
0.05 0.08 
VC1310 0.06 0.04 
 
0.06 0.07 
VC1311 0.03 0.03 
 
0.06 0.05 
VC1312 0.04 0.05 
 
0.06 0.10 
VC1313 0.09 0.05 
 
0.05 0.05 
VC1314 0.05 0.05 
 
0.06 0.05 
VC1315 0.04 0.05 
 
0.07 0.05 
VC1316 0.09 0.06 
 
0.07 0.08 
VC1317 0.05 0.05 
 
0.07 0.06 
VC1319 0.00 0.04 
 
0.05 0.06 
VC1320 0.03 0.03 
 
0.03 0.03 
VC1321 0.02 0.02 
 
0.03 0.05 
VC1322 0.07 0.06 
 
0.04 0.03 
VC1323 0.04 0.04 
 
0.07 0.06 
VC1324 0.07 0.06 
 
0.03 0.03 
VC1325 0.05 0.05 
 
0.09 0.08 
VC1326 0.12 0.14 
 
0.03 0.03 
VC1327 0.02 0.03 
 
0.04 0.04 
VC1329 0.03 0.04 
 
0.05 0.04 
VC1330 0.10 0.08 
 
0.05 0.04 
VC1331 0.01 0.03 
 
0.05 0.04 
VC1332 0.02 0.02 
 
0.02 0.05 
VC1332 0.01 0.02 
 
0.04 0.04 
VC1333 0.03 0.02 
 
0.07 0.11 
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VC1334 0.03 0.02 
 
0.04 0.05 
VC1335 0.02 0.03 
 
0.06 0.07 
VC1336 0.07 0.07 
 
0.04 0.05 
VC1337 0.06 0.06 
 
0.04 0.04 
VC1338 0.04 0.04 
 
0.08 0.04 
VC1339 0.04 0.04 
 
0.06 0.05 
VC1340 0.05 0.03 
 
0.04 0.03 
VC1341 0.05 0.05 
 
0.10 0.08 
VC1341 0.01 0.01 
 
0.05 0.05 
VC1342 0.02 0.01 
 
0.04 0.04 
VC1343 0.03 0.05 
 
0.05 0.05 
VC1344 0.08 0.07 
 
0.07 0.07 
VC1345 0.08 0.08 
 
0.11 0.15 
VC1346 0.05 0.03 
 
0.06 0.06 
VC1348 0.45 0.44 
 
0.43 0.41 
VC1349 0.10 0.12 
 
0.03 0.03 
VC1350 0.06 0.06 
 
0.09 0.08 
VC1351 0.04 0.04 
 
0.06 0.05 
VC1352 0.03 0.05 
 
0.04 0.05 
VC1353 0.01 0.01 
 
0.01 0.00 
VC1354 0.05 0.05 
 
0.06 0.05 
VC1355 0.06 0.06 
 
0.04 0.05 
VC1356 0.05 0.06 
 
0.09 0.12 
VC1357 0.07 0.08 
 
0.06 0.02 
VC1358 0.07 0.07 
 
0.05 0.04 
VC1359 0.04 0.05 
 
0.10 0.07 
VC1360 0.05 0.04 
 
0.07 0.08 
VC1361 0.04 0.05 
 
0.07 0.07 
VC1362 0.07 0.04 
 
0.06 0.07 
VC1363 0.02 0.06 
 
0.06 0.07 
VC1364 0.06 0.07 
 
0.05 0.04 
VC1365 0.07 0.08 
 
0.04 0.06 
VC1366 0.08 0.04 
 
0.05 0.05 
VC1367 0.02 0.05 
 
0.06 0.07 
VC1368 0.04 0.05 
 
0.06 0.06 
VC1369 0.03 0.03 
 
0.06 0.04 
VC1370 0.40 0.43 
 
0.40 0.39 
VC1371 0.05 0.04 
 
0.04 0.05 
VC1372 0.04 0.02 
 
0.03 0.04 
VC1373 0.07 0.07 
 
0.07 0.06 
VC1374 0.08 0.05 
 
0.05 0.04 
VC1375 0.06 0.05 
 
0.05 0.07 
VC1377 0.04 0.05 
 
0.04 0.04 
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VC1378 0.04 0.05 
 
0.07 0.07 
VC1379 0.07 0.08 
 
0.08 0.07 
VC1380 0.05 0.05 
 
0.05 0.05 
VC1381 0.08 0.07 
 
0.05 0.05 
VC1382 -0.01 0.02 
 
0.03 0.05 
VC1382 0.02 0.04 
 
0.05 0.04 
VC1383 0.03 0.04 
 
0.08 0.07 
VC1384 0.02 0.03 
 
0.03 0.03 
VC1385 0.09 0.06 
 
0.10 0.06 
VC1386 0.07 0.04 
 
0.06 0.05 
VC1387 0.06 0.05 
 
0.04 0.04 
VC1388 0.06 0.05 
 
0.08 0.07 
VC1389 0.04 0.05 
 
0.07 0.06 
VC1390 0.06 0.06 
 
0.05 0.04 
VC1391 0.02 0.03 
 
0.08 0.06 
VC1392 0.05 0.06 
 
0.04 0.06 
VC1393 0.02 0.02 
 
0.04 0.03 
VC1394 0.08 0.13 
 
0.06 0.05 
VC1395 0.04 0.04 
 
0.07 0.04 
VC1396 0.07 0.06 
 
0.04 0.04 
VC1397 0.08 0.07 
 
0.06 0.06 
VC1398 0.07 0.07 
 
0.03 0.04 
VC1399 0.04 0.05 
 
0.04 0.03 
VC1400 0.05 0.06 
 
0.05 0.05 
VC1401 0.01 0.03 
 
0.05 0.05 
VC1402 0.02 0.02 
 
0.04 0.04 
VC1403 0.07 0.08 
 
0.06 0.06 
VC1404 0.09 0.08 
 
0.02 0.03 
VC1405 0.02 0.02 
 
0.13 0.10 
VC1406 0.07 0.06 
 
0.14 0.14 
VC1407 0.05 0.05 
 
0.02 0.04 
VC1408 0.01 0.02 
 
0.04 0.04 
VC1409 0.06 0.04 
 
0.03 0.02 
VC1410 0.06 0.05 
 
0.05 0.05 
VC1411 0.03 0.03 
 
0.03 0.03 
VC1412 0.09 0.07 
 
0.06 0.08 
VC1413 0.10 0.10 
 
0.00 0.02 
VC1414 0.02 0.02 
 
0.05 0.03 
VC1415 0.09 0.09 
 
0.06 0.06 
VC1416 0.04 0.06 
 
0.04 0.05 
VC1417 0.03 0.03 
 
0.07 0.07 
VC1418 0.01 0.02 
 
0.01 0.01 
VC1419 0.02 0.03 
 
0.05 0.03 
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VC1420 0.02 0.02 
 
0.02 0.03 
VC1421 0.01 0.02 
 
0.00 0.03 
VC1422 0.08 0.05 
 
0.06 0.06 
VC1423 0.06 0.05 
 
0.05 0.05 
VC1424 0.03 0.04 
 
0.05 0.04 
VC1425 0.05 0.06 
 
0.05 0.04 
VC1426 0.06 0.06 
 
0.06 0.05 
VC1427 0.07 0.03 
 
0.04 0.04 
VC1428 0.02 0.02 
 
0.04 0.08 
VC1429 0.04 0.03 
 
0.05 0.04 
VC1430 0.02 0.04 
 
0.03 0.00 
VC1431 0.06 0.06 
 
0.06 0.04 
VC1432 0.01 0.03 
 
0.06 0.05 
VC1433 0.01 0.01 
 
0.03 0.03 
VC1434 0.04 0.07 
 
0.05 0.06 
VC1435 0.05 0.04 
 
0.03 0.03 
VC1436 0.04 0.04 
 
0.04 0.03 
VC1437 0.02 0.03 
 
0.06 0.06 
VC1438 0.06 0.05 
 
0.06 0.05 
VC1439 0.01 0.02 
 
0.04 0.04 
VC1440 0.06 0.05 
 
0.06 0.04 
VC1441 0.02 0.01 
 
0.06 0.09 
VC1442 -0.01 -0.01 
 
0.07 0.05 
VC1443 0.02 0.03 
 
0.03 0.04 
VC1444 0.03 0.03 
 
0.02 0.04 
VC1445 0.03 0.02 
 
0.04 0.05 
VC1446 0.09 0.06 
 
0.04 0.05 
VC1447 0.01 0.02 
 
0.09 0.07 
VC1448 0.03 0.05 
 
0.03 0.05 
VC1449 0.03 0.04 
 
0.07 0.06 
VC1450 0.03 0.04 
 
0.04 0.03 
VC1452 0.07 0.05 
 
0.07 0.08 
VC1453 0.03 0.05 
 
0.06 0.05 
VC1454 0.05 0.07 
 
0.06 0.04 
VC1455 0.04 0.04 
 
0.07 0.06 
VC1456 0.04 0.04 
 
0.05 0.04 
VC1457 0.07 0.08 
 
0.05 0.05 
VC1458 0.03 0.04 
 
0.07 0.04 
VC1459 0.06 0.07 
 
0.04 0.03 
VC1460 0.06 0.06 
 
0.10 0.08 
VC1461 0.09 0.10 
 
0.04 0.04 
VC1462 0.05 0.08 
 
0.06 0.05 
VC1463 0.07 0.07 
 
0.05 0.05 
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VC1464 0.06 0.05 
 
0.04 0.05 
VC1465 0.03 0.01 
 
0.08 0.08 
VC1466 0.03 0.02 
 
0.07 0.07 
VC1467 0.04 0.05 
 
0.02 0.02 
VC1468 0.10 0.10 
 
0.05 0.04 
VC1469 -0.01 0.00 
 
0.04 0.07 
VC1470 0.07 0.08 
 
0.09 0.08 
VC1471 0.06 0.07 
 
0.06 0.03 
VC1472 0.04 0.04 
 
0.07 0.06 
VC1473 0.06 0.05 
 
0.07 0.07 
VC1474 0.09 0.10 
 
0.00 0.05 
VC1475 0.05 0.06 
 
0.04 0.04 
VC1476 0.00 0.01 
 
0.03 0.05 
VC1477 0.00 0.02 
 
0.04 0.06 
VC1478 0.06 0.08 
 
0.05 0.05 
VC1479 -0.01 0.00 
 
0.04 0.07 
VC1480 0.07 0.07 
 
0.03 0.02 
VC1481 0.04 0.02 
 
0.04 0.06 
VC1482 0.02 0.02 
 
0.04 0.04 
VC1483 0.03 0.03 
 
0.07 0.06 
VC1484 0.03 0.06 
 
0.06 0.07 
VC1485 0.03 0.05 
 
0.05 0.04 
VC1486 0.02 0.01 
 
0.05 0.08 
VC1487 0.00 0.02 
 
0.04 0.04 
VC1488 0.07 0.07 
 
0.04 0.06 
VC1489 0.09 0.09 
 
0.03 0.04 
VC1490 0.08 0.09 
 
0.03 0.04 
VC1491 0.00 0.04 
 
0.09 0.10 
VC1492 0.03 0.03 
 
0.05 0.06 
VC1492 0.01 0.03 
 
0.04 0.04 
VC1493 0.08 0.07 
 
0.04 0.05 
VC1494 0.04 0.06 
 
0.07 0.06 
VC1495 0.01 0.01 
 
0.08 0.08 
VC1496 0.05 0.04 
 
0.04 0.04 
VC1497 0.05 0.06 
 
0.05 0.05 
VC1498 0.05 0.04 
 
0.02 0.02 
VC1499 0.05 0.07 
 
0.04 0.05 
VC1500 0.04 0.06 
 
0.05 0.05 
VC1500 0.05 0.04 
 
0.02 0.02 
VC1501 0.07 0.06 
 
0.03 0.08 
VC1502 0.11 0.15 
 
0.02 0.05 
VC1503 0.06 0.04 
 
0.05 0.07 
VC1505 0.03 0.03 
 
0.05 0.05 
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VC1506 0.05 0.07 
 
0.06 0.07 
VC1507 0.03 0.04 
 
0.08 0.07 
VC1508 0.05 0.06 
 
0.02 0.05 
VC1509 0.05 0.04 
 
0.07 0.07 
VC1510 0.03 0.05 
 
0.07 0.06 
VC1511 0.09 0.09 
 
0.08 0.10 
VC1512 0.05 0.05 
 
0.08 0.09 
VC1513 0.08 0.05 
 
0.07 0.06 
VC1514 0.04 0.04 
 
0.05 0.07 
VC1515 0.09 0.08 
 
0.07 0.06 
VC1516 0.06 0.05 
 
0.07 0.04 
VC1517 0.04 0.05 
 
0.05 0.04 
VC1518 0.05 0.12 
 
0.07 0.10 
VC1519 0.08 0.06 
 
0.05 0.06 
VC1520 0.05 0.05 
 
0.04 0.05 
VC1521 0.04 0.04 
 
0.07 0.08 
VC1523 0.12 0.08 
 
0.04 0.04 
VC1524 0.03 0.06 
 
0.05 0.05 
VC1525 0.07 0.07 
 
0.03 0.06 
VC1526 0.06 0.05 
 
0.06 0.06 
VC1527 0.12 0.12 
 
0.05 0.06 
VC1528 0.02 0.02 
 
0.03 0.03 
VC1529 0.03 0.03 
 
0.06 0.04 
VC1530 0.04 0.04 
 
0.08 0.06 
VC1531 0.04 0.06 
 
0.08 0.08 
VC1532 0.05 0.06 
 
0.04 0.06 
VC1533 0.04 0.05 
 
0.03 0.03 
VC1534 0.03 0.02 
 
0.09 0.10 
VC1535 0.02 0.01 
 
0.04 0.03 
VC1537 0.03 0.03 
 
0.04 0.03 
VC1538 0.04 0.06 
 
0.05 0.06 
VC1539 0.05 0.04 
 
0.06 0.06 
VC1540 0.00 0.04 
 
0.04 0.04 
VC1541 0.02 0.04 
 
0.05 0.07 
VC1542 0.03 0.02 
 
0.05 0.04 
VC1543 0.03 0.04 
 
0.07 0.06 
VC1544 0.03 0.03 
 
0.03 0.03 
VC1545 0.05 0.06 
 
0.06 0.06 
VC1546 0.02 0.04 
 
0.02 0.03 
VC1547 0.03 0.03 
 
0.06 0.05 
VC1548 0.02 0.02 
 
0.05 0.04 
VC1549 0.05 0.05 
 
0.03 0.05 
VC1550 0.02 0.03 
 
0.07 0.06 
	   187	  
VC1551 0.06 0.06 
 
0.05 0.07 
VC1552 0.03 0.05 
 
0.09 0.11 
VC1553 0.05 0.05 
 
0.05 0.06 
VC1554 0.09 0.09 
 
0.07 0.05 
VC1555 0.06 0.04 
 
0.09 0.08 
VC1556 0.04 0.03 
 
0.06 0.06 
VC1557 0.02 0.03 
 
0.06 0.05 
VC1558 0.04 0.05 
 
0.05 0.05 
VC1559 0.05 0.05 
 
0.03 0.08 
VC1560 0.08 0.06 
 
0.08 0.11 
VC1561 0.05 0.07 
 
0.04 0.07 
VC1562 0.03 0.04 
 
0.05 0.05 
VC1563 0.02 0.08 
 
0.04 0.04 
VC1565 0.08 0.11 
 
0.07 0.07 
VC1566 0.07 0.07 
 
0.06 0.05 
VC1567 0.13 0.14 
 
0.07 0.08 
VC1568 0.05 0.08 
 
0.05 0.06 
VC1569 0.06 0.06 
 
0.04 0.05 
VC1570 0.03 0.08 
 
0.06 0.06 
VC1571 0.05 0.05 
 
0.04 0.03 
VC1572 0.00 0.03 
 
0.04 0.04 
VC1573 0.06 0.08 
 
0.06 0.06 
VC1574 0.04 0.07 
 
0.05 0.04 
VC1575 0.08 0.11 
 
0.05 0.05 
VC1576 0.05 0.08 
 
0.04 0.06 
VC1577 0.04 0.06 
 
0.07 0.06 
VC1578 0.04 0.04 
 
0.10 0.10 
VC1579 0.00 0.02 
 
0.04 0.04 
VC1580 0.04 0.07 
 
0.03 0.05 
VC1581 0.08 0.07 
 
0.03 0.03 
VC1582 0.06 0.05 
 
0.05 0.05 
VC1583 0.08 0.09 
 
0.04 0.04 
VC1584 0.03 0.04 
 
0.03 0.05 
VC1585 0.12 0.12 
 
0.04 0.06 
VC1586 0.07 0.08 
 
0.05 0.04 
VC1586 0.06 0.07 
 
0.04 0.05 
VC1587 0.03 0.07 
 
0.06 0.06 
VC1588 0.07 0.08 
 
0.09 0.07 
VC1589 0.05 0.07 
 
0.07 0.07 
VC1590 0.06 0.08 
 
0.04 0.03 
VC1591 0.06 0.07 
 
0.07 0.07 
VC1592 0.00 0.01 
 
0.00 0.00 
VC1593 0.05 0.06 
 
0.05 0.05 
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VC1595 0.07 0.07 
 
0.06 0.06 
VC1596 0.09 0.09 
 
0.06 0.07 
VC1597 0.05 0.04 
 
0.07 0.05 
VC1598 0.04 0.06 
 
0.06 0.06 
VC1599 -0.03 0.02 
 
-0.01 -0.01 
VC1600 0.02 0.08 
 
0.10 0.10 
VC1601 0.13 0.11 
 
0.03 0.04 
VC1602 0.04 0.05 
 
0.07 0.07 
VC1603 0.04 0.07 
 
0.04 0.04 
VC1604 0.07 0.06 
 
0.05 0.07 
VC1605 0.01 0.01 
 
0.03 0.03 
VC1606 0.04 0.05 
 
0.07 0.08 
VC1607 0.02 0.03 
 
0.05 0.04 
VC1608 0.05 0.04 
 
0.06 0.05 
VC1609 0.01 0.01 
 
0.06 0.06 
VC1610 0.04 0.05 
 
0.07 0.07 
VC1611 0.05 0.04 
 
0.05 0.05 
VC1612 0.02 0.02 
 
0.07 0.06 
VC1613 0.07 0.07 
 
0.01 0.02 
VC1614 0.03 0.03 
 
0.07 0.05 
VC1615 0.06 0.07 
 
0.07 0.07 
VC1616 0.07 0.08 
 
0.05 0.06 
VC1617 0.05 0.07 
 
0.07 0.06 
VC1618 0.05 0.04 
 
0.05 0.08 
VC1619 0.03 0.03 
 
0.05 0.04 
VC1621 0.03 0.01 
 
0.05 0.08 
VC1622 0.09 0.09 
 
0.07 0.06 
VC1623 0.06 0.05 
 
0.05 0.04 
VC1624 0.09 0.07 
 
0.05 0.05 
VC1625 0.03 0.06 
 
0.05 0.05 
VC1627 0.03 0.02 
 
0.03 0.05 
VC1628 0.05 0.04 
 
0.03 0.02 
VC1629 0.01 0.01 
 
0.07 0.06 
VC1630 0.04 0.04 
 
0.05 0.04 
VC1631 0.03 0.06 
 
0.05 0.07 
VC1632 0.10 0.09 
 
0.06 0.06 
VC1633 0.04 0.06 
 
0.06 0.07 
VC1634 0.05 0.05 
 
0.05 0.05 
VC1635 0.15 0.05 
 
0.10 0.11 
VC1636 0.07 0.09 
 
0.04 0.07 
VC1637 0.05 0.03 
 
0.02 0.05 
VC1638 0.02 0.03 
 
0.06 0.08 
VC1639 0.01 0.03 
 
0.05 0.08 
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VC1640 0.05 0.06 
 
0.06 0.05 
VC1641 0.56 0.56 
 
0.58 0.60 
VC1642 0.07 0.05 
 
0.09 0.11 
VC1643 0.01 0.01 
 
0.05 0.03 
VC1644 0.01 0.02 
 
0.04 0.07 
VC1646 0.07 0.08 
 
0.05 0.05 
VC1647 0.02 0.01 
 
0.04 0.03 
VC1648 0.05 0.09 
 
0.05 0.06 
VC1648 0.06 0.06 
 
0.01 0.04 
VC1649 0.01 0.03 
 
0.02 0.02 
VC1651 0.01 0.01 
 
0.04 0.04 
VC1652 0.29 0.28 
 
0.04 0.03 
VC1653 0.06 0.06 
 
0.05 0.06 
VC1654 0.06 0.06 
 
0.04 0.04 
VC1656 0.05 0.06 
 
0.04 0.04 
VC1657 0.07 0.09 
 
0.04 0.04 
VC1658 0.07 0.11 
 
0.06 0.05 
VC1659 0.05 0.08 
 
0.13 0.06 
VC1660 0.05 0.06 
 
0.07 0.05 
VC1661 0.05 0.06 
 
0.04 0.04 
VC1662 0.05 0.06 
 
0.06 0.07 
VC1663 0.09 0.11 
 
0.06 0.06 
VC1664 0.04 0.12 
 
0.07 0.07 
VC1665 0.08 0.08 
 
0.05 0.05 
VC1666 0.04 0.05 
 
0.04 0.05 
VC1667 0.03 0.02 
 
0.05 0.05 
VC1668 0.03 0.04 
 
0.06 0.06 
VC1669 0.02 0.02 
 
0.01 0.04 
VC1670 0.06 0.06 
 
0.05 0.06 
VC1671 0.07 0.06 
 
0.15 0.12 
VC1672 0.06 0.05 
 
0.12 0.09 
VC1673 0.04 0.05 
 
0.08 0.11 
VC1674 0.06 0.06 
 
0.12 0.09 
VC1675 0.03 0.03 
 
0.10 0.09 
VC1676 0.06 0.07 
 
0.09 0.10 
VC1677 0.03 0.04 
 
0.06 0.06 
VC1678 0.08 0.07 
 
0.15 0.15 
VC1679 0.05 0.05 
 
0.09 0.08 
VC1680 0.05 0.04 
 
0.05 0.03 
VC1681 0.05 0.06 
 
0.09 0.09 
VC1682 0.06 0.06 
 
0.12 0.10 
VC1683 0.04 0.05 
 
0.02 0.02 
VC1684 0.05 0.06 
 
0.09 0.09 
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VC1685 0.05 0.05 
 
0.10 0.08 
VC1686 0.11 0.12 
 
0.09 0.05 
VC1687 0.07 0.08 
 
0.16 0.10 
VC1688 0.09 0.05 
 
0.05 0.06 
VC1689 0.07 0.06 
 
0.08 0.04 
VC1690 0.04 0.04 
 
0.06 0.05 
VC1691 0.10 0.05 
 
0.01 0.05 
VC1692 0.03 0.04 
 
0.06 0.04 
VC1693 0.06 0.03 
 
0.03 0.04 
VC1695 0.07 0.06 
 
0.13 0.09 
VC1696 0.08 0.08 
 
0.10 0.09 
VC1697 0.07 0.08 
 
0.15 0.11 
VC1698 0.06 0.05 
 
0.05 0.04 
VC1699 0.04 0.05 
 
0.02 0.06 
VC1700 0.06 0.05 
 
0.03 0.03 
VC1701 0.04 0.05 
 
0.05 0.05 
VC1702 0.05 0.05 
 
0.08 0.08 
VC1703 0.03 0.03 
 
0.09 0.06 
VC1704 0.04 0.05 
 
0.05 0.06 
VC1705 0.03 0.03 
 
0.04 0.03 
VC1706 0.06 0.07 
 
0.10 0.08 
VC1707 0.07 0.07 
 
0.12 0.12 
VC1708 0.04 0.06 
 
0.07 -0.05 
VC1709 0.02 0.02 
 
0.02 0.07 
VC1710 0.34 0.30 
 
0.30 0.26 
VC1711 0.04 0.05 
 
0.04 0.05 
VC1712 0.02 0.02 
 
0.06 0.04 
VC1713 0.10 0.10 
 
0.10 0.08 
VC1714 0.01 0.02 
 
0.06 0.05 
VC1714 0.02 0.03 
 
0.04 0.04 
VC1715 0.07 0.06 
 
0.05 0.03 
VC1716 0.09 0.11 
 
0.05 0.05 
VC1717 0.06 0.07 
 
0.07 0.13 
VC1718 0.08 0.09 
 
0.10 0.08 
VC1719 0.01 0.03 
 
0.05 0.04 
VC1720 0.04 0.06 
 
0.05 0.04 
VC1721 0.05 0.06 
 
0.07 0.07 
VC1722 0.05 0.05 
 
0.04 0.04 
VC1724 0.06 0.06 
 
0.06 0.05 
VC1725 0.07 0.08 
 
0.10 0.10 
VC1726 0.02 0.02 
 
0.02 0.02 
VC1727 0.01 0.01 
 
0.05 0.04 
VC1728 0.04 0.06 
 
0.02 0.04 
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VC1729 0.07 0.07 
 
0.05 0.08 
VC1730 0.02 0.02 
 
0.03 0.04 
VC1730 0.00 0.04 
 
0.05 0.05 
VC1731 0.03 0.04 
 
0.06 0.05 
VC1732 0.06 0.07 
 
0.07 0.09 
VC1733 0.05 0.08 
 
0.07 0.06 
VC1734 0.06 0.06 
 
0.04 0.03 
VC1735 0.07 0.08 
 
0.05 0.04 
VC1736 0.04 0.06 
 
0.05 0.04 
VC1737 0.05 0.06 
 
0.07 0.07 
VC1738 0.02 0.02 
 
0.05 0.07 
VC1740 0.05 0.04 
 
0.04 0.03 
VC1741 0.08 0.07 
 
0.06 0.06 
VC1742 0.04 0.05 
 
0.09 0.06 
VC1743 0.06 0.06 
 
0.06 0.05 
VC1744 0.06 0.09 
 
0.07 0.06 
VC1745 0.04 0.05 
 
0.04 0.04 
VC1746 0.05 0.07 
 
0.05 0.08 
VC1747 0.04 0.07 
 
0.05 0.05 
VC1748 0.06 0.07 
 
0.05 0.04 
VC1749 0.11 0.08 
 
0.06 0.06 
VC1750 0.15 0.05 
 
0.02 0.02 
VC1751 0.06 0.07 
 
0.07 0.06 
VC1752 0.06 0.07 
 
0.04 0.03 
VC1753 0.03 0.04 
 
0.05 0.05 
VC1754 0.06 0.07 
 
0.06 0.06 
VC1755 0.07 0.07 
 
0.06 0.06 
VC1756 0.04 0.04 
 
0.07 0.05 
VC1757 0.02 0.03 
 
0.05 0.04 
VC1758 0.05 0.08 
 
0.06 0.06 
VC1759 0.07 0.06 
 
0.05 0.06 
VC1760 0.02 0.04 
 
0.04 0.04 
VC1761 0.03 0.05 
 
0.04 0.03 
VC1762 0.06 0.09 
 
0.06 0.05 
VC1763 0.02 0.03 
 
0.03 0.03 
VC1764 0.02 0.03 
 
0.02 0.03 
VC1765 0.04 0.04 
 
0.02 0.02 
VC1766 0.08 0.10 
 
0.04 0.05 
VC1767 0.04 0.05 
 
0.06 0.03 
VC1768 0.06 0.07 
 
0.07 0.08 
VC1769 0.02 0.02 
 
0.05 0.05 
VC1770 0.03 0.03 
 
0.05 0.04 
VC1771 0.02 0.03 
 
0.06 0.07 
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VC1772 0.05 0.06 
 
0.07 0.07 
VC1773 0.09 0.07 
 
0.04 0.06 
VC1774 0.06 0.07 
 
0.09 0.10 
VC1775 0.06 0.06 
 
0.05 0.07 
VC1776 0.04 0.05 
 
0.06 0.06 
VC1777 0.06 0.08 
 
0.07 0.06 
VC1778 0.05 0.05 
 
0.06 0.06 
VC1779 0.06 0.07 
 
0.06 0.04 
VC1780 0.04 0.06 
 
0.08 0.08 
VC1781 0.08 0.09 
 
0.08 0.06 
VC1782 0.06 0.08 
 
0.07 0.07 
VC1783 0.05 0.06 
 
0.07 0.06 
VC1784 0.04 0.06 
 
0.05 0.03 
VC1785 0.05 0.06 
 
0.06 0.08 
VC1786 0.06 0.08 
 
0.06 0.07 
VC1787 0.06 0.07 
 
0.07 0.07 
VC1788 0.07 0.07 
 
0.04 0.05 
VC1789 0.05 0.05 
 
0.03 0.04 
VC1790 0.11 0.08 
 
0.04 0.06 
VC1791 0.06 0.07 
 
0.04 0.05 
VC1792 0.09 0.08 
 
0.07 0.05 
VC1793 0.10 0.08 
 
0.04 0.05 
VC1794 0.08 0.08 
 
0.10 0.11 
VC1795 0.10 0.08 
 
0.06 0.07 
VC1796 0.08 0.06 
 
0.04 0.06 
VC1797 0.08 0.07 
 
0.04 0.04 
VC1798 0.01 0.01 
 
-0.01 0.01 
VC1799 0.10 0.12 
 
0.05 0.09 
VC1800 0.02 0.02 
 
0.04 0.04 
VC1801 0.01 0.01 
 
0.09 0.08 
VC1802 0.13 0.11 
 
0.07 0.09 
VC1803 0.10 0.09 
 
0.04 0.05 
VC1804 0.10 0.09 
 
0.05 0.04 
VC1805 0.09 0.07 
 
0.05 0.07 
VC1806 0.07 0.07 
 
0.05 0.05 
VC1807 0.01 0.04 
 
0.05 0.03 
VC1807 0.00 0.03 
 
0.05 0.04 
VC1808 0.09 0.08 
 
0.05 0.06 
VC1809 0.06 0.07 
 
0.04 0.05 
VC1810 0.08 0.07 
 
0.05 0.05 
VC1811 0.04 0.07 
 
0.04 0.04 
VC1812 0.06 0.08 
 
0.06 0.07 
VC1813 0.04 0.05 
 
0.06 0.09 
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VC1814 0.06 0.07 
 
0.09 0.07 
VC1815 0.07 0.06 
 
0.07 0.06 
VC1816 0.03 0.05 
 
0.07 0.08 
VC1817 0.06 0.06 
 
0.05 0.06 
VC1818 0.02 0.04 
 
0.06 0.05 
VC1819 0.05 0.06 
 
0.03 0.05 
VC1820 0.11 0.08 
 
0.08 0.10 
VC1821 0.05 0.06 
 
0.02 0.04 
VC1822 0.08 0.06 
 
0.08 0.05 
VC1823 0.11 0.12 
 
0.04 0.06 
VC1824 0.10 0.11 
 
0.07 0.05 
VC1825 0.14 0.15 
 
0.05 0.06 
VC1826 0.04 0.04 
 
0.04 0.06 
VC1827 0.06 0.04 
 
0.07 0.07 
VC1828 0.09 0.09 
 
0.07 0.05 
VC1829 0.04 0.06 
 
0.09 0.10 
VC1830 0.05 0.05 
 
0.06 0.04 
VC1830 0.06 0.07 
 
0.09 0.07 
VC1831 0.03 0.04 
 
0.05 0.06 
VC1831 0.02 0.01 
 
0.03 0.02 
VC1832 0.03 0.02 
 
0.08 0.05 
VC1833 0.10 0.11 
 
0.04 0.04 
VC1834 0.08 0.07 
 
0.05 0.04 
VC1835 0.03 0.02 
 
0.06 0.06 
VC1836 0.06 0.06 
 
0.06 0.06 
VC1837 0.03 0.06 
 
0.09 0.09 
VC1838 0.09 0.08 
 
0.07 0.07 
VC1839 0.06 0.06 
 
0.07 0.08 
VC1840 0.06 0.04 
 
0.05 0.05 
VC1841 0.05 0.07 
 
0.05 0.06 
VC1842 0.04 0.05 
 
0.04 0.03 
VC1842 0.05 0.06 
 
0.06 0.07 
VC1843 0.01 0.01 
 
0.00 0.00 
VC1844 0.09 0.09 
 
0.04 0.06 
VC1845 0.09 0.08 
 
0.08 0.07 
VC1846 0.18 0.14 
 
0.08 0.05 
VC1847 0.04 0.03 
 
0.06 0.06 
VC1848 0.03 0.05 
 
0.08 0.06 
VC1849 0.05 0.05 
 
0.10 0.09 
VC1851 0.00 -0.02 
 
0.00 -0.01 
VC1852 0.10 0.09 
 
0.11 0.09 
VC1853 0.07 0.16 
 
0.04 0.04 
VC1854 0.15 0.13 
 
0.08 0.09 
	   194	  
VC1855 0.01 0.03 
 
0.04 0.04 
VC1856 0.11 0.12 
 
0.06 0.04 
VC1857 0.05 0.04 
 
0.09 0.07 
VC1858 0.05 0.05 
 
0.05 0.06 
VC1859 0.03 0.04 
 
0.05 0.04 
VC1860 0.12 0.12 
 
0.05 0.06 
VC1861 0.04 0.04 
 
0.06 0.05 
VC1862 0.09 0.10 
 
0.05 0.06 
VC1863 0.12 0.11 
 
0.04 0.05 
VC1864 0.05 0.06 
 
0.05 0.06 
VC1865 0.10 0.11 
 
0.05 0.04 
VC1866 0.04 0.04 
 
0.04 0.05 
VC1868 0.07 0.08 
 
0.03 0.07 
VC1869 0.03 0.05 
 
0.05 0.06 
VC1870 0.03 0.04 
 
0.05 0.05 
VC1871 0.04 0.08 
 
0.03 0.03 
VC1872 0.04 0.02 
 
0.08 0.06 
VC1873 0.06 0.05 
 
0.06 0.06 
VC1874 0.08 0.10 
 
0.06 0.04 
VC1875 0.07 0.08 
 
0.07 0.07 
VC1876 0.05 0.04 
 
0.06 0.05 
VC1877 0.01 0.01 
 
0.01 0.01 
VC1878 0.06 0.06 
 
0.05 0.06 
VC1879 0.04 0.03 
 
0.04 0.06 
VC1879 0.02 0.01 
 
0.04 0.04 
VC1880 0.09 0.10 
 
0.04 0.05 
VC1881 0.07 0.08 
 
0.04 0.04 
VC1882 0.02 0.02 
 
0.00 0.01 
VC1883 0.11 0.10 
 
0.05 0.05 
VC1884 0.12 0.11 
 
0.05 0.04 
VC1885 0.10 0.11 
 
0.05 0.07 
VC1886 0.01 0.01 
 
0.07 0.06 
VC1887 0.10 0.10 
 
0.04 0.03 
VC1888 0.02 0.01 
 
0.04 0.05 
VC1889 0.13 0.13 
 
0.05 0.04 
VC1890 0.13 0.13 
 
0.07 0.07 
VC1891 0.04 0.04 
 
0.04 0.05 
VC1891 0.07 0.07 
 
0.04 0.03 
VC1892 0.11 0.10 
 
-0.02 0.02 
VC1893 0.15 0.14 
 
0.02 0.04 
VC1894 0.07 0.05 
 
0.03 0.03 
VC1895 0.01 0.02 
 
0.03 0.00 
VC1896 0.08 0.08 
 
0.03 0.05 
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VC1897 0.10 0.09 
 
0.00 0.00 
VC1898 0.04 0.05 
 
0.06 0.06 
VC1899 0.12 0.10 
 
-0.01 0.03 
VC1900 0.03 0.03 
 
0.07 0.03 
VC1901 0.09 0.08 
 
0.03 0.03 
VC1902 0.16 0.13 
 
0.02 0.02 
VC1903 0.06 0.05 
 
0.06 0.03 
VC1904 0.10 0.09 
 
0.00 0.01 
VC1905 0.13 0.12 
 
0.00 0.01 
VC1906 0.14 0.12 
 
0.00 0.02 
VC1907 0.05 0.05 
 
0.00 0.01 
VC1908 0.06 0.07 
 
0.08 0.06 
VC1909 0.04 0.07 
 
0.04 0.04 
VC1910 0.04 0.07 
 
0.04 0.03 
VC1911 0.05 0.04 
 
0.03 0.03 
VC1912 0.06 0.03 
 
0.06 0.09 
VC1913 0.06 0.05 
 
0.04 0.04 
VC1914 0.04 0.05 
 
0.03 0.03 
VC1915 0.06 0.09 
 
0.05 0.05 
VC1916 0.04 0.04 
 
0.08 0.07 
VC1917 0.04 0.03 
 
0.06 0.04 
VC1918 0.06 0.07 
 
0.04 0.03 
VC1919 0.09 0.09 
 
0.07 0.07 
VC1920 0.05 0.06 
 
0.06 0.07 
VC1921 0.01 0.02 
 
0.02 0.04 
VC1922 0.06 0.05 
 
0.05 0.05 
VC1923 0.06 0.06 
 
0.08 0.08 
VC1924 0.06 0.05 
 
0.05 0.02 
VC1925 0.07 0.07 
 
0.07 0.05 
VC1926 0.04 0.04 
 
0.10 0.09 
VC1927 0.05 0.06 
 
0.04 0.04 
VC1928 0.03 0.03 
 
0.08 0.06 
VC1929 0.09 0.07 
 
0.07 0.09 
VC1930 0.05 0.06 
 
0.04 0.04 
VC1931 0.06 0.05 
 
0.04 0.05 
VC1932 0.02 0.02 
 
0.02 0.04 
VC1933 0.11 0.12 
 
0.06 0.05 
VC1934 0.10 0.11 
 
0.01 0.02 
VC1935 0.01 0.01 
 
0.05 0.06 
VC1936 0.02 0.02 
 
0.04 0.05 
VC1937 0.05 0.05 
 
0.06 0.06 
VC1938 0.03 0.04 
 
0.04 0.07 
VC1938 0.02 0.02 
 
0.05 0.04 
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VC1939 0.03 0.04 
 
0.05 0.05 
VC1940 0.05 0.05 
 
0.05 0.04 
VC1941 0.06 0.05 
 
0.04 0.05 
VC1942 0.00 0.02 
 
0.10 0.11 
VC1943 0.04 0.05 
 
0.04 0.05 
VC1943 0.06 0.06 
 
0.01 0.03 
VC1944 0.06 0.07 
 
0.08 0.08 
VC1945 0.06 0.06 
 
0.03 0.04 
VC1946 0.05 0.08 
 
0.03 0.05 
VC1947 0.03 0.03 
 
0.06 0.06 
VC1948 0.05 0.06 
 
0.04 0.05 
VC1949 0.08 0.04 
 
0.05 0.05 
VC1950 0.03 0.03 
 
0.06 0.05 
VC1951 0.05 0.05 
 
0.03 0.03 
VC1952 0.04 0.06 
 
0.04 0.04 
VC1953 0.08 0.04 
 
0.09 0.14 
VC1954 0.02 0.02 
 
0.03 0.04 
VC1955 0.02 0.03 
 
0.09 0.04 
VC1956 0.04 0.03 
 
0.04 0.03 
VC1957 0.08 0.06 
 
0.07 0.07 
VC1958 0.06 0.06 
 
0.03 0.03 
VC1959 0.03 0.02 
 
0.02 0.06 
VC1960 0.04 0.06 
 
0.04 0.04 
VC1961 0.05 0.05 
 
0.05 0.07 
VC1962 0.01 0.02 
 
0.08 0.07 
VC1963 0.07 0.09 
 
0.05 0.04 
VC1964 0.08 0.08 
 
0.06 0.04 
VC1965 0.06 0.07 
 
0.06 0.07 
VC1966 0.04 0.03 
 
0.01 0.02 
VC1967 0.01 0.02 
 
0.06 0.06 
VC1968 0.06 0.07 
 
0.06 0.06 
VC1969 0.05 0.06 
 
0.04 0.05 
VC1970 0.02 0.02 
 
0.02 0.02 
VC1971 0.03 0.06 
 
0.06 0.05 
VC1972 0.08 0.07 
 
0.04 0.04 
VC1973 0.06 0.06 
 
0.06 0.06 
VC1974 0.06 0.07 
 
0.06 0.05 
VC1975 0.07 0.06 
 
0.03 0.02 
VC1976 0.01 0.03 
 
0.03 0.04 
VC1977 0.02 0.01 
 
0.05 0.05 
VC1978 0.02 0.02 
 
0.05 0.06 
VC1979 0.02 0.03 
 
0.11 0.11 
VC1980 0.03 0.02 
 
0.06 0.06 
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VC1981 0.03 0.02 
 
0.04 0.06 
VC1982 0.06 0.08 
 
0.03 0.03 
VC1983 0.08 0.09 
 
0.04 0.04 
VC1984 0.03 0.04 
 
0.04 0.02 
VC1985 0.09 0.10 
 
0.04 0.05 
VC1986 0.03 0.05 
 
0.08 0.05 
VC1987 0.02 0.02 
 
0.05 0.05 
VC1988 0.05 0.05 
 
0.06 0.04 
VC1989 0.03 0.02 
 
0.09 0.07 
VC1990 0.05 0.05 
 
0.05 0.04 
VC1991 0.03 0.05 
 
0.04 0.04 
VC1992 0.04 0.04 
 
0.07 0.06 
VC1993 0.03 0.03 
 
0.04 0.06 
VC1994 0.05 0.04 
 
0.04 0.04 
VC1995 0.03 0.02 
 
0.11 0.11 
VC1996 0.05 0.05 
 
0.04 0.03 
VC1997 0.06 0.07 
 
0.03 0.03 
VC1998 0.07 0.07 
 
0.03 0.02 
VC1999 0.06 0.07 
 
0.05 0.03 
VC2000 0.03 0.05 
 
0.06 0.06 
VC2001 0.05 0.05 
 
0.07 0.05 
VC2002 0.01 0.01 
 
0.05 0.05 
VC2003 0.07 0.07 
 
0.03 0.04 
VC2004 0.06 0.07 
 
0.05 0.04 
VC2005 0.09 0.10 
 
0.03 0.04 
VC2006 0.06 0.03 
 
0.05 0.04 
VC2007 0.06 0.07 
 
0.09 0.08 
VC2008 0.05 0.07 
 
0.05 0.04 
VC2009 0.07 0.06 
 
0.05 0.05 
VC2010 0.06 0.06 
 
0.05 0.06 
VC2011 0.01 0.01 
 
0.01 0.01 
VC2012 0.03 0.04 
 
0.05 0.03 
VC2013 0.03 0.03 
 
0.06 0.04 
VC2014 0.09 0.10 
 
0.02 0.03 
VC2015 0.06 0.06 
 
0.04 0.03 
VC2016 0.04 0.04 
 
0.02 0.02 
VC2017 0.06 0.07 
 
0.04 0.04 
VC2018 0.08 0.07 
 
0.02 0.02 
VC2019 0.06 0.06 
 
0.07 0.04 
VC2021 0.06 0.09 
 
0.06 0.05 
VC2022 0.06 0.07 
 
0.07 0.05 
VC2023 0.04 0.04 
 
0.05 0.05 
VC2024 0.00 0.03 
 
0.02 0.03 
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VC2025 0.04 0.04 
 
0.06 0.06 
VC2026 0.04 0.04 
 
0.05 0.05 
VC2027 0.04 0.04 
 
0.05 0.07 
VC2028 0.05 0.06 
 
0.05 0.06 
VC2029 0.05 0.05 
 
0.03 0.04 
VC2030 0.01 0.02 
 
0.00 0.01 
VC2031 0.00 0.02 
 
0.05 0.04 
VC2032 0.03 0.03 
 
0.04 0.04 
VC2033 0.05 0.07 
 
0.08 0.09 
VC2034 0.07 0.07 
 
0.06 0.07 
VC2035 0.04 0.05 
 
0.07 0.06 
VC2036 0.03 0.03 
 
0.06 0.03 
VC2037 0.09 0.09 
 
0.05 0.07 
VC2039 0.06 0.07 
 
0.05 0.05 
VC2040 0.06 0.05 
 
0.06 0.06 
VC2041 0.00 0.01 
 
0.04 0.07 
VC2042 0.10 0.07 
 
0.04 0.06 
VC2043 0.04 0.06 
 
0.04 0.05 
VC2044 0.05 0.06 
 
0.06 0.07 
VC2045 0.02 0.05 
 
0.08 0.06 
VC2046 0.04 0.05 
 
0.02 0.04 
VC2047 0.06 0.05 
 
0.07 0.09 
VC2048 0.03 0.03 
 
0.02 0.02 
VC2049 -0.01 0.01 
 
0.04 0.03 
VC2051 0.06 0.07 
 
0.04 0.06 
VC2052 0.01 0.02 
 
0.05 0.05 
VC2053 0.06 0.06 
 
0.03 0.03 
VC2054 0.00 0.02 
 
0.03 0.05 
VC2055 0.00 0.03 
 
0.03 0.03 
VC2056 0.01 0.03 
 
0.01 0.05 
VC2057 0.04 0.04 
 
0.04 0.04 
VC2058 0.05 0.03 
 
0.04 0.06 
VC2059 0.03 0.03 
 
0.07 0.06 
VC2060 0.03 0.02 
 
0.05 0.04 
VC2061 0.01 0.01 
 
0.05 0.04 
VC2062 0.03 0.04 
 
0.04 0.05 
VC2063 0.04 0.06 
 
0.06 0.05 
VC2064 0.03 0.02 
 
0.05 0.05 
VC2065 0.10 0.09 
 
0.04 0.04 
VC2066 0.04 0.04 
 
0.21 0.22 
VC2067 0.05 0.03 
 
0.04 0.05 
VC2068 0.00 0.01 
 
0.03 0.03 
VC2069 0.06 0.06 
 
0.05 0.06 
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VC2070 0.02 0.01 
 
0.05 0.05 
VC2071 0.05 0.05 
 
0.04 0.05 
VC2072 0.07 0.05 
 
0.05 0.04 
VC2073 0.03 0.04 
 
0.03 0.07 
VC2074 0.06 0.05 
 
0.02 0.01 
VC2075 0.07 0.08 
 
0.03 0.03 
VC2076 0.08 0.06 
 
0.08 0.06 
VC2077 0.03 0.02 
 
0.05 0.06 
VC2078 0.11 0.12 
 
0.04 0.03 
VC2079 0.08 0.08 
 
0.02 0.05 
VC2080 0.03 0.05 
 
0.04 0.04 
VC2081 0.05 0.05 
 
0.05 0.04 
VC2082 0.06 0.08 
 
0.04 0.03 
VC2083 0.02 0.01 
 
0.09 0.07 
VC2084 0.02 0.02 
 
0.03 0.03 
VC2085 0.02 0.03 
 
0.01 0.01 
VC2086 0.04 0.04 
 
0.01 0.03 
VC2087 0.01 0.01 
 
0.06 0.05 
VC2088 0.03 0.03 
 
0.07 0.05 
VC2089 0.01 0.02 
 
0.15 0.13 
VC2090 -0.01 0.02 
 
0.03 0.03 
VC2091 0.04 0.04 
 
0.05 0.04 
VC2092 0.06 0.06 
 
0.07 0.07 
VC2093 0.05 0.06 
 
0.03 0.04 
VC2094 0.04 0.04 
 
0.11 0.10 
VC2095 0.04 0.05 
 
0.16 0.14 
VC2096 0.02 0.03 
 
0.24 0.20 
VC2097 0.04 0.04 
 
0.12 0.11 
VC2098 0.02 0.03 
 
0.02 0.00 
VC2099 0.03 0.02 
 
0.00 0.00 
VC2100 0.03 0.04 
 
0.11 0.12 
VC2101 0.06 0.06 
 
0.03 0.04 
VC2102 0.05 0.07 
 
0.02 0.04 
VC2103 0.02 0.01 
 
0.06 0.05 
VC2105 0.07 0.08 
 
0.04 0.04 
VC2106 0.03 0.03 
 
0.01 0.02 
VC2107 0.03 0.02 
 
0.05 0.05 
VC2108 0.01 0.03 
 
0.05 0.06 
VC2109 0.02 0.02 
 
0.07 0.10 
VC2110 0.08 0.05 
 
0.04 0.04 
VC2111 0.05 0.06 
 
0.03 0.02 
VC2112 0.02 0.03 
 
0.06 0.06 
VC2112 0.01 0.01 
 
0.05 0.05 
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VC2113 0.06 0.06 
 
0.03 0.03 
VC2114 0.05 0.06 
 
0.01 0.02 
VC2115 0.07 0.05 
 
0.04 0.06 
VC2116 0.03 0.03 
 
0.06 0.08 
VC2117 0.04 0.05 
 
0.03 0.05 
VC2118 0.02 0.03 
 
0.05 0.06 
VC2119 0.04 0.03 
 
0.05 0.03 
VC2120 0.02 0.03 
 
0.04 0.03 
VC2121 0.04 0.04 
 
0.08 0.06 
VC2122 0.06 0.07 
 
0.02 0.04 
VC2123 0.00 0.00 
 
0.04 0.05 
VC2124 0.03 0.05 
 
0.03 0.04 
VC2125 0.04 0.04 
 
0.02 0.04 
VC2126 0.01 0.01 
 
0.05 0.05 
VC2127 0.03 0.03 
 
0.04 0.04 
VC2128 0.02 0.02 
 
0.04 0.04 
VC2129 0.07 0.08 
 
0.03 0.03 
VC2130 -0.01 0.04 
 
0.05 0.04 
VC2131 0.06 0.08 
 
0.06 0.08 
VC2132 0.06 0.05 
 
0.05 0.04 
VC2133 0.01 0.02 
 
0.04 0.04 
VC2134 0.02 0.02 
 
0.07 0.05 
VC2134 -0.02 0.00 
 
0.04 0.04 
VC2135 0.05 0.04 
 
0.10 0.10 
VC2136 0.02 0.02 
 
0.04 0.05 
VC2137 0.02 0.04 
 
0.15 0.15 
VC2138 0.05 0.07 
 
0.06 0.07 
VC2139 0.05 0.05 
 
0.08 0.08 
VC2140 0.01 0.02 
 
0.04 0.04 
VC2141 0.03 0.04 
 
0.06 0.06 
VC2142 0.05 0.03 
 
0.03 0.14 
VC2143 0.04 0.02 
 
0.07 0.06 
VC2144 0.02 0.02 
 
0.09 0.09 
VC2145 0.05 0.04 
 
0.11 0.09 
VC2146 0.00 0.03 
 
0.00 0.01 
VC2147 0.03 0.03 
 
0.03 0.02 
VC2148 0.03 0.04 
 
0.04 0.03 
VC2149 0.03 0.03 
 
0.06 0.04 
VC2150 0.02 0.01 
 
0.06 0.07 
VC2151 0.04 0.05 
 
0.04 0.04 
VC2152 0.05 0.02 
 
0.08 0.07 
VC2153 0.02 0.03 
 
0.04 0.07 
VC2154 0.05 0.06 
 
0.03 0.03 
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VC2155 0.02 0.02 
 
0.05 0.06 
VC2156 0.03 0.04 
 
0.08 0.06 
VC2157 0.04 0.04 
 
0.03 0.03 
VC2158 0.05 0.06 
 
0.06 0.06 
VC2159 0.00 0.01 
 
0.10 0.09 
VC2160 0.04 0.07 
 
0.08 0.10 
VC2161 -0.01 0.00 
 
0.07 0.09 
VC2162 0.05 0.05 
 
0.06 0.05 
VC2163 0.05 0.06 
 
0.05 0.05 
VC2164 0.09 0.09 
 
0.05 0.07 
VC2165 0.06 0.06 
 
0.09 0.08 
VC2166 0.02 0.03 
 
0.07 0.07 
VC2167 0.04 0.04 
 
0.06 0.06 
VC2168 0.07 0.07 
 
0.03 0.02 
VC2169 0.04 0.05 
 
0.05 0.05 
VC2170 0.05 0.05 
 
0.04 0.04 
VC2171 0.05 0.05 
 
0.04 0.05 
VC2172 0.01 0.01 
 
0.06 0.05 
VC2174 0.07 0.07 
 
0.03 0.03 
VC2175 0.05 0.05 
 
0.04 0.02 
VC2176 0.04 0.05 
 
0.04 0.04 
VC2177 -0.01 -0.01 
 
0.06 0.04 
VC2178 0.06 0.06 
 
0.04 0.02 
VC2179 0.02 0.03 
 
0.02 0.02 
VC2180 0.02 0.02 
 
0.08 0.04 
VC2181 0.03 0.03 
 
0.03 0.06 
VC2182 0.03 0.05 
 
0.04 0.04 
VC2183 0.01 0.02 
 
0.01 0.02 
VC2184 0.15 0.08 
 
0.02 0.02 
VC2185 0.04 0.04 
 
0.03 0.00 
VC2186 0.08 0.08 
 
0.06 0.02 
VC2187 0.04 0.04 
 
0.05 0.06 
VC2188 0.03 0.03 
 
0.06 0.09 
VC2189 0.01 0.05 
 
0.05 0.05 
VC2190 0.07 0.04 
 
0.05 0.07 
VC2191 0.04 0.03 
 
0.05 0.05 
VC2192 0.03 0.03 
 
0.04 0.05 
VC2193 0.03 0.04 
 
0.03 0.03 
VC2194 0.03 0.03 
 
0.04 0.03 
VC2195 0.01 0.11 
 
0.03 0.04 
VC2196 0.03 0.04 
 
0.04 0.03 
VC2197 0.03 0.03 
 
0.07 0.06 
VC2198 0.05 0.05 
 
0.05 0.05 
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VC2199 0.03 0.03 
 
0.03 0.04 
VC2200 0.02 0.03 
 
0.05 0.06 
VC2201 0.02 0.04 
 
0.03 0.04 
VC2202 0.03 0.07 
 
0.05 0.04 
VC2203 0.02 0.03 
 
0.02 0.03 
VC2204 0.06 0.07 
 
0.04 0.03 
VC2205 0.04 0.07 
 
0.07 0.06 
VC2206 0.03 0.10 
 
0.05 0.04 
VC2207 0.08 0.09 
 
0.02 0.03 
VC2208 0.02 0.02 
 
0.01 0.01 
VC2209 0.00 0.01 
 
0.03 0.05 
VC2210 0.03 0.04 
 
0.04 0.04 
VC2211 0.02 0.02 
 
0.04 0.13 
VC2212 0.01 0.02 
 
0.07 0.09 
VC2213 0.02 0.03 
 
0.01 0.01 
VC2214 0.01 0.01 
 
0.00 0.01 
VC2215 0.01 0.02 
 
0.04 0.04 
VC2216 0.06 0.06 
 
0.04 0.03 
VC2217 0.01 0.01 
 
0.02 0.02 
VC2218 0.09 0.08 
 
0.02 0.03 
VC2219 0.08 0.06 
 
0.01 0.01 
VC2220 0.02 0.03 
 
0.00 0.01 
VC2221 0.09 0.07 
 
0.05 0.05 
VC2222 0.07 0.07 
 
0.07 0.08 
VC2223 0.04 0.05 
 
0.03 0.04 
VC2224 0.02 0.02 
 
0.01 0.02 
VC2225 0.09 0.08 
 
0.03 0.04 
VC2226 0.05 0.06 
 
0.06 0.04 
VC2227 0.06 0.05 
 
0.07 0.07 
VC2228 0.09 0.08 
 
0.02 0.02 
VC2229 0.05 0.07 
 
0.04 0.03 
VC2230 0.06 0.06 
 
0.06 0.07 
VC2231 0.04 0.05 
 
0.05 0.05 
VC2232 0.05 0.08 
 
0.06 0.06 
VC2233 0.03 0.02 
 
0.01 0.01 
VC2234 0.05 0.06 
 
0.08 0.05 
VC2235 0.05 0.07 
 
0.04 0.05 
VC2236 0.14 0.13 
 
0.08 0.08 
VC2237 0.03 0.03 
 
0.05 0.01 
VC2238 0.08 0.08 
 
0.09 0.07 
VC2239 0.08 0.09 
 
0.08 0.09 
VC2240 0.05 0.06 
 
0.05 0.04 
VC2241 0.05 0.06 
 
0.05 0.06 
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VC2242 0.03 0.03 
 
0.09 0.08 
VC2243 0.04 0.06 
 
0.05 0.05 
VC2244 0.05 0.06 
 
0.05 0.06 
VC2245 0.07 0.07 
 
0.08 0.05 
VC2246 0.05 0.06 
 
0.03 0.04 
VC2247 0.05 0.05 
 
0.05 0.04 
VC2248 0.07 0.07 
 
0.09 0.10 
VC2249 0.06 0.08 
 
0.06 0.05 
VC2250 0.04 0.04 
 
0.04 0.04 
VC2252 0.01 0.02 
 
0.04 0.05 
VC2253 0.01 0.02 
 
0.05 0.04 
VC2254 0.02 0.03 
 
0.05 0.05 
VC2255 0.01 0.02 
 
0.01 0.01 
VC2256 0.05 0.06 
 
0.06 0.07 
VC2258 0.02 0.02 
 
0.05 0.06 
VC2258 0.04 0.05 
 
0.09 0.06 
VC2259 0.09 0.09 
 
0.05 0.04 
VC2260 0.03 0.03 
 
0.01 0.02 
VC2261 0.06 0.07 
 
0.07 0.07 
VC2262 0.06 0.06 
 
0.05 0.04 
VC2263 0.04 0.09 
 
0.05 0.03 
VC2263 0.05 0.06 
 
0.04 0.05 
VC2264 0.05 0.05 
 
0.09 0.05 
VC2265 0.11 0.13 
 
0.06 0.07 
VC2266 0.03 0.05 
 
0.05 0.06 
VC2267 0.11 0.09 
 
0.05 0.09 
VC2268 0.08 0.07 
 
0.11 0.07 
VC2269 0.06 0.04 
 
0.12 0.08 
VC2270 0.05 0.05 
 
0.08 0.07 
VC2271 0.01 0.01 
 
0.01 0.01 
VC2272 0.08 0.06 
 
0.05 0.05 
VC2273 0.08 0.06 
 
0.04 0.04 
VC2274 0.04 0.04 
 
0.07 0.06 
VC2275 0.07 0.07 
 
0.09 0.09 
VC2276 0.10 0.11 
 
0.06 0.08 
VC2277 0.06 0.08 
 
0.09 0.09 
VC2278 0.03 0.05 
 
0.01 0.03 
VC2279 0.05 0.05 
 
0.06 0.05 
VC2280 0.08 0.07 
 
0.13 0.12 
VC2281 0.05 0.05 
 
0.06 0.06 
VC2282 0.00 0.02 
 
0.00 0.04 
VC2282 0.01 0.05 
 
0.05 0.06 
VC2283 0.12 0.15 
 
0.07 0.07 
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VC2284 0.05 0.04 
 
0.05 0.06 
VC2285 -0.02 0.00 
 
-0.01 -0.01 
VC2286 0.03 0.05 
 
0.07 0.08 
VC2287 0.06 0.03 
 
0.04 0.06 
VC2288 0.06 0.06 
 
0.00 0.03 
VC2289 0.03 0.03 
 
0.04 0.03 
VC2290 0.09 0.07 
 
0.06 0.06 
VC2291 0.04 0.05 
 
0.02 0.03 
VC2292 0.04 0.05 
 
0.06 0.06 
VC2293 0.05 0.05 
 
0.08 0.08 
VC2294 0.03 0.03 
 
0.05 0.05 
VC2295 0.08 0.07 
 
0.05 0.06 
VC2296 0.05 0.06 
 
0.09 0.09 
VC2297 0.06 0.06 
 
0.05 0.05 
VC2298 0.09 0.07 
 
0.08 0.10 
VC2299 0.04 0.05 
 
0.03 0.04 
VC2300 0.05 0.06 
 
0.06 0.05 
VC2301 0.07 0.08 
 
0.00 0.02 
VC2302 0.05 0.06 
 
0.09 0.06 
VC2303 0.05 0.05 
 
0.04 0.04 
VC2304 0.03 0.03 
 
0.05 0.04 
VC2305 0.08 0.07 
 
0.04 0.05 
VC2306 0.04 0.05 
 
0.04 0.04 
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0.06 0.05 
VC2721 0.03 0.03 
 
0.04 0.05 
VC2722 0.02 0.06 
 
0.06 0.05 
VC2723 0.02 0.05 
 
0.05 0.06 
VC2724 0.02 0.03 
 
0.00 0.00 
VC2725 0.08 0.09 
 
0.04 0.06 
VC2726 0.11 0.08 
 
0.04 0.05 
VC2727 0.03 0.03 
 
0.05 0.05 
VC2728 0.05 0.06 
 
0.06 0.07 
VC2729 0.04 0.05 
 
0.04 0.04 
VC2730 0.04 0.04 
 
0.06 0.03 
VC2731 0.04 0.05 
 
0.04 0.04 
VC2732 0.05 0.06 
 
0.04 0.03 
VC2733 0.03 0.03 
 
0.03 0.02 
VC2734 0.02 0.03 
 
0.04 0.04 
VC2735 0.04 0.04 
 
0.07 0.07 
VC2736 0.03 0.04 
 
0.05 0.04 
VC2737 0.08 0.08 
 
0.01 0.05 
VC2738 0.05 0.06 
 
0.04 0.05 
VC2739 0.03 0.03 
 
0.03 0.07 
VC2740 0.08 0.09 
 
0.06 0.08 
VC2741 0.05 0.05 
 
0.03 0.03 
VC2742 0.03 0.04 
 
0.05 0.05 
VC2743 0.04 0.09 
 
0.06 0.07 
VC2744 0.07 0.08 
 
0.06 0.04 
VC2745 0.05 0.04 
 
0.04 0.04 
VC2746 0.06 0.06 
 
0.04 0.04 
VC2747 0.05 0.05 
 
0.04 0.04 
VC2748 0.00 0.03 
 
0.05 0.08 
VC2749 0.06 0.07 
 
0.07 0.05 
VC2750 -0.01 0.00 
 
0.03 0.03 
VC2751 0.04 0.03 
 
0.04 0.05 
VC2752 0.06 0.05 
 
0.06 0.06 
VC2754 0.06 0.07 
 
0.06 -0.04 
VC2755 0.05 0.05 
 
0.07 0.07 
VC2756 0.07 0.06 
 
0.00 0.01 
VC2757 0.08 0.06 
 
0.01 0.01 
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VC2758 0.08 0.07 
 
0.08 0.07 
VC2759 0.02 0.02 
 
0.00 0.02 
VC2760 0.03 0.03 
 
0.07 0.06 
VC2761 0.02 0.02 
 
0.04 0.05 
VC2762 0.10 0.09 
 
0.06 0.08 
VC2763 0.03 0.03 
 
0.08 0.06 
VC2764 0.03 0.01 
 
0.00 -0.01 
VC2765 0.02 0.03 
 
0.06 0.05 
VC2767 0.04 0.04 
 
0.03 0.02 
VC2768 0.04 0.03 
 
0.00 0.01 
VC2769 0.09 0.03 
 
0.07 0.07 
VC2770 0.08 0.04 
 
0.04 0.03 
VC2771 0.05 0.05 
 
0.05 0.05 
VC2772 0.05 0.07 
 
0.10 0.10 
VC2773 0.02 0.03 
 
0.04 0.08 
VC2774 0.03 0.03 
 
0.05 0.06 
VC2775 0.04 0.03 
 
0.06 0.07 
VCA0001 0.10 0.05 
 
0.05 0.04 
VCA0002 0.02 0.02 
 
0.04 0.04 
VCA0003 0.05 0.03 
 
0.07 0.08 
VCA0004 0.03 0.04 
 
0.06 0.07 
VCA0005 0.02 0.03 
 
0.07 0.07 
VCA0006 0.03 0.03 
 
0.02 0.02 
VCA0007 0.03 0.04 
 
0.11 0.08 
VCA0008 0.04 0.04 
 
0.02 0.02 
VCA0009 0.03 0.03 
 
0.03 0.04 
VCA0010 0.04 0.03 
 
0.03 0.02 
VCA0011 0.02 0.04 
 
0.05 0.05 
VCA0012 0.06 0.06 
 
0.05 0.05 
VCA0013 0.01 0.04 
 
0.06 0.06 
VCA0014 0.04 0.04 
 
0.06 0.06 
VCA0016 0.11 0.05 
 
0.04 0.05 
VCA0017 0.05 0.06 
 
0.06 0.07 
VCA0018 0.03 0.04 
 
0.05 0.04 
VCA0019 0.00 0.02 
 
0.06 0.08 
VCA0020 0.05 0.05 
 
0.05 0.04 
VCA0021 0.03 0.02 
 
0.04 0.03 
VCA0022 0.03 0.01 
 
0.03 0.04 
VCA0023 0.03 0.03 
 
0.13 0.11 
VCA0024 0.03 0.01 
 
0.03 0.03 
VCA0025 0.02 0.02 
 
0.02 0.03 
VCA0026 0.02 0.03 
 
0.07 0.06 
VCA0027 0.07 0.05 
 
0.07 0.06 
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VCA0028 0.04 0.09 
 
0.05 0.05 
VCA0029 0.04 0.06 
 
0.08 0.09 
VCA0030 0.06 0.07 
 
0.02 0.07 
VCA0031 0.08 0.09 
 
0.03 0.03 
VCA0032 0.05 0.07 
 
0.07 0.06 
VCA0033 0.04 0.06 
 
0.05 0.04 
VCA0034 0.03 0.05 
 
0.04 0.06 
VCA0035 0.06 0.09 
 
0.06 0.06 
VCA0036 0.15 0.15 
 
0.09 0.05 
VCA0037 0.09 0.12 
 
0.06 0.07 
VCA0038 0.04 0.05 
 
0.05 0.04 
VCA0039 0.03 0.08 
 
0.04 0.06 
VCA0040 0.06 0.08 
 
0.06 0.06 
VCA0041 0.06 0.06 
 
0.05 0.05 
VCA0042 0.58 0.62 
 
0.49 0.55 
VCA0043 0.05 0.06 
 
0.08 0.08 
VCA0044 0.03 0.07 
 
0.04 0.05 
VCA0046 0.03 0.04 
 
0.06 0.06 
VCA0047 0.08 0.08 
 
0.07 0.05 
VCA0048 0.06 0.12 
 
0.04 0.04 
VCA0049 0.04 0.04 
 
0.02 0.00 
VCA0050 0.11 0.08 
 
0.04 0.04 
VCA0051 0.02 0.01 
 
0.06 0.08 
VCA0052 0.04 0.04 
 
0.04 0.05 
VCA0053 0.04 0.07 
 
0.06 0.07 
VCA0054 0.03 0.05 
 
0.08 0.07 
VCA0055 0.05 0.06 
 
0.08 0.06 
VCA0056 0.05 0.08 
 
0.06 0.05 
VCA0057 0.10 0.10 
 
0.11 0.11 
VCA0058 0.07 0.08 
 
0.07 0.05 
VCA0060 0.06 0.09 
 
0.04 0.04 
VCA0061 0.04 0.04 
 
0.06 0.06 
VCA0062 0.04 0.05 
 
0.04 0.03 
VCA0062 0.04 0.04 
 
0.06 0.06 
VCA0063 0.06 0.09 
 
0.03 0.03 
VCA0064 0.03 0.03 
 
0.05 0.06 
VCA0065 0.06 0.05 
 
0.05 0.04 
VCA0066 0.05 0.04 
 
0.04 0.04 
VCA0067 0.04 0.05 
 
0.07 0.05 
VCA0068 0.03 0.03 
 
0.06 0.05 
VCA0069 0.06 0.07 
 
0.02 0.03 
VCA0069 0.05 0.06 
 
0.05 0.05 
VCA0070 0.04 0.05 
 
0.09 0.07 
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VCA0071 0.15 0.13 
 
0.19 0.22 
VCA0072 0.07 0.07 
 
0.11 0.09 
VCA0073 0.06 0.05 
 
0.09 0.04 
VCA0074 0.00 0.02 
 
0.06 0.01 
VCA0075 0.02 0.02 
 
0.05 0.05 
VCA0076 0.03 0.03 
 
0.02 0.05 
VCA0077 0.04 0.03 
 
0.03 0.03 
VCA0078 0.04 0.05 
 
0.02 0.01 
VCA0079 0.06 0.06 
 
0.07 -0.04 
VCA0080 0.13 0.14 
 
-0.01 -0.01 
VCA0081 0.06 0.06 
 
0.04 0.04 
VCA0082 0.09 0.08 
 
0.09 0.08 
VCA0083 0.06 0.05 
 
0.09 0.06 
VCA0084 0.07 0.06 
 
0.11 0.08 
VCA0085 0.07 0.06 
 
0.11 0.05 
VCA0086 0.06 0.06 
 
0.12 0.10 
VCA0087 0.07 0.06 
 
0.05 0.04 
VCA0089 0.05 0.05 
 
0.03 0.04 
VCA0090 0.03 0.03 
 
0.04 0.04 
VCA0091 0.07 0.07 
 
0.12 0.09 
VCA0092 0.07 0.08 
 
0.09 0.09 
VCA0093 0.06 0.10 
 
0.07 0.06 
VCA0093 0.06 0.07 
 
0.04 0.05 
VCA0094 0.07 0.07 
 
0.10 0.12 
VCA0095 0.06 0.06 
 
0.08 0.06 
VCA0096 0.02 0.01 
 
0.09 0.09 
VCA0097 0.06 0.10 
 
0.06 0.05 
VCA0098 0.04 0.04 
 
0.03 0.03 
VCA0099 0.07 0.06 
 
0.12 0.09 
VCA0100 0.05 0.06 
 
0.09 0.08 
VCA0101 0.07 0.05 
 
0.04 0.08 
VCA0102 0.05 0.06 
 
0.06 0.05 
VCA0103 0.04 0.03 
 
0.02 0.05 
VCA0104 0.07 0.06 
 
0.04 0.08 
VCA0105 0.05 0.07 
 
0.10 0.08 
VCA0106 0.03 0.03 
 
0.05 0.04 
VCA0107 0.06 0.06 
 
0.12 0.08 
VCA0108 0.02 0.06 
 
0.05 0.04 
VCA0109 0.07 0.06 
 
0.09 0.09 
VCA0110 0.04 0.03 
 
0.03 0.05 
VCA0111 0.03 0.05 
 
0.09 0.06 
VCA0112 0.04 0.05 
 
0.06 0.06 
VCA0113 0.06 0.05 
 
0.05 0.10 
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VCA0114 0.06 0.06 
 
0.16 0.09 
VCA0115 0.03 0.04 
 
0.01 0.02 
VCA0116 0.13 0.09 
 
0.05 0.06 
VCA0117 0.08 0.08 
 
0.04 0.08 
VCA0118 0.04 0.05 
 
0.09 0.06 
VCA0119 0.03 0.04 
 
0.07 0.07 
VCA0120 0.03 0.03 
 
0.06 0.06 
VCA0121 0.05 0.06 
 
0.12 0.06 
VCA0122 0.06 0.05 
 
0.12 0.10 
VCA0123 0.05 0.04 
 
0.04 0.04 
VCA0124 0.05 0.06 
 
0.15 0.13 
VCA0125 0.07 0.07 
 
0.14 0.09 
VCA0126 0.07 0.07 
 
0.09 0.07 
VCA0127 0.04 0.04 
 
0.04 0.05 
VCA0128 0.03 0.03 
 
0.06 0.04 
VCA0129 0.03 0.03 
 
0.06 0.06 
VCA0130 0.06 0.09 
 
0.07 0.07 
VCA0131 0.05 0.05 
 
0.06 0.06 
VCA0132 0.06 0.08 
 
0.08 0.07 
VCA0133 0.03 0.03 
 
0.03 0.04 
VCA0134 0.01 0.02 
 
0.04 0.04 
VCA0135 0.08 0.09 
 
0.05 0.05 
VCA0136 0.03 0.08 
 
0.05 0.03 
VCA0137 0.01 0.02 
 
0.06 0.01 
VCA0138 0.08 0.09 
 
0.03 0.03 
VCA0139 0.06 0.06 
 
0.10 0.09 
VCA0140 0.04 0.07 
 
0.08 0.07 
VCA0141 0.01 0.01 
 
0.05 0.05 
VCA0142 0.06 0.06 
 
0.04 0.05 
VCA0143 0.07 0.07 
 
0.05 0.04 
VCA0144 0.03 0.05 
 
0.06 0.05 
VCA0145 0.05 0.05 
 
0.04 0.05 
VCA0146 0.01 0.00 
 
0.03 0.04 
VCA0147 0.05 0.07 
 
0.07 0.09 
VCA0148 0.08 0.08 
 
0.07 0.04 
VCA0149 0.07 0.09 
 
0.04 0.04 
VCA0150 0.06 0.07 
 
0.07 0.07 
VCA0151 0.04 0.04 
 
0.05 0.05 
VCA0152 0.05 0.06 
 
0.09 0.08 
VCA0153 0.04 0.06 
 
0.06 0.04 
VCA0154 0.06 0.08 
 
0.05 0.05 
VCA0155 0.05 0.07 
 
0.07 0.09 
VCA0156 0.05 0.07 
 
0.10 0.10 
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VCA0157 0.04 0.04 
 
0.04 0.06 
VCA0158 0.06 0.07 
 
0.05 0.05 
VCA0159 0.06 0.06 
 
0.06 0.08 
VCA0160 0.04 0.05 
 
0.05 0.05 
VCA0161 0.03 0.05 
 
0.06 0.04 
VCA0162 0.07 0.07 
 
0.07 0.06 
VCA0163 0.08 0.08 
 
0.06 0.05 
VCA0164 0.06 0.08 
 
0.06 0.05 
VCA0165 -0.04 -0.02 
 
-0.01 0.01 
VCA0166 0.06 0.07 
 
0.06 0.04 
VCA0167 0.05 0.05 
 
0.03 0.04 
VCA0168 0.04 0.05 
 
0.04 0.06 
VCA0171 0.07 0.04 
 
0.04 0.04 
VCA0172 0.06 0.08 
 
0.09 0.10 
VCA0173 0.07 0.07 
 
0.08 0.06 
VCA0174 0.05 0.05 
 
0.09 0.08 
VCA0175 0.05 0.06 
 
0.07 0.06 
VCA0176 0.12 0.12 
 
0.05 0.06 
VCA0177 0.06 0.07 
 
0.09 0.06 
VCA0178 0.10 0.09 
 
0.05 0.05 
VCA0179 0.04 0.05 
 
0.09 0.09 
VCA0180 0.06 0.06 
 
0.05 0.05 
VCA0181 0.05 0.08 
 
0.06 0.07 
VCA0182 0.08 0.09 
 
0.06 0.05 
VCA0183 0.07 0.06 
 
0.12 0.07 
VCA0184 0.05 0.06 
 
0.06 0.06 
VCA0185 0.06 0.07 
 
0.05 0.05 
VCA0186 0.05 0.05 
 
0.04 0.03 
VCA0187 0.06 0.07 
 
0.06 0.04 
VCA0188 0.03 0.05 
 
0.04 0.03 
VCA0189 0.04 0.04 
 
0.06 0.03 
VCA0190 0.05 0.04 
 
0.03 0.05 
VCA0191 0.01 0.04 
 
0.07 0.06 
VCA0192 0.00 -0.01 
 
0.05 0.07 
VCA0193 0.01 0.01 
 
0.05 0.05 
VCA0194 0.00 0.01 
 
0.07 0.06 
VCA0195 0.06 0.07 
 
0.02 0.02 
VCA0196 0.05 0.05 
 
0.03 0.02 
VCA0197 0.04 0.04 
 
0.07 0.05 
VCA0199 0.06 0.06 
 
0.07 0.05 
VCA0200 0.01 0.01 
 
0.03 0.03 
VCA0201 0.01 0.01 
 
0.08 0.08 
VCA0202 0.05 0.05 
 
0.05 0.06 
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VCA0203 0.04 0.05 
 
0.04 -0.09 
VCA0204 0.06 0.06 
 
0.08 0.08 
VCA0205 0.03 0.05 
 
0.05 0.04 
VCA0206 0.10 0.04 
 
0.10 0.07 
VCA0207 0.04 0.04 
 
0.09 0.09 
VCA0208 0.03 0.03 
 
0.04 0.05 
VCA0209 0.05 0.02 
 
0.09 0.07 
VCA0210 0.11 0.09 
 
0.27 0.23 
VCA0211 0.00 0.01 
 
0.05 0.06 
VCA0212 0.00 0.01 
 
0.03 0.04 
VCA0213 0.03 0.02 
 
0.06 0.05 
VCA0214 0.00 0.01 
 
0.04 0.04 
VCA0214 -0.01 0.00 
 
0.04 0.05 
VCA0215 0.02 0.10 
 
0.04 0.05 
VCA0216 0.01 0.02 
 
0.00 0.05 
VCA0216 0.01 0.03 
 
0.04 0.03 
VCA0217 0.03 0.04 
 
0.05 0.04 
VCA0218 0.02 0.02 
 
0.06 0.06 
VCA0219 0.04 0.04 
 
0.06 0.04 
VCA0220 0.00 0.01 
 
0.06 0.05 
VCA0221 0.03 0.03 
 
0.02 0.02 
VCA0222 0.01 0.01 
 
0.06 0.04 
VCA0224 0.03 0.04 
 
0.05 0.03 
VCA0225 0.07 0.07 
 
0.07 0.09 
VCA0226 0.04 0.04 
 
0.06 0.05 
VCA0227 0.02 0.03 
 
0.04 0.04 
VCA0228 0.01 0.02 
 
0.05 0.05 
VCA0229 0.04 0.06 
 
0.04 0.04 
VCA0230 0.04 0.06 
 
0.10 0.10 
VCA0231 0.03 0.03 
 
0.05 0.04 
VCA0232 0.01 0.02 
 
0.05 0.02 
VCA0233 -0.02 0.01 
 
0.05 0.05 
VCA0233 0.01 0.01 
 
0.06 0.05 
VCA0234 0.03 0.04 
 
0.03 0.04 
VCA0235 0.05 0.05 
 
0.06 0.06 
VCA0236 0.03 0.03 
 
0.04 0.02 
VCA0237 0.05 0.01 
 
0.06 0.05 
VCA0238 0.03 0.01 
 
0.05 0.05 
VCA0239 0.05 0.05 
 
0.10 0.10 
VCA0240 0.03 0.03 
 
0.08 0.07 
VCA0241 0.02 0.03 
 
0.07 0.07 
VCA0242 0.04 0.05 
 
0.13 0.10 
VCA0243 0.03 0.04 
 
0.05 0.05 
	   221	  
VCA0244 0.05 0.05 
 
0.06 0.06 
VCA0245 0.04 0.05 
 
0.04 0.04 
VCA0246 0.09 0.09 
 
0.04 0.04 
VCA0247 0.00 0.00 
 
0.07 0.06 
VCA0248 -0.02 -0.01 
 
0.04 0.02 
VCA0249 -0.01 -0.01 
 
0.06 0.04 
VCA0250 0.02 0.02 
 
0.06 0.04 
VCA0251 0.04 0.06 
 
0.02 0.02 
VCA0252 0.05 0.07 
 
0.05 0.06 
VCA0253 0.05 0.06 
 
0.04 0.04 
VCA0255 0.01 0.02 
 
0.05 0.05 
VCA0256 0.07 0.06 
 
0.06 0.06 
VCA0258 0.05 0.05 
 
0.05 0.07 
VCA0259 0.08 0.06 
 
0.03 0.02 
VCA0260 0.07 0.07 
 
0.08 0.04 
VCA0262 0.05 0.10 
 
0.04 0.04 
VCA0263 0.07 0.05 
 
0.08 0.09 
VCA0264 0.02 0.03 
 
0.05 0.05 
VCA0265 0.03 0.03 
 
0.05 0.05 
VCA0266 0.03 0.13 
 
0.04 0.04 
VCA0267 0.02 0.03 
 
0.04 0.03 
VCA0268 0.02 0.03 
 
0.04 0.02 
VCA0269 0.05 0.06 
 
0.04 0.04 
VCA0270 0.03 0.03 
 
0.02 0.08 
VCA0271 0.04 0.04 
 
0.05 0.05 
VCA0272 0.05 0.05 
 
0.05 0.03 
VCA0273 0.06 0.07 
 
0.07 0.02 
VCA0274 0.04 0.03 
 
0.04 0.04 
VCA0275 0.07 0.08 
 
0.04 0.03 
VCA0276 0.05 0.04 
 
0.04 0.04 
VCA0277 0.04 0.04 
 
0.06 0.05 
VCA0278 0.03 0.05 
 
0.04 0.04 
VCA0279 0.05 0.06 
 
0.07 0.07 
VCA0280 0.03 0.03 
 
0.03 0.04 
VCA0281 0.01 0.02 
 
0.04 0.04 
VCA0282 0.02 0.03 
 
0.01 0.03 
VCA0283 0.05 0.06 
 
0.04 0.06 
VCA0284 0.07 0.07 
 
0.04 0.07 
VCA0285 0.07 0.08 
 
0.04 0.03 
VCA0286 0.07 0.06 
 
0.04 0.02 
VCA0287 0.03 0.02 
 
0.09 0.08 
VCA0288 0.08 0.07 
 
0.05 0.06 
VCA0289 0.08 0.07 
 
0.04 0.04 
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VCA0290 0.04 0.05 
 
0.07 0.07 
VCA0291 0.06 0.07 
 
0.05 0.05 
VCA0292 0.07 0.05 
 
0.04 0.04 
VCA0294 0.07 0.07 
 
0.05 0.04 
VCA0295 0.07 0.06 
 
0.02 0.05 
VCA0296 0.10 0.10 
 
0.03 0.05 
VCA0297 0.07 0.06 
 
0.02 0.03 
VCA0298 0.07 0.07 
 
0.08 0.08 
VCA0299 0.10 0.09 
 
0.07 0.06 
VCA0300 0.09 0.07 
 
0.05 0.02 
VCA0301 0.09 0.07 
 
0.10 0.09 
VCA0303 0.07 0.08 
 
0.05 0.04 
VCA0304 0.08 0.07 
 
0.14 0.16 
VCA0305 0.01 0.03 
 
0.06 0.06 
VCA0306 0.07 0.07 
 
0.06 0.06 
VCA0307 0.03 0.02 
 
0.05 0.06 
VCA0307 -0.01 0.00 
 
0.08 0.07 
VCA0308 0.03 0.02 
 
0.09 0.07 
VCA0308 0.01 0.00 
 
0.05 0.05 
VCA0309 0.10 0.09 
 
0.09 0.10 
VCA0310 0.07 0.07 
 
0.04 0.04 
VCA0312 0.08 0.06 
 
0.05 0.04 
VCA0313 0.11 0.09 
 
0.06 0.03 
VCA0314 0.10 0.08 
 
0.06 0.06 
VCA0315 0.07 0.06 
 
0.07 0.05 
VCA0316 0.07 0.06 
 
0.06 0.06 
VCA0317 0.08 0.07 
 
0.03 0.04 
VCA0319 0.07 0.07 
 
0.04 0.07 
VCA0320 0.06 0.08 
 
0.06 0.08 
VCA0321 0.09 0.08 
 
0.04 0.07 
VCA0322 0.13 0.10 
 
0.05 0.04 
VCA0323 0.04 0.04 
 
0.00 0.01 
VCA0324 0.01 0.01 
 
0.07 0.07 
VCA0326 0.06 0.08 
 
0.03 0.04 
VCA0327 0.02 0.02 
 
0.08 0.07 
VCA0328 0.00 0.01 
 
0.14 0.12 
VCA0329 0.04 0.06 
 
0.08 0.07 
VCA0330 0.01 0.01 
 
0.07 0.06 
VCA0331 0.03 0.03 
 
0.04 0.04 
VCA0333 0.07 0.06 
 
0.07 0.05 
VCA0334 0.02 0.02 
 
0.06 0.04 
VCA0335 0.06 0.06 
 
0.01 0.02 
VCA0336 0.05 0.06 
 
0.04 0.04 
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VCA0337 0.02 0.01 
 
0.13 0.08 
VCA0338 0.02 0.02 
 
0.03 0.05 
VCA0338 0.01 0.02 
 
0.04 0.06 
VCA0339 0.04 0.06 
 
0.03 0.04 
VCA0340 -0.01 -0.01 
 
0.18 0.14 
VCA0341 0.02 0.02 
 
0.04 0.04 
VCA0341 -0.02 -0.01 
 
0.05 0.06 
VCA0342 0.02 0.01 
 
0.11 0.09 
VCA0343 0.06 0.05 
 
0.05 0.03 
VCA0344 0.04 0.04 
 
0.04 0.02 
VCA0345 0.00 0.00 
 
0.10 0.07 
VCA0346 0.13 0.01 
 
0.02 0.02 
VCA0347 0.03 0.04 
 
0.05 0.06 
VCA0349 0.01 0.02 
 
0.03 0.05 
VCA0349 0.01 0.03 
 
0.04 0.05 
VCA0350 0.05 0.07 
 
0.05 0.02 
VCA0351 0.00 0.00 
 
0.08 0.08 
VCA0352 0.02 0.03 
 
0.00 0.03 
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VCA0581 0.03 0.03 
 
0.03 0.06 
VCA0582 0.04 0.06 
 
0.06 0.06 
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VCA0761 0.12 0.09 
 
0.02 0.02 
VCA0762 0.05 0.06 
 
0.05 0.06 
VCA0763 0.10 0.10 
 
0.07 0.07 
VCA0764 0.06 0.05 
 
0.05 0.05 
VCA0765 0.13 0.10 
 
0.03 0.01 
VCA0766 0.15 0.13 
 
-0.01 -0.01 
VCA0767 0.08 0.09 
 
0.03 0.02 
VCA0768 0.13 0.13 
 
0.02 0.02 
VCA0769 0.12 0.11 
 
0.00 0.00 
VCA0770 0.06 0.05 
 
0.06 0.05 
VCA0770 0.06 0.06 
 
0.04 0.05 
VCA0771 0.06 0.07 
 
0.05 0.04 
VCA0772 0.10 0.07 
 
0.02 0.02 
VCA0773 0.09 0.10 
 
0.08 0.08 
VCA0774 0.05 0.04 
 
0.04 0.04 
VCA0775 0.03 0.03 
 
0.06 0.07 
VCA0776 0.02 0.02 
 
0.05 0.05 
VCA0777 0.06 0.06 
 
0.06 0.04 
VCA0778 0.09 0.07 
 
0.08 0.05 
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VCA0779 0.04 0.03 
 
0.01 0.01 
VCA0780 0.08 0.09 
 
0.03 0.04 
VCA0781 0.05 0.06 
 
0.03 0.03 
VCA0782 0.04 0.05 
 
0.08 0.06 
VCA0783 0.05 0.04 
 
0.04 0.03 
VCA0784 0.09 0.06 
 
0.06 0.06 
VCA0785 0.04 0.05 
 
0.00 -0.01 
VCA0786 0.07 0.06 
 
0.02 0.02 
VCA0787 0.06 0.06 
 
0.03 0.04 
VCA0788 0.07 0.08 
 
0.06 0.06 
VCA0789 0.10 0.09 
 
0.05 0.04 
VCA0790 0.06 0.07 
 
0.02 0.03 
VCA0791 0.06 0.05 
 
0.06 0.06 
VCA0792 0.05 0.03 
 
0.04 0.05 
VCA0793 0.05 0.09 
 
0.10 0.08 
VCA0794 0.04 0.07 
 
0.07 0.05 
VCA0795 0.06 0.06 
 
0.07 0.05 
VCA0796 0.09 0.10 
 
0.04 0.05 
VCA0796 0.06 0.07 
 
0.08 0.07 
VCA0797 0.06 0.11 
 
0.08 0.07 
VCA0798 0.04 0.05 
 
0.11 0.10 
VCA0799 0.07 0.06 
 
0.07 0.04 
VCA0800 0.07 0.06 
 
0.11 0.08 
VCA0801 0.08 0.08 
 
0.05 0.04 
VCA0802 0.03 0.04 
 
0.02 0.04 
VCA0803 0.02 0.02 
 
0.04 0.05 
VCA0804 0.04 0.04 
 
0.05 0.01 
VCA0805 0.04 0.04 
 
-0.02 -0.02 
VCA0806 0.07 0.05 
 
0.06 0.04 
VCA0807 0.06 0.07 
 
0.06 0.06 
VCA0808 0.06 0.05 
 
0.03 0.02 
VCA0809 0.04 0.04 
 
0.02 0.02 
VCA0810 0.05 0.05 
 
0.04 0.05 
VCA0810 0.05 0.06 
 
0.04 0.05 
VCA0811 0.06 0.07 
 
0.03 0.05 
VCA0812 0.16 0.17 
 
0.06 0.06 
VCA0813 0.08 0.08 
 
0.06 0.06 
VCA0814 0.06 0.07 
 
0.08 0.08 
VCA0815 0.05 0.06 
 
0.03 0.03 
VCA0815 -0.03 0.00 
 
0.02 0.04 
VCA0816 0.05 0.08 
 
0.04 0.05 
VCA0816 0.05 0.07 
 
0.04 0.05 
VCA0817 0.05 0.06 
 
0.06 0.07 
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VCA0819 0.09 0.09 
 
0.06 0.05 
VCA0820 0.02 0.02 
 
0.09 0.08 
VCA0821 0.05 0.05 
 
0.04 0.05 
VCA0822 0.09 0.10 
 
0.01 0.05 
VCA0823 0.07 0.06 
 
0.05 0.05 
VCA0824 0.01 0.03 
 
0.04 0.05 
VCA0824 0.01 0.03 
 
0.04 0.04 
VCA0825 0.06 0.07 
 
0.05 0.08 
VCA0826 0.06 0.07 
 
0.05 0.04 
VCA0826 0.06 0.06 
 
0.04 0.04 
VCA0827 0.12 0.11 
 
0.05 0.05 
VCA0828 0.05 0.06 
 
0.08 0.09 
VCA0830 0.01 0.01 
 
0.04 0.04 
VCA0831 0.03 0.04 
 
0.06 0.06 
VCA0832 0.06 0.03 
 
0.06 0.07 
VCA0833 0.05 0.04 
 
0.05 0.06 
VCA0834 0.05 0.03 
 
0.08 0.06 
VCA0835 0.03 0.05 
 
0.03 0.05 
VCA0836 0.03 0.02 
 
0.04 0.06 
VCA0836 0.01 0.01 
 
0.05 0.05 
VCA0837 0.05 0.05 
 
0.09 0.13 
VCA0838 0.06 0.05 
 
0.08 0.07 
VCA0839 0.02 0.02 
 
0.06 0.07 
VCA0840 0.10 0.10 
 
0.06 0.08 
VCA0841 0.05 0.06 
 
0.09 0.09 
VCA0842 0.05 0.05 
 
0.03 0.03 
VCA0842 0.05 0.06 
 
0.05 0.05 
VCA0843 0.11 0.10 
 
0.09 0.09 
VCA0844 0.05 0.06 
 
0.03 0.03 
VCA0845 0.04 0.05 
 
0.05 0.05 
VCA0846 0.08 0.06 
 
0.06 0.08 
VCA0847 0.01 0.02 
 
0.04 0.04 
VCA0848 0.01 0.01 
 
-0.01 0.02 
VCA0850 0.04 0.04 
 
0.06 0.11 
VCA0851 0.08 0.07 
 
0.05 0.08 
VCA0852 0.03 0.06 
 
0.04 0.07 
VCA0853 0.11 0.09 
 
0.04 0.04 
VCA0854 0.05 0.04 
 
0.07 0.07 
VCA0855 0.08 0.09 
 
0.06 0.03 
VCA0855 0.06 0.06 
 
0.07 0.05 
VCA0856 0.05 0.07 
 
0.06 0.08 
VCA0857 0.05 0.06 
 
0.08 0.07 
VCA0858 0.04 0.05 
 
0.05 0.05 
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VCA0861 0.06 0.06 
 
0.03 0.04 
VCA0862 0.06 0.06 
 
0.04 0.05 
VCA0863 0.07 0.06 
 
0.05 0.05 
VCA0864 0.04 0.01 
 
0.03 0.04 
VCA0865 0.03 0.04 
 
0.08 0.06 
VCA0866 0.03 0.03 
 
0.04 0.04 
VCA0867 0.02 0.03 
 
0.02 0.02 
VCA0868 0.06 0.07 
 
0.02 0.03 
VCA0869 0.05 0.06 
 
0.05 0.05 
VCA0870 0.05 0.05 
 
0.08 0.08 
VCA0871 0.05 0.03 
 
0.02 0.02 
VCA0872 0.02 0.01 
 
0.03 0.05 
VCA0873 0.05 0.07 
 
0.03 0.03 
VCA0874 0.05 0.06 
 
0.10 0.11 
VCA0875 0.05 0.05 
 
0.07 0.06 
VCA0876 0.03 0.04 
 
0.10 0.10 
VCA0878 0.07 0.09 
 
0.04 0.04 
VCA0879 0.04 0.07 
 
0.03 0.04 
VCA0879 0.07 0.07 
 
0.06 0.05 
VCA0880 0.08 0.06 
 
0.04 0.03 
VCA0882 0.04 0.05 
 
0.05 0.04 
VCA0883 0.12 0.13 
 
0.05 0.08 
VCA0884 0.03 0.03 
 
0.04 0.05 
VCA0885 0.07 0.05 
 
0.07 0.07 
VCA0886 0.07 0.07 
 
0.08 0.08 
VCA0887 0.06 0.06 
 
0.09 0.06 
VCA0888 0.07 0.05 
 
0.06 0.04 
VCA0889 0.05 0.09 
 
0.11 0.09 
VCA0890 0.08 0.06 
 
0.09 0.11 
VCA0891 0.05 0.04 
 
0.02 0.03 
VCA0892 0.08 0.09 
 
0.04 0.03 
VCA0893 0.09 0.09 
 
0.04 0.05 
VCA0894 0.06 0.08 
 
0.08 0.07 
VCA0895 0.06 0.05 
 
0.24 0.27 
VCA0896 0.04 0.05 
 
0.05 0.05 
VCA0897 0.08 0.08 
 
0.03 0.05 
VCA0898 0.05 0.05 
 
0.05 0.07 
VCA0899 0.06 0.06 
 
0.04 0.04 
VCA0900 0.06 0.05 
 
-0.03 -0.02 
VCA0901 0.03 0.03 
 
0.06 0.06 
VCA0902 0.04 0.03 
 
0.08 0.06 
VCA0903 0.07 0.05 
 
0.09 0.08 
VCA0904 0.06 0.03 
 
0.10 0.09 
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VCA0905 0.05 0.04 
 
0.04 0.04 
VCA0906 0.04 0.04 
 
0.05 0.04 
VCA0907 0.06 0.04 
 
0.10 0.10 
VCA0908 0.02 0.04 
 
0.04 0.04 
VCA0909 0.04 0.04 
 
0.05 0.06 
VCA0910 0.03 0.06 
 
0.07 0.06 
VCA0911 0.08 0.08 
 
0.03 0.03 
VCA0912 0.03 0.04 
 
0.04 0.05 
VCA0913 0.04 0.09 
 
0.07 0.06 
VCA0914 0.04 0.04 
 
0.04 0.04 
VCA0915 0.05 0.04 
 
0.04 0.05 
VCA0916 0.03 0.05 
 
0.06 0.05 
VCA0917 0.11 0.07 
 
0.07 0.08 
VCA0918 0.03 0.03 
 
0.03 0.03 
VCA0918 0.03 0.06 
 
0.05 0.06 
VCA0919 0.06 0.05 
 
0.11 0.09 
VCA0920 0.03 0.04 
 
0.04 0.09 
VCA0921 0.09 0.08 
 
0.01 0.01 
VCA0922 0.05 0.06 
 
0.07 0.05 
VCA0923 -0.01 -0.01 
 
0.06 0.05 
VCA0924 -0.01 -0.01 
 
0.01 0.00 
VCA0925 0.07 0.07 
 
0.08 0.06 
VCA0926 0.04 0.07 
 
0.05 0.03 
VCA0927 0.00 0.01 
 
0.08 0.06 
VCA0928 0.00 0.00 
 
0.07 0.04 
VCA0929 0.04 0.07 
 
0.00 0.01 
VCA0930 0.02 0.02 
 
0.05 0.04 
VCA0931 0.47 0.48 
 
0.35 0.30 
VCA0932 0.06 0.06 
 
0.07 0.06 
VCA0933 0.04 0.05 
 
0.08 0.08 
VCA0934 0.05 0.06 
 
0.04 0.04 
VCA0935 0.04 0.05 
 
0.05 0.04 
VCA0936 0.03 0.03 
 
0.09 0.08 
VCA0937 0.05 0.05 
 
0.06 0.06 
VCA0938 0.03 0.03 
 
0.05 0.04 
VCA0939 0.03 0.04 
 
-0.01 -0.02 
VCA0940 -0.01 0.02 
 
0.04 0.07 
VCA0941 0.07 0.08 
 
0.06 0.08 
VCA0942 0.07 0.06 
 
0.03 0.03 
VCA0943 0.03 0.03 
 
0.04 0.04 
VCA0944 0.04 0.03 
 
0.04 0.05 
VCA0945 0.02 0.02 
 
0.02 0.19 
VCA0946 0.05 0.05 
 
0.03 0.04 
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VCA0947 0.01 0.01 
 
0.06 0.23 
VCA0948 0.08 0.07 
 
0.03 0.04 
VCA0949 0.05 0.06 
 
0.02 0.02 
VCA0950 0.08 0.07 
 
0.02 0.04 
VCA0951 0.02 0.01 
 
0.03 0.04 
VCA0952 0.07 0.07 
 
0.10 0.08 
VCA0953 0.04 0.06 
 
0.02 0.04 
VCA0954 0.05 0.06 
 
0.05 0.05 
VCA0955 0.00 0.00 
 
0.03 0.07 
VCA0956 0.00 -0.02 
 
-0.01 0.00 
VCA0957 0.06 0.06 
 
0.04 0.03 
VCA0958 0.04 0.04 
 
0.05 0.05 
VCA0959 0.12 0.07 
 
0.06 0.05 
VCA0960 0.05 0.03 
 
0.06 0.08 
VCA0961 0.04 0.05 
 
0.03 0.05 
VCA0962 0.05 0.04 
 
0.05 0.06 
VCA0963 0.01 0.01 
 
0.16 0.04 
VCA0964 0.01 0.02 
 
0.04 0.03 
VCA0965 0.00 0.01 
 
0.11 0.14 
VCA0966 0.03 0.02 
 
0.05 0.06 
VCA0967 0.06 0.07 
 
0.03 0.04 
VCA0968 0.07 0.07 
 
0.07 0.06 
VCA0969 0.07 0.08 
 
0.05 0.07 
VCA0970 0.03 0.03 
 
0.04 0.07 
VCA0971 0.03 0.03 
 
0.03 0.05 
VCA0972 0.05 0.06 
 
0.07 0.09 
VCA0973 0.07 0.08 
 
0.07 0.05 
VCA0974 0.02 0.03 
 
0.04 0.03 
VCA0975 0.03 0.03 
 
0.05 0.05 
VCA0976 0.01 0.02 
 
0.04 0.04 
VCA0977 0.04 0.05 
 
0.06 0.05 
VCA0979 0.02 0.04 
 
0.06 0.04 
VCA0980 0.02 0.00 
 
0.04 0.05 
VCA0981 0.04 0.04 
 
0.05 0.04 
VCA0982 0.01 0.01 
 
0.07 0.05 
VCA0983 0.03 0.03 
 
0.04 0.05 
VCA0984 0.03 0.07 
 
0.06 0.04 
VCA0985 0.02 0.02 
 
0.04 0.04 
VCA0986 0.02 0.02 
 
0.06 0.05 
VCA0987 0.03 0.05 
 
0.04 0.06 
VCA0988 0.03 0.03 
 
0.04 0.05 
VCA0989 0.03 0.04 
 
0.04 0.04 
VCA0990 0.03 0.03 
 
0.07 0.07 
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VCA0991 0.07 0.11 
 
0.05 0.06 
VCA0992 0.04 0.07 
 
0.09 0.10 
VCA0993 0.06 0.06 
 
0.09 0.09 
VCA0994 0.05 0.07 
 
0.07 0.06 
VCA0995 0.05 0.08 
 
0.07 0.06 
VCA0996 0.04 0.04 
 
0.04 0.03 
VCA0997 0.04 0.04 
 
0.06 0.05 
VCA0998 0.06 0.05 
 
0.09 0.07 
VCA0999 0.05 0.07 
 
0.10 0.09 
VCA1000 0.06 0.07 
 
0.03 0.02 
VCA1001 0.08 0.11 
 
0.06 0.05 
VCA1002 0.03 0.04 
 
0.02 0.02 
VCA1003 0.05 0.07 
 
0.08 0.06 
VCA1004 0.03 0.04 
 
0.07 0.06 
VCA1005 0.02 0.05 
 
0.06 0.05 
VCA1006 0.04 0.04 
 
0.09 0.07 
VCA1007 0.05 0.07 
 
0.06 0.07 
VCA1008 0.02 0.03 
 
0.06 0.07 
VCA1009 0.05 0.06 
 
0.07 0.04 
VCA1009 0.06 0.06 
 
0.04 0.04 
VCA1010 0.12 0.13 
 
0.06 0.07 
VCA1011 0.03 0.07 
 
0.06 0.05 
VCA1012 0.07 0.12 
 
0.06 0.04 
VCA1013 0.08 0.16 
 
0.13 0.10 
VCA1014 0.04 0.13 
 
0.03 0.03 
VCA1014 0.06 0.07 
 
0.04 0.05 
VCA1015 0.03 0.02 
 
0.09 0.09 
VCA1016 0.04 0.06 
 
0.03 0.02 
VCA1017 0.03 0.04 
 
0.06 0.06 
VCA1018 0.04 0.04 
 
0.06 0.05 
VCA1019 0.05 0.03 
 
0.04 0.03 
VCA1019 0.05 0.05 
 
0.04 0.03 
VCA1021 0.04 0.05 
 
0.07 0.08 
VCA1024 0.06 0.06 
 
0.07 0.05 
VCA1025 0.08 0.10 
 
0.07 0.08 
VCA1026 0.05 0.06 
 
0.05 0.05 
VCA1027 0.05 0.11 
 
0.06 0.05 
VCA1028 0.04 0.04 
 
0.06 0.02 
VCA1029 0.07 0.03 
 
0.02 0.03 
VCA1030 0.06 0.05 
 
0.05 0.05 
VCA1031 0.01 0.05 
 
0.02 0.03 
VCA1032 0.08 0.10 
 
0.08 0.10 
VCA1033 0.08 0.05 
 
0.06 0.10 
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VCA1034 0.06 0.06 
 
0.06 0.04 
VCA1035 0.03 0.05 
 
0.06 0.06 
VCA1037 0.01 0.06 
 
0.04 0.05 
VCA1038 0.03 0.04 
 
0.06 0.06 
VCA1039 0.02 0.02 
 
0.04 0.03 
VCA1040 0.03 0.03 
 
0.04 0.06 
VCA1041 0.06 0.07 
 
0.06 0.05 
VCA1042 0.00 0.01 
 
0.08 0.08 
VCA1043 0.03 0.03 
 
0.04 0.05 
VCA1044 0.08 0.08 
 
0.05 0.09 
VCA1045 0.07 0.07 
 
0.05 0.04 
VCA1046 0.08 0.08 
 
0.07 0.10 
VCA1047 0.07 0.08 
 
0.08 0.10 
VCA1048 0.08 0.07 
 
0.04 0.05 
VCA1049 0.03 0.03 
 
0.04 0.04 
VCA1050 0.09 0.07 
 
0.18 0.13 
VCA1051 0.05 0.08 
 
0.05 0.06 
VCA1052 0.03 0.04 
 
0.07 0.07 
VCA1053 0.04 0.04 
 
0.04 0.06 
VCA1054 0.05 0.06 
 
0.06 0.09 
VCA1055 0.03 0.02 
 
0.04 0.06 
VCA1056 0.05 0.05 
 
-0.02 -0.01 
VCA1057 0.05 0.05 
 
0.05 0.06 
VCA1058 0.04 0.03 
 
0.08 0.10 
VCA1059 0.06 0.06 
 
0.04 0.04 
VCA1060 0.07 0.08 
 
0.06 0.09 
VCA1061 0.05 0.05 
 
0.03 0.04 
VCA1062 0.04 0.05 
 
0.06 0.08 
VCA1063 0.05 0.05 
 
0.06 0.04 
VCA1064 0.05 0.04 
 
0.04 0.05 
VCA1065 0.07 0.08 
 
0.05 0.06 
VCA1065 0.08 0.05 
 
0.05 0.05 
VCA1066 0.07 0.05 
 
0.05 0.05 
VCA1067 0.07 0.07 
 
0.03 0.02 
VCA1068 -0.01 -0.02 
 
0.08 0.07 
VCA1069 0.06 0.05 
 
0.06 0.04 
VCA1070 0.03 0.03 
 
0.09 0.08 
VCA1071 0.03 0.04 
 
0.06 0.06 
VCA1072 0.06 0.05 
 
0.01 0.03 
VCA1073 0.06 0.05 
 
0.05 0.04 
VCA1074 0.06 0.07 
 
0.14 0.16 
VCA1075 0.02 0.02 
 
0.04 0.04 
VCA1076 0.04 0.04 
 
0.06 0.06 
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VCA1077 0.06 0.07 
 
0.03 0.04 
VCA1078 0.03 0.03 
 
0.04 0.03 
VCA1079 0.08 0.08 
 
0.02 0.04 
VCA1080 0.03 0.03 
 
0.06 0.05 
VCA1081 0.08 0.10 
 
0.04 0.03 
VCA1083 0.61 0.61 
 
0.54 0.58 
VCA1084 0.04 0.03 
 
0.04 0.06 
VCA1085 0.06 0.06 
 
0.05 0.04 
VCA1086 0.08 0.09 
 
0.06 0.06 
VCA1087 0.08 0.09 
 
0.06 0.07 
VCA1088 0.04 0.03 
 
0.04 0.04 
VCA1089 0.02 0.05 
 
0.05 0.05 
VCA1090 0.06 0.07 
 
0.04 0.04 
VCA1091 0.04 0.06 
 
0.05 0.06 
VCA1092 0.04 0.03 
 
0.12 0.09 
VCA1093 0.06 0.05 
 
0.05 0.06 
VCA1094 0.04 0.05 
 
0.00 -0.01 
VCA1095 0.04 0.04 
 
0.02 0.02 
VCA1096 0.04 0.03 
 
0.07 0.06 
VCA1097 0.03 0.03 
 
0.03 0.08 
VCA1098 0.05 0.03 
 
0.01 0.02 
VCA1099 0.01 0.04 
 
0.07 0.08 
VCA1100 0.03 0.03 
 
0.04 0.08 
VCA1101 0.02 0.02 
 
0.06 0.04 
VCA1102 0.16 0.15 
 
0.03 0.03 
VCA1103 0.07 0.07 
 
0.03 0.04 
VCA1104 0.00 0.03 
 
0.04 0.04 
VCA1105 0.00 0.02 
 
0.06 0.04 
VCA1106 0.01 0.02 
 
0.04 0.05 
VCA1106 0.00 0.02 
 
0.05 0.04 
VCA1107 0.02 0.03 
 
0.05 0.04 
VCA1108 0.01 0.03 
 
0.05 0.06 
VCA1109 0.03 0.05 
 
0.05 0.06 
VCA1110 0.01 0.00 
 
0.17 0.15 
VCA1111 0.04 0.04 
 
0.01 0.00 
VCA1112 0.04 0.05 
 
0.04 0.04 
VCA1113 0.05 0.04 
 
0.08 0.05 
VCA1114 0.08 0.08 
 
0.03 0.03 
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